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Thesis summary 
Alzheimer’s disease is a complex neurodegenerative disorder, characterised by progressive 
neurological and cognitive impairment. Genome-wide association studies have shown the 
significant association of several endocytosis-related genes with Alzheimer’s disease, 
including BIN1. With multiple tissue-specific isoforms, BIN1 functions are wide-ranging and 
its involvement in mediating Alzheimer’s disease risk is not fully understood. 
The initial aim of this thesis was to develop a neuronal cell model from induced pluripotent 
stem cells (iPSCs) derived from peripheral blood mononuclear cells (PBMCs) for the study 
of endocytosis in Alzheimer’s disease. The development of PBMC-derived iPSC models is a 
novel field and this thesis demonstrates that PBMC-derived iPSCs can be differentiated into 
cortical neurons through dual SMAD inhibition. This protocol was carried out for the first 
time in the current lab and has therefore established these iPSC protocols for future use. 
Secondly, this thesis aimed to further develop knowledge on the role of BIN1 in clathrin-
mediated endocytosis (CME) in a non-neuronal context. The hCMEC/D3 human brain 
microvascular endothelial cell line was used as an in vitro model of the blood-brain barrier 
(BBB) to investigate the effect of siRNA-mediated BIN1 depletion. Evidence is presented 
suggesting BIN1 is involved in the amyloidogenic processing of APP by an increase in β-
CTF upon BIN1 depletion, in the absence of changes in levels of APP, Aβ and soluble APP 
or putative α- β- and γ- secretases. This was not suggested to be due to altered CME as 
transferrin uptake and recycling remained unaffected. While caveolin-2 levels increased with 
BIN1 depletion, lactosylceramide internalisation, a measure of caveolar endocytosis, was not 
affected, suggesting BIN1 was not crucial for this mechanism in hCMEC/D3 cells. Impaired 
degradative clearance of β-CTF was also hypothesised, however an absence of gross changes 
in lysosome morphology suggested that BIN1 was not central to normal lysosome function. 
This thesis provides novel insight into the role of BIN1 in the amyloidogenic processing of 
APP and endocytosis at the BBB, furthering understanding on the functional relevance of 
AD risk mediated by BIN1. 
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Chapter 1 
1! Introduction 
 
1.1!Alzheimer’s Disease 
1.1.1! History 
Alzheimer’s disease is a neurodegenerative disorder characterised by progressive 
neurological impairment and decline in cognitive function.  In 1906, Alois Alzheimer first 
described an unusual psychiatric disease with severe cerebral histopathology in the brain of 
a 51-year-old female patient named Auguste Deter (Alzheimer, 1907). Her symptoms 
included rapidly increasing memory impairment, disorientation, aphasia, poor 
comprehension, paranoia and auditory hallucinations. Following her death, after 4 ½ years 
of illness, Alzheimer studied the neuropathology of her brain, where he observed “military 
foci”, now known as β-amyloid plaques, and neurofibrillary degeneration. In 1909, Gaetano 
Perusini reinvestigated Auguste Deter’s symptoms and histopathology in addition to three 
further cases and presented illustrations of the amyloid plaques and neurofibrillary tangles 
(Perusini, 1909).  
Emil Kraepelin, director of the Royal Psychiatric Clinic in Frankfurt where Alzheimer 
worked, first introduced the aponym Alzheimer’s disease (AD) in 1910 following other 
reports of cases with similar symptoms and histopathology with extremely serious cell 
alterations and cell death (Kraepelin, 1910). While this diagnosis was originally referred to 
as presenile dementia, a rare disease occurring in middle age, it later became apparent that 
the disease commonly affected the elderly and the terminology was later extended to 
describe the largest cause of primary dementia; Senile Dementia of Alzheimer Type 
(SDAT, (Maurer et al., 1997). Over 100 years later and Alzheimer’s original observations 
still form the basis of the well-known pathological hallmarks of the disease. 
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1.1.2! Clinical diagnosis 
In 1984, the National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
assembled a uniform set of criteria for the clinical diagnosis of AD (McKhann et al., 1984). 
The diagnoses were divided into possible, probable and definite AD. Possible AD was 
diagnosed on the basis of the dementia syndrome; the decline of memory and other 
cognitive functions in comparison to a patient’s previous level of functioning. While a 
clinical diagnosis of definite AD could only be made by histopathological evidence from 
biopsy or autopsy, probable AD was characterised by dementia as established by 
neuropsychological tests, deficits in two or more areas of cognition, described below, 
accompanied by progressive decline in memory and cognition, onset between the ages of 
40-90 and the absence of other systemic disorders or brain disease (McKhann et al., 1984).  
The major cognitive domains impaired in AD are memory, orientation, language, attention, 
motor coordination, visual perception, problem-solving and social functioning. Cognitive 
tests such as the Mini-Mental State Exam (MMSE), Montreal Cognitive Assessment 
(MoCA) and Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog) are 
used to assess an individual’s ability in these areas (Folstein et al., 1975, Nasreddine et al., 
2005, Rosen et al., 1984). These are often combined with physical and neurological 
assessments, in addition to structural imaging by computerised tomography (CT) and 
magnetic resonance imaging (MRI). Although impairments in memory and cognitive 
function are thought to be the primary features of AD, many non-cognitive 
neuropsychiatric symptoms also present with the disease, such as apathy, hallucinations and 
delusions, aggression, depression, disinhibition, and motor impairments (Lyketsos et al., 
2011). 
With advances in our understanding of the disease, the NINCDS-ADRDA criteria were 
reviewed as it is now recognised that the AD spectrum is broader than previously thought 
(McKhann et al., 2011). This is based on literature emerging since the mid 1990s showing a 
transitional state between the cognitive changes of normal aging and AD, known as mild 
cognitive impairment (MCI) (Petersen et al., 2013). These gradual impairments in cognitive 
function precede the point where significant interference in daily activity occurs but they 
do not meet the accepted criteria for clinical probable AD and not all MCI leads to AD. 
The reviewed guidelines were published in 2011 and also introduced recommendations for 
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a newly defined stage of disease intended purely for research purposes; the diagnosis of 
preclinical (presymptomatic) AD, reflecting emerging evidence that measurable biomarker 
changes in the brain may occur years before symptoms become apparent (Dickerson et al., 
2011). While research is ongoing to source an easily testable biomarker for AD, the 
strongest candidates include brain imaging studies such as molecular tracing by MRI or 
positron emission tomography (PET).  
1.1.3! Prevalence 
Over 46.8 million people worldwide are living with dementia, of which AD is recognised as 
the leading cause, accounting for up to 70% of all dementia cases (Prince, 2015). Globally, 
the number of people living with dementia is predicted to increase to 131.5 million by 
2050, an increase of 281% (Prince, 2015). Within the UK, 850,000 people are thought to 
suffer from dementia, accounting for 7.1% of people over the age of 65 while 40,000 
people in the UK under the age of 65 suffer from early onset forms of dementia (Prince, 
2014). With age being the biggest risk factor for dementia, increasing life expectancy is the 
key driving force behind the projected rise in cases to over 1 million by 2025 (Prince, 
2014). Indeed, the risk of developing dementia rises from 1 in 14 over the age of 65, to 1 in 
6 over the age of 80 (Prince, 2014). Women are more likely to develop dementia in their 
lifetime, with 65% dementia sufferers being female (Prince, 2014). While this may partly be 
accounted for by the longer life expectancy of women, research is ongoing to elucidate the 
reason for this gender difference, which is still unclear. Dementia not only causes huge 
emotional burden for people who have a close friend or relative with the condition, but the 
financial burden to UK society is estimated at £24 billion in health and social care costs, 
with a projected rise to £59 billion by 2050 (Lewis, 2014). 
1.1.4! Neurobiology and Pathological hallmarks 
Post mortem analysis of brain tissue from AD patients has revealed the presence of distinct 
neuropathological changes at both the anatomical and cellular level. The primary hallmarks 
of AD are extracellular neuritic protein aggregations, or plaques, predominantly composed 
of the Aβ peptide, intracellular neurofibrillary tangles (NFTs), comprising filamentous 
aggregates of hyper phosphorylated tau protein (ptau) and neuronal and synapse loss. 
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1.1.4.1! Brain atrophy 
One of the most distinctive hallmarks of AD is the considerable neuronal loss observed 
throughout the cortical and subcortical structures upon examination of post-mortem brain 
tissue. Error! Reference source not found. shows the spread of AD pathology 
throughout the brain with progression of disease and highlights the areas particularly 
affected by comparison to a healthy brain. A typical symmetric pattern of brain atrophy 
affecting the medial temporal lobes while relatively sparing the primary motor, sensory and 
visual cortices is characteristic of AD pathology (Dickerson et al., 2009). Reliable atrophy 
was identifiable in asymptomatic individuals nearly a decade before dementia onset, 
representing a potentially important biomarker of neurodegeneration (Dickerson et al., 
2011). The symptoms of AD arise from the selective neuronal loss within the paralimbic 
and heteromodal association areas with early neuronal loss occurring in the entorhinal, 
parahippocampal and temporo-parietal cortex (Juottonen et al., 1998, Jack et al., 1992). 
This mirrors the time course of cognitive impairment, extending into anterior regions as 
the disease progresses (Serrano-Pozo et al., 2011). The use of MRI has allowed researchers 
to non-invasively monitor cerebral volume throughout disease progression. Cortical 
thinning in AD patients has been shown to increase with decreasing cognitive performance 
(Sabuncu et al., 2011). This association followed a sigmoidal pattern, exhibiting early 
acceleration followed by deceleration while hippocampal volume loss exhibited positive 
acceleration throughout disease progression. MRI volumetric measurements have shown a 
40% loss in entorhinal cortex volume compared to controls, which correlated significantly 
with severity of the disease (Juottonen et al., 1998). Hippocampal volumes have shown a 
24% reduction between AD patients and controls, with a 3.3% loss in hippocampal volume 
over just 6 months, compared with a 0.9% loss in volume in the age-matched control 
group (Schuff et al., 2009). Therefore, hippocampal volume may also be an early indicator 
of AD. 
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Figure 1.1: The progression of Alzheimer’s pathology in the human brain 
A schematic depicting the progression of Alzheimer’s disease pathology starting in the 
medial temporal lobes, where the hippocampus and associated structures are first affected. 
The pathology spreads in a symmetrical pattern, extending to the anterior regions as the 
disease progresses. A schematic representing a coronal cross-section of the brain is also 
shown, illustrating the shrinkage of the cortex and hippocampus, and enlargement of the 
ventricles. 
1.1.4.2! Neuritic plaques 
Neuritic plaques are microscopic foci of extracellular beta-amyloid (Aβ) deposition which 
principally occurs in the filamentous form with a high content of β-pleated secondary 
structure. The plaques contain dystrophic neurites which are defective in synaptic function 
and neurotransmission (Ferrer et al., 1998). Aβ is a 39-43 amino acid peptide of 4 kDa and 
is produced from the sequential cleavage of amyloid precursor protein (APP), a type I 
transmembrane glycoprotein (Kang et al., 1987), by β- and γ -secretases on the N- and C- 
terminal ends of the Aβ region, respectively. The most common forms of Aβ produced are 
40 and 42 residues in length, with much of the Aβ found in neuritic plaques comprising the 
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more hydrophobic 42 amino acid species which is particularly prone to aggregation (Jarrett 
et al., 1993). The mechanisms underlying the pathological accumulation of Aβ are yet to be 
fully determined, however the formation of plaques is known to involve the polymerisation 
of monomeric Aβ into oligomers, protofibrils and amyloid fibrils (Ward et al., 2000). The 
accumulation of Aβ in the brain is thought to arise from increased Aβ production, 
decreased clearance from the brain or a culmination of the two (Selkoe and Hardy, 2016). 
Heiko and Eva Braak categorised the progression of amyloid deposition throughout the 
brain in AD into three stages (Braak and Braak, 1991). In stage A, low densities of amyloid 
deposits were present, particularly in the basal frontal, temporal and occipital lobes while 
no amyloid was present in the hippocampus. Stage B tissue demonstrated more extensive 
amyloid deposition in almost all isocortical areas with only the primary motor and sensory 
areas free of, or showing minimal, amyloid deposits and the hippocampus showed only 
mild pathology. Stage C tissue exhibited a greater extent of amyloid pathology throughout 
isocortical layers but the hippocampus remained mildly affected. The striatum and nuclei of 
the thalamus and hypothalamus showed evidence of deposition, while the substantia nigra 
and pars compacta remained amyloid-free. These defined stages, known as Braak stages, 
are used to classify the degree of pathology both in research and in clinical diagnoses of 
disease from post-mortem. A further six stages (I- VI) were also defined to characterise 
neurofibrillary changes throughout disease progression which are further described in 
Section 1.1.4.3.  
Together with extracellular Aβ deposits in the parenchyma, fibrillary amyloid deposition is 
also commonly observed in the cerebral blood vessels, a feature known as cerebral amyloid 
angiopathy (CAA). CAA increases with age, occurring in approximately half of elderly 
individuals (Yamada et al., 1987), while the prevalence in AD patients is estimated at 80-
90% (Yamada, 2002). CAA is mainly observed in the leptomeningeal and cortical vessels 
where amyloid fibrils are initially deposited in the outer basement membrane of vessels and 
later accumulate in place of degenerated smooth muscle cells of the media (Yamada, 2015).  
1.1.4.3! Neurofibrillary tangles 
Hyperphosphorylated tau is the major component of intracellular neurofibrillary tangles, 
one of the key pathological hallmarks of AD. Tau is a microtubule-associated protein 
(MAP) that stimulates tubule assembly into microtubules, which act as a scaffold for the 
                                  Chapter 1: Introduction       
 
 
7 
cell cytoskeleton and are involved in vesicular trafficking (Weingarten et al., 1975). Tau has 
been the focus of much research since it was discovered to form the paired helical 
filaments of NFTs in the AD brain (Grundke-Iqbal et al., 1986). Phosphorylation of tau at 
critical sites inhibits it binding to microtubules by varying degrees (Sengupta et al., 2017) 
with further phosphorylation promoting self-aggregation into filaments. 
Hyperphosphorylated tau appears to gain the toxic ability to sequester normal tau and 
other MAPs, causing microtubule disassembly (Alonso et al., 1997). Despite extensive 
research, the causes leading to the abnormal phosphorylation of tau are still not fully 
elucidated and the exact molecular basis of its toxicity remains an area of intense research. 
The development of NFTs throughout the brain was categorised into six stages with the 
stages I-II classified as transentorhinal, stages III-IV as the limbic stages and stages V-VI as  
the  isocortical  stages (Braak and Braak, 1991). As AD progresses, tau pathology spreads 
from the entorhinal cortex in a uniform and reproducible fashion, suggesting that tau 
pathology may be transmitted between neighbouring neurons (Pooler et al., 2013). 
Although the complex interplay between Aβ and tau is yet to be defined, the prevailing 
hypothesis of AD pathogenesis is that deleterious effects on synaptic function leading to 
cognitive impairment caused by tau are initiated by Aβ. This theory was coined The 
Amyloid Cascade Hypothesis (ACH) and is further explained in Section 1.2.3. 
1.1.4.4! Protein aggregates: cause or consequence? 
While gross aggregations of Aβ and hyperphosphorylated tau are hallmarks of AD 
pathology, the extent to which these end products of polymerisation contribute towards 
neuronal toxicity has recently come under scrutiny. Amyloid plaque burden correlates 
much less well with degree of cognitive impairment than neurofibrillary tangle pathology 
(Nelson et al., 2012, Guillozet et al., 2003) while plaques have been detected in cognitively 
normal individuals (Erten-Lyons et al., 2009), some with plaque burdens equivalent to 
those seen in demented patients (Rentz et al., 2010). The presence of significant plaque 
burden without brain atrophy or cognitive impairment (Erten-Lyons et al., 2009) suggests 
that Aβ plaques are not directly responsible for neurodegeneration.  
Soluble Aβ oligomers, however, have been shown to produce cognitive deficits in APP-
overexpressing mice in the absence of plaques (Gandy et al., 2010) and evidence of 
neurodegeneration in MCI patients has been reported without observed amyloid 
                                  Chapter 1: Introduction       
 
 
8 
deposition, suggesting that large Aβ aggregates are not essential for cognitive impairment 
(Petersen et al., 2013). Aβ oligomers bind to post-synaptic excitatory sites in neurons 
(Lacor et al., 2004) and interfere with synaptic plasticity by blocking long term potentiation 
(LTP) (Wang et al., 2002). They have also been shown to interfere with calcium 
homeostasis in neurons, inducing oxidative stress and tau hyperphosphorylation (De Felice 
et al., 2008). Other brain cell types have also shown evidence of toxic responses to Aβ 
oligomers such as disruption of blood-cerebrospinal fluid (CSF) barrier integrity (Brkic et 
al., 2015). DaRocha-Souto et al. (2011) demonstrated that oligomeric Aβ deposits, but not 
total plaque burden, correlated with neuronal loss in the entorhinal cortex of double-
transgenic mice overexpressing human mutant APP and tau. Therefore, there is much 
evidence to suggest that Aβ is neurotoxic in its oligomeric form. 
Likewise, studies have challenged the idea that NFTs are causative of neuronal death. For 
example, a mouse model expressing a mutant form of human tau (rTg4510) showed 
dissociation of neuronal loss and NFT pathology, with neurodegeneration observed before 
neurofibrillary lesions appeared in the dentate gyrus while NFTs appeared without major 
cell loss in the striatum (Spires et al., 2006). Growing evidence suggests that pre-
filamentous forms of tau, specifically oligomers, are neurotoxic. Indeed, tau oligomers 
derived from human AD brain can induce synaptic and mitochondrial dysfunction and 
memory impairment when intracranially-administered to wild-type mice (Lasagna-Reeves et 
al., 2011). Although the debate between the correlation of oligomers or mature fibrils with 
disease severity is ongoing, recent progress in this area is promising. The identification of 
toxic oligomeric species formed during protein aggregation has presented Aβ and tau 
oligomers as potential biomarkers for the accurate and early detection of AD (Holtta et al., 
2013, Sengupta et al., 2017).  
  
                                  Chapter 1: Introduction       
 
 
9 
1.2!The Genetic Landscape of Alzheimer’s 
Disease 
Historically, Alzheimer’s disease has been categorised into two broad categories; early-
onset Alzheimer’s disease (EOAD), which is characterised by disease onset before the age 
of 65 and accounts for 5% of all AD cases (Zhu et al., 2015) and the more common late-
onset Alzheimer’s disease (LOAD), with onset after the age of 65. The genetics of AD also 
falls into two categories, Mendelian or familial forms of AD (fAD) and sporadic forms of 
AD (sAD). Mendelian forms of AD are rare, accounting for less than 1% of all AD cases 
(Wingo et al., 2012), typically characterised by early-onset and have heritability estimates of 
92-100% (Wingo et al., 2012). Rare mutations in the amyloid precursor protein (APP) and 
presenilin 1 and 2 (PSEN1 and PSEN2) genes have been shown to cause early-onset cause 
fAD and will be further described in Section 1.2.1. However, only 5% of EOAD patients 
carry a known pathogenic mutation, with the majority of EOAD cases remaining 
unexplained (Cacace et al., 2016). The vast majority of AD cases, however, fall under the 
sAD category which has a much more complex pattern of inheritance. The majority of 
sAD comprises the late-onset form of the disease, while early-onset forms of sAD are rare, 
accounting for less than 5% of all early-onset AD cases. For clarity, this project will 
predominantly refer to the genetically-defined categories of AD, familial and sporadic. 
1.2.1! Familial Alzheimer’s Disease 
Initial attempts to understand the genetic basis of AD focused on autosomal dominant 
early-onset forms of the disease, resulting in the discovery of pathogenic mutations in APP 
(Goate et al., 1991), Presenilin 1 (Broeckhoven et al., 1992) and Presenilin 2 (Sherrington et 
al., 1996) through autosomal dominant AD pedigrees. These findings provided the basis 
for much of our understanding of AD pathogenesis today and underpin the ACH, further 
described in Section 1.2.3.  
1.2.1.1! Amyloid Precursor Protein 
The APP gene is located on chromosome 21 and encodes a transmembrane glycoprotein. 
Alternative splicing of the APP transcript generates 3 major isoforms; the 695 amino acid 
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isoform is predominantly expressed in neurons while the 751 and 770 isoforms are 
expressed both in the brain and ubiquitously (Rohan de Silva et al., 1997). APP is a 
transmembrane protein which is proteolytically processed by α-, β- and γ -secretases, 
following one of two pathways (Figure 1.2).  
The non-amyloidogenic pathway involves an initial α -cleavage of APP by members of the 
ADAM (a disintegrin and metalloproteinase) family of transmembrane proteins, such as 
ADAM17 (Buxbaum et al., 1998), ADAM10 (Lopez-Perez et al., 2001) and ADAM9 
(Koike et al., 1999). This cleaves APP within the Aβ domain, therefore precludes Aβ 
generation. The α-cleavage of APP occurs at a site in the extracellular domain, releasing a 
large soluble ectodomain, termed sAPPα, thought to be involved in neuronal plasticity and 
protective against excitotoxicity (Furukawa et al., 1996). The carboxy-terminal fragment (α 
-CTF) remains membrane-bound and is subsequently cleaved by γ -secretase to release P3, 
which is rapidly degraded, and the APP intracellular domain (AICD). AICD has been 
implicated in the transcriptional regulation of multiple genes, including APP itself (von 
Rotz et al., 2004, Muller et al., 2008).  
The amyloidogenic pathway of APP proteolysis involves cleavage of APP by β-secretase 
which releases the soluble ectodomain, sAPPβ, that has been reported to function in 
axonal pruning and neuronal cell death (Nikolaev et al., 2009). Following β-cleavage, the 
membrane-associated carboxy-terminal fragment, β-CTF, is further cleaved by γ -secretase 
to release intact Aβ and the AICD. The length of the Aβ fragment produced depends 
where exactly the γ -cleavage occurs, the majority of Aβ produced is of the 40 amino acid 
species, Aβ40 and to a lesser extent Aβ42, the more aggregation-prone species 
predominantly present in neuritic plaques. The β-secretase was identified as the 
transmembrane aspartic protease, β-site APP-cleaving enzyme 1 (BACE1) (Sinha et al., 
1999, Vassar et al., 1999) while Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) proteins 
are catalytic subunits of the γ-secretase complex (Wolfe et al., 1999). The γ-secretase 
enzyme is a multiprotein complex comprised of Presenilin, Nicastrin, Anterior pharynx-
defective 1 (APH-1), and Presenilin enhancer 2 (PEN-2) in a 1:1:1:1 ratio and all four 
proteins are necessary for full proteolytic activity (De Strooper, 2003). The fate of APP 
largely depends on where in the cell it is proteolytically cleaved and this will be further 
described within a cellular trafficking context in Section 1.4.3. 
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According to the Alzheimer Disease & Frontotemporal Dementia Mutation Database 
(http://www.molgen.ua.ac.be/ADMutations), a total of 51 mutations in 121 families have 
been identified in the APP gene (Cruts, 2017). APP mutations located close to the β- or γ - 
cleavage sites can increase overall Aβ production, but most affect the ratio of Aβ species 
produced in favour of Aβ42 ( Citron et al., 1992, De Jonghe et al., 2001, Zhou et al., 2011). 
Additionally, APP duplications in autosomal dominant early-onset families (Rovelet-Lecrux 
et al., 2005) lead to abundant parenchymal and vascular deposits of amyloid-beta peptides. 
A recessive mutation has been identified in APP that only resulted in AD in its 
homozygous state, with co-incubation of mutated and wild-type peptides conferring 
instability on Aβ aggregates, inhibiting amyloidosis and neurotoxicity (Fede et al., 2009). A 
coding mutation in APP was also recently identified that confers a protective value against 
sAD, this will be further described in Section 1.2.2.3. 
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Figure 1.2: The pathways of APP processing 
A schematic depicting the non-amyloidogenic and amyloidogenic routes of APP 
processing. In the non-amyloidogenic pathway, the α-secretase cleaves APP within the Aβ 
region, forming sAPPα and α-CTF which is subsequently cleaved into P3 and the 
membrane-bound AICD. In the amyloidogenic pathway, β-secretase cleavage results in the 
production of sAPPβ and β-CTF which is subsequently cleaved by γ -secretase to form Aβ. 
This amyloidogenic processing of APP is thought to occur predominantly in the endocytic 
pathway. 
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1.2.1.2! The Presenilins 
PSEN1 and PSEN2 are highly homologous genes that encode essential components of the 
catalytic site of the γ -secretase complex which cleaves membrane proteins, including APP. 
With 219 AD-causing mutations identified in PSEN1 and a further 16 in PSEN2 (Cruts, 
2017), they contribute a considerable proportion of the known causes of fAD. Mutations 
in PSEN1 are highly variable in terms of their effect on age of onset, disease severity and 
rate of progression. However, all PSEN1 mutations show complete penetrance and can 
cause severe forms of AD with age of onset as early as 25 years (Tanzi, 2012). Gene 
knockout studies in mice suggest that PSEN1 is the major γ-secretase and that it 
contributes disproportionately to Aβ generation, whereas PSEN2 plays a more minor role 
(Herreman et al., 1999). This is consistent with an earlier age of onset and death observed 
in fAD patients with PSEN1 mutations compared to those harboring PSEN2 mutations 
(Lippa et al., 2000).  
The precise mechanism by which PSEN mutations cause fAD has undergone much 
debate, with early reports suggesting a gain-of-function mechanism mediated by selective 
overproduction of Aβ42 (Borchelt et al., 1996, Scheuner et al., 1996). However, several 
lines of evidence have brought into question this view, suggesting that loss of PSEN 
function could better explain neurodegeneration in AD. Firstly, conditional PSEN 
inactivation in mice results in progressive memory impairment and neurodegeneration, 
which models based on Aβ overproduction have failed to demonstrate (Saura et al., 2004). 
Secondly, expression of PSEN mutants on a Psen-negative background resulted in 
accumulation of APP-CTFs and decreased generation of cytoplasmic AICD, suggestive of 
decreased PSEN activity (Bentahir et al., 2006), (Kumar-Singh et al., 2006). Furthermore, 
PSEN1 knockin mice carrying fAD mutations have shown a complete loss of PSEN1 
function in vivo, abolishing γ -secretase activity, suggesting PSEN1 mutations cause fAD by 
a loss-of-function mechanism (Xia et al., 2015).  
Loss of PSEN function is thought to result in the incomplete digestion of APP, with fewer 
but longer Aβ peptides generated (Yagishita et al., 2006). This is because the proteolytic 
function of γ –secretase is thought to occur sequentially. The first cut represents the 
endopeptidase cleavage which releases the C-terminal domain of substrates. The enzyme 
remains bound to the N-terminal fragment which is then processed by carboxypeptidase-
like activity which successively removes short peptides (Chavez-Gutierrez, 2013). Although 
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the precise molecular mechanisms of different PSEN mutations vary considerably, in all 
cases the mutations appear to decrease the carboxypeptidase-like activity of γ –secretase, 
resulting in an increase in the relative production of longer Aβ peptides. Szaruga et al. 
(2015) reported that brain samples from fAD patients harbouring PSEN1 mutations had 
similar overall γ -secretase activity levels to controls, suggesting that loss of the 
endopeptidase function of γ-secretase is not an essential part of fAD pathogenesis. 
However impaired carboxypeptidase function was observed in all fAD brains (Szaruga et 
al., 2015). Interestingly, the authors also reported that some sAD patient brain samples 
displayed γ -secretase dysfunction, suggesting that γ -secretase may also play a role in some 
sAD cases, however the majority of sAD samples displayed normal endo- and 
carboxypeptidase-like γ -secretase activity. Nevertheless, more than 99% of all AD patients, 
including sporadic and all other forms of fAD, express wild-type presenilins, therefore it is 
highly unlikely that the loss of PSEN function is a general mechanism of AD pathogenesis. 
1.2.2!Sporadic Alzheimer’s Disease 
Sporadic forms of AD account for over 95% of all cases and predominantly manifest as 
LOAD (Zhu et al., 2015). The inheritance pattern of sporadic forms of AD is complex. 
With heritability estimates of 58-79% (Gatz et al., 2006), both genetic and environmental 
factors are thought to play a role in pathogenesis. The search for genetic factors 
contributing to sAD has evolved significantly since the identification of fully penetrant 
mutations in APP, PSEN1 and PSEN2 as a cause of autosomal dominant fAD. 
1.2.2.1! Apolipoprotein E 
The first locus identified to reliably associate with AD risk was within the apolipoprotein E 
(APOE) gene where the expression of the APOE type epsilon 4 (ε4) allele had a highly 
significant association with sAD (Saunders et al., 1993). The differential expression of three 
APOE alleles (ε2, ε3, and ε4) is dependent on two single nucleotide polymorphisms 
(SNPs), rs429358 and rs7412, within exon 4 of the gene (Weisgraber et al., 1981). In 
humans, these variants result in three homozygous (ε2/ε2, ε3/ε3, and ε4/ε4), and three 
heterozygous (ε2/ε3, ε2/ε4, and ε3/ε4) phenotypes. Based on these variants, the APOE 
gene encodes 3 possible protein isoforms; E2, E3 and E4 (Agosta et al., 2009). The ε3 
allele is the most common, followed by ε4 and ε2, although these frequencies vary between 
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populations (Singh et al., 2006). Homozygosity for the ε4 allele confers a nearly 15-fold 
increased risk of developing AD, while heterozygous individuals carrying only one copy 
have a 3-fold increased risk (Farrer et al., 1997) compared to those homozygous for APOE 
ε3, the most common genotype (Corbo and Scacchi, 1999). The APOE ε2 allele, on the 
other hand, confers a protective effect with individuals carrying at least one copy having a 
40% decreased risk of developing AD compared to ε3 homozygous individuals (Farrer et 
al., 1997). Genin et al. (2011) assessed AD lifetime risk of 7351 cases and 10 132 controls 
from Caucasian ancestry based on APOE genotype and concluded that findings were 
consistent with semi-dominant model of inheritance whereby the homozygous ε4 or ε2 
genotypes confer a greater risk or protective value, respectively, than ε3ε4 or ε3ε2 
heterozygotes.  
Mechanistic studies have explored the functional relationship between APOE and AD and 
found that APOE has an important role in Aβ metabolism. Studies in humans and 
transgenic mice showed that brain Aβ levels and amyloid plaque loads are APOE isoform-
dependent as fibrillary amyloid deposits increased progressively with each additional ε4 
allele in the brains of cognitively normal individuals (Reiman et al., 2009). Increased 
vascular and plaque Aβ deposits have also shown greater abundance in ε4 carriers 
compared to non-carriers (Schmechel et al., 1993). Despite the clear association of APOE 
with AD risk and amyloid pathology, the pathway(s) by which APOE4 may increase Aβ 
levels are unclear and the subject of continued inquiry. APOE is a glycoprotein mainly 
expressed in the brain by non-neuronal cells, such as astrocytes and microglia (Pitas et al., 
1987). It functions as a ligand in receptor-mediated endocytosis of lipoproteins and plays a 
major role in calcium homeostasis (Mahley, 2016). There is no current consensus on the 
mechanism by which APOE isoforms affect AD risk, however, the prevailing view 
involves the modulation of Aβ metabolism. Studies have suggested that APOE4 accelerates 
Aβ deposition to form amyloid plaques (Wisniewski et al., 1994). In an AD mouse model 
expressing mutated human APP and human APOE isoforms under control of the mouse 
regulatory elements, APOE4 was shown to increase Aβ deposition relative to APOE3 and 
APOE2 due to defective clearance of Aβ from the brain (Castellano et al., 2011). Whether 
the APOE ε4 allele influences AD pathogenesis by a gain of toxic function, a loss of 
protective function or a combination of both remains to be elucidated. 
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1.2.2.2! Common Genetic Variants associated with Alzheimer’s Disease  
With the advent of genome wide association studies (GWAS), our knowledge of the 
genetic landscape of sAD has vastly improved. Since 2009, several well-powered GWAS 
have been published in addition to a landmark meta-analysis carried out by the joint 
International Genomics of Alzheimer’s Project (IGAP) consortium. This included 17,008 
sAD cases and 37,154 controls, with replication in an independent sample of 8,572 sAD 
cases and 11,312 controls, which identified 11 new susceptibility loci (Lambert et al., 2013). 
While APOE remains the most significant genetic risk factor for sAD, genetic analyses 
over the past decade have led to the discovery of over 20 susceptibility loci for sAD that 
consistently reach the genome-wide significance threshold of p < 5 × 10 –8.  
Early GWAS identified variants in or near the CLU, PICALM and CR1 genes to be 
associated with sAD risk (Harold et al., 2009, Lambert et al., 2009). BIN1 was first 
identified as a significant AD susceptibility gene in 2010 (Seshadri et al., 2010) followed by 
EPHA1, MS4A, CD2AP and ABCA7 in 2011(Hollingworth et al., 2011, Naj et al., 2011). 
A further 11 novel susceptibility loci were identified in 2013: HLA-DRB5/ HLA-DRB1, 
PTK2B, SORL1, SLC24A4 - RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, 
FERMT2 and CASS4(Lambert et al., 2013). In 2014, 2 further novel loci, TP53INP1 and 
IGHV1–67, showed genome-wide association for sAD (Escott-Price et al., 2014). TRIP4 
was also confirmed as a sAD susceptibility gene when SNP data from the IGAP dataset 
was combined with additional genotyping in an independent follow-up study (Ruiz et al., 
2014). 
Although the precise biological function of these polymorphisms in AD is yet to be 
defined, the susceptibility loci identified tend to converge onto select areas of biology. 
Pathway analysis has been carried out to explore whether certain biological pathways are 
significantly enriched in the genetic association data, including loci that associate with 
disease but failed to reach the genome-wide significance threshold. A significant 
enrichment for certain biological pathways was identified within the IGAP dataset, 
including the immune response, endocytic regulation, cholesterol transport and 
proteasome-ubiquitin activity (Jones et al., 2015). This enrichment was shown to be 
independent of known genetic risk factors as the association remained once all genes 
within linkage disequilibrium (LD) of APOE or any of the genes reaching genome-wide 
significance in the IGAP meta-analysis had been removed. These biological processes 
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therefore represent prime targets for AD therapeutics. However, it has been estimated that 
over 60% of the genetic variance of sAD is not accounted for by the identified common 
variation from GWAS studies or that available by imputation (Ridge et al., 2013). It is likely 
that the remaining heritability is accounted for by susceptibility genes of small effect that 
current GWAS are underpowered to detect, in addition to rare variants that are poorly 
represented on GWAS platforms. 
1.2.2.3! Rare Genetic Variants associated with Alzheimer’s Disease 
Rare variants in the population can have substantial effect sizes which may account for 
some of the missing heritability following GWAS studies. Next generation sequencing 
(NGS) has been used to detect rare SNPs that may be associated with sAD. Through 
studying whole-genome sequence data from 1,795 Icelanders, a rare coding mutation in the 
APP gene was identified that protects against Alzheimer's disease and cognitive decline in 
the elderly by encoding a sub-optimal BACE1-cleavage site resulting in decreased Aβ 
production (Jonsson et al., 2012). This finding provided proof of principle that reduced 
BACE1 cleavage of APP may protect against AD. Furthermore, the APP mutation also 
protected against cognitive decline in the elderly without AD, suggesting the possible 
shared pathogenesis of AD and normal cognitive decline of the elderly. 
NGS has also resulted in the discovery of TREM2 as an AD risk gene which showed a 
highly significant association with sAD (Guerreiro et al., 2013). The same study 
corroborated this association by analyzing Trem2 expression in APP transgenic mice and 
found Trem2 expression was increased compared to wild-types and found to be expressed 
in large activated microglia (Guerreiro et al., 2013), suggesting increased Trem2 expression 
may represent a response to rising levels of Aβ. In the same year, Jonsson et al. (2013) 
identified the same missense mutation in TREM2 to be associated with sAD and further 
found that carriers of the risk allele (rs75932628) aged 80-100 who did not have sAD, 
showed poorer cognitive function than non-carriers. While a SNP is defined as a single 
nucleotide polymorphism which is found in more than 1% of the population, a single 
nucleotide variant (SNV) is variation in a single nucleotide without any limitations of 
frequency. A significant SNV in TREM2 was recently published from genome-wide exome 
genotyping of the IGAP dataset (Sims et al., 2017). In addition to a new association in 
TREM2, two novel susceptibility loci, PLCG2 and ABI3 were identified (Sims et al., 2017), 
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all three of which are predominantly expressed in microglia (Zhang et al., 2010). Together 
with the aforementioned implication of the immune system in AD from pathway analysis, 
these findings further corroborate a role for microglial-mediated innate immunity in sAD 
pathogenesis.  
1.2.2.4! The Heritability of Alzheimer’s Disease 
Despite recent success in the genetics field through GWAS and NGS studies, the estimate 
of heritability explained by genetic findings to date remains relatively low due to the small 
effect sizes of known variants, illustrating the multifactorial nature of AD. Polygenic risk 
scores take into account SNPs that fail to meet the GWAS threshold and are based on a 
calculation of the collective contribution of common SNPs and their associated effect 
sizes. Using the IGAP data, significant evidence that individuals with higher polygenic risk 
scores were at greater risk of AD was reported after APOE and other genome-wide 
associated regions were excluded (Escott-Price et al., 2015). This suggested that the 
association was not dependent on previously identified susceptibility loci or associations as 
a result of linkage disequilibrium (LD). As sAD is thought to develop 10-30 years before 
the onset of symptoms, the predictive utility of polygenic risk scores was also analysed, 
with the probability of correctly predicting a case status reaching 75% when APOE 
genotype and SNPs with sAD association p values <0.5 were included (Escott-Price et al., 
2015). Individuals at the extremes of polygenic risk score (highest and lowest 2%) can give 
prediction accuracy of over 90% (Escott-Price et al., 2015). This could allow the 
identification of asymptomatic populations at greatest and lowest risk of AD which would 
have important benefits for clinical diagnosis and selection of participants for clinical trials. 
Furthermore, polygenic signals for specific biological pathways can also be calculated, 
allowing for the development of cell models to explore functional outputs through 
reprogrammed induced pluripotent stem cells from individuals with selected risk profiles. 
1.2.3!The Amyloid Cascade Hypothesis 
The most widely recognised theory of AD pathogenesis to date is the ACH, proposed by 
Hardy and Allsop in 1991, which was formed on the basis that AD is driven by the 
accumulation of Aβ in the brain and that NFTs, cell loss, vascular damage and 
neurodegeneration follow as a direct result of Aβ deposition (Hardy, 1992, Selkoe, 1991). It 
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was argued that impaired cleavage of APP results in increased Aβ, particularly the longer 
42-residue peptide. This hypothesis was formed on the basis of several lines of evidence, 
including the discovery that the principal component of neuritic plaques is Aβ (Masters et 
al., 1985), evidence that people with Trisomy 21, resulting in triplication of the APP gene, 
inevitably develop AD-like pathology (Olson and Shaw, 1969) and that genetic mutations 
near the cleavage sites of APP favour amyloidogenic processing by β- and γ -secretases 
(Citron et al., 1992). The mechanism by which Aβ results in tangle formation and neuronal 
loss was not elucidated (Hardy and Allsop, 1991). 
The later discovery that PSEN mutations alter Aβ production in fAD further supported 
the ACH (Borchelt et al., 1996). Furthermore, mutations in the gene encoding the tau 
protein do not lead to Aβ deposition, even in the most severe cases of NFT pathology, 
suggesting NFTs in AD are likely deposited after changes in Aβ metabolism (Hardy et al., 
1998). Transgenic mice overexpressing human APP and mutant human MAPT, the gene 
that encodes tau, further substantiated this hypothesis. These mice showed increased 
formation of NFTs, without altering amyloid plaque load, suggesting altered APP 
processing occurs before tau alterations (Lewis et al., 2001). Indeed, mouse hippocampal 
neurons expressing either mouse or human tau proteins degenerated in the presence of Aβ 
while tau-depleted neurons showed no signs of degeneration in the presence of Aβ, 
suggesting its toxicity is tau-dependent (Rapoport et al., 2002).  
Initially, the ACH was based on Aβ plaque load but was later updated to reflect the fact 
that soluble oligomeric species of Aβ are thought to be the toxic species and this 
reappraisal was published 100 years after Alzheimer's first description of the disease 
(Hardy, 2006). The ACH indeed offers a tractable and testable theory of pathogenic events 
underlying AD. However, it fails to provide a detailed explanation for the origin of the 
disease and several lines of evidence fail to fit with the hypothesis. Critics have argued that 
the theory cannot account for many aspects of AD pathogenesis (Hardy and Selkoe, 2002). 
Significant plaque burden has been demonstrated in individuals, by positron emission 
tomography (PET) scan, without evidence of cognitive impairment (Klunk et al., 2009). 
However, Aβ oligomer levels per plaque in these cases were shown to be much lower than 
in AD brains (Esparza et al., 2013). Furthermore, the theory that deposition of Aβ triggers 
the formation of NFT ultimately leading to cell death can be disputed by the lack of 
correlation in the temporal and regional distribution of NFTs and Aβ plaques in AD 
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(Serrano-Pozo et al., 2011). In fact, Braak and Braak (1991) showed evidence that tau 
pathology first develops in the transentorhinal cortex, often in the absence of plaque 
pathology, suggesting that NFTs may precede Aβ plaque formation (Schonheit et al., 2004). 
However, it was argued that such studies may not have taken into account diffuse plaques 
or soluble Aβ oligomers in the brain which require a more systematic search effort (Selkoe 
and Hardy, 2016). Arguments against Aβ being the preceding factor in AD pathogenesis 
also include the fact that amyloid plaque burden correlates much less well with degree of 
cognitive impairment than do neurofibrillary tangle counts (Nelson et al., 2012). However, 
Selkoe and Hardy (2016) argue that Aβ deposits are an early pathological event that may 
occur some length of time before clinical dementia and can lead to downstream cellular 
changes, such as neuritic dystrophy and tangles, that are more causative of neuronal 
dysfunction. The proposed relationship between Aβ and tau is further questioned by the 
lack of NFT pathology in APP and APP/PSEN1 transgenic mice, despite producing 
elevated levels of Aβ (Sasaguri et al., 2017). However, the absence of tauopathy in these 
models may be due to the time course of the disease, with mice living less than 3 years 
while at least two decades are required for Aβ amyloidosis to induce cortical tauopathy and 
neurodegeneration in humans (Bateman et al., 2012). Furthermore, it has been suggested 
that mouse and human brains express different profiles of tau species (McMillan et al., 
2008) and therefore the adequacy of transgenic AD mice, from which much of our 
knowledge of Aβ physiology derives, is brought into question. As these mice carry 
mutations found in fAD patients, it is also difficult to establish the extent to which their 
pathophysiology is applicable to sAD, despite the two forms of AD showing similar 
neuropathological features (Serrano-Pozo et al., 2011).  
Many studies investigating the genetic basis of sAD have shown support for the ACH, 
including the discovery that the APOE ε4 allele markedly increased AD risk by decreased 
brain clearance of Aβ, leading to excess Aβ aggregation and typical AD neuropathology 
(Castellano et al., 2011). The identification of other risk loci for sAD, through GWAS and, 
more recently, exome and genome sequencing have helped in identifying important 
biological processes in the context of AD pathogenesis, in particular cholesterol/sterol 
metabolism, the immune system and endocytosis (Jones et al., 2015). Follow-up studies 
investigating the function of susceptibility genes within these pathways have provided new 
support for the ACH as a driving factor in AD pathogenesis. For example, the SORL1, 
PICALM and BIN1 genes are associated with risk of sAD (Lambert et al., 2013) and all 
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have involvement in endocytic processes. SORL1 has been shown to act as a sorting 
receptor for APP, protecting it from amyloidogenic processing (Andersen et al., 2005), 
PICALM has been implicated in regulating Aβ clearance from the brain and BIN1 was 
reported to be involved in the endocytic trafficking of β-secretase, ultimately regulating Aβ 
production (Miyagawa et al., 2016). These mechanistic studies, among others, have linked 
several recently identified sAD risk genes to aspects of Aβ homeostasis, providing further 
support for the ACH. 
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1.3!The AD Risk Gene Bridging Integrator 1 (BIN1) 
Bridging Integrator 1 (BIN1) is currently identified as the second most significant sAD risk 
gene, after APOE (www.alzgene.org). BIN1 first came to light in the field of sAD genetics 
in 2009 in a two-stage GWAS involving over 16,000 individuals from the Genetic and 
Environmental Risk in Alzheimer’s Disease (GERAD) consortium (Harold et al., 2009). 
Two loci approximately 30 kb 5’ of the BIN1 gene, rs7561528 and rs744373, showed 
suggestive association with sAD but did not reach the genome-wide significance threshold 
with p-values of 3.0 x 10-6 and 3.2 x 10-6, respectively (Harold et al., 2009). The rs744373 
polymorphism, however, reached genome-wide significance (p = 1.6 x 10-11) in a 
subsequent three-stage GWAS in the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium (Seshadri et al., 2010), which was then combined 
with data from the GERAD consortium at Stage 3. The odds ratio (OR) of rs744373 was 
1.13 and the minor allele frequency (MAF) 0.29. The OR is the unit used to report effect 
sizes in GWAS and is the ratio of two odds: the odds of having disease for individuals with 
a specific allele and the odds of having disease for individuals who do not have that same 
allele. MAF, on the other hand, is the frequency at which the second most common allele 
is found in a population. The association of BIN1 was further confirmed at the rs7561528 
SNP in a GWAS in The Alzheimer’s Disease Genetics Consortium (ADGC) showing 
significance at p = 4.2×10−14 (Naj et al., 2011). A combined analysis of four GWAS datasets 
was then carried out and termed GERAD+ which further supported the association at 
rs744373 (p = 2.6x10-14) (Hollingworth et al., 2011). The GERAD, CHARGE, ADGC and 
EADI1 consortia were combined in the largest AD GWAS to date, with a total of 25,580 
cases and 48,466 controls of European ancestry, comprising the IGAP (Lambert et al., 
2013). In addition to the APOE locus, 21 loci reached genome-wide significance, of which 
BIN1 was the most highly associated with the top SNP, rs6733839, reaching p = 6.9 x 10-44. 
This was a newly-identified SNP, located 27.1 kb upstream from the BIN1 coding locus, 
with the minor allele (T) conferring a genetic risk for AD (OR = 1.22, MAF = 0.409) 
(Lambert et al., 2013). Table 1.1 shows a summary of the key GWAS results implicating 
BIN1 as a sAD susceptibility gene. All the aforementioned sAD-associated SNPs were 
found to lie within a 6.7 kb LD block approximately 30 kb upstream of the BIN1 promoter 
(Chapuis et al., 2013), suggesting they are representative of the same association signal.   
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Table 1.1: Key GWAS Identifying BIN1 as a sAD Susceptibility Gene 
Consortium SNP Odds Ratio Minor Allele 
Frequency 
P-value Reference 
CHARGE rs744373 1.13 
 
(G) 0.29 1.6×10-11 (Seshadri et al., 2010) 
ADGC rs7561528 1.18 (A) 0.35 4.2×10-14 (Naj et al., 2011) 
GERAD+ rs744373 1.17 (G) 0.29 2.6x10-14 (Hollingworth et al., 
2011) 
IGAP rs6733839 1.22 (T) 0.409 6.9x10-44 (Lambert et al., 2013) 
 
1.3.1! The Functional Relevance of the Genetic Association of 
BIN1 with sAD 
While GWAS identified a large number of novel risk-influencing loci, understanding the 
functional link between these genetic determinants and sAD presents a challenge given the 
functional risk variant(s) are yet to be determined. The sAD-associated index variant 
rs7561528, 5’ of the BIN1 gene, has been reported to show a cis-regulatory effect on the 
transcription of BIN1 in peripheral blood mononuclear cells (PBMCs) (Raj et al., 2012), 
suggesting, that changes in gene expression may be a possible mechanism by which BIN1 
mediates sAD risk. The 6.7 kb LD region containing the BIN1 association SNPs was 
sequenced from 47 sAD cases and 47 controls, resulting in the identification of 8 new 
polymorphisms (Chapuis et al., 2013). A sample of 338 controls was used for genotyping 
of these 8 polymorphisms which then acted as a reference for imputation in the GWAS 
EADI1 cohort where a three base pair insertion, rs59335482, was associated with higher 
risk of sAD (OR = 1.21, p = 1.3 x 10-6) (Chapuis et al., 2013). This insertion allele was 
shown to affect the transcriptional activity through a luciferase assay, showing a 101% and 
33% increase in luciferase activity in the human neuroblastoma SH-SY5Y and human 
embryonic kidney (HEK) cell lines, respectively. Furthermore, rs59335482 was associated 
with an increase in BIN1 mRNA expression levels in the brain and lymphoblastoid cell 
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lines, suggesting that BIN1 polymorphisms may mediate AD risk by increasing BIN1 
expression. The originally identified BIN1 SNP rs744373 (Hollingworth et al., 2011, 
Seshadri et al., 2010) has also shown association with BIN1 expression levels in temporal 
lobe epilepsy patients with severely impaired memory performance. Higher BIN1 mRNA 
expression levels were significantly associated with individuals homozygous for the risk 
allele at rs744373 compared to the non-risk allele (Bungenberg et al., 2016). 
Conditional analysis on the top BIN1 SNP (rs6733839) has identified a secondary 
association signal at rs7584040 within the first intron of BIN1, ~30kb from rs6733839 (In 
house unpublished data). Both these SNPs showed evidence of a functional role as 
expression quantitative trait loci (eQTLs). These are regions of the genome containing 
variants that influence the expression of one or more genes. Furthermore, rs7584040 has 
been reported to lie within a differentially methylated region (DMR) in lymphoblastoid cell 
lines (Kuleshov et al., 2014). DMRs are genomic regions which differ in DNA methylation 
status across phenotypes and are regarded as possible functional regions involved in gene 
transcriptional regulation. Methylation at intragenic sites is thought to associate with a 
decrease in gene expression (Lorincz et al., 2004). Further evidence of BIN1 methylation in 
sAD comes from the identification of a CpG locus, cg22883290, which is located 5 kb 
from the 5′ end of the BIN1 gene that was significantly associated with burden of AD 
pathology in 708 brain autopsy samples (De Jager et al., 2014). Methylation of CpG 
dinucleotides is a prime epigenetic mechanism and a frequent biochemical modification of 
DNA in the human genome. The BIN1 index SNP rs744373, located 92 kb from 
cg22883290, was moderately associated with level of methylation at this CpG locus (P = 
0.0003). However, the association of this methylation site with sAD was not found to be 
driven by rs744373 as adjusting for this variant did not change the effect size of CpG 
association to sAD burden (De Jager et al., 2014). Collectively, however, these studies 
suggest that genetic and epigenetic associations of BIN1 with sAD may have functional 
consequences for BIN1 expression. 
1.3.2!BIN1 Expression in Alzheimer’s disease 
With the region of association in BIN1 implicated in AD pathogenesis by multiple genetic 
analyses (Harold et al., 2009, Lambert et al., 2009, Seshadri et al., 2010, Naj et al., 2011, 
Hollingworth et al., 2011), BIN1 protein expression levels in AD became the next source 
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of interest. Evidence of BIN1 expression in AD to date has been conflicting. Glennon et 
al. (2013) reported that BIN1 protein was reduced by 87% in 24 frontal cortex samples 
from sAD patients compared to age-matched controls. In the same study, no significant 
difference was found in BIN1 expression when comparing 6 hippocampal samples from 
fAD patients compared to age-matched controls, suggesting that BIN1 expression level 
changes may be specific to the sporadic form of the disease. While the brain areas analysed 
differed, both the frontal cortex and the hippocampus are pathologically affected in AD 
(Braak and Braak, 1991, Jack et al., 1992). The sAD-specific nature of BIN1 expression 
changes suggest that BIN1 is a primary contributor to the disease rather than a secondary 
consequence of sAD. Glennon et al. (2013) also reported that BIN1 levels showed a trend 
towards a decrease with age in a cohort of 16 control samples between 25-88 years, 
although this observation did not reach statistical significance and requires replication.  
In contrast, BIN1 mRNA transcript levels have been reported to show an increase in sAD 
prefrontal cortex samples compared to controls in two independent studies (Chapuis et al., 
2013, De Jager et al., 2014). Karch et al. (2012) reported that BIN1 mRNA expression 
levels were marginally upregulated with sAD (p = 0.0540) in 112 parietal lobe samples, 
however this did not reach statistical significance. Interestingly, however, the same study 
reported that higher BIN1 expression levels were associated with later age at onset and 
shorter disease duration in neurons of sAD brain tissue from the parietal lobe (Karch et al., 
2012), therefore it still remains unclear how BIN1 expression changes are associated with 
AD pathogenesis.  
Subcellular changes in BIN1 expression with AD have been reported (Adams et al., 2016), 
suggesting that analysis of expression levels in brain samples containing a mixed population 
of cells may be too broad and this could, in part, account for the discrepancy in findings. 
Adams et al. (2016) reported that AD patients showed decreased BIN1-immunoreactive 
neuropil areas, rich in unmyelinated axons, dendrites and glial cells compared to controls, 
but an increase in the number of BIN1-positive neurons in the prefrontal cortex and CA1 
region of the hippocampus, the site of the earliest AD-associated neurodegeneration (West 
et al., 2000), compared to controls. Furthermore, the percentage of BIN1-positive 
pyramidal neurons in the CA1 region positively correlated with hippocampal neuritic 
plaque score in patients with AD (Adams et al., 2016). These findings further implicate 
altered BIN1 expression in AD pathogenesis and highlight the diversification of BIN1 
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expression among cell types of the brain. BIN1 has also shown isoform-dependent 
expression in AD (Holler et al., 2014). BIN1 is subject to extensive alternative splicing, 
generating at least 10 tissue-specific isoforms, as discussed in detail in Section 1.3.3. The 
largest isoform, isoform 1, showed significantly reduced expression in sAD brain tissue 
compared to age-matched controls whereas smaller BIN1 isoforms showed increased 
expression (Holler et al., 2014). The conflicting direction of evidence in addition to the 
differential expression patterns presented by different BIN1 isoforms suggests that BIN1 
expression does relate to AD pathogenesis, albeit it in a tissue-, cell-type- or isoform-
dependent manner. 
1.3.3!Genetic Architecture and Protein Structure of BIN1 
The BIN1 gene is 58,975bp in length and is found at position 2q14.3. It contains at least 20 
exons, of which 7 are differentially spliced (Wechsler-Reya et al., 1997). Initially identified 
as box-dependent myc-interacting protein 1 (Sakamuro et al., 1996), a tumour suppressor, 
BIN1 was originally denoted Amphiphysin 2 as it is a close homologue of the endocytic 
protein Amphiphysin 1 (AMPH1), sharing 55% protein homology (Butler et al., 1997). 
Together with the yeast protein RVS167, Bin1 and Amph1 comprise the founding 
members of the BIN1/Amphiphysin/RVS167-related (BAR) domain family of proteins, 
defined by the presence of a homologous α -helical domain of 250-280 amino acids 
(Sivadon et al., 1995, Sakamuro et al., 1996). While BAR domain proteins have been 
implicated in a wide range of cellular functions, this conserved feature suggests a common 
molecular mechanism may be underlying these diverse processes (Ren et al., 2006).  
The protein structure of BIN1 and its major splice variants are illustrated in Figure 1.3.   
All isoforms of BIN1 contain an N-terminal BAR domain: a kinked, tri-helical banana-
shaped homodimer exhibiting a positive charge on its concave surface to induce membrane 
curvature (Casal et al., 2006). The C-terminal SRC homology 3 (SH3) domain of BIN1 
mediates the interaction with endocytic proteins such as dynamin by binding to its proline-
rich domain (Grabs et al., 1997), an interaction which is important for clathrin-mediated 
endocytosis (CME) (Wigge et al., 1997b) which will be further described in Section 1.4.2. 
BIN1 isoforms exhibit tissue-specific expression and differ by the alternative splicing of 7 
exons: 6a, 10, 12a-d and 13 (Wechsler-Reya et al., 1997). The original nomenclature 
described by Wechsler-Reya et al. (1997) has been used here for consistency, but it should 
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be noted that exon 6a was previously overlooked and is more recently referred to as exon 
7, with all subsequent exons n + 1 from their original designation (Ren et al., 2006). Exon 
6a encodes a brain-specific 31-residue N-terminal insert domain (NTID) which has been 
shown to strongly promote an interaction with dynamin 2 (Ellis et al., 2012) and is 
important for membrane targeting and dimerization of Bin1 during endocytosis (Ramjaun 
et al., 1999). Exon 10 is predominantly found in the muscle-specific BIN1 isoform, which 
is involved in transverse tubule (T-tubule) biogenesis in striated muscle (Lee et al., 2002). 
Exon 10 encodes a 15-residue sequence which associates with certain phosphoinositides to 
enable membrane association, crucial for the T-tubule localization, and induces tubulation 
(Lee et al., 2002). Exon 12 includes a series of brain-specific exons divided into subtypes a-
d that encode the clathrin and AP2 binding (CLAP) domain. This facilitates binding with 
clathrin and associated adapter proteins, such as adaptor protein 2 (AP2), during CME 
(Ramjaun and McPherson, 1998). While exons 12a-d are spliced only into BIN1 isoforms 
found in the brain, the inappropriate inclusion of exon 12a in melanoma cells has been 
reported, which abolished the ability of Bin1 to inhibit c-Myc (malignant transformation by 
cellular homolog of avian myelocytomatosis virus oncogene) and to induce programmed 
cell death (Ge et al., 1999). Exon 12d is also found in BIN1 isoforms without exons 12a-c 
however the functional relevance of these exons to BIN1 function, when expressed in 
isolation, is yet to be elucidated. Finally, exon 13 encodes part of the Myc-binding domain 
(MBD) which binds c-Myc, an important regulator of cell proliferation and terminal 
differentiation which is mutated in human cancers (Pineda-Lucena et al., 2005). BIN1 was 
first identified as a protein that interacts with the N-terminus of c-Myc (Sakamuro et al., 
1996) and acts as a tumour suppressor by actively inhibiting c-Myc activation (Elliott et al., 
1999). 
  
                                  Chapter 1: Introduction       
 
 
28 
 
 
 
Figure 1.3: The Isoforms of BIN1 
A schematic depicting the protein domain structure and corresponding exons that 
comprise the 11 alternatively-spliced isoforms of BIN1. Known binding partners of the 
protein domains are indicated. Exons 1-7 encode the BAR domain, exon 10 encodes a 
nuclear-localisation-signal-like motif (NLS). Exons 12a-2 encode the clathrin-associated 
protein binding region (CLAP) domain while the Myc-binding domain (MBD) is encoded 
by exons 13 and 14. Finally, exons 15 and 16 encode the C-terminal SH3 domain. Isoforms 
1-7 show brain-specific expression while isoform 8 is muscle-specific and isoforms 9 and 
10 are ubiquitous. Inclusion of exon 12a has been identified in cancers (Ge et al., 1999). 
Alternatively-spliced exons are indicated in white text. Schematic adapted from Prokic et al. 
(2014). 
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1.4!The Functional Role of BIN1 
The mammalian genome contains two distinct amphiphysin genes denoted Amphiphysin 1 
(AMPH1) and Amphiphysin 2/BIN1. While AMPH1 is predominantly expressed in the 
brain (Wigge et al., 1997b), showing strict neuronal expression and presynaptic localisation 
(De Rossi et al., 2017), BIN1 shows widespread expression with brain-specific, muscle-
specific and ubiquitous isoforms (Tsutsui et al., 1997, Wechsler-Reya et al., 1997). All 
isoforms contain the N-terminal BAR domain that binds lipid membranes, inducing 
membrane curvature in numerous contexts including T-tubules in muscular cells, endocytic 
pits and intracellular membranes (Wechsler-Reya et al., 1997, Peter et al., 2004). The 
concave shape of the membrane-binding face of the BAR domain provides a simple 
mechanical explanation for its preferential binding to curved membranes. Membrane 
invagination/tubulation is mediated through dimerisation of the BAR domains of BIN1 
(Peter et al., 2004). The formation of both Bin1 homodimers and Bin1/Amph1 
heterodimers has been demonstrated in rat brain extracts (Ramjaun et al., 1999).  Drosophila 
only possess a single Amphiphysin gene and studies suggest this is always present in 
membrane domains that undergo great changes in curvature and surface area, for example 
at the apical membrane of epithelial cells (Zelhof et al., 2001). 
The mechanisms that underlie the pathogenic nature of BIN1 in sAD are not yet fully 
understood. However, BIN1 has shown involvement in two of the key biological pathways 
to be implicated in sAD from genetic studies; immune function and endocytosis. Aged 
mosaic BIN1 knockout mice show a higher incidence of inflammation compared to age-
matched controls (Chang et al., 2007) while BIN1 mouse knockout studies indicate that 
BIN1 regulates the expression of indoleamine 2,3-dioxygenase (IDO1) (Muller et al., 2005). 
This is upregulated as an immune defence mechanism and is also found to be associated 
with Aβ plaques and NFTs (Bonda et al., 2010). 
As a member of the Amphiphysin family, BIN1 binds to the GTPase dynamin and is 
thought to play an important role in CME (Wigge and McMahon, 1998). There are 7 brain-
specific isoforms of BIN1, all of which contain at least one of the exon 12 variants (a-d), 
exon 13 and three of which contain exon 6a (Figure 1.3). Isoform 4 also contains exon 10 
although the functional relevance of this in the brain is unclear. In neurons, Bin1 binds 
dynamin 1 through its SH3 domain (Ramjaun et al., 1997) and forms heterodimers with 
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Amph1 which are thought to aid endocytic uptake at the synaptic clathrin coated pit 
(Wigge et al., 1997a). Evidence both supporting and questioning the role of BIN1 in CME 
is further described in Section 1.4.2. 
1.4.1! Clathrin-mediated Endocytosis 
Endocytosis is the process by which cells internalise molecules from their environment by 
invagination of the plasma membrane and the formation of a membrane-bound vesicle 
called an endosome. It is a universally important cell function, enabling nutrient uptake, 
receptor recycling and degradation and the delivery of cargo to intracellular organelles. 
Internalised cargo may be shuttled through this internal membrane system for metabolic 
utilization or trafficked to late endosomes for further sorting resulting in retrograde 
transport to the Golgi apparatus, transcytosis to the opposing plasma membrane or 
degradation in lysosomes. There are multiple methods by which mammalian cells 
endocytose material from their extracellular environment. Macroscale endocytic processes 
include phagocytosis, the ingestion of larger objects, such as viruses, bacteria, or other 
particles, and macropinocytosis, the bulk non-selective uptake of solute molecules, 
nutrients and antigens (Kumari et al., 2010). Microscale endocytic events can also be non-
selective, such as fluid-phase and adsorptive endocytosis which describe the non-specific 
uptake of solutes from the immediate extracellular environment. Adsorptive endocytosis 
involves electrostatic interactions and requires the solute to have an excess positive charge, 
allowing it to bind the negatively-charged plasma membrane (Tamai et al., 1997). 
Microscale endocytic events are often categorised according to their requirement for 
dynamin scission. For example, CME and caveolar endocytosis depend on dynamin activity 
for vesicle formation (Wigge et al., 1997b, Oh et al., 1998), while the flotillin-mediated 
endocytic route can be independent of dynamin function (Glebov et al., 2006, Kumari et 
al., 2010). With BIN1 possessing both clathrin and dynamin-binding domains, this project 
will principally investigate CME and other dynamin-dependent endocytic processes such as 
caveolar endocytosis. 
To date, the best characterised endocytic mechanism is CME. As illustrated in Figure 1.4, it 
involves the formation of clathrin-coated pits (CCPs) around transmembrane receptors and 
their ligands at the plasma membrane, which subsequently develop into intracellular 
clathrin-coated vesicles (CCVs) (Mousavi et al., 2004). Clathrin is a soluble cytosolic 
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protein which functions as a heterohexamer, consisting of three heavy chains and three 
light chains in a triskelion shape (Young, 2007). It has no direct contact with the plasma 
membrane but is recruited by adaptor proteins, polymerising into a lattice around the 
inward-budding pit. There are five major steps of CME including nucleation, cargo 
selection, coat assembly, vesicle scission and uncoating.  
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Figure 1.4: Clathrin-mediated Endocytosis 
A schematic illustrating the five key stages in CME. Firstly, a nucleation module forms 
around the cargo-bound receptor and adaptor proteins are recruited to the endocytic pit. 
The adaptor proteins bind to the cargo-receptor complex and the assembly of the clathrin 
coat occurs. Meanwhile, BAR-domain proteins, such as BIN1, enable curvature of the 
membrane to produce the clathrin-coated pit and dynamin is recruited which results in 
scission of the vesicle from the plasma membrane. Once the vesicle is internalised, the 
clathrin coat and associated adaptor proteins disassemble and uncoat the vesicle. Adapted 
from (McMahon and Boucrot, 2011).  
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1.4.1.1! Nucleation 
CME is initiated by the assembly of various endocytic accessory proteins at the plasma 
membrane into CCPs. However, many of the CCPs formed quickly diminish into abortive 
events, with the remainder undergoing stabilization and maturing into CCVs (Ehrlich et al., 
2004). Although not yet fully understood, the initiation of the CCP is thought to involve 
the formation of a nucleation module. F-BAR domain-containing FCHo1/2 proteins 
(Fer/Cip4 homology domain only proteins 1 and 2) bind Phosphatidylinositol-(4,5)-
bisphosphate (PIP2)-rich regions of the plasma membrane (Jost et al., 1998) and recruit 
AP2 via interactions with scaffold proteins eps15 and intersectin (Henne et al., 2010). At 
least five adaptor protein complexes have been identified in eukaryotes (Hirst et al., 2011), 
each have a distinct localisation and function but all are involved in the sorting of cargo 
into vesicles for transport between membrane-bound compartments. AP2, the most 
thoroughly characterised of the five complexes, facilitates CME by linking clathrin and 
accessory proteins to the plasma membrane during CME, acting as a hub of interactions. 
AP2 is recruited to the nucleation module in addition to other cargo-specific adaptor 
proteins to mediate cargo selection (McMahon and Boucrot, 2011). 
1.4.1.2! Cargo selection 
The heterotetrameric complex of AP2 comprises two large subunits α and β2, the medium 
subunit µ2 and the smallest subunit !2 (Owen et al., 2004, Figure 1.5). The large subunits 
can be divided into a trunk and an appendage domain, joined by a flexible hinge region. 
Initially, the α subunit of AP2 interacts with PIP2 in the plasma membrane {Rohde, 2002 
#276} while the µ2 subunit targets cargo for internalisation by binding to linear 
internalization motifs on the cytoplasmic tails of transmembrane cargo molecules (Owen et 
al., 1998). The appendage domains are attached to the trunk domain by long flexible hinge 
regions, allowing for recruitment of accessory proteins from the cytosol such as BIN1, 
AMPH1, AP180 (or its functional homologue PICALM) and auxilin (Owen et al., 1999). 
AP2 binds clathrin via interactions with the β2 hinge region and the appendage domains 
(Shih et al., 1995, ter Haar et al., 2000, Owen et al., 2000), completing the interaction 
between the endocytic cargo, accessory proteins and the clathrin coat. AP2 is the major 
hub of interactions in the maturing CCP and is essential for CCP and CCV formation at 
the plasma membrane (Boucrot et al., 2010). 
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1.4.1.3! Coat assembly 
Clathrin molecules comprise a triskelia shape and are recruited from the cytosol by the AP2 
hub, polymerising through their simultaneous binding to the β2 appendage and the β2 
hinge region (Owen et al., 2000) into hexagons and pentagons to form a coat around the 
nascent pit. Clathrin polymerises at the forming pit and stabilises membrane curvature. The 
two-site binding of clathrin to both the β2 hinge region and appendage domain of AP2 
displaces accessory proteins from the appendage domains to which they are bound (Owen 
et al., 2000).  
1.4.1.4! Vesicle scission 
Budding of the CCV from the plasma membrane requires the GTPase dynamin (Damke et 
al., 1994) which is recruited by BAR domain-containing proteins, such as BIN1, through 
binding of their SH3 homology domains to the C-terminal proline-rich domain of dynamin 
(Shpetner et al., 1996). BAR domain-containing proteins form dimers and mediate 
membrane curvature through electrostatic interactions with lipid head groups (Peter et al., 
2004). Vesicle scission is facilitated by dynamin forming a helical collar around the neck of 
the invaginating CCV. In vitro evidence suggests that upon GTP hydrolysis, this helix 
extends lengthways (Stowell et al., 1999), eventually pinching the vesicle from the 
membrane. Both GTPase activity of dynamin and this associated conformational change 
are required for endocytosis (Marks et al., 2001). 
The self-assembly of dynamin into a multimeric ring structure during endocytosis greatly 
enhances its GTPase activity (Warnock et al., 1996). It is therefore essential that the 
formation of this structure is temporally and spatially regulated. BIN1 and Amph1 have 
been proposed to selectively bind dynamin in its dissociated form, targeting it to the CCP 
prior to ring formation (Owen et al., 1998). This is based on evidence that dynamin ring 
formation and amphiphysin binding are mutually exclusive events and the SH3 domains of 
BIN1 and Amph1 prevent the formation of dynamin rings in solution (Owen et al., 1998). 
Indeed, the amphiphysin SH3 domains are unique in their ability to inhibit CME when 
overexpressed in fibroblasts (Wigge et al., 1997b) which may be due to the sequestration of 
dynamin away from the CCP. 
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1.4.1.5! Uncoating 
Once detached from the plasma membrane, the clathrin coat is disassembled from the 
vesicle prior to fusion with the target endosome by the ATPase heatshock cognate 70 
(HSC70) (Schlossman et al., 1984) and in conjunction with auxilin in neuronal cells 
(Ungewickell et al., 1995) or cyclin G-associated kinase (GAK) in non-neuronal cells 
(Greener et al., 2000). Both these cofactors function catalytically to support uncoating of 
the clathrin basket by binding to clathrin triskelia and recruiting HSC70 (Schlossman et al., 
1984). Uncoating releases clathrin and other endocytic machinery into the cytoplasm to be 
used in the next round of CME. 
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Figure 1.5: The protein structure of AP2 
A schematic of the AP2 adaptor complex, a multimeric protein consisting of four adaptin 
subunits in the trunk domain, β2, σ2, µ2 and α, and two appendage domains attached by 
polypeptide hinges. The trunk domain binds to membranes and cargo via the β2 and µ2 
subunits while the hinge regions bind clathrin and the appendage domains bind endocytic 
accessory proteins, such as BIN1. Adapted from Owen et al. (2004). 
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1.4.2!The Role of BIN1 in Clathrin-mediated Endocytosis 
As a member of the amphiphysin family, BIN1 binds the GTPase dynamin through 
interactions with its SH3 domain (Wigge et al., 1997b) and brain-specific isoforms 
demonstrate binding to both clathrin and AP2 through the CLAP domain (Ramjaun and 
McPherson, 1998), implicating BIN1 in CME in a number of cell types. The evidence for 
the role of BIN1 in CME originates from research into the role of AMPH1, which shares 
55% homology with BIN1 (Butler et al., 1997). The enrichment of AMPH1 at presynaptic 
terminals in the brain (Ramjaun et al., 1997) and interactions with dynamin and AP2 first 
implicated this family of proteins in the endocytic pathway (David et al., 1996). 
Furthermore, in vivo, disruption of the Amph1-dynamin interaction has been demonstrated 
to block synaptic vesicle endocytosis in the lamprey reticulospinal synapse, suggesting that 
this interaction is essential for this process (Shupliakov et al., 1997). Following the 
discovery of BIN1, much research focused on investigating whether, like AMPH1, BIN1 
had a role in CME. Early in vitro studies supported a role for BIN1 in CME and suggested 
that AMPH1 and BIN1 interact to form heterodimers in the brain (Wigge et al., 1997a). 
Indeed, Amph1 knockout mice were found to exhibit dramatically reduced expression of 
the brain-specific Bin1 isoforms (Di Paolo et al., 2002). Expression of either full-length 
Amph1 or Bin1 alone inhibited endocytosis in COS monkey fibroblast cells, possibly due to 
a dominant negative effect, while coexpression of these two genes rescued endocytic 
inhibition (Wigge et al., 1997a). This suggested that both Amph1 and Bin1 were required in 
these cells for endocytic function. Indeed, depletion of both Amph1 and Bin1 by siRNA in 
the skin fibroblast cell line SK-MEL-2 led to defective uptake of transferrin, a marker of 
CME (Meinecke et al., 2013).  
However, immunohistochemical analysis of human brain sections for BIN1 and AMPH1 
provides compelling evidence that these homologs show a different pattern of expression 
in the brain. Unlike AMPH1, the large majority of BIN1 immunoreactivity was not 
associated with neurons and showed predominant expression in mature oligodendrocytes 
(De Rossi et al., 2016). This suggests that BIN1 and AMPH1 may also function 
independently. The role of BIN1 in CME has been questioned by several findings. For 
example, the disruption of the sole BAR domain-containing gene identified in Drosophila 
(likely the Bin1 homolog) did not detectably affect synaptic vesicle endocytosis (Zelhof et 
al., 2001). Furthermore, primary neurons from Bin1 knockout mice showed no deficiency 
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in synaptic vesicle uptake (Muller et al., 2003), suggesting that the function of Bin1 in the 
brain may differ from Amph1. Indeed, Bin1 is broadly expressed in many tissues, unlike 
Amph1, and shows tissue-specific expression of at least 10 different isoforms (Wechsler-
Reya et al., 1997). The relative importance of the alternatively-spliced CLAP domain for 
CME is unclear and while Bin1 may be important for CME in certain cell types, it may lack 
a necessary functional role in generalised endocytosis. 
1.4.3!The Endocytic Pathway and the Fate of APP 
Following internalization by CME, cargo contained within CCVs are trafficked through the 
cell via a number of highly dynamic membrane-enclosed tubulo-vesicular structures. 
Firstly, the newly budded vesicles can fuse with each other or early endosomes under the 
direction of the small GTPase Rab5 (Gorvel et al., 1991). The early endosome acts as a 
major sorting station, from which some receptors and membrane-bound lipids may be 
recycled back to the plasma membrane of origin via the endosome recycling complex 
(ERC) (Grant and Donaldson, 2009). Dissociated ligands are transported to late 
endosomes and lysosomes, where they are proteolysed. Endosomes transition from early to 
late by the transition from association with Rab5 to Rab7 (Poteryaev et al., 2010). During 
the transition, endosomes move along microtubules to the perinuclear region which is 
accompanied by increasing intravacuolar acidification (Hu et al., 2015). Late endosomes are 
involved in the formation of intraluminal vesicles, which bud inward from the endosome 
membrane. Late endosomes containing many intraluminal vesicles are referred to as 
multivesicular bodies (MVBs). Late endosomes and MVBs fuse with lysosomes where 
cargo proteins and intraluminal vesicles are degraded. Alternatively, MVBs may directly 
fuse with the plasma membrane, releasing their contents as exosomes. The luminal pH 
decreases along the endo-lysosomal pathway from pH 6-6.5 to pH 4.5-5.5 in late 
endosomes and lysosomes, reflecting the optimal pH of the enzymes that function within 
these vesicles (Hu et al., 2015). 
CME is an important mechanism in the context of LOAD as APP is internalised via this 
method (Carey et al., 2005) and alterations in intracellular trafficking are thought to 
influence whether it enters the non-amyloidogenic or amyloidogenic pathway. BACE1 has 
an acidic pH optimum and therefore resides predominantly in endosomes (Vassar et al., 
1999) whereas α-secretase has been shown to cleave APP almost exclusively at the cell 
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surface (Parvathy et al., 1999). This suggests that the cleavage of APP by β-secretase, and 
the amyloidogenic processing of APP, is more likely to occur if APP undergoes 
endocytosis. The importance of the endocytic pathway to APP processing and Aβ 
generation is illustrated by observations of reduced Aβ production when APP 
internalization is inhibited in APP transgenic mice (Carey et al., 2005). Furthermore, 
acceleration of APP metabolism and Aβ secretion upon endocytosis stimulation was 
demonstrated by overexpressing Rab5, a positive regulator of endocytosis, in mouse 
fibroblasts (Grbovic et al., 2003). Altered endocytosis has also been implicated in early AD 
pathogenesis as an increase in the number and size of Rab5-positive endosomes was one of 
the earliest detectable pathologies in post-mortem AD brains, preceding Aβ deposition 
(Cataldo et al., 2000). Inhibition of CME by the expression of a Rab5-specific GTPase-
activating protein in Neuro-2a (N2a) mouse neuroblastoma cells significantly reduced 
levels of β-CTF and secreted Aβ without affecting APP biosynthesis, suggesting 
endocytosis is important for the β-cleavage of APP (Ehehalt et al., 2003). With 
aforementioned evidence implicating BIN1 in CME, research investigating BIN1 function 
in APP processing has yielded interesting results to suggest it is involved in Aβ production 
in both neuronal and non-neuronal cell lines (Miyagawa et al., 2016). The tissue-specific 
expression of BIN1 isoforms brings into question whether BIN1 has a generalised function 
in endocytosis or if this is cell-type specific. Further findings implicating BIN1 function in 
APP processing will be described in Chapter 4. 
  
                                  Chapter 1: Introduction       
 
 
40 
1.5!Endocytosis at the Blood-Brain Barrier 
The blood-brain barrier (BBB) is a crucial interface between the nervous tissue of the brain 
and the circulating blood within the brain microvasculature. It is composed of an extensive 
network of endothelial cells which, alongside neurons, pericytes and astrocytes, form the 
neurovascular unit (Figure 1.6). The BBB is highly specialised to maintain the precise 
microenvironment required by the central nervous system by regulating the flux of 
nutrients, ions and other molecules, while providing protection from toxins and pathogens 
(Keaney and Campbell, 2015). Brain microvascular endothelial cells (BMECs) line the 
capillaries and form intercellular tight junctions, severely restricting the paracellular 
diffusion of macromolecules, ions and other polar solutes (Smith and Gumbleton, 2006). 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The Neurovascular Unit 
A schematic showing the structure of the neurovascular unit of the blood-brain barrier as a 
cross-section through a brain capillary. Brain microvascular endothelial cells line the 
capillary and are supported in their barrier function through interactions with pericytes, 
astrocytes and neurons. Adapted from Wolff et al., (2015). 
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1.5.1! The Neurovascular Unit 
1.5.1.1! Brain microvascular endothelial cells 
The primary anatomical units of the BBB are BMECs which line the brain capillaries, 
bearing much resemblance to other somatic endothelial cell types. However, these cells are 
highly specialized with unique properties that facilitate essential functions of the BBB, 
including acting as a barrier to passive diffusion, enabling active transport of molecules and 
facilitating communication between the CNS and the periphery (Keaney and Campbell, 
2015), further described in Section 1.5.2. BMECs form a tightly packed lining and maintain 
this structural integrity through intercellular adherens junctions. These are regions of cell-
to-cell contact composed of cadherin proteins spanning the intercellular cleft and are 
anchored to the cell cytoplasm by the scaffolding proteins α β and γ catenin (Keaney and 
Campbell, 2015). Adherens junctions provide structural support and are a vital component 
for BBB function as they are essential for the formation of tight junctions (TJs) which also 
span the intercellular cleft (Niessen, 2007).  
TJs are dynamic structures consisting of a number of transmembrane and membrane-
associated cytoplasmic proteins with the principal function of severely restricting 
paracellular diffusion (Keaney and Campbell, 2015). The transendothelial electrical 
resistance (TEER) is a powerful, non-invasive measure of the tightness of a cellular barrier 
in vitro and TJs allow the BBB to obtain a high in vivo TEER of 1000 Ωcm2 (Butt et al., 
1990). TJs consist of a complex of occludins, claudins and junctional adhesion molecules 
(JAMs) involved in intercellular contact and interactions with intracellular scaffold proteins 
such as zonula occludens (ZO) – proteins which anchor TJ proteins to the cytoskeleton 
(Fanning et al., 1998). While occludins are not required for the formation of tight junctions, 
they regulate barrier properties including maintaining the tightness of TJs and are involved 
in the formation of the apical (blood-facing) and basolateral (brain-facing) domains, as 
discussed below (Balda et al., 1996). Claudin-3 and claudin-5 are expressed in BMECs and 
support TJ integrity (Wolburg et al., 2003, Ohtsuki et al., 2007) while JAMs are thought to 
be involved in the facilitation of TJ assembly and the establishment of cell polarity (Ebnet 
et al., 2004). 
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The apical-basolateral polarity of BMECs is an essential property of the BBB which 
enables these cells to segregate receptors into plasma membrane domains, specific to their 
required direction of transcytosis. The receptor for the iron-binding ligand transferrin, for 
example, which undergoes CME, is predominantly found on the apical side of BMECs, 
largely limiting its endocytosis to the blood side and transport in a blood-to-brain direction 
(Roberts et al., 1993). The lipid composition also differs in the apical and basolateral 
membranes of BMECs and the basolateral membrane has been reported to display more 
caveolae, flask-shaped invaginations involved in clathrin-independent endocytosis 
(Bendayan et al., 2006). This suggests that endocytic mechanisms are also polarised at the 
BBB and that this is an important feature to maintain the function of the BBB. The 
establishment and maintenance of polarity in BMECs is thought to involve polarity 
regulator proteins and endocytic regulators which coordinate and promote each others 
activities (Shivas et al., 2010). While the molecular mechanisms governing endothelial 
apical-basolateral polarity are not fully elucidated, the regulation of polarity in epithelial 
cells is more fully understood. Indeed, differential regulation of endocytic mechanisms at 
the apical and basolateral domains has been demonstrated in polarised epithelial MDCK 
cells where clathrin-independent endocytosis of the protein toxin ricin was able to be 
stimulated on the apical membrane without increasing the uptake at the basolateral side 
(Eker et al., 1994). 
1.5.1.2! Basement membranes 
There are two basement membranes (BMs) that separate the endothelium from associated 
cell types within the brain; the endothelial BM and the astroglial BM. Integrins expressed 
by the endothelial cells can bind to most proteins of the BM while astrocyte end feet attach 
to the BM through dystroglycan, therefore the BMs act as important scaffolding structures 
allowing endothelial cells close proximity to astrocytes for optimal communication 
(Alvarez, 2013). 
1.5.1.3! Astrocytes 
While the endothelial cells make up the primary component of the BBB, their function is 
highly regulated by associated cell types which comprise the neurovascular unit. Microglia, 
astrocytes and nerve terminals all release vasoactive agents and cytokines which can modify 
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tight junction assembly and barrier permeability (Abbott et al., 2006). The contribution of 
astrocytes to BBB formation and maintenance was first demonstrated in 1987 both in vivo 
and in vitro by the groups of Raff and Brightman, respectively. Subcultured bovine BMECs 
showed fragmentation and decreased frequency of tight junctions, however when co-
cultured with rat astrocytes, enhancement of tight junction width and complexity was 
shown (Tao-Cheng et al., 1987). Janzer and Raff (1987), meanwhile, demonstrated that 
astrocytes have the ability to enhance tightness of microvascular endothelial cells in vivo. In 
this study, both purified rat cerebral cortex astrocytes and neonatal meningeal cells formed 
vascularised aggregates when injected into the rat anterior eye chamber. While endogenous 
albumin was detected in meningeal cell aggregates, it was not present in astrocyte 
aggregates, thus the endothelial cells lining the vasculature were functionally tight in the 
presence of astrocytes but functionally leaky in meningeal cell aggregates (Janzer and Raff 
1987). Indeed, more recently it has been demonstrated that significantly higher TEER can 
be induced in BMECs in vitro by co-culturing with astrocytes (Wang et al., 2015). 
1.5.1.4! Pericytes 
Pericytes are peripheral cells of mesodermal origin which show extensive coverage of CNS 
vasculature and have an important role in regulating cerebral blood flow, BBB permeability 
and clearing toxic cellular byproducts (Keaney and Campbell, 2015). Pericytes, like 
endothelial cells, are attached to extracellular matrix proteins of the basement membrane 
by integrins and project elongated processes that ensheath the capillary wall (Stratman et 
al., 2009). Platelet-derived growth factor receptor β (Pdgfrβ) knockout mice have defects in 
pericyte generation and demonstrate structural abnormalities in TJs, increased BBB 
permeability and increased rate of transcytosis (Daneman et al., 2010b). This suggests that 
pericytes are required for BBB formation during development and that pericyte coverage 
controls BBB permeability. Furthermore, purified wild-type murine BMECs cultured alone 
showed large gaps between cell connections, whereas when cultured with a feeding layer of 
purified brain pericytes, the endothelial junctions sealed and a 4-fold increase in TEER was 
recorded (Daneman et al., 2010b).  
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1.5.2!Function of the Blood-Brain Barrier 
The primary function of the BBB is to regulate the flux of molecules between the blood 
and the brain in order to maintain different homeostasis of these separate compartments. It 
is essential that the ionic composition of the brain is kept optimal for synaptic signalling 
function and therefore specific ion channels and transporters are present in brain 
endothelial cells to regulate this (Smith and Gumbleton, 2006). The concentration of ions 
in blood plasma may dramatically differ from that of the interstitial fluid (ISF) surrounding 
neurons and this may also fluctuate with environmental stimuli which could have 
neurotoxic effects if disseminated to the brain (Begley, 2007). The BBB therefore needs to 
prevent passive diffusion from either side while ensuring the essential uptake and removal 
of molecules to/from the brain.  
The BBB also serves as a protective barricade to neurotoxic substances that may be 
circulating in the blood, such as endogenous metabolites, proteins and xenobiotics. Brain 
endothelial cells have ATP-binding cassette (ABC) transporters which actively pump many 
of these damaging agents out of the brain. There is a much lower protein content in CSF 
than blood plasma (Begley, 2007) and therefore the transport of macromolecules between 
blood and brain is also restricted by the BBB, which prevents exposure of nervous tissue to 
factors that may convert endogenous proteins to damaging products in the brain. 
1.5.3!Methods of transport at the Blood-Brain Barrier 
Transport of substances across the BBB is predominantly an active process due to the 
severe restriction of the passive paracellular transport pathway. Passive diffusion across 
BMECs is limited to lipid-soluble molecules of approximately <180 Da in size due to the 
obstruction of the paracellular space by TJs (Kozler and Pokorny, 2003). Active transport, 
on the other hand, occurs at the BBB in the form of specialised transcellular transport 
systems that tightly restrict entry and exit of hydrophilic molecules to and from the CNS.  
Figure 1.6 shows the various modes of transport across BMECs. Some substrates, such as 
glucose, have specific protein transporters found in the plasma membrane of BMECs that 
mediate the facilitated diffusion of these polar substrates across the BBB. For example, the 
glucose transporter GLUT-1 is highly expressed in BMECs on both apical and basolateral 
membranes (Laterra et al., 1999) and mediates the transport of glucose into the brain by 
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carrier-mediated transport (Winkler et al., 2015). Receptor-mediated transport mechanisms 
are also found in BMECs, such as CME. Cargo is transported across the cell through 
endocytic vesicles which bypass the lysosome for exocytosis at the opposing domain by 
means of transcytosis. Electrostatic charge may also mediate the uptake of cationic 
substances and transport across the BBB by interactions with anionic sites on the cell 
surface, termed adsorptive-mediated endocytosis (Tamai et al., 1997). While the 
aforementioned transport mechanisms may be involved in both influx and efflux from the 
brain, a number of transport and carrier systems are expressed and polarised on the apical 
or basolateral surface of BMECs. Protein transporters such as ABC active efflux 
transporters are integral membrane proteins that use the energy of ATP hydrolysis to 
translocate neurotoxic substances from the brain and also prevent them entering in the first 
instance. P-glycoprotein (Pgp) is an ABC transporter involved in Aβ efflux and is further 
discussed in Section 1.5.4.   
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Figure 1.7: Methods of transport across the BBB 
A schematic illustrating the structure and various modes of transport at the BBB. The 
membrane location of the receptors or where the cargo binds (apical/basolateral) is 
indicated and the arrows signify whether the process occurs from blood to brain, brain to 
blood or both. Methods of transport at the BBB include transcellular diffusion of lipophilic 
molecules, active efflux pumps, carrier-mediated transcytosis by transport proteins, 
receptor-mediated transcytosis, adsorptive transcytosis and the largely restricted 
paracellular diffusion pathway. Adapted from Abbott et al. (2006). 
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1.5.4!Aβ transport at the Blood-Brain Barrier 
1.5.4.1! Influx and efflux of Aβ across the BBB 
APP is expressed in a variety of tissues and can also be detected at low levels in blood 
(Seubert et al., 1992). Aβ is therefore continuously produced by cells of the CNS and 
peripheral tissues, raising the question of whether circulating Aβ in the periphery could 
contribute to Aβ in the brain parenchyma. Maness et al. (1994) demonstrated that 
radioactive Aβ40 is capable of crossing the murine BBB and accumulating in the brain 
(Maness et al., 1994). Cerebral capillary sequestration and specific transport of synthetic 
Aβ40 and Aβ42, identical to endogenous Aβ, into guinea pig brain parenchyma was 
subsequently demonstrated by an intracarotid brain infusion method (Martel et al., 1996). 
The BBB expresses several transporter systems that are involved in receptor-mediated flux 
of Aβ, including receptor for advanced glycation end products (RAGE), low-density 
lipoprotein receptor-related protein (LRP1), and P-glycoprotein (Pgp). RAGE has been 
identified as the likely transporter responsible for mediating apical-to-basolateral 
transcytosis of Aβ across the BBB (Deane et al., 2003). Interruption of the RAGE-ligand 
interaction prevented circulating Aβ passing across the brain endothelium in vivo, reducing 
Aβ-mediated vasoconstriction and neurovascular stress, while BBB transport of Aβ in 
RAGE-null mice was undetectable (Deane et al., 2003). This study further demonstrated 
that RAGE contributes to the transport of pathophysiologically-relevant concentrations of 
Aβ in a mouse model overexpressing APP. These levels were comparable to baseline 
plasma Aβ levels. While RAGE is capable of rapidly transporting free Aβ into the CNS, Aβ 
in the brain parenchyma is primarily cleared to the bloodstream across the BBB by LRP1 
(Shibata et al., 2000). LRP1 is expressed mainly at the basolateral side of the BBB (Zhao et 
al., 2015) where it is involved in the endocytosis of more than 40 different ligands including 
APOE, APP and Aβ (Zlokovic et al., 2010). Pgp is an ABC transporter that is highly 
expressed in BMECs, showing strong enrichment in the apical membrane (Beaulieu et al., 
1997), consistent with its role as an efflux pump. Pgp actively transports a wide variety of 
agents from BMECs into the vascular lumen and is important for mediating Aβ efflux 
from the brain (Cirrito et al., 2005). Indeed, in Pgp-null mice, decreased Aβ clearance and 
enhanced Aβ deposition were reported (Cirrito et al., 2005). Based on its apical location in 
BMECs, it has been suggested that Pgp functions to expel Aβ into the bloodstream which 
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has been internalised from the brain by LRP1 (Hartz et al., 2010). However, antioxidant 
treatment that preserves LRP1 but not Pgp under inflammatory conditions also preserves 
Aβ efflux, suggesting that LRP1 can also function independently of Pgp (Erickson et al., 
2012). 
1.5.4.2! Defective Aβ transport in AD 
Changes in transport mechanisms across the BBB have a critical impact on the 
concentration of soluble Aβ in the CNS which is central to the formation of neurotoxic Aβ 
oligomers. The observation that LRP1 expression was decreased in the AD brain 
microvasculature (Shibata et al., 2000) lead to the neurovascular hypothesis of AD, 
originally stating that defects in Aβ efflux across the BBB because of LRP1 deficiency 
contributed to Aβ accumulation in the brain (Zlokovic, 2005, Jaeger et al., 2009). Indeed, 
depletion of LRP1 in the BBB by antisense oligonucleotides impairs Aβ efflux, resulting in 
Aβ accumulation in the brain and cognitive impairment in young wild-type mice (Jaeger et 
al., 2009). Reports of decreased Aβ efflux in rodent models of AD and human AD patients 
have substantiated the association between the disease and impaired Aβ efflux (Banks et al., 
2003, Kandimalla et al., 2005, Mawuenyega et al., 2010). Alterations in Pgp-mediated 
transport have also been reported in association with AD with PET imaging studies 
indicating Pgp dysfunction in human AD patients (van Assema et al., 2012). An increase in 
RAGE expression levels has been reported in AD endothelium (Yan et al., 1996), 
suggesting enhanced Aβ influx may be associated with AD pathogenesis. Indeed, RAGE 
inhibition was shown to reduce Aβ40 and Aβ42 levels in the brain and rescued cognitive 
performance in aged transgenic mice overexpressing human APP, representing a transgenic 
mouse model of AD with established Aβ pathology (Deane et al., 2012). Collectively, these 
data suggest that the cumulative effects of reduced expression of LRP1 and Pgp, with 
increased expression of RAGE may contribute to brain Aβ accumulation in AD. 
Recent evidence has implicated PICALM, one of the AD susceptibility genes, in regulation 
of Aβ efflux across the BBB, citing it as having a central role in Aβ clearance and thus 
demonstrating a mechanistic role in AD pathogenesis (Zhao et al., 2015). While a role for 
PICALM in CME of APP has previously been established in neuronal-like cell lines (Xiao 
et al., 2012, Thomas et al., 2016), Zhao et al. were the first to bring together a mechanistic 
role for PICALM at the BBB(Zhao et al., 2015). This study demonstrated that PICALM 
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regulated CME of Aβ bound to LRP1 and its transcytosis across the BBB. Furthermore, 
the AD risk SNP rs3851179 decreased PICALM expression by cis-regulation in induced 
pluripotent stem cell (iPSC)-derived endothelial cells and this resulted in higher Aβ 
clearance compared to isogenic controls containing the non-risk SNP (Zhao et al., 2015). 
This study therefore demonstrated the mechanism by which an AD susceptibility variant, 
identified by GWAS (Harold et al., 2009, Seshadri et al., 2010), is associated with reduced 
risk of sAD. With advances in sequencing efficiency, the number of genes identified to be 
associated with AD risk is ever-increasing, yet the function of these genes remains largely 
unknown. This demonstration of a mechanism that may explain the association of 
PICALM with sAD provides promise for future work elucidating the functional role of 
other AD risk genes. 
1.6!Thesis Aims 
With the aforementioned research in Section 1.4.2 implicating BIN1 in CME and the 
demonstration that internalisation of APP via CME is important for Aβ production (Carey 
et al., 2005), the extent to which BIN1 may mediate AD risk by its involvement in APP 
processing remains to be elucidated. Much of the in vitro research to date into the role of 
BIN1 in APP processing and CME has been conducted in cell lines derived from neuronal 
tumours, including mouse and human neuroblastoma cell lines (Glennon et al., 2013, 
Miyagawa et al., 2016). The use of an oncogenically-transformed cell line does not 
accurately reflect neuronal physiology and the degree to which these cell lines can 
recapitulate the in vivo physiology of polarised neurons with functional excitatory synapses 
is a key aspect regarding the validity of these models. Research into a potential role for 
BIN1 in other brain-associated cell types is also limited. The ubiquitous expression of 
BIN1, in addition to its 10 alternatively spliced isoforms indicate that it may function in 
multiple mechanisms, which may be tissue- or cell type-specific. While much work 
investigating the role of BIN1 in AD has focused on its function in neuronal-like cells, 
endocytic mechanisms involved in transcytosis at the BBB are also highly relevant in the 
context of AD. With its high level of splicing, it is important to consider the role BIN1 has 
in other brain cell types. Indeed, BMECs of the BBB also express BIN1 but a possible role 
in brain endothelial transport mechanisms is yet to be investigated. 
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The aims of this project are two-fold. Firstly, this project aims to utilise novel advances in 
the development of iPSCs in order to create a more accurate neuronal cell model to study 
the role of BIN1 and endocytic mechanisms in neurons. In particular, the creation of a 
cortical neuronal model from PBMC-derived iPSCs offers an attractive prospect to the AD 
research field whereby an extensive resource of blood samples is available, accompanying 
the genetic data obtained from GWAS. This currently untapped resource offers the 
potential to reprogram iPSCs from patients with a known genetic background in order to 
develop models to investigate the function of AD susceptibility genes. This project will 
address the initial stages of this research, involving the demonstration of a protocol to 
produce cortical neurons from blood-derived iPSCs. The hypothesis of this study is that 
cortical neurons can be differentiated from blood-derived iPSCs. 
Secondly, this study aims to further develop knowledge in the field of BIN1 function in the 
brain, in a non-neuronal context, by investigating the role of BIN1 in CME at the BBB. 
The current knowledge of BIN1 function is largely limited to its role in CME in a neuronal 
context, however its involvement in the pathogenesis of AD and its general function in 
non-neuronal cells is largely unknown. Through siRNA-mediated BIN1 depletion, the 
function of BIN1 in a human brain endothelial cell line, as an in vitro model of the BBB, 
will be investigated. With previous studies demonstrating the involvement of BIN1 in APP 
processing through endocytic trafficking, products of APP proteolysis will be analysed in 
order to elucidate whether the amyloidogenic processing of APP is affected by BIN1 
depletion. Furthermore, trafficking of fluorescence-conjugated ligands will be used to 
analyse whether BIN1 attenuation affects clathrin-dependent and independent forms of 
endocytosis to further examine the normal functioning of BIN1 in these cells. Ultimately, 
this study will expand on current knowledge regarding the function of BIN1 in a novel 
cellular context which may give further insights into the possible mechanisms by which 
BIN1 mediates risk of sAD. The hypothesis of this study is that the depletion of BIN1 
affects APP processing in hCMEC/D3 brain endothelial cells. 
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Chapter 2 
2! Materials and Methods 
 
All experiments used analytical grade chemicals from either ThermoFisher Scientific 
(Waltham, Massachusetts, USA) or Sigma (St. Louis, Missouri, USA) unless otherwise 
indicated. 
2.1!The hCMEC/D3 cell line 
2.1.1! Origin 
The hCMEC/D3 cell line was derived from human temporal lobe microvessels isolated 
from an adult female with epilepsy in the lab of Prof. Pierre-Olivier Couraud, Cochin 
Institute, Paris, France and were obtained for the present work from Dr. Ann Ager, Cardiff 
University. Cells were immortalized by lentiviral vector transduction with the human 
telomerase catalytic subunit (hTERT) and SV40 large T antigen, as previously described 
(Weksler et al., 2005). 
2.1.2!Maintenance 
All culture vessels were pre-coated with 100 µl per cm2 of 50 µg/ml human plasma 
fibronectin (Millipore, Billerica, Massachusetts, USA) for at least 30 min which was then 
removed prior to cell culture. Cells were grown in 75 cm2 cell culture treated flasks in 
EGM-2 media, supplied as the EGM-2 BulletKit (Catalogue numbers: CC-3156 and CC-
4176, Lonza, Basel, Switzerland) which comprised 475 ml Endothelial Cell Basal Medium-
2, 50 µl Hydrocortisone, 500 µl hFGF-B, 125 µl VEGF, 125 µl R3-IGF-1, 125 µl Ascorbic 
Acid, 125 µl Heparin, 125 µl hEGF and 125 µl GA-1000 supplemented with 25ml FBS 
(ThermoFisher Scientific)) in a 37°C, 5% CO2 humidified incubator. Growth medium was 
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changed every other day and cells passaged once 90-95% confluency was reached. In order 
to passage cells or for plating, media was aspirated from the culture vessel and cells were 
washed twice with 10 ml room temperature (RT) phosphate buffered saline (PBS). Cells 
were incubated at RT in PBS for 10-15 min before replacing this with 8 ml 0.025% 
Trypsin/EDTA (Lonza) until cells were in suspension, aided by gentle tapping of the side 
of the flask every 30 seconds. 4ml of 0.025% trypsin neutralizing solution (Lonza) was 
added to the culture vessel and cell suspension was transferred to a sterile tube. The flask 
was rinsed with 8 ml 25 mM HEPES Buffered Saline Solution (Lonza) to collect residual 
cells, and the rinse added to the cell suspension. The harvested cells were centrifuged at 
130 x g for 5 min, supernatant removed and cells resuspended in 1 ml EGM-2 media. Cells 
were split at a ratio of 1:15 and added to a fibronectin-coated culture vessel containing 
EGM-2 media. The culture vessel was gently rocked to evenly distribute the cells and 
returned to the 37°C incubator. 
2.1.3!Thawing 
Culture vessels were pre-coated with human plasma fibronectin, as described in section 
2.1.2. One million cells were quickly thawed from a single cryovial in a 37°C bead bath and 
centrifuged at 130 x g for 4 min. The supernatant was poured off and 1ml of EGM-2 
media was added to resuspend the cells. Cell suspension was dispensed into a fibronectin-
coated 75 cm2 culture vessel with 15 ml EGM-2 media. The culture vessel was gently 
rocked to evenly distribute the cells and returned to the 37°C incubator. 
2.1.4!Cryopreservation 
Cells were counted using the Trypan Blue (Sigma) exclusion method, as detailed below, in a 
haemocytometer and pelleted by centrifugation at 130 x g for 5 min. Cells were then 
resuspended at a concentration of 1 million cells per ml of RT freezing medium (30% FCS 
(ThermoFisher Scientific), 10% DMSO (Sigma) in EGM2 medium) and 1 ml was 
dispensed into each cryovial (Greiner, Kremsmünster, Austria) which were placed in a RT 
Mr FrostyTM freezing container (ThermoFisher Scientific) at -80°C overnight. The next day, 
cryovials were transferred to liquid nitrogen storage. 
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2.1.5!Trypan Blue Exclusion 
The hemocytometer was cleaned with 70% ethanol before use and a moistened coverslip 
affixed to the surface. The cell suspension was mixed thoroughly and 20 µl of cells was 
added to 20 µl 0.4% Trypan Blue (ThermoFisher Scientific) and gently mixed. Using a 
pipette, the Trypan Blue-treated cell suspension was applied to the hemocytometer until 
both chambers underneath the coverslip were full, allowing the cell suspension to be drawn 
out by capillary action. Using a microscope, the live, unstained cells were counted in each 
set of 16 squares and the average cell count from each set of 16 corner squares was 
calculated. To calculated the total number of cells per ml, the average was multiplied by 2, 
to account for the dilution factor, then multiplied by 104 to give the number of cells per ml. 
2.2!siRNA Transfection 
For transfection, cells were plated at 21,000 cells per cm2 (2 million cells per well of a 6-
well plate) of a Nunc cell culture treated multidish (ThermoFisher Scientific) 18-20 hours 
prior to treatment. For lysates, 6-well plates were used with the volumes described here. 
Volumes were adjusted accordingly for 12-well and 24-well plates. Custom-designed 
oligonucleotides were designed in silico using Eurofins Genomics (Ebersberg, Germany) as 
21mer oligonucleotides with dTdT overhangs for nuclease resistance. Sequences used in 
this thesis are shown in Table 2.1. Oligonucleotide and OligofectamineTM transfection 
reagent (Invitrogen) complexes were pre-formed for 20 min at RT using the optimised 
concentration of oligonucleotide as indicated in Table 2.1 per 4 µl Oligofectamine in a total 
volume of 200 µl OptiMEM reduced serum medium (ThermoFisher Scientific). Cells were 
washed once with OptiMEM and the complex added to give the final oligonucleotide 
concentration specified in Table 2.1 in a total of 1ml OptiMEM. For each treatment, cells 
were incubated with media alone, siRNA targeting green fluorescent protein (GFP) to 
control for off-target effects and target siRNA sequences for 4 hours before 500 µl 
OptiMEM supplemented with 15% FBS was added directly to cells, to give a final 
concentration of 5% FBS in the media. After a further 48 hours, cells were processed as 
required.  
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Table 2.1 siRNA sequences used to knock down protein expression. 
siRNA 
target Sequence 
Amount 
added per 
reaction 
Final 
concentration Reference 
Total 
BIN1 ‘a’ 
5’-CCAGAACCUCAAUGAUGUGdTdT-3’ 50 pmol 50 nM Custom 
designed 
Total 
BIN1 ‘b’ 
5’-GGAGAUGAGCAAGCUCAACdTdT-3’ 50 pmol 50 nM Custom 
designed 
AP2µ2 5’-AAGUGGAUGCCUUUCGGGUCAdTdT-3’ 25 pmol 25 nM (Moody et 
al., 2015) 
CAV1 5’-AGACGAGCUGAGCGAGAAGdTdT-3’ 50 pmol 50 nM (Al Soraj et 
al., 2012) 
GFP 5’-GGCUACGUCCAGGAGCGCAdTdT-3’ To match 
target siRNA 
To match target 
siRNA 
(Moody et 
al., 2015) 
 
2.3!Protein Quantification 
2.3.1!Cell Lysis 
Lysates were prepared from the treated cells in 6-well plates using 100 µl per well of lysis 
buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% 
Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 
µg/ml leupeptin, Cell Signaling, Danvers, Massachusetts, USA) with 1 mM PMSF added 
immediately before use, according to manufacturer’s instructions. Briefly, conditioned 
media was removed and stored at -20°C, cells were washed once with PBS then incubated 
on ice for 5 min, collected using a cell scraper (VWR, Radnor, Pennsylvania), briefly 
sonicated and centrifuged at 14,000 x g for 10 minutes at 4°C. Supernatant was removed 
for use and stored at -20°C. 
2.3.2!Protein concentration 
Total protein concentration of lysate was quantified by Pierce BCA assay (ThermoFisher 
Scientific) as per manufacturers guidelines. Briefly, 5 µl of each sample was tested in 
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duplicate alongside a 9-point standard curve ranging from 0-2 mg/ml protein 
concentration in a flat-bottomed plate. Pierce BCA reagents A and B were added to 
samples at a ratio of 50:1, respectively, with 200 µl per well and incubated for 30 min at 
37°C. Absorbance was read at 562 nm on a uQuant plate reader (Biotek, Winooski, 
Vermont, USA). 
2.3.3!Sample Preparation 
Protein samples to be resolved by SDS-PAGE were diluted in ¼ volume of 5X sample 
buffer (0.125M Tris pH 6.8, 4% (w/v) sodium dodecyl sulfate (SDS), 20% (v/v) Glycerol, 
5% 2-mercaptoethanol, 0.001% (w/v) bromophenol blue). Proteins were denatured by 
boiling samples at 95°C for 5 min prior to loading. 
2.3.4!Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
The Mini-PROTEAN® Tetra Handcast System (Bio-Rad, Hercules, California, USA) was 
used for SDS-PAGE. Depending on the molecular mass of the protein of interest, proteins 
were routinely visualized using 7% or 10% resolving gels (380mM Tris-HCL pH 8.8, 7-8% 
(v/v) acrylamide (30% (w/v) acrylamide: 0.8% Bis-acrylamide (37.5:1), 0.1% (w/v) SDS, 
0.1% (w/v) ammonium persulphate (APS), 0.08% N,N,N’N’ – 
Tetramethylethylenediamine (TEMED)). Isopropanol was layered on the resolving gel to 
ensure a level interface with the stacking gel. Once the gel had polymerised, the 
isopropanol was washed off three times with dH2O and the stacking gel was applied 
(125mM Tris-HCl pH 6.8, 5% (v/v) acrylamide (30% (w/v) acrylamide: 0.8% Bis-
acrylamide (37.5:1)), 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% TEMED) with a 10-well 
comb inserted. Gels were submerged in SDS-PAGE running buffer (25mM Tris-base, 
192mM glycine, 1% (w/v) SDS) and 20µg sample loaded per well with 2 µl molecular 
weight marker (Prism Ultra Protein Ladder, Abcam). Gels were run at 150V for 
approximately 90 min, dependent on the molecular weight of the protein of interest, until 
appropriate resolution of the protein standard was achieved. 
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2.3.5!Western Blotting 
Protein was transferred onto 0.2 µm nitrocellulose membranes (GE Healthcare, 
Amersham, England) for 60 minutes at 85V in transfer buffer (20% methanol in SDS-
PAGE running buffer). Blots were blocked in 5% milk for 1 hour, washed three times in 
PBST (Phosphate Buffered Saline with 0.1% Tween 20) and incubated with the relevant 
primary antibody in 2% BSA or 1-5% milk in PBST for 2-20 hours, depending on 
optimised conditions. Blots were washed three times in PBST and incubated with the 
relevant horseradish peroxidase-conjugated secondary antibody (Vector Laboratories, 
Burlingame, California) at 1:15,000 in 1-5% milk in PBST. Blots were initially detected 
using SuperSignal West Dura Extended Duration Substrate (ThermoFisher Scientific) and 
SuperSignal West Femto Maximum Sensitivity Substrate if a stronger signal was required. 
Blots were then developed on Amersham hyperfilm (GE Healthcare) using an Ecomax 
automatic developer (Wolflabs, York, England). 
2.3.6!Densitometric Analysis 
Signal intensity of protein bands from Western blots was determined by densitometric 
analysis using ImageJ software, as described in Figure 2.1. The grey mean value for each 
protein band was measured using a defined identical-sized area and the same for the 
background of each well. An inverted value was calculated by subtracting the Background 
values were subtracted from the white pixel value of 255. The inverted background value 
was subtracted from the corresponding protein of interest inverted value to give the net 
protein of interest value. The same was carried out for each corresponding housekeeping 
protein band and a ratio of protein of interest : housekeeping protein was generated. These 
ratios were then expressed as a percentage of expression in the non-transfected cells. 
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Figure 2.1: The Method used for Densitometry analysis of Western blots 
The grey mean value was determined for each protein of interest band (A) and its 
corresponding background (B) using identical sized rectangles. Values were also obtained 
for the housekeeping protein (C) and corresponding background (D) by the same method. 
These values were inverted by subtracting from the white pixel value of 255 and the 
background inverted value was then subtracted from the corresponding protein inverted 
value. A ratio of protein of interest to housekeeping protein was then determined for each 
sample. 
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2.4!Protein Visualisation 
Cells were fixed either by paraformaldehyde (PFA) or methanol prior to 
immunocytochemistry. The method used is identified in the relevant section. 
2.4.1!Paraformaldehyde Fixation 
To fix cells, 4% (w/v) paraformaldehyde (PFA) (Sigma) was prepared by dissolving 4 g 
PFA in 60 ml dH2O at 60°C and adding a drop of 2M NaOH to adjust the pH. A third of 
the total volume (33.3 ml) of 3x PBS was then added and the pH adjusted to 7.2 with HCl. 
The volume was made up to 100 ml with dH2O and the solution cooled to 4°C. Media was 
removed and cells were gently washed twice with PBS at RT. Cells were fixed in 4% PFA 
at RT for 10-15 min before washing three times with PBS. Cells were stored in PBS at 4°C 
with plates wrapped in parafilm until staining. 
2.4.2!Methanol Fixation 
Media was removed and cells were gently washed twice with PBS at RT before fixing for 5 
min in ice-cold 100% methanol. Cells were washed three times with PBS and stored in PBS 
at 4°C with plates wrapped in parafilm until staining. 
2.4.3!Immunocytochemistry 
Round 13 mm glass coverslips (VWR) were pre-sterilised by washing with 70% ethanol, 
air-drying and exposing to UV light for at least 1 hour. Coverslips were then pre-coated 
with fibronectin, as previously described in Section 2.1.2.  Cells were PFA or methanol-
fixed, as described in sections 2.4.1 and 2.4.2. Cells were permeabilised with 0.1% Triton-X 
(Sigma) in PBS for 15 minutes, blocked with 5% bovine serum albumin (BSA), 5% goat 
serum, 0.3% Triton-X (all Sigma) in PBS and incubated with the appropriate primary 
antibodies diluted in antibody diluent (0.1% BSA, 0.3% Triton-X in PBS) overnight at 4°C.  
Cells were washed 3 x 3 minutes with antibody diluent before incubating with the 
appropriate secondary antibody diluted in antibody diluent for 2 hours at RT, minimizing 
light exposure from now on. The Alexa Fluor secondary antibodies used in this thesis were: 
goat-anti-mouse 594 (1-2 µg/ml), goat-anti-mouse 488 (2 µg/ml), goat-anti-rabbit 594 (2 
µg/ml), goat-anti-rabbit 488 (2 µg/ml) and goat-anti-rat 488 (2 µg/ml, all ThermoFisher 
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Scientific). Cells were washed 3 x 3 minutes with antibody diluent before incubating with 1 
µg/ml DAPI for 5 minutes at RT. Cells were washed 3 x 3 minutes with PBS before 
mounting onto glass slides with ProLong Gold Antifade Mountant (ThermoFisher 
Scientific). IPS cells were not cultured on coverslips and were instead overlaid with 
coverslips directly into the well using Vectashield mounting medium (Vectorlabs, 
Peterborough, England). Plates were imaged on either the Evos FL imaging system 
(ThermoFisher Scientific), the DMI6000B Inverted Time-lapse Microscope (Leica, 
Wetzlar, Germany) or the Axio Observer A1 (Zeiss, Oberkochen, Germany) and images 
processed using LAS AF software (Leica) and ImageJ. For each experiment, negative 
controls were performed (see Appendix I) using the secondary antibody only, to confirm a 
lack of background staining. 
2.5!Cell Viability Assay 
Cell viability following siRNA treatment was assessed using the CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, Wisconsin, USA). Cells were plated 
and transfected as previously described in Section 2.2 in 96-well cell culture plates. 48 
hours post-transfection, cells were incubated with CellTiter 96® Aqueous One Solution 
Reagent 1-4 hours. Readings were taken at 1, 1.5, 2, 3 and 4 hours on a uQuant plate reader 
at 490nm. Absorbance readings were plotted against time. The absorbance at 1.5 hours 
best represented the exponential phase of the curve and was therefore selected for 
comparisons between siRNA treatments. In addition to BIN-depleted, GFP siRNA-treated 
cells and non-transfected cells, a control without cells was included to measure background 
absorbance levels which was subtracted from all other readings. 
2.6!Statistical Analysis 
Western blots were quantified using ImageJ, as described in Section 2.3.6, And expressed 
as percentage of the non-transfected control. Absorbance readings from ELISA assays 
were quantified by comparing to standard curves generated on each plate using GraphPad 
Prism 7. Data were then normalized to total protein concentration of each sample, 
calculated as described in Section 2.3.2, and expressed as the percentage of non-transfected 
control values. Data from flow cytometry experiments were expressed as the geometric 
mean of fluorescent intensity.  
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All statistical analysis was calculated using GraphPad Prism 7. For data with sufficient 
replicates (at least 8), the D'Agostino-Pearson test for normality was used in addition to an 
F test for equality of variance. For normally-distributed data, where there were only two 
factors, data were compared to GFP siRNA-treated values using unpaired Student’s t tests. 
For comparisons of more than two factors, ANOVA was used as specified in the 
appropriate experiments. Data that was not normally-distributed was analysed using the 
non- parametric Mann-Whitney test, as specified in the appropriate experiments. Unless 
otherwise stated, a sample size (n) of at least 3 was used for all quantified experiments. N is 
defined as a sample taken from a separate culture vessel and using separate reagents to all 
other replicate samples within the experiment. 
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1! Chapter 3 
2! Neuronal Differentiation of Human 
Induced Pluripotent Stem Cells 
3! 3 
3.1!Introduction 
Cell culture has been the mainstay of biomedical research for decades, providing countless 
novel insights into normal cellular biology and pathologically processes. In vitro culture of 
human primary cells has limited potential for long term objectives due to the short lifespan 
of primary cells in culture. Human cell lines, either derived from cancerous tissue or that 
have undergone artificial immortalization, evade normal cellular senescence and can 
undergo division indefinitely. Many cell lines are now available for a huge variety of cell 
types, permitting long term culture and reproducibility. However, the culture of neuronal 
cells for the study of neurodegenerative disease, in particular, is challenging as mature 
neurons do not undergo cell division at all. This has largely been overcome through the use 
of cell lines derived from neuronal tumours, including the mouse and human 
neuroblastoma cell lines N2a and SH-SY5Y, respectively. These can be differentiated into a 
neuronal-like phenotype (Pahlman et al., 1984, Tremblay et al., 2010), however still retain 
the genetic and epigenetic signatures of neuroblastoma tissue which may impact on 
disease-specific networks in AD (Krishna et al., 2014).  
Induced pluripotent stem cells (iPSCs), on the other hand, provide the opportunity to 
reprogram patient-specific somatic cells and differentiate these into cells of any type whilst 
retaining the genetic signature of the individual from which they were originally derived. 
Chapter 3 describes the process of differentiating iPSCs derived from PBMCs into cortical 
neurons as an in vitro model for the study of BIN1 function in the context of AD. While 
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still a relatively new field, studies researching iPSC models in sAD to date have mainly 
focused on fibroblast-derived iPSCs (Israel et al., 2012, Kondo et al., 2013). However, with 
an extensive bank of blood samples alongside genome-wide genotyping data available, the 
opportunity for furthering genetic leads in PBMC-derived iPSC models offers great scope 
for disease modelling in AD. Furthermore, much of the in vitro research surrounding 
endocytic mechanisms in AD to date has involved the use of neuroblastoma, neuroglioma 
or non-neuronal cell lines, such as human embryonic kidney (HEK) or human cervical 
cancer HeLa cells (Chapuis et al., 2013, Miyagawa et al., 2016). These cannot recapitulate 
the morphology and physiology of neurons in vivo. A gap in the literature is therefore 
apparent within the AD field to create human cortical neurons from a peripheral blood 
source. 
3.1.1! Discovery of Stem Cells 
The presence of stem cells in human cord blood was discovered in 1978 (Prindull et al., 
1978), shortly followed by the very first isolation and establishment of embryonic stem 
cells (ESCs) in vitro from mouse blastocysts in 1981 (Evans, 1981).  These ES cell lines 
were among the first demonstrated to grow in culture in an undifferentiated state for long 
periods, and were capable of differentiating both in vitro and in vivo by teratoma formation 
in a mouse host (Evans, 1981). Teratoma formation in vivo demonstrates 3-germ-layer 
differentiation capability and is considered the most rigorous test for pluripotency (Hentze 
et al., 2009). This was a revolutionary discovery in the field of disease modeling, leading to 
the creation of gene targeting technology in mouse ES cells in order to create genetically 
modified mouse models for a host of human diseases.  
 Human embryonic stem cells (hESCs) were first derived from early embryos in 1998 
(Thomson et al., 1998) and were demonstrated to proliferate in an undifferentiated state 
for 4-5 months, owing to their high telomerase activity, maintaining the potential to 
differentiate into derivatives of all three embryonic germ layers; endoderm, mesoderm and 
ectoderm. These cells not only offered insights into developmental events in the human 
embryo, but also provided a platform by which directed differentiation could offer a 
potentially limitless source of specific cell types for regenerative medicine and drug 
discovery.  Human pluripotent stem cells (hPSCs), by definition, have the ability to give 
rise to any cell of the human body and can self-propagate indefinitely in an undifferentiated 
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state (Thomson et al., 1998). Indeed, in 2000, somatic differentiation of hESCs in vitro was 
demonstrated for the first time (Reubinoff et al., 2000.) By culturing at high density 
without replacement of the feeder layer, Reubinoff et al. (2000) observed cells at the early 
neuroectoderm stage develop. These were then isolated and went on to demonstrate 
morphology and expression of markers characteristic of mature neuronal differentiation 
(Reubinoff et al., 2000). The possibility of creating hESC-derived cells of any type in vitro 
greatly excited the research community, offering the prospective of novel disease-relevant 
models, particularly for which standard cell culture lines do not exist and which are difficult 
to obtain in their primary form from patients, such as neurons. 
3.1.2! Induced Pluripotent Stem Cells and Reprogramming 
The stem cell field moved rapidly and while hESCs provided a revolutionary research tool, 
the ethical concerns surrounding their source and the way they are acquired could not be 
escaped. In 2006, the creation of pluripotent stem cells by the ectopic expression of just 
four genes led to the invention of iPSCs (Takahashi and Yamanaka, 2006). The four factors 
were selected from 24 candidate genes based on their hypothesised role in maintaining 
ESC identity. By systematically withdrawing factors one at a time from the pool of factors 
transduced into mouse embryonic fibroblasts (MEFs), Takahashi and Yamanaka (2006) 
determined Octamer-binding transcription factor 4 (OCT4), sex determining region Y box 
2 (SOX2), c-Myc and kruppel-like factor 4 (KLF4) were necessary and sufficient for 
reprogramming. By retroviral transduction, the four factors were incorporated into the 
genome of terminally differentiated MEFs, reprogramming them back to a pluripotent 
state. This was later replicated in adult human fibroblasts, where pluripotency was 
characterised by the ability to form teratomas in vivo and embryoid bodies in vitro that 
expressed markers of all three germ layers (Takahashi, 2007). The ability to generate 
patient-specific human iPSCs and differentiate them into pathophysiologically-relevant cell 
types offers the potential for previously inaccessible insights into disease mechanisms. 
Development of human disease can be observed at the single cell level using models that 
are isogenic with the patient from whom they were derived. For the AD field, this was 
revolutionary; allowing direct observation of genetic variation on phenotype while 
eliminating the need to obtain primary brain tissue. However, this procedure presents 
challenges, while being technically difficult in itself, obtaining fibroblasts from elderly 
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subjects and reprogramming cells at this late stage may add an additional level of 
complexity. 
There are multiple methods to generate iPSCs. Initially, retroviruses were used to insert 
their DNA into the genome of the somatic cell (Takahashi and Yamanaka, 2006). 
However, integration of viral DNA into the host genome carried the risk of multiple 
insertions and tumorigenicity, posing safety concerns for potential gene therapy 
applications (Okita et al., 2007). Non-integrating reprogramming methods were therefore 
sought, such as the use of Sendai Virus (SeV) vectors, which replicate in the form of 
negative-sense single-stranded RNA in the cytoplasm of infected cells (Fusaki et al., 2009). 
Each vector contains one of the four Yamanaka factors and replicates independent of the 
cell cycle, producing very high copy numbers of the target gene without the requirement 
for cell division to occur. The SeV is lost from the iPSCs after propagation for 10-13 
passages (Chen et al., 2013) so no genomic integration or viral remnants remain. In 
addition, SeV can infect a broad host range and is non-pathogenic to humans. The 
efficiency of iPSC reprogramming by SeV has been shown to significantly surpass that of 
retroviral transduction (Takahashi, 2007,Fusaki et al., 2009). The reprogramming efficiency 
was calculated as the number of alkaline phosphatase-positive, ESC-like colonies formed 
per number of infected cells seeded, which reached 1% using SeV (Fusaki et al., 2009) 
compared to just 0.02% using retrovirus (Takahashi, 2007). 
3.1.3!Stem Cell Characterisation 
Stem cells are characterised by their capacity for indefinite self-renewal and differentiation 
into all three germ layers. Therefore, the confirmation of true pluripotency is a prerequisite 
for any experiment involving the use of ESCs or iPSCs. Pluripotency can be determined by 
the expression of well characterised and widely accepted pluripotency markers, including 
alkaline phosphatase, OCT4, TRA-1-60, SSEA4 and NANOG and demonstrating the 
ability of cells to differentiate into ectoderm, endoderm and mesoderm by the formation of 
embryoid bodies (Baghbaderani et al., 2016). Karyotype analysis ensures the starting 
material undergoing the reprogramming process is normal and that no chromosomal 
abnormalities are incurred in the reprogramming and expansion process. 
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3.1.4! Induction of Neural Fate 
For neurodegenerative disorders, whereby disease-relevant cell types are difficult to obtain 
in their primary form, iPSCs have been used to create neuronal in vitro models. While this 
field is still in its infancy, several groups have demonstrated neuronal differentiation to 
produce cellular models to study AD (Israel et al., 2012, Shi et al., 2012b, Kondo et al., 
2013, Vazin et al., 2014). Neural induction represents the earliest step in the determination 
of cell fates from the ectoderm (Chambers et al., 2009). Inhibition of bone morphogenetic 
protein (BMP) signaling activates neural rather than epidermal fates in ectodermal cells 
while inhibition of the activin/nodal branch of the transforming growth factor beta 
(TGFβ) signaling pathway prevents induction of mesodermal gene expression in 
ectodermal cells (Hemmati-Brivanlou and Melton, 1994). Efficient neurogenesis in 
chemically defined medium is based on minimising these extrinsic and intrinsic signals that 
divert differentiation to alternate fates and allowing cells to follow the default model of 
neurogenesis. Inhibition of both the activin/nodal and BMP arms of the TGFβ signaling 
pathways, through dual inhibition of SMAD (an acronym from the fusion of Caenorhabditis 
elegans Sma genes and the Drosophila Mad, Mothers against decapentaplegic) signaling, was 
shown to be necessary for rapid and complete neural conversion of hESCs (Chambers et 
al., 2009), forming the basis by which different neuronal cell types can be created. 
SB431542, a small molecule activin/nodal receptor kinase inhibitor, and Noggin, an 
endogenous mammalian BMP inhibitor (Groppe et al., 2002), were administered to hESCs 
and iPSCs for an 11-day treatment period resulting in uniform neural conversion 
(Chambers et al., 2009). Derivation of relevant neuron subtypes, including motor neurons 
and dopamine neurons, was subsequently demonstrated presenting an efficient, defined 
and robust platform for the rapid generation of iPSC-derived neurons. 
3.1.5!Cortical Differentiation  
3.1.5.1! Human neurulation 
During human embryonic development, the process of neurulation takes place to form the 
neural tube, the embryonic structure that ultimately forms the brain and spinal cord. The 
neural tube develops from elongated neural plate cells of the ectoderm migrating towards 
the midline of the embryo where they form the neural groove (Caviness et al., 1995). This 
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then fuses at the dorsal midline, creating a hollow neural tube (O'Rahilly and Muller, 1994). 
Induction of neural fate in vitro results in the cells undergoing similar morphological 
changes in the formation of neural rosettes (Shi et al., 2012c). These rosettes bear striking 
resemblance to the neural tube in vivo with a radially arrangement of progenitor cells 
possessing apical-basolateral polarity (Shi et al., 2012a). Neural rosettes are the 
developmental signature of neural precursors in vitro, from which neuronal subtypes then 
develop. 
3.1.5.2! Corticogenesis in vitro 
In order to create a neuronal model for the study of AD, the desired neuronal subtype 
must be designated to direct iPSCs down this lineage. Early histopathological studies 
reported widespread damage and loss of cortical and hippocampal neurons in AD brains 
(Mann et al., 1985). Pyramidal neurons, which constitute at least 70% of the total neuron 
population in the healthy mammalian cortex (Hendry et al., 1987), were shown to be 
particularly affected by NFT pathology in AD (Mann et al., 1985). Cortical pyramidal 
neurons are thought to utilise the excitatory amino acid transmitter glutamate and 
disruption of glutamatergic circuits is associated with cognitive impairment in AD (Francis 
et al., 1993). The creation of cortical glutamatergic projection neurons in vitro has been 
demonstrated by several groups through directed differentiation of iPSCs (Shi et al., 2012a, 
Espuny-Camacho et al., 2013 Vazin et al., 2014). The adult cortex undergoes development 
by the stereotyped generation of six layers in a temporal manner from deep layer neurons 
through to the upper layers (Leone et al., 2008). This process takes over 70 days in humans 
and just 6 in mice (Caviness et al., 1995). The identity and proportions of different types of 
cortical projection neurons can be defined by their combinatorial expression of a core set 
of transcription factors (Shi et al., 2012c) and depicted in Figure 3.1. 
Two major classes of neurons are found in the neocortex; interneurons and projection 
neurons (Leone et al., 2008). While interneurons make local connections within the 
neocortex and are largely inhibitory, excitatory projection neurons reach their axons to 
distant brain targets. Cortical projection neurons are derived from mitotically active 
progenitor cells found within two populations: radial glial cells in the ventricular zone and 
radial glia-derived basal progenitors in the subventricular zone (Leone et al., 2008). 
Newborn neurons migrate towards the margin of the cerebral wall and take their positions 
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in the cortical plate in an inside-out sequence, with newly arriving cells migrating through 
existing cell layers to reach the top of the plate (Bystron et al., 2008). The cortex is 
organised radially into six layers (Figure 3.1) with the first neurons to exit the cell cycle 
from the ventricular zone forming the deepest cortical layers, 6 and 5 while the 
subventricular zone provides the source of neurons in layers 2-4. Each layer contains 
neurons with distinct morphologies, neurotransmitter phenotype and projection patterns. 
Layer 1, referred to as the molecular layer, is the latest born upper layer which contains 
many dendritic and axonal synapses extending from the lower levels of the neocortex with 
very few cell bodies (Leone et al., 2008). Layers 2 and 4 correspond to the external and 
internal granule layers, respectively, and are composed of many granular neurons with very 
small cell bodies. These encase layer 3, the external pyramidal layer containing small and 
medium-sized pyramidal neurons while layer 5 comprises the internal pyramidal layer with 
cells larger than those in layer 3 (Leone et al., 2008). Finally, layer 6 has a very 
heterogeneous composition and is therefore known as the multiform layer with all 
morphological forms present.  
While the layers of the cortex were primarily defined based on morphological assessment, a 
large extent of cellular heterogeneity exists across the cerebral cortex rendering 
classification based on developmental age and cellular morphology alone difficult (Leone et 
al., 2008). However, a number of molecular markers have been identified for neurons of 
distinct cortical layers, many of which are not expressed uniformly within a given layer, but 
can be used to confirm cortical developmental stages in vitro. Well-recognised markers of 
cortical development stages including primary progenitor, secondary progenitor and layer-
specific markers are indicated in Table 3.1 and have been used in several studies 
demonstrating cortical development from iPSCs (Chambers et al., 2009, Shi et al., 2012a, 
Shi et al., 2012c, Espuny-Camacho et al., 2013). 
3.1.5.3! Directed cortical differentiation in vitro 
Directed differentiation of iPSCs in vitro can generate all classes of cortical neurons over a 
period of several weeks, providing a suitable model by which patient-specific neurons can 
be examined to investigate the aetiology of AD (Shi et al., 2012c). These human iPSC-
derived neurons exhibited action potential generation and formed functional excitatory 
glutamatergic synapses after 50 days in culture. The process encapsulated a number of 
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crucial steps, starting with the formation of a complex population of cortical stem and 
progenitor cells, followed by an extended period of cortical neurogenesis, astrocyte genesis, 
neuronal terminal differentiation and the acquisition of electrophysiological properties, 
culminating in synaptogenesis and network formation (Shi et al., 2012c). An effective 
cellular model for AD should not only accurately represent the physiology of the 
appropriate cell type, but also develop the relevant molecular pathology including Aβ 
aggregation and tau hyperphosphorylation in a reproducible manner within a practical time 
frame. One of the major hurdles facing iPSC cell models within AD research is whether a 
disease of ageing that takes decades to manifest in humans can be effectively recapitulated 
in vitro within a realistic timescale.  
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Figure 3.1: Cortical development in vivo 
A schematic adapted from depicting the layers of the human cortex, and the pattern of 
layer-specific cortical neuron markers used in the present study. Newly-born neurons 
migrate through the intermediate zone to form the cortical layers in an inside-out 
arrangement, from layer VI to layer I. 
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3.1.6!Stem Cell Models of Familial AD 
Much of what we know about the molecular mechanisms of sAD is based on studies of 
fAD. Yagi et al. (2011) were the first to successfully demonstrate AD-related phenotypes in 
iPSC-derived neuronal models of fAD by reprogramming fibroblasts derived from a 
patient with mutations in the PSEN1 (A246E) and PSEN2 (N141I) genes. Both mutations 
have previously been reported to increase Aβ42 levels in human plasma, patient-derived 
fibroblasts and transgenic mice (Scheuner et al., 1996, Borchelt et al., 1996, Oyama et al., 
1998). Neurons from these fAD-iPSCs had increased Aβ42 secretion and an increased 
Aβ42:Aβ40 ratio compared to controls, recapitulating the pathological mechanisms 
established for these fAD mutations (Yagi et al., 2011). However, abnormal tau protein 
accumulation or tangle formation was not detected suggesting the culture period of 2 
weeks may not have been sufficient for tau pathology to develop. These results were 
subsequently supported by Mahairaki et al. (2014) who found the extracellular Aβ42:Aβ40 
ratio was significantly higher in iPSC-derived neurons from patients with the A246E 
PSEN1 mutation compared to controls. (Sproul et al., 2014) took a different approach to 
modelling fAD using iPSCs by not continuing differentiation right through to the neuron 
stage. Instead, comparisons between control cells and those with the A246E PSEN1 
mutation were made at the neural precursor cell stage as this was considered a more 
homogenous population than the wide variety of neurons produced by general neuronal 
differentiation protocols at the time (Sproul et al., 2014). Interestingly, greater ratios of 
Aβ42 to Aβ40 were reported in PSEN1 neural precursors relative to their control 
counterparts and this elevated ratio was even more prominent in neural precursor cells 
compared to the original fibroblasts from which they were derived, demonstrating more 
pronounced Aβ-related changes following neuronal differentiation (Sproul et al., 2014).  
3.1.7!Modelling Sporadic AD through Patient-derived iPSCs 
The success in demonstrating AD-related phenotypes in iPSC-derived neurons harboring 
fAD mutations led studies to explore the possibility of modelling sAD in this manner. 
Israel et al. (2012) generated two iPSC lines from sAD patients and two from patients with 
an APP duplication before differentiating them into neurons by BMP and activin/nodal 
inhibition and subsequent fluorescence-activated cell sorting (FACS) purification. The cell 
surface marker signature CD184(+)/CD271(-)/CD44(-)/CD24(+) was used for 
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purification, which had previously been identified as a cell-surface signature for isolating 
neural stem cell populations (Yuan et al., 2011). Higher levels of secreted Aβ40 were 
reported compared to non-demented control neurons in both fAD lines and one sAD line 
but Aβ42 did not reach sufficient detection levels due to the small number of purified 
neurons (Israel et al., 2012). Tau phosphorylation at Thr231 correlates with neurofibrillary 
tangle number and cognitive decline (Buerger et al., 2006) therefore the amount of 
phosphorylated tau at Thr231 (p-tau) was measured relative to total tau in fAD, sAD and 
control neurons. Neurons from both fAD patients showed a significant increase in p-
tau/total tau compared to controls, as did the same sAD line that showed increased Aβ40 
previously (Israel et al., 2012). GSK-3β levels were also investigated as this kinase can 
phosphorylate tau at Thr231 in vitro and colocalises with NFT in AD post-mortem brain 
tissue (Goedert et al., 1994, Buerger et al., 2002, Buerger et al., 2006). The cell lines 
showing an increase in p-tau also showed significant increases in the amount of GSK-3β 
lacking phosphorylation at Ser 9, indicating its active form. Collectively, this study 
demonstrated strong correlations between Aβ40, p-tau/total tau and active GSK-3β in 
fAD and sAD-derived neuronal cultures suggesting AD-related phenotypes were achieved 
(Israel et al., 2012). However, the second sAD line showed no difference in these measures 
compared to controls, illustrating the difficulties in reproducibility when modelling a 
complex disease with lines from different individuals. This also highlights that AD in 
different individuals is likely attributed to defects in different cell types which a neuronal 
model alone cannot recapitulate.  
Subsequently, Kondo et al. (2013) generated seven iPSC lines, five from two fAD patients 
each carrying a different APP mutation and two sAD lines from unrelated patients. The 
authors differentiated iPSCs into cortical neurons by BMP and activin/nodal inhibition and 
showed that Aβ oligomers accumulated inside iPSC-derived neurons derived from a patient 
with the APP (E693D) mutation and one of the patients with sAD. Aβ oligomers were not 
present in APP (V717L) iPSC-derived neurons but there was an increase in the 
extracellular Aβ42/Aβ40 ratio, suggesting a distinction in pathology between intracellular 
and extracellular Aβ production. Again, one of the sAD lines failed to show the AD-related 
phenotypes measured in this study, emphasizing the importance of individual differences in 
AD and the selection of patients for related studies.  
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These studies provide an important proof-of-principle for the field of iPSC modelling in 
the context of AD; that iPSC technology can be used to observe phenotypes of AD 
patients, despite the disease taking decades to manifest in vivo (Israel et al., 2012, Kondo et 
al., 2013). However, they also illustrate the challenges presented by patient-derived iPSC 
models of a complex disease, without a known cause, with much inter-individual variability 
making reproducibility difficult. Minimising intra-individual variability, however, is 
paramount and was demonstrated in the study by Israel et al. (2012) with each individual 
represented by three clonal iPSC lines. In order to map out the metabolic pathways 
involved in AD pathogenesis, patient-derived iPSC models should be informed by genetic 
data to determine the appropriate cell type to create and functional assays to pursue. 
3.1.8!Aims of this Chapter 
While the aforementioned studies used dermal fibroblasts as a starting source, the vast 
repositories of blood available, in addition to the invasive nature of skin biopsies, makes 
PBMCs an attractive source for iPSC creation. As part of the large scale GWAS conducted 
by the IGAP consortium, an untapped potential resource of patient blood samples with 
GWAS data for over 1500 participants is available for analysis. While still a novel field, 
transgene-free iPSCs can be reliably produced directly from peripheral blood mononuclear 
cells (Trokovic et al., 2014). Differentiation of PBMC-derived iPSCs into cortical neurons, 
however, is yet to be documented. Therefore, the initial aim of this work is to characterise 
and successfully differentiate PBMC-derived iPSCs into cortical glutamatergic neurons. 
This nature of work has not yet been carried out in my home lab and it will therefore be 
the aim to set up and establish these iPSC and differentiation protocols within the lab for 
intended future use on participant-derived iPSCs.  
The creation of these iPSCs will provide an in vitro model in which early pathology features 
of AD can be modelled such as endocytic pathway abnormalities which have been shown 
to precede the extracellular deposition of Aβ (Cataldo et al., 2000). In the aforementioned 
study by Israel et a. (2012), accumulation of large Rab5-positive early endosomes was 
observed in neurons from sAD patients, which are evident in pyramidal neurons of the 
post-mortem brain from early stage AD patients (Cataldo et al., 2000, Israel et al., 2012). 
As an early disease phenotype, the regulation of endocytosis presents an ideal pathway to 
study through iPSC creation. 
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The creation of iPSC-derived neurons from patients with known genotypes would allow 
novel insights into cellular mechanisms in AD. Previous work investigating the role of AD 
susceptibility genes in vitro have largely involved the use of neuronal-type cell lines, such as 
the SHSY5Y neuroblastoma cell line (Glennon et al., 2013) and the H4 neuroglioma cell 
line (Thomas et al., 2016). While hugely informative, these are not ideal models as they only 
provide a neuronal-like phenotype and there is a need for a more representative in vitro 
neuronal model to accurately assess the function of these genes. The primary aim of this 
chapter is to optimise a protocol for differentiation of cortical neurons from PBMC-
derived iPSCs with a view to utilizing the IGAP GWAS cohort (Harold et al., 2009) for 
iPSC modelling in the future. This will create a more representative in vitro neuronal model 
to study the role of AD susceptibility genes in endocytic function. 
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3.2!Experimental Design 
3.2.1! Induced Pluripotent Stem Cells (iPSCs) 
3.2.1.1! Isolation and storage of PBMCs 
Processing of blood samples and the isolation of PBMCs was carried out by Newcells 
Biotech (Newcastle, England) by the following methods. A blood sample donated from a 
30-year-old female with a chromosome 20 duplication was separated by Ficoll-Paque® 
density gradient, with the PBMC layer removed and washed in RPMI 1640 medium 
(ThermoFisher Scientific) and centrifuged. This was repeated and cells were resuspended in 
10% DMSO (Sigma) in FBS (ThermoFisher Scientific). Cells were frozen in a rate-
controlled freezer at -80°C and transferred to liquid nitrogen for long-term storage. 
3.2.1.2! Reprogramming 
PBMCs were reprogrammed using Cytotune 2.0 Sendai Reprogramming Kit 
(ThermoFisher Scientific) according to the manufacturer’s instructions by Lyle Armstrong 
and colleagues at Newcells Biotech. The kit utilises SeV particles to deliver the Yamanaka 
factors Klf4, Oct3/4, Sox2 and c-Myc within a single transfection. Twenty-one days post-
transfection, clonal iPSC colonies were picked and cultured for expansion, according to 
section 3.2.1.3 
3.2.1.3! Maintenance 
Culture vessels were coated with Matrigel matrix (Corning, New York, USA), using 1 ml 
per well of a 6-well plate at 37 °C for at least 1 hour and washed with RT PBS prior to 
plating of cells. iPSCs were cultured on matrigel-coated vessels in mTeSR1 medium (Stem 
Cell Technologies, Vancouver, Canada) at 37°C in a 5% CO2 humidified chamber. Media 
was warmed to 37°C and replaced every day. All cell culture was carried out in sterile 
conditions in a biosafety cabinet. When iPSCs reached 70% confluency, colonies were 
cleaned manually for differentiated areas using a 10 µl pipette tip. This involved removing 
any cells forming dense clumps in the centre of colonies or those losing characteristic iPSC 
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morphology, such as round defined borders and high nuclear:cytoplasm ratio. Cells were 
washed once with RT PBS and once with 0.02% EDTA (Lonza) before incubating for 2-5 
min in 0.02% EDTA at 37°C. EDTA was then carefully removed and cells were flushed 
with RT mTeSR1 media to allow resuspension of small clumps of cells. Cells from one well 
of a 6-well plate were then divided between 3-6 matrigel-coated wells for expansion, with 
1.5 ml mTeSR1 per well, manually shaken to allow even distribution and left to attach at 
37°C for at least 24 hours before the first media change. 
3.2.1.4! Cryopreservation 
The iPSC cultures were cleaned for areas of differentiation as previously described in 
Section 3.2.1.3. Cells were washed with RT PBS and RT 0.02% EDTA before incubating in 
0.02% EDTA for 2-5 min at 37°C. EDTA was carefully removed and cells flushed with 
cold mTeSR1 media. Cells were pooled from all dishes and centrifuged at 200 x g for 4 min 
before resuspending in cold mTeSR1 medium. Cells were counted according to the trypan 
blue exclusion method (Chapter 2, Section 2.1.4) and resuspended in equal volumes of 
mTeSR1 and 2x freezing medium (20% DMSO, 60% FBS, 20% knockout (KO)-DMEM) 
to achieve 1 million cells/ml. Cryovials containing 1 ml cells each were transferred to a 
chilled Mr Frosty and stored at -80°C overnight. Cryovials were transferred to liquid 
nitrogen storage the following day. 
3.2.1.5! Thawing 
IPSCs were removed from liquid nitrogen and quickly thawed by swirling in a 37°C bead 
bath until only a small ice crystal remained. Cells were transferred to a 15 ml centrifuge 
tube and 11 ml mTeSR1 with 10 µM Y-27632 dihydrochloride (inhibitor of Rho-
associated, coiled-coil containing protein kinase (ROCK), Abcam) at RT was added 
dropwise. Cells were washed by centrifugation at 200 x g for 5 min and resuspended in 
mTeSR1 with 10 µM Y-27632 dihydrochloride at RT. The vial of cells was divided between 
two wells of a matrigel-coated 6-well plate with 80% in the first well and 20% in the second 
and manually shaken in vertical and horizontal motions to allow even plating. Cells were 
left to attach for at least 24 hours in the incubator before the first media change. 
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3.2.2!Immunofluorescence Staining 
Immunocytochemistry was used to confirm expression of key pluripotency and 
differentiation markers. Cells were fixed in plates with 10% neutral buffered formalin 
solution (Sigma) for 15-20 min at RT before washing 3x 5 min with 500 µl PBS. If storing 
long-term, 1 drop of 10% sodium azide (0.5g sodium azide (Sigma) in 5 ml dH20) was 
added to each well before storing at 4°C. Immunocytochemistry was carried out as 
previously described in Chapter 2, Section 2.4.3 with the antibodies used in Table 3.1: 
Primary antibodies used in . For surface markers, SSEA4 and Tra-1-60, the 
permeabilisation step was omitted. As cells were grown in plates and not plated onto 
coverslips, cells were mounted by adding a drop of Vectashield directly onto the cells and 
covering with a glass coverslip. Cells were then imaged using either the Evos FL imaging 
system or the Leica DMI6000B Inverted Time-lapse Microscope and images processed 
using LAS AF software and ImageJ. For each experiment, negative controls were 
performed (see Appendix I) using the secondary antibody only, to confirm a lack of 
background staining. 
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Table 3.1: Primary antibodies used in Chapter 3  
Antibody 
(clone) 
Antigen 
location Species Supplier Concentration Expression 
OCT4 Nucleus Mouse Santa Cruz 4 µg/ml Pluripotent stem cells 
SOX2 Nucleus Rabbit Millipore 10 µg/ml Pluripotent stem cells 
Tra-1-60 
(2A6) 
Cell 
membrane 
Mouse Abcam 20 µg/ml Pluripotent stem cells 
SSEA-4 
(MC813) 
Cell 
membrane Mouse Abcam 0.3 µg/ml Pluripotent stem cells 
Nanog Nucleus Rabbit Abcam 2 µg/ml Pluripotent stem cells 
AFP Cytoplasm Rabbit Dako 2.8 µg/ml Endoderm 
SMA 
(ASM-1) 
Cytoplasma, 
cytoskeleton 
Mouse Millipore 1 µg/ml Mesoderm 
TUJ1 
(Poly18020) 
Cytoplasma, 
cytoskeleton 
Mouse Biolegend 1 µg/ml 
Ectoderm 
Neural lineage 
PAX6 
(Poly19013) 
Nucleus Rabbit Biolegend 6.67 µg/ml 
Primary progenitor 
cells 
FOXG1 Nucleus  Rabbit Abcam 3.33 µg/ml 
Primary progenitor 
cells 
Nestin (10C2) Cytoplasm Mouse Abcam 3.33 µg/ml Primary progenitor 
cells 
Ki-67 (B56) Nucleus Mouse BD 
Biosciences 
0.42 µg/ml Cycling cells 
CTIP2 (25B6) Nucleus  Rat Abcam 3.33 µg/ml Deep-layer neurons 
TBR1 Nucleus Rabbit Abcam 3.3 µg/ml Layer 1 and deep 
layer neurons 
TBR2 Nucleus  Rabbit Abcam 5 µg/ml 
Secondary progenitor 
cells 
CUX1(M-222) Golgi  Rabbit Santa Cruz 0.67 µg/ml Upper layer neurons 
BRN2 (H-60) Nucleus  Rabbit Santa Cruz 0.5 µg/ml Upper layer neurons 
SATB2 
(SATBA4B10) 
Nucleus Mouse Abcam 0.1 µg/ml Upper layer neurons 
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3.2.4!Spontaneous Differentiation into Embryoid Bodies 
IPSCs were cultured until 70–80% confluency was reached and cleaned of differentiated 
areas, as described in section 3.2.1.3. Media was aspirated and cells were washed twice with 
RT PBS. Fresh embryoid body (EB) medium (20% Knockout Serum Replacement, 1% 
GlutaMAX, 1% non-essential amino acids, 0.1mM 2-mercaptoethanol in KO-DMEM/F-
12, all ThermoFisher Scientific) was added to each well. Wells were scored with a 26-gauge 
needle (ThermoFisher Scientific) into a grid of 10x10 sections and cells were gently scraped 
off the surface in large clumps using a cell scraper. IPSC colonies were transferred to a 
non-treated bacterial grade dish (Corning) and incubated at 37°C. Media was replaced every 
other day by transferring the entire cell suspension to a 15 ml centrifuge tube and allowing 
colonies to settle at the bottom for 5 min. The supernatant was then removed and fresh 
EB medium added to cells and the suspension returned to the dish. After 4 days the EBs 
were transferred to 0.1% gelatin-coated 24-well plates to allow attachment and further 
differentiation. EBs were cultivated for a further 16 days before fixing in 10% formalin 
solution and staining for AFP, SMA and TUJ1, markers of endoderm, mesoderm and 
ectoderm respectively, as previously described in Section 3.2.2. 
3.2.5!Cortical Neuron Differentiation 
Neural induction was based on the SMAD inhibition method (Chambers et al., 2009), 
previously described in Section 3.1.4, with the use of the small molecule inhibitors 
LDN193189 (Stemcell Technologies, Cambridge, UK) and SB431542 (Tocris Bioscience, 
Bristol, England) which inhibit BMP type I receptors and TGF-β type I receptor activin 
receptor-like kinases, respectively. The cortical differentiation protocol was adapted to 
feeder-free culture conditions from that published by (Shi et al., 2012a). This protocol 
provided detailed descriptions of a simple and robust culture system to generate both deep- 
and upper-layer excitatory neurons from hPSCs. Unless otherwise stated, all media was 
added to cells pre-warmed to 37°C and cells were incubated at 37°C in a 5% CO2 
humidified chamber. 
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3.2.5.1! Preparation of iPSCs for neural differentiation 
Plates were coated with growth factor-reduced Matrigel (Corning) using 1 ml per well of a 
6-well plate for 1 hour at 37°C. Wells were washed with PBS before iPSCs were plated in 
mTeSR1 medium at a density of approximately 45,000-50,000 cells/cm2, as described in 
Section 3.2.1.3, and maintained until 70-80% confluent up to a maximum of 4 days with 
daily media changes.  
3.2.5.2! Neural induction 
To commence neural induction, cells were washed with PBS and cultured in N2B27 
medium (2/3 DMEM/F-12, 1/3 Neurobasal, 1% L-Glutamine, 0.5% N2 supplement, 1% 
B-27 supplement without vitamin A and 0.1 mM 2-mercaptoethanol, all Life Technologies) 
with 100 nM LDN193189 and 10 nM SB431542. This was denoted Day 0, or 0 days in vitro 
(DIV). Cells were cultured for 8 days with half media changes every other day. Once a 
tightly compacted neuroepithelial sheet had formed at 8 DIV, media was changed to 
N2B27 with 10µM Y-27632 dihydrochloride and cells incubated at 37°C for 1 h. This 
media was then removed and kept aside while cells were washed once with RT PBS and 
incubated with 0.02% EDTA for 1-2 min at 37°C. EDTA was then carefully removed and 
the N2B27 media with 10µM Y-27632 dihydrochloride, saved from the previous step, was 
added to cells. The surface of the well was gently scratched with the tip of a 5 ml 
serological pipette in a zig-zag pattern, holding it perpendicular to keep large clusters of 
cells which were then gently triturated off the surface. Cells were collected and added to 
the appropriate amount of N2B27 with 10µM Y-27632 dihydrochloride to split the cells at 
a 2:3 ratio (based on the area of the wells). Cells were divided into plates which had been 
coated in 25 µg/ml fibronectin (Millipore) for 1 hour at 37°C and washed with RT PBS. 
Plates were shaken vertically and horizontally to allow even distribution of cells. At 13 
DIV, a sample of cells were fixed and stained as previously described in Section 3.2.2 for 
PAX6, TUJ1, FOXG1 and Nestin to confirm neural progenitor identity, as per Table 3.1.  
3.2.5.3! Neural maturation 
After passaging onto fibronectin-coated plates, cells were cultured for a further 8 days with 
half media changes every other day. Upon widespread appearance of neural rosettes at 16 
                                                                                  
                                                                                                                    Chapter 3: Results 
 
 
80 
DIV, cells were passaged at a ratio of 1 well : 3 wells onto poly-D-lysine (10µg/ml, Sigma) 
and Laminin (10µg/ml, ThermoFisher Scientific) coated plates. For this second passage, 
the media was removed and cells washed with PBS. Cells were incubated in 0.02% EDTA 
for 1-2 min at 37ºC before removing this and adding N2B27 medium. The plate surface 
was scratched with the tip of a 5ml serological pipette, this time keeping small clusters of 
cells. The cells were then collected into a 15 ml centrifuge tube and resuspended before 
plating. At 21 DIV, a sample of cells was fixed and stained for CTIP2, TBR1, PAX6, TUJ1, 
TBR2 and Ki-67, as described in section 3.2.2, to identify deep-layer neuron formation and 
the expression pattern of neural rosettes. Remaining cells were then cultured in N2B27 
medium with media changes every other day until 26 DIV when B-27 supplement with 
vitamin A replaced B-27 supplement without vitamin A in the N2B27 media. Half media 
changes took place every day and cells were cultured for up to 90 days. A sample of cells 
were fixed and stained for CTIP2, TBR1, CUX1, TUJ1 and BRN2 at 35 DIV and CUX1, 
TUJ1, BRN2 and SATB2 at 50 DIV, as described in section 3.2.2, in order to monitor the 
development of deep-layer and upper-layer cortical neurons.  
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3.3!Results 
3.3.1! iPSC Characterisation 
The characterisation of iPSCs for pluripotency is essential to ensure a uniform starting 
population of pure iPSCs for differentiation. For the current project, characterisation 
assays were performed as guided by the StemBANCC iPSC workflow 
(www.stembancc.org) and included immunocytochemical staining for hPSC markers and 
spontaneous in vitro EB differentiation. A thorough characterisation including karyotype 
analysis and gene expression profiling constitute a considerable expense and were therefore 
not deemed necessary in this optimisation stage but would be carried out an any future 
newly generated iPSC line. 
3.3.1.1! Pluripotency markers  
In terms of morphology, iPSCs formed characteristic ESC-like colonies with smooth 
borders and a high nuclear to cytoplasmic ratio (Figure 3.2). Intracellular transcription 
factors OCT4, SOX2 and Nanog and the extracellular membrane glycosphingolipid stage-
specific embryonic antigen 4 (SSEA-4) and the Tra-1-60 antigen are well-recognised 
markers used to confirm pluripotency. These are expressed in hPSCs and are lost upon 
differentiation (Schöler et al., 1989, Loh et al., 2006, Choi et al., 2011, Barrett et al., 2014). 
OCT4 and SOX2 were both readily expressed in the vast majority of iPSCs, showing 
uniform expression within colonies (Figure 3.3). Very few, if any, cells were detectable that 
lacked OCT4 and SOX2 expression and both proteins colocalised with DAPI, showing 
their expression within the nuclei. NANOG is a homeodomain-containing transcription 
factor that is essential for the maintenance of pluripotency (Silva et al., 2009). Uniform 
expression of Nanog was apparent throughout iPSC colonies, showing diffuse expression 
throughout the cytoplasm of iPSCs (Figure 3.3).  SSEA-4 and Tra-1-60 are stage-specific 
embryonic antigens that are tightly regulated during embryogenesis and widely used as PSC 
markers. The Tra-1-60 antibody reacts with an epitope of a proteoglycan on the cell surface 
of hPSCs (Schopperle and DeWolf, 2007) and is widely used as a marker of identifying and 
isolating ESCs and iPSCs. Both cell surface antigens showed widespread cell surface 
expression in iPSC colonies (Figure 3.3). Tra-1-60 cell surface expression showed variation 
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across the colony with strong expression in some cells and weaker expression in others but 
this did not follow a specific pattern. SSEA4 showed more uniform expression across the 
cell surface of iPSCs, with slightly stronger expression observed at the colony edges. 
Collectively, the positive expression of these proteins confirmed the pluripotent state of 
iPSCs. 
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Figure 3.2: PBMC-derived iPSC colonies displaying characteristic iPSC 
morphology 
Phase-contrast images of iPSC colonies in culture at x10, x20 and x40 magnification (top to 
bottom). Colonies are rounded in shape with smooth defined borders containing tightly 
packed iPSCs with a high nuclear to cytoplasmic ratio (example indicated with red arrow). 
Scale bar = 100µm 
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Figure 3.3: Pluripotency markers to characterise PBMC-derived iPSCs 
Representative images of immunocytochemical staining of iPSCs with pluripotency 
markers OCT4, SOX2, Nanog, Tra-1-60 and SSEA4. DAPI was used to counterstain the 
nuclei and images were taken at x20 magnification, scale bar = 100 µm.  
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3.3.1.2! Spontaneous differentiation into embryoid bodies demonstrating three germ layers 
To confirm the ability of iPSCs to differentiate into all three germ layers; endoderm, 
mesoderm and ectoderm, the formation of EBs and subsequent undirected differentiation 
was permitted. IPSCs were cultured in suspension for 4 days in non-tissue-culture treated 
dishes to encourage 3D colony formation rather than the formation of an adherent 
monolayer (Figure 3.4). After 4 DIV, the EBs were plated onto tissue culture-treated dishes 
to continue growth and encourage further differentiation. EBs continued to grow, showing 
a 3-fold increase in size and had started to loosely adhere to the plate surface 8 days after 
re-plating (Figure 3.4). Over time, this attachment allowed further differentiation of neural-
like cells at the edge of the EBs, evident by the neural processes projecting from the EB 
core (Figure 3.4). After 20 DIV, the adherent EBs were fixed and showed expression of 
markers representative of all three germ layers α-fetoprotein (AFP, endoderm), α-smooth 
muscle actin (SMA, mesoderm) and β-III tubulin (TUJ1, ectoderm). SMA and TUJ1 
showed more widespread expression than AFP. The cells of endoderm lineage, expressing 
AFP, were more often found within the dense cell mass of the EB, possibly reducing their 
exposure to the antibody. However, all three germ layer markers showed evidence of 
expression in multiple embryoid bodies, therefore confirming the pluripotent capability of 
these iPSCs. 
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Figure 3.4: Spontaneous EB differentiation of PBMC-derived iPSCs 
Representative photographs of embryoid bodies on day 2, 8 and 20 of differentiation taken 
at x10 magnification. After day 2, large cell masses began to form and these were plated 
onto gelatin-coated plates on day 4. By day 8, EBs had increased in size 3-fold and adhered 
to the plate surface. By day 20, EBs showed evidence of a variety of cell types, including 
neural-like processes emanating from the EB core. Scale bar = 400 μm 
Day 2
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Figure 3.5 Expression of germ layer-specific markers in embryoid bodies 
Representative immunofluorescence images of PBMC-iPSC-derived embryoid bodies fixed 
at 20 DIV, showing positive cells for AFP (marker for endoderm), SMA (marker for 
mesoderm) and TUJ1 (marker for ectoderm). DAPI was used to counterstain the nuclei 
and images were taken at x40 magnification, scale bar = 50 µm.  
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3.3.2!Differentiation of PBMC-iPSCs to Neural Stem Cells 
Over 8 days in vitro (DIV), in which SMAD signalling inhibitors LDN193189 and 
SB431542 were administered, iPSCs became gradually more compacted as they formed a 
neuroepithelial sheet (Figure 3.6). The cells were closely monitored for morphological 
changes during differentiation and iPSCs with large nuclei were gradually replaced by 
tightly packed neuroepithelial cells with notably smaller nuclei (Figure 3.6). At this stage (8 
DIV) they were passaged onto fibronectin. As neural progenitors are very fragile, the cells 
were passaged in as large clumps as possible by scraping each well in a large zig-zag pattern 
and gently triturating the cell clumps off the surface. Confirmation of neural progenitor 
identity was performed at 13 DIV by immunocytochemical analysis. By observation, almost 
all of the cells in the culture (>90%) stained positive for paired box 6 (PAX6), which 
colocalised with DAPI, suggesting nuclear localisation (Figure 3.7). Expression of the 
neuron-specific tubulin TUJ1 showed the presence of neural processes emanating from the 
neural progenitor cells, confirming neural identity (Figure 3.7), however this was not 
detected in all PAX6-positive cells. The neural stem cell marker Nestin showed cytoplasmic 
expression in nearly all cells, which also stained positively for Forkhead box G1 (FOXG1), 
found to colocalise in the nucleus with DAPI (Figure 3.8). SOX2 is expressed at high levels 
in the neuroepithelium of the CNS and was indeed abundantly expressed in these cells, 
with an observational estimate of >95% positive staining (Figure 3.9). Ki-67 is a mitotic 
marker and its expression was apparent in approximately 60% of SOX2-positive cells, 
illustrating actively cycling neural progenitors (Figure 3.9). Together, these data show that a 
neural identity can be induced over 8 DIV in PBMC-derived iPSCs. 
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Figure 3.6: Neural induction and rosette formation of PBMC-derived iPSCs 
Representative images of PBMC-derived iPSCs up to 12 DIV. Cells were subjected to dual 
SMAD inhibition for 8 days and passaged onto fibronectin matrix without inhibitors 
thereafter. Cells became gradually more compacted over this time with cells containing 
large nuclei gradually replaced by tightly packed neuroepithelial cells with notably smaller 
nuclei. By day 12, neural rosettes containing radially arranged columnar cells, began to 
appear (indicated by arrows). Photographs were taken at x10 and x20 magnification, scale 
bars represent 400µm and 200 µm, respectively. 
Day 10 
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Figure 3.7: Immunofluorescence staining with PAX6 and TUJ1 to confirm the 
neural identity of induced neural tissue at 13 DIV 
Representative immunofluorescence images of PBMC-iPSC-derived neural progenitors 
fixed at 13 DIV, showing positive nuclear staining for PAX6 and expression of neuron-
specific tubulin TUJ1 in the emanating processes of neural progenitors. DAPI was used to 
counterstain the nuclei. Images taken at x20 magnification, scale bar = 100 µm.  
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Figure 3.8: Immunofluorescence staining with FOXG1 and Nestin to confirm the 
neural identity of induced neural tissue at 13 DIV 
Representative immunofluorescence images of PBMC-iPSC-derived neural progenitors 
fixed at 13 DIV, showing strong nuclear staining of FOXG1 and cytoplasmic expression of 
Nestin in almost all cells in culture. DAPI was used to counterstain the nuclei. Images 
taken at x20 magnification, scale bar = 100 µm. 
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Figure 3.9: Immunofluorescence staining with SOX2 and Ki-67 to confirm the 
cortical identity of induced neural tissue at 13 DIV expression 
Representative immunofluorescence images of PBMC-iPSC-derived neural progenitors 
fixed at 13 DIV, showing positive nuclear staining for SOX2 in nearly all cells and the pool 
of actively cycling neural progenitors staining positively for Ki67. DAPI was used to 
counterstain the nuclei. Images taken at x20 magnification, scale bar = 100 µm. 
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3.3.3!The Formation of Neural Rosettes 
From 12 DIV, neural rosettes started to become apparent (Figure 3.6), consistent with 
expectations from the literature (Shi et al., 2012a). The neural rosette is the developmental 
signature of differentiating neural progenitors in vitro. It comprises a radial arrangement of 
elongated columnar neural progenitor cells, which express many proteins that are present 
in the neuroepithelium of the neural tube in vivo (Wilson and Stice, 2006). On the 
widespread appearance of neural rosettes at 16 DIV, cells were passaged onto poly-D-
lysine/laminin-coated plates for expansion. In order not to disturb the cells too vigorously, 
the same principle as the first passage was applied but creating a finer zig-zag pattern to 
generate smaller clumps. Cells were fixed at 21 DIV and strong PAX6 expression was still 
observed, indicating the presence of cortical stem and progenitor cells (Figure 3.10). Ki-67 
expression indicated actively cycling cells, which could be seen predominantly at the apical 
and basal areas of the rosette (Figure 3.10). T-box brain protein 2 (TBR2) and Ki-67 co-
expression identifies secondary progenitor cells that form a basal layer around the rosette 
structure (Shi et al., 2012a). However, TBR2 was not identified by immunofluorescence. 
TUJ1 expression shows neuronal processes are present, mainly localised to the periphery of 
neural rosettes (Figure 3.10). To assess the development of early-born deep-layer cortical 
neurons, expression of T-Box Brain Protein 1 (TBR1) and chicken ovalbumin upstream 
promoter transcription factor-interacting protein 2 (CTIP2) was analysed. While TBR1 
expression was apparent around the edges of the rosettes, a minimal proportion of cells 
showed strong positive staining. CTIP2 expression was not detected at all at this stage in of 
differentiation, suggesting early born deep-layer neurons had not yet developed. 
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Figure 3.10: Immunofluorescence staining of neural rosettes at 21 DIV derived from 
PBMC-iPSCs 
At 21 days after neural induction, neural rosettes plated on poly-D-lysine/laminin were 
analysed for CTIP2, TBR1, PAX6, TUJ1, and Ki-67 expression to confirm neural 
progenitor identity. CTIP2 and TBR2 failed to show positive staining. Minimal expression 
of TBR1 was shown while Ki-67+ cycling progenitors were evident in the apical and basal 
regions of rosettes and PAX6 was abundantly expressed. DAPI was used to counterstain 
the nuclei. Images were taken at x40 magnification, scale bar = 50µm. 
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3.3.4!Differentiation of Cortical Neurons 
Following the second passage at 16 DIV, it became apparent with further culture that the 
clusters of neural rosettes were not broken up sufficiently to allow neural expansion, thus 
impairing the differential potential of cells to progress from the compacted neural rosette 
stage. Neuronal-like processes became apparent at the edge of rosettes suggesting the 
formation of neurons, however the large dense clusters of neural rosettes became loosely 
attached over time and some were lost during media changes. Cells were fixed at 35 DIV 
and expression of CTIP2 and TBR1 were again tested. Both were shown to be expressed in 
cultures, colocalising with DAPI in the nucleus and suggesting the successful development 
of deep-layer cortical neurons (Figure 3.11). The absence of BRN2 and CUX1 expression 
also supports this identification, as these define later-born upper-layer neurons (Shi et al., 
2012a). At this stage, the cells tend to become very fragile and passaging cells after day 35 
was not recommended in the protocol, due to a low survival rate following passage (Shi et 
al., 2012a). Despite the observed clumping and loss of some neural rosettes, the positive 
expression of deep layer cortical neuron markers CTIP2 and TBR1 gave rationale to 
continuing culture without further passaging.  
Neurons were maintained in culture, with media changes every second day for a further 55 
days. As cells approached day 50, cultures were becoming increasingly sparse as many of 
the pools of progenitor cells contained within the neural rosettes had formed dense clumps 
and detached. Cells were fixed at 50 DIV and tested for expression of later-born, upper-
layer neuron markers CUX1, BRN1 and SATB2 (Figure 3.12) Despite the sparse 
distribution of neurons, expression of CUX1 in the cytoplasm was detected while 
colocalisation of BRN2 with DAPI in the nucleus was apparent, suggesting the successful 
development of upper-layer neurons. However, SATB2 expression was not detected. Cells 
were successfully maintained in culture up to 90 DIV, however became further fragmented 
and fragile over this time which did not allow for further analysis of neuronal marker 
expression. Large clumps of cells developed with processes extending from them and a 
large variation in morphology was evident in cell cultures, suggesting a heterogeneous 
population of cell types was present (Figure 3.13). 
For exploratory purposes, one well of cells was passaged, as before, at 40 DIV but 
resuspending more vigorously, to determine if cells would survive passaging at this late 
stage and if this would help their morphological development. This well was denoted 
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Culture B. Indeed, these cells showed much less clumping than the non-passaged cells 
(Culture A) and displayed more neuronal-like processes and morphology (Figure 3.13). At 
68 DIV, Culture B exhibited clear neuronal-like morphology with many neural processes, 
far fewer were observed in Culture A where many of the cells were contained within dense 
three-dimensional clumps. However, upon long term culture up to 90 DIV, Culture B still 
developed dense, clumped morphology, similar to that observed in Culture A (Figure 3.13). 
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Figure 3.11: Immunofluorescence staining of markers indicating the presence of 
early-born deep-layer cortical neurons at 35 DIV 
Representative immunofluorescence images of PBMC-iPSC-derived cortical neurons fixed 
at 35 DIV, showing positive staining for CTIP2, TBR1 and TUJ1. Cells were negative for 
CUX1 and BRN2 expression, consistent with a deep-layer cortical phenotype. DAPI was 
used to counterstain the nuclei. Images taken at x40 magnification, scale bar = 50 µm. 
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Figure 3.12: Immunofluorescence staining indicating the presence of late-born 
upper-layer cortical neurons at 50 DIV 
Representative immunofluorescence images of PBMC-iPSC-derived cortical neurons fixed 
at 50 DIV, showing positive staining for CUX1, BRN2 and TUJ1. Cells were negative for 
SATB2 expression. DAPI was used to counterstain the nuclei. Images taken at x40 
magnification, scale bar = 50 µm. 
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Figure 3.13: The effect of a third passage at 40 DIV on cellular morphology 
Representative images showing a comparison between cortical neurons that were only 
passaged twice at 8 DIV and 16 DIV (Culture A) compared to those that underwent an 
additional passage with vigorous resuspension at 40 DIV (Culture B). At 45 DIV, Culture 
A showed areas of dense clumped cells and heterogeneous morphology whereas Culture B 
showed a more uniform morphology and dense three-dimensional clumps were not 
apparent. At 68 DIV, Culture B exhibited clear neuronal-like morphology with many neural 
processes however far fewer were observed in Culture A where many of the cells were 
contained within the dense clumps. By 90 DIV, however, Culture B exhibited similar cell 
clumping to that observed in Culture A. Images were taken at x20 magnification, scale bar 
= 100 µm.   
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3.4!Discussion 
This study has confirmed the expression of pluripotency markers OCT4, SOX2, Nanog, 
TRA-1-6- and SSEA4 in PBMC-iPSCs and demonstrated the ability of PBMC-iPSCs to 
differentiate into all three germ layers by layer-specific gene expression in embryoid bodies. 
This provided an ideal starting population of stem cells for neural differentiation. By dual 
SMAD inhibition, neural identity was induced in PBMC-iPSCs to form a neuroepithelial 
sheet followed by the efficient formation of neural rosettes. Successful neural induction 
was confirmed by positive staining for key progenitor markers. Evidence of deep-layer 
cortical neurons was confirmed at 35 DIV by CTIP2 and TBR1 expression, while CUX1 
and BRN2 expression were indicative of later-born, upper-layer neurons present at 50 
DIV. 
3.4.1!Confirmation of Pluripotency 
IPSCs are characterised by the observation of ESC-like morphology (high nuclear to 
cytoplasmic ratio and forming colonies with clear-cut borders), expression of pluripotency 
markers and the ability to differentiate into all three germ layers (Baghbaderani et al., 2016). 
This study successfully demonstrates these characterisation steps to ensure the cells are 
truly pluripotent. The positive expression of pluripotency markers is routinely carried out 
in iPSC studies ( Yagi et al., 2011, Shi et al., 2012b, Espuny-Camacho et al., 2013). Both 
OCT4 and SOX2 are two of the four reprogramming factors shown by Takahashi and 
Yamanaka to be required for induction of pluripotency in somatic cells (Takahashi and 
Yamanaka, 2006) and showed strong nuclear staining across iPSC colonies in this study. 
Oct4 is a member of the POU family of transcription factors and is a key developmental 
regulator with important roles in early embryogenesis, showing expression in unfertilised 
oocytes, early embryos and primordial germ cells but not in adult tissues (Schöler et al., 
1989). SOX2 is also critical in controlling pluripotency and differentiation of hPSCs. SOX2 
is indispensable for embryonic development (Avilion et al., 2003) and critical for 
maintaining pluripotency of ESCs and iPSCs, forming a core transcriptional regulatory 
network with OCT4 and NANOG to maintain self-renewal (Loh et al., 2006). NANOG, a 
homeodomain-containing transcription factor, was surprisingly not among the quartet of 
reprogramming factors sufficient to create iPSCs (Takahashi and Yamanaka, 2006). 
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However, it is critical for the maintenance of pluripotency in stem cells and, although 
required at a later point than OCT4 during development, both control a cascade of 
pathways to govern self-renewal and pluripotency (Yuin-Han Loh, 2006). NANOG is in 
fact a target of TGFβ/Activin-mediated SMAD signaling and the binding of SMADs to the 
NANOG promoter plays an essential role in sustaining stem cell self-renewal (Xu et al., 
2008). The cell surface pluripotency markers SSEA4 and Tra-1-60 showed strong 
expression across iPSC colonies in this study, however showed less uniform expression 
compared to the aforementioned intracellular markers. As the cells grow within tightly 
packed colonies and were not permeabilised for the staining of these two antibodies, access 
of the antibody to the cell surface may have been impaired. The pattern of staining is 
however consistent with that observed in the literature confirming the pluripotency of 
blood-derived iPSCs (Choi et al., 2011, Barrett et al., 2014).  
The creation of cells expressing endodermal, mesodermal and ectodermal markers through 
spontaneous differentiation into EBs demonstrated the pluripotent capacity of PBMC-
iPSCs in this study. While the expression of AFP, a marker of endodermal origin, was not 
as widespread as SMA and TUJ1, it was expected that only certain areas would show 
positive staining due to the heterogeneous nature of the EBs. This assay provides a cheaper 
and less labour-intensive alternative to teratoma assay, which is considered the gold 
standard for demonstrating stem cell pluripotency (Hentze et al., 2009). This involves the 
injection of PSCs into immunodeficient mice to form a non-malignant tumour comprising 
cells of all three germ layers. However, these assays are expensive and the cost, in terms of 
animal usage, was not justified for this study. Both of these pluripotency assays, however, 
are limited in their ability to distinguish between high quality iPSC lines, with a high 
proportion of pure PSCs, and those that are more heterogeneous in nature, with a smaller 
proportion of truly pluripotent cells. This is particularly important due to the large number 
of cells lines required in any iPSC study to exclude the interference of variability, including 
multiple clones from each individual. Fluorescent cytometry can be used to stain for cell 
surface markers, such as TRA-1-60 and SSEA4, quantifying the fluorescence per sample, 
thus distinguishing between high quality uniform cultures and those that are heterogeneous 
in pluripotency. Gene expression-based assays can also provide an extensive 
characterisation of pluripotency, such as the robust open-access bioinformatic assay 
PluriTest (Muller et al., 2011). This can give an accurate view of pluripotency by comparing 
the expression of a large number of genes to a database of ~450 genome-wide 
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transcriptional profiles from diverse stem cell preparations, including 223 hESC and 41 
iPSC lines, in addition to differentiated cell types, and developing and adult human tissues 
(Muller et al., 2011). While these approaches were not justified in this optimisation study, 
they would be incorporated into the thorough characterisation necessary for determining 
pluripotency in newly-generated patient-derived iPSCs. 
3.4.2!Successful Neural Induction of PBMC-iPSCs 
This study has demonstrated the ability to induce neuronal differentiation in a PBMC-
derived iPSC line. Neural induction appeared to be highly efficient by the abundant 
formation of neural rosettes by day 12 and their positive staining for neural progenitor 
markers PAX6, FOXG1, Nestin and TUJ1. PAX6 expression was observed in >90% cells 
at both the neuroepithelial (13 DIV) and neural rosette (21 DIV) stage. This is in line with 
that previously demonstrated in the literature using dual SMAD inhibition protocols, with 
Shi et al. (2012) reporting that >95% of cells were PAX6-positive 15 days after initiation of 
neural induction (Shi et al., 2012a) and further studies demonstrating similar expression 
levels after 15-19 DIV (Shi et al., 2012b, Espuny-Camacho et al., 2013). Although 
colocalisation of PAX6 and FOXG1 was not possible in the present study due to the 
antibodies available being derived from the same species, similar expression and 
localisation of these two proteins was observed in neural progenitors at 13 DIV, 
confirming their cortical identity (Shi et al., 2012a).  
Nestin and SOX2 also showed widespread expression at 13 DIV, consistent with the levels 
of coexpression with FOXG1 during neural induction in the literature (Shi et al., 2012a). 
The neuron-specific tubulin, TUJ1, was expressed at 13 DIV and throughout 
differentiation, confirming neural identity. Prominent TUJ1 staining was localised 
predominantly outside or at the periphery of rosettes, resembling the accumulation of 
neurons at the basal domain of the neural tube, outside of the apical proliferative zone. Shi 
et al. (2012c) also stated that the critical step in generating cortical neurons is the highly 
efficient differentiation to neural progenitor cell rosettes and the genesis of apical and basal 
progenitors in the system (Shi et al., 2012c). This was demonstrated in the present study, 
with apical and basal Ki-67 expression within the rosettes replicating that reported by Shi et 
al. (2012c) and confirming the presence of mitotically cycling neural progenitors. Due to 
the small starting pool of cells for this differentiation, only observational estimates of the 
                                                                                  
                                                                                                                    Chapter 3: Results 
 
 
103 
percentage of positive staining per marker was possible, however an expansion of this 
study in patient-derived iPSCs would allow an accurate quantification of 
immunofluorescence positive staining. This would enable comparisons to be made 
between lines and a more thorough analysis of differentiation efficiency. Collectively, 
however, the abundance of these markers, as judged by eye, was considered sufficient to 
confirm their expression.  
The lack of CTIP2 expression at 21 DIV may be due to the neural progenitors not yet 
being mature enough to express this protein therefore it would perhaps be more 
appropriate to stain for this protein at a later time point. Espuny-Camacho et al. (2013) 
differentiated cortical neurons by dual SMAD inhibition and found CTIP2/TBR1 co-
expression at 24-28 DIV and CTIP2 positive layer V neurons at 37 DIV while others also 
report early-born deep-layer neurons only becoming a major population around day 35 (Shi 
et al., 2012a). Neural rosettes were fixed at 21 DIV which is likely too early for these 
markers, particularly as PAX6-positive progenitors were still abundant. Indeed, CTIP2 and 
TBR1 expression were observed at 35 DIV, with many of the neurons showing positive 
double staining for both these markers, indicating the successful development of layer VI 
cortical neurons (Espuny-Camacho et al., 2013). The same may be true for TBR2 
expression as this identifies newly-born post-mitotic neurons which may not yet have 
developed. TBR2 was not present at 21 DIV but expression has been shown at day 24 in 
the literature (Shi et al., 2012a) and as the primary progenitor marker PAX6 expression was 
still abundant at 21 DIV in the present study, it may be that the cultures were fixed too 
early for secondary progenitor cells to have developed. 
Upper layer CUX1/BRN2-positive neurons were detected at 50 DIV and TUJ1 further 
confirmed neural identity of cells in culture, however this expression was not as widespread 
as published results have shown (Shi et al., 2012a, Chambers et al., 2009), suggesting 
heterogeneous cell types in the cultures. SATB2 expression, which corresponds to callosal 
neurons, could not be detected. Espuny-Camacho et al. (2013) found that SATB2 and 
CUX1/BRN2-positive cells started to appear at the latest time points in culture around 61-
72 DIV. It could be that the upper layer callosal neurons had not yet developed at 50 DIV 
and further immunocytochemistry at 70 DIV would have been informative. One of the 
great limitations with neuronal differentiation studies is the post-mitotic nature of mature 
neurons which does not allow sources to be replenished. This means that a very large 
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starting batch of neural precursors is essential for sufficient quantities of neurons to be 
generated, both for characterisation and the final population for functional assays. Due to 
the insufficient separation of neural rosettes at the second passage, large clumps of neural 
precursors formed and were prevented from differentiating. Many of these detached over 
time, therefore further reducing the number of cells available for characterisation. For this 
reason, cells were not fixed as frequently after 50 DIV as was planned with the aim of 
fixing at 90 DIV to maximise the chance of observing late-born mature neuronal markers. 
Unfortunately, this was not possible due to a cell culture infection, demonstrating the 
challenges of long-term culture in the absence of antibiotics. In future, expansion of cell 
cultures at the progenitor stage to produce frozen stocks would be employed to ensure a 
plentiful supply of neural precursors. This would save the time required to prepare iPSCs 
from scratch for neural induction and also allow back-up stocks to be cultured 
simultaneously in case of such unforeseen circumstances. 
3.4.3!The use of PBMCs for iPSC Modelling  
While the precise timing of differentiation is highly line-dependent and likely to differ when 
it comes to sAD patient-derived iPSCs, testing the procedure in this trial PBMC-derived 
iPSC line provides promise that the method will be effective in future PBMC-derived iPSC 
models and validates their use in this project.  Until recently, the most common source 
from which to derive human iPSCs has been skin fibroblasts. However, PBMCs provide an 
ideal starting source for iPSC models of neurodegeneration as they eliminate the 
requirement for patient skin biopsies to generate dermal fibroblast lines. This is particularly 
invasive for elderly participants as it can cause bleeding, infection, and scarring and may 
also be unethical to carry out on an individual who lacks the mental capacity to understand 
the procedure. Blood, on the other hand, is a cell source that can easily be obtained from 
patients and several groups have successfully generated iPSCs from PBMCs (Loh et al., 
2010, Mack et al., 2011, Seki et al., 2010).  
PBMCs collected from blood are advantageous as they can be reprogrammed immediately 
following extraction due to the large numbers of cells available in a blood sample whereas 
time is required for the expansion of dermal fibroblasts obtained from a skin biopsy before 
reaching adequate numbers for reprogramming (Takahashi and Yamanaka, 2006). Blood 
collection is routinely performed therefore reduces the need for highly-specialised staff 
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trained in skin biopsy collection. The less invasive nature of the procedure also helps 
participants to overcome the psychological barrier of participating in research which may 
lead to greater recruitment for such studies. Undeniably, blood is becoming a routinely 
used source for iPSC generation and studies differentiating these into neuronal cell types 
are on the increase. DeRosa et al. (2012), for example, generated patient-specific iPSCs 
from individuals with autistic spectrum disorder and differentiated these into GABAergic 
neurons (DeRosa et al., 2012). Recent studies have also demonstrated the successful 
derivation of iPSCs from PBMCs collected from elderly AD patients (Tancos et al., 2016, 
Chandrasekaran et al., 2016, Ochalek et al., 2016, Nemes et al., 2016, Zhang et al., 2017) 
providing evidence that this approach is suitable and effective for AD research. Indeed, 
reprogramming success is not adversely affected when performed on PBMCs from elderly 
patients, unlike dermal fibroblasts extracted from elderly participants (El Hokayem et al., 
2016).  
While an exciting emerging field, PBMC-iPSCs are subject to limitations, including the 
handling of samples immediately following collection. Temperature fluctuations and an 
extended time period before PBMCs are isolated from whole blood can adversely affect 
sample quality (El Hokayem et al., 2016). Agu et al. (2015) demonstrated that iPSCs can be 
derived from whole blood held for 48 hours at room temperature before isolating PBMCs, 
however reprogramming efficiency at 48 hours was 10-fold lower than those held for 5 
hours. Furthermore, evidence from mouse iPSCs derived from fibroblasts, hematopoietic 
and myogenic cells has suggested that early-passage iPSCs retain a transient epigenetic 
memory of their somatic cells of origin (Polo et al., 2010). Epigenetic marks carried over 
from PBMCs to iPSCs could make differentiation into certain cell types difficult, however, 
the demonstration of neural induction in the current study suggests this is not problematic. 
Polo et al. (2010) reported that the retention of PBMC epigenetic marks could be 
circumvented by extending the number of passages iPSCs undergo, indicating that 
reprogramming is a gradual process extending beyond the activation of pluripotency genes. 
While several recent studies have demonstrated the successful derivation of iPSCs from 
PBMCs collected from elderly AD patients (Tancos et al., 2016, Chandrasekaran et al., 
2016, Ochalek et al., 2016, Nemes et al., 2016), studies demonstrating successful terminal 
differentiation of PBMC-iPSCs into disease-relevant cell types are scarce suggesting the 
field is in its infancy and may still be subject to methodological issues.  
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While the storage of PBMC samples in liquid nitrogen for 4 months prior to 
reprogramming results in no obvious change in reprogramming efficiency (Agu et al., 
2015), the implications of longer term frozen storage of PBMCs on reprogramming 
efficiency has yet to be determined. The PBMC samples available for AD research 
purposes within the GERAD cohort have been collected over many years and have 
therefore undergone a long-term period in liquid nitrogen storage. Attempts by Lyle 
Armstrong to reprogram 2 case and 2 control PBMCs samples collected between 2002-
2004 took much longer than the 21-day protocol described in the Cytotune 2.0 protocol 
for reprogramming PBMCs. The cells were slow to eliminate the SeV reprogramming 
vector and produced very small numbers of pickable colonies, representing low 
reprogramming efficiency. The colonies were also difficult to expand because they were 
very prone to differentiation down a neuroepithelial pathway. It was thought that this 
behaviour was likely due to the PBMCs being in storage over 10 years, based on anecdotal 
reports of this behaviour in fibroblasts which had been in storage for a number of years. It 
is possible that storage for this length of time had affected their quality.  
3.4.4!Models of Neurodegeneration: Future Challenges  
3.4.4.1! Recapitulating ageing in vitro 
It has proven difficult to generate in vivo models that recapitulate typical late-stage features 
of AD including the presence of plaques, tangles and neuronal death, with rodent models 
relying on the overexpression of multiple mutant genes to demonstrate this pathology 
(Oddo et al., 2003). A key finding that would support the recapitulation of true AD 
pathology in iPSC models is the demonstration of these advanced stage features which 
would ultimately allow iPSC models to be used to probe the links between Aβ and tau. 
Despite iPSC-derived neuronal models from sAD patients showing elevated levels of toxic 
amyloid-β species and phosphorylated tau (Kondo et al., 2013, Israel et al., 2012), amyloid-
β plaques or neurofibrillary tangles have not been demonstrated. Recent implementation of 
3D culture models has uncovered a breakthrough in reproducing these hallmark features, 
previously unseen in cellular or animal AD models. Choi et al. (2014) successfully 
recapitulated amyloid-β and tau pathology in an immortalised human neural precursor cell 
line derived from fetal brain but this also required the overexpression of mutant genes. 
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APP and PSEN1 containing fAD mutations were overexpressed in human neural stem 
cells and differentiated into 3D cultures of neuronal and glial cells, representative of 
different brain regions (Choi et al., 2014). The authors hypothesised that a 3D culture 
system would accelerate Aβ deposition by limiting its diffusion, which classically occurs 
into a large volume of media in 2D cultures. Indeed, robust extracellular deposition of Aβ 
and the formation of plaques was demonstrated in fAD 3D cultures in addition to high 
levels of p-tau aggregates in the soma and neurites (Choi et al., 2014). The use of β- or γ-
secretase inhibitors not only decreased Aβ pathology but attenuated tauopathy, supporting 
the amyloid hypothesis that accumulation of Aβ drives tauopathy (Hardy, 1992). Together, 
these data support the utility of 3D organoids for AD research, yet it remains to be 
determined whether both amyloid and tau tangle pathologies can be recapitulated in vitro in 
the absence of mutant fAD genes. 
This lack of late-stage pathology recapitulation in sAD models could be due to the resetting 
of donor age during somatic cell reprogramming, removing all biological signatures of 
ageing. Gene expression profiling of iPSC-derived neurons has shown that these cells 
differentiate at a rate comparable to their fetal counterparts (Mariani et al., 2012). How can 
90 days in culture effectively recapitulate 80 years in the human brain? Efforts to genetically 
trigger age-like features in iPSC derivatives have involved manipulation of a genetic 
mutation responsible for premature ageing (Miller et al., 2013) and telomere shortening 
(Vera et al., 2016). However, with the complex pathogenesis that AD already presents, 
introduction of further impairments through ‘artificial ageing’ has the potential to interfere 
with true readouts. 
3.4.4.2! Inter-line variability 
The demonstration of AD-related phenotypes in iPSC-derived neurons from patients with 
sAD (Israel et al., 2012, Kondo et al., 2013) provides great promise for modelling such 
complex disorders in vitro. However, both these studies reported contradictory results 
between different sAD cell lines, with only one of the two demonstrating phenotypes 
consistent with the fAD lines (Israel et al., 2012, Kondo et al., 2013). This variability speaks 
to the complexity of each human genetic background and the challenge of modelling 
complex diseases in this manner still hinders progress in the field. It also illustrates that 
there are likely multiple causes of sAD which cannot all be modelled by one system. 
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Furthermore, iPSC models cannot escape from the interference of individual differences in 
genetic background when multiple patient lines are used. Recent advances in genome 
editing technology with the use of clustered regularly interspaced short palindromic repeats 
(CRISPR) and their associated protein-9 nuclease (Cas9) have allowed the creation of 
isogenic iPSC lines to eliminate this source of variation. The CRIPSR/Cas9 system 
efficiently introduces targeted double stranded breaks which can be repaired by homology-
directed repair using a DNA repair template. The repair template supplied can be designed 
to selectively introduce a mono- or bi-allelic sequence to allow a targeted mutational knock-
in of single alleles to model heterozygous or homozygous mutations. The generation of 
knock-in iPSC-derived cortical neurons with the APP or PSEN1 mutation has recently 
been demonstrated (Paquet et al., 2016). These neurons displayed genotype-dependent 
disease-associated phenotypes such as increased total Aβ generation and secreted 
Aβ42:Aβ40 ratio, which correlated with mutation load. This approach has also been 
applied to investigating the genetic basis of sAD by genetically modifying iPSCs to 
incorporated AD risk SNPs into the genome. For example, Zhao et al. (2015) investigated 
whether certain AD-associated PICALM variants could influence PICALM expression and 
Aβ clearance in iPSC-derived endothelial cells. CRISPR/Cas9 genome editing was used to 
generate isogenic homozygous iPSC lines for two homozygous allelic variants, one of 
which was associated with a decreased risk of AD (Harold et al., 2009, Lambert et al., 2009, 
Lambert et al., 2013). Indeed, they reported that iPSC-derived endothelial cells 
homozygous for the protective rs3851179A allele had higher PICALM mRNA and protein 
levels and increased Aβ clearance than those expressing the non-protective rs3851179G 
allele (Zhao et al., 2015). This presents an avenue for the future use of iPSC models, such 
as the cortical neurons demonstrated in this chapter, to investigate the function of SNPs 
associated with sAD risk through the creation of isogenic lines by genome editing. 
3.4.4.3! Selection of appropriate cell type 
This study investigating PICALM function in brain endothelial cells also highlights the 
importance of creating iPSC models of the appropriate cell type for the gene of interest. 
While much of the focus for modelling AD in vitro has surrounded the generation of 
neuronal models, other brain cell types including astrocytes, microglia, oligodendrocytes 
and endothelial cells have remained relatively underexplored, despite each showing 
evidence suggesting participation in the pathogenesis and progression of AD (Olabarria et 
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al., 2010, Desai et al., 2010, Zhao et al., 2015). Atrophic astrocytes, for example, have been 
detected in the early stages of disease in AD mouse models (Olabarria et al., 2010). 
Recently, Jones et al. (2017) reported that both fAD and sAD iPSC-derived astrocytes 
display cellular atrophy and a smaller degree of branching compared to controls, as 
calculated using the astrocyte marker glial fibrillary acidic protein (GFAP) to measure 
surface area, volume and the relative ratio. The enormous potential of iPSCs for AD 
modelling has been demonstrated through neuronal models and extended with the recent 
introduction of 3D culture systems to better reflect the in vivo system. Specific selection of 
appropriate cell type is crucial when applying these methods to analyse gene function in 
AD and the field is now being extended to include these equally important non-neuronal 
cell types. 
3.4.5!Conclusion 
This chapter has provided proof of principle that iPSCs derived from PBMCs can be 
directed to differentiate into cortical neurons through dual SMAD inhibition. This protocol 
was carried out for the first time in the current lab and has therefore established these iPSC 
protocols for future use and optimisation. This approach to in vitro modelling of AD is 
limited in terms of the feasibility of reprogramming samples from patients with AD. 
Whether the difficulties encountered during the reprogramming of these samples were due 
to the age of the donor or the long duration in storage is yet to be determined. 
Unfortunately, with the unanticipated delay in reprogramming the patient-derived PBMCs, 
the feasibility of optimising neural differentiation in an AD patient line was not possible 
within the time constraints of this PhD project. However, the protocols are now available 
for the future use of the team, allowing the potential creation of iPSC-derived neuronal 
cultures for the study of AD susceptibility genes.  
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Chapter 4 
4! The Involvement of BIN1 in APP 
Processing at the Blood-Brain Barrier 
 
4.1!Introduction 
Chapter 4 introduces the exploration of the role of BIN1, a gene implicated in LOAD 
aetiology by numerous genetic studies (Chapter 1, Section 1.3) in the proteolytic processing 
of APP at the BBB. The amyloidogenic processing of APP by neurons coupled with poor 
Aβ clearance across the BBB have been classically attributed to plaque formation. 
However, APP from BMECs and the peripheral circulation represents a significant 
potential source of Aβ in the brain and surrounding vasculature (Devraj et al., 2016). With 
APP processing evident in BMECs (Devraj et al., 2016) and CME central to this 
mechanism, this chapter seeks to explore whether BIN1 has a role in APP proteolysis at 
the BBB. BIN1 function has not previously been investigated in BMECs, therefore a well-
characterised immortalised human brain endothelial cell line will be used to investigate the 
effect that siRNA-mediated depletion of BIN1 has on APP processing. 
4.1.1! APP Processing at the BBB 
While the role of the BBB in the clearance of brain-derived Aβ has been studied in great 
detail, the involvement of BMECs in the amyloidogenic processing of APP is yet to be 
fully investigated. Several studies have reported that over 70% of AD cases also 
demonstrate CAA with deposition of Aβ in the walls of cerebral blood vessels (Mandybur, 
1975, Attems and Jellinger, 2004) yet the origin of these deposits remains unclear. The 
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formation of Aβ plaques and CAA have classically been attributed to the production and 
release of Aβ by neurons, coupled with poor clearance of Aβ at the BBB. However, 
BMECs have been shown to express APP at comparable levels to primary neurons 
(Kitazume et al., 2010). APP has three major alternatively spliced isoforms: 770, 751 and 
695 residues in length which show cell-specific expression in the brain. Neurons solely 
express APP695 (Wertkin et al., 1993, Kitazume et al., 2010) while APP770 and APP751 exhibit 
a more ubiquitous expression pattern and contain a Kunitz Protease Inhibitor (KPI) 
domain, which favours the amyloidogenic processing of APP (Ho et al., 1996). Kitazume et 
al. (2010) showed that BMECs express APP770 and detected both sAPPα and sAPPβ in 
media from cultured BMECs, providing evidence for α- and  β-secretase activity. However, 
Aβ40 and Aβ42 were only detectable in the media upon overexpression of APP770 in 
BMECs, suggesting that while the capability to produce Aβ is present in BMECs, 
production of Aβ from endogenous APP is limited and highlights the difficulty in detecting 
Aβ in non-transfected cells. 
Platelets also represent a substantial peripheral source of APP at a concentration 
comparable to that found in the brain (Bush et al., 1990) and this may contribute to Aβ 
accumulation in the brain and cerebral vasculature in AD. Indeed, peripherally applied Aβ 
was shown to result in plaque formation in the brain (Eisele et al., 2010). As BMECs 
possess the capacity for amyloidogenic processing of APP, it is plausible that BMECs may 
contribute to Aβ deposits in the brain and cerebral vessel walls by utilise platelet-derived 
APP.  
A recent study investigated the expression of BACE1 in BMECs of human, mouse and 
bovine origin, showing strong expression of the full-length active isoform in bovine 
microvessels (Devraj et al., 2016). BACE1 expression showed a predominant basolateral 
distribution with a 2.5-fold higher concentration compared to the luminal membrane, 
suggesting that Aβ generation within the endothelium may considerably contribute to 
amyloid formation in the walls of the blood vessels. Upon inhibition of BACE1 in mouse 
BMECs, an increase in mature APP and sAPPα was observed, indicating that in the 
absence of BACE1, the majority of full-length APP was not cleaved and that when cleaved, 
α-secretase-mediated cleavage predominated (Devraj et al., 2016). In BBB microvessels of a 
transgenic AD mouse model over-expressing human APP751, a 4-fold increase in BACE1 
mRNA expression compared to age-matched wild-type mice was observed, suggesting an 
increase in APP processing activity by BACE1 (Devraj et al., 2016). In addition, 
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basolaterally-expressed LRP1 was upregulated. LRP-1 is known to be involved in the 
endocytosis of APP, therefore increased BACE1 activity coupled with increased 
endocytosis of neuronal-derived APP may result in increased Aβ production in BMECs. 
The apical Aβ influx transporter RAGE also showed increased transcript levels in this 
study while apically expressed Pgp, involved in Aβ efflux at the BBB, was downregulated. 
BMECs could therefore be contributing to brain Aβ by increased APP processing, 
enhanced influx of blood-derived Aβ and/or decreased efflux of Aβ into circulation. 
4.1.2! Investigating BIN1 Protein Function in vitro 
With endocytic trafficking central to the proteolysis of APP, the identification of several 
AD risk genes implicated in CME has stimulated research into the function of these genes 
in the brain and how they may affect APP processing. As the second most associated AD 
susceptibility loci after APOE, the genetic evidence associating BIN1 with AD 
pathogenesis (Chapter 1, Section 1.3) has resulted in many follow-up studies using cellular 
models (Glennon et al., 2013, Chapuis et al., 2013, Miyagawa et al., 2016, Ubelmann et al., 
2017).  
A widely-used method of investigating protein function in vitro involves the use of RNA 
interference. This is the process by which RNA molecules inhibit gene expression by 
inactivating the corresponding mRNA using double-stranded RNA. The phenomenon is 
based on the endogenously induced gene silencing effects of micro RNAs and the 
machinery involved can be exploited for downregulation of target genes by foreign double-
stranded RNA (dsRNA) (Valencia-Sanchez et al., 2006). Short interfering RNAs (siRNAs) 
and dsRNAs target a specific mRNA for degradation, resulting in depletion of the 
corresponding protein, and are therefore a useful tool for studying protein function. As 
siRNAs carry a net negative charge, in order to enter the cell, they can be packaged into 
liposomes containing cationic lipids that mimic the natural phospholipids present in the 
plasma membrane. Lipid based-transfection is a highly efficient and reproducible method 
of siRNA delivery that can be used in many different cell types. Once inside the cell, the 
siRNA binds with the RNA-induced silencing complex (RISC) and unwinds to become 
single stranded (Valencia-Sanchez et al., 2006). It is then capable of binding to its 
complementary mRNA which induces mRNA cleavage by RNase activity within the RISC 
complex and targets it for degradation. While siRNAs are relatively resistant to 
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degradation, the level and duration of knockdown depends on the rate of cell growth and 
the dilution of siRNAs below a crucial threshold that is necessary to maintain inhibition of 
gene expression. Gene knockdown by siRNA is therefore a transient mechanism, with 
significant protein depletion usually achieved between 48-72 hours post-transfection 
(Moore, 2007). 
In order to investigate the role of BIN1 in APP processing at the BBB, depletion of BIN1 
protein followed by analysis of intracellular and extracellular products of APP proteolysis, 
may yield useful clues to inform future studies. This methodology does not require the 
development of a stable knockdown and therefore siRNA-mediated depletion offers a 
time-sensitive approach to the research question. It is also more representative of the 
parent cells which express endogenous levels of BIN1 prior to transfection and therefore it 
can give more information on the normal function of BIN1 in these cells. RNA 
interference has been used by many recent studies to investigate BIN1 function in vitro 
(Glennon et al., 2013, Meinecke et al., 2013, Ubelmann et al., 2017, Nakajo et al., 2016, 
Miyagawa et al., 2016) but the use of BIN1 siRNA in BMECs remains to be explored. 
4.1.3!BIN1 and APP Processing 
One of the first studies post-GWAS to investigate BIN1 protein expression in AD was 
conducted by Glennon et al. (2013), who found that BIN1 was reduced by 87% (p=0.007) 
in sporadic AD frontal cortex compared to non-dementia controls. With the hypothesised 
role of BIN1 in APP processing, they investigated whether there was a correlation between 
BIN1 and the levels of soluble and insoluble Aβ and Aβ plaque load. None of these 
parameters correlated with BIN1 expression, suggesting that decreased BIN1 is unlikely to 
affect the generation or degradation of Aβ. This was corroborated, in the same study, in 
vitro by siRNA-mediated depletion of BIN1 in a human neuroblastoma cell line (SH-
SY5Y). No change in APP expression in cell lysate was observed nor in the production of 
Aβ and the soluble ectodomain resulting from α (sAPPα) or β (sAPPβ) cleavage in 
conditioned media (Glennon et al., 2013), suggesting that BIN1 may not be involved in the 
processing of APP.  
These findings were recently supported by Ubelmann et al. (2017) who investigated the 
effects of Bin1 depletion in both mouse primary cortical neurons and N2a mouse 
neuroblastoma cells. The authors showed that siRNA-mediated depletion of Bin1 in N2a 
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cells did not affect cell surface APP or its endocytosis and its rate of trafficking to the 
lysosome was comparable to control cells, suggesting Bin1 does not control APP endocytic 
trafficking (Ubelmann et al., 2017). Similarly, BACE1, the β-secretase involved in APP 
cleavage, showed no change in surface expression or internalisation with Bin1 depletion. 
However, a reduction in the amount of BACE1 recycled back to the plasma membrane 
was detected, suggesting Bin1 is important for the endocytic recycling of BACE1 but not 
APP. The accumulated BACE1 that failed to recycle in Bin1-depleted N2a cells was found 
to associate with early endosomes. Furthermore, no change in BACE1 degradation was 
observed, suggesting that BACE1 accumulated in the early endosomes because of defective 
recycling mechanisms, rather than impaired lysosomal degradation.  
The same defects were observed in Bin1-depleted mouse primary cortical neurons where 
increased intracellular Aβ42 was reported, suggesting BACE1 accumulation increased the 
amyloidogenic processing of APP (Ubelmann et al., 2017). A significant decrease in 
extracellular Aβ40 was observed with Bin1 depletion although no change in extracellular 
Aβ42 was reported. These findings suggest that Bin1 depletion may enhance the 
production of intracellular but not secreted Aβ. This was further supported by increased 
APP-CTFs, suggesting that BACE1 early endosome accumulation increases the 
amyloidogenic processing of APP. It was proposed that this is due to the increase in 
encounters between BACE1 and APP in early endosomes with Bin1 depletion, as an 
increase in APP and BACE1 colocalisation was observed in Bin1-depleted neurons. The 
retention of BACE1 in early endosomes was therefore sufficient to increase the encounter 
of BACE1 with APP contained within early endosomes. 
Interestingly, the increase in Aβ42 in neurons and impairment of BACE1 recycling in N2a 
cells was rescued by re-expressing neuronal Bin1 but not ubiquitous Bin1, suggesting a 
specific function of the neuronal isoform. However, the impairment of BACE1 recycling 
with BIN1 depletion has also been demonstrated by Miyagawa et al. (2016) in both N2a 
cells and non-neuronal HeLa cells. This suggests that regulation of intracellular trafficking 
by BACE1 can be regulated by other ubiquitous isoforms of BIN1 and is not just a 
neuron-specific function. With an involvement in APP processing identified in both 
neuronal and non-neuronal cell lines and the aforementioned plausibility of the 
involvement of BMECS in amyloidosis, it brings into question whether BIN1 is involved in 
APP processing at the blood-brain barrier. 
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4.1.4!The hCMEC/D3 Cell Line as a Model of the BBB 
Endothelial cells lining the CNS microvasculature possess unique morphological and 
functional properties involved in regulating exchanges between the circulating blood and 
brain parenchyma, distinguishing them from other vascular endothelia. The requirement 
for an in vitro culture system that accurately mimics the BBB has been recognised since 
brain capillaries were first isolated in the early 1970s (Brendel et al., 1974). It is difficult to 
investigate these properties in vivo as brain capillaries represent such a small proportion of 
total brain tissue. While utilisation of primary human brain endothelial cells represents an 
ideal model, the paucity of fresh human brain tissue makes this an impractical solution for 
large-scale studies. 
The hCMEC/D3 cell line represents the first extensively characterised human brain 
endothelial cell line recapitulating most of the unique properties of the BBB (Weksler et al., 
2005). Cells were derived from human temporal lobe microvessels isolated from a female 
epilepsy patient by surgical excision and transduced sequentially with the human telomerase 
reverse transcriptase (hTERT) and SV40 large T antigen lentiviral vectors. The clonal 
population of hCMEC/D3 cells was then selected which exhibited a normal diploid 
karyotype and elongated morphology in a tightly packed monolayer with contact inhibition 
at confluence, similar to primary brain endothelial cultures (Weksler et al., 2005). The cell 
line was extensively characterised for appropriate expression and localisation of endothelial 
and BBB-specific markers, including von Willebrand factor and junctional proteins VE-
cadherin, β- and γ-catenins, ZO-1, JAM-1 and claudin-5, suggesting maintenance of both 
tight junction and adherens junction organization (Weksler et al., 2005). Immunological 
characteristics included expression of leukocyte adhesion molecules and chemokine 
receptors, such as CXCR-1 to CXCR-5 and CCR-3 to -CCR-6 (Weksler et al., 2005). 
However, only low to medium TEER levels of 30-50 Ω/cm2 were achieved in 
hCMEC/D3 monolayers, compared to in vivo mammalian levels of 1000 Ω/cm2, indicating 
suboptimal formation of tight junctions (Butt et al., 1990). Nevertheless, highly restricted 
permeability to drugs at a range of hydrophobicity was demonstrated in line with in vivo 
values (Weksler et al., 2005). Stable cell growth and endothelial characteristics were 
maintained at least until the 35th passage (Weksler et al., 2013). 
The hCMEC/D3 brain endothelial cell line is widely utilised in BBB studies and the best-
characterised human BMEC line. It displays a close phenotype and APP expression level to 
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human primary BMECs (Urich et al., 2012), therefore presents a good predictive human 
BBB model to study APP processing and endocytic processes. 
4.1.5!Aims of this Chapter 
The aim of this chapter was to achieve depletion of total BIN1 (all isoforms) in a human 
brain endothelial cell line in order to provide an in vitro model to investigate BIN1 function 
at the BBB. This was then to be used for the characterization of the role of BIN1 in APP 
processing in BMECs. Specifically, the level and localisation of intracellular APP was 
determined with BIN1 depletion, in addition to an analysis of the products of APP 
proteolysis: Aβ40, β-CTF, sAPPα and sAPPβ. Components of the secretases that mediated 
APP cleavage were also analysed for expression levels in BIN1 depleted cells, including 
BACE1, PSEN1 and ADAM10. The immortalised human hCMEC/D3 cell line was 
chosen for this study as it displays characteristics of the BBB in a species-relevant cell line 
for the study of BIN1 in AD. 
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4.2!Experimental Design 
4.2.1!Optimisation of siRNA-mediated BIN1 Depletion  
Cells were transfected in 6-well plates as described in Chapter 2, Section 2.2. An 
optimisation experiment was carried out using two different BIN1 siRNA oligonucleotides, 
sequence ‘a’ binds within exon 9 of the BIN1 mRNA while sequence ‘b’ targets a region 
spanning the exon 8/9 junction. Both these regions are common to all BIN1 isoforms in 
order to target total BIN1 depletion. For each treatment with BIN1 siRNA, two controls 
were run alongside; cells in OptiMEM without Oligofectamine or oligonucleotide and cells 
transfected with siRNA targeting green fluorescent protein (GFP), which is not expressed 
in mammalian cells. Non-transfected and GFP siRNA-treated cells were used as controls in 
all further experiments, with quantitative comparisons made between BIN1-depleted and 
GFP siRNA-treated cells as this control allows the transfection procedure and off-target 
effects to be accounted for. A sample size (n) of at least 3 replicates was used for all 
quantified experiments, with n defined as a biological replicate performed on one passage 
of cells with separate reagents to any other replicates. 
Table 4.1: siRNA sequences used to analyse BIN1 depletion 
siRNA target Sequence Reference 
Total BIN1 ‘a’ CCAGAACCUCAAUGAUGUG Custom designed (Eurofins) 
Total BIN1 ‘b’ GGAGAUGAGCAAGCUCAAC Custom designed (Eurofins) 
GFP GGCUACGUCCAGGAGCGCA (Moody et al., 2015) 
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4.2.2!Western Blotting 
Western blotting was performed as described in Chapter 2, Section 2.3 using the primary 
antibodies detailed in Table 4.2. For each sample, 10-20 µg protein was used per well and 
samples were electrophoresed on a 10% acrylamide gel. Some of the blots were carried out 
by Catherine Matheson and Robert Greening as part of a final year undergraduate project, 
co-supervised by myself. All densitometry analysis was re-analysed by myself. 
Quantification of protein was calculated by densitometry analysis normalizing to GAPDH 
expression, previously described in Chapter 2, Section 2.3.6. A sample size (n) of at least 3 
replicates was used for all quantified experiments, as previously described. 
4.2.3!Immunocytochemistry Conditions 
Immunoctochemistry was carried out on a sample size of 3 per experiment as described in 
Chapter 2, Section 2.4 with cells fixed in 4% PFA according to Chapter 2, Section 2.4.1. 
For surface labelling of APP, triton X-100 was omitted from all wash buffers and antibody 
diluent. Alexa Fluor 488 Phalloidin (ThermoFisher Scientific) was used to stain filamentous 
actin (F-actin) at a 1/40 dilution for 20 min at RT, according to the manufacturer’s 
instructions. For colocalisation experiments, cells were stained sequentially with each 
antibody one at a time and controls were carried out alongside using each antibody alone. 
Details of the antibodies used in this chapter can be found in Table 4.2 
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Table 4.2: Primary Antibodies used in Chapter 4 
   WB = Western blotting, ICC = Immunocytochemistry 
 
4.2.4!Cell Viability 
Cell viability following siRNA treatment was assessed using the CellTiter 96® AQueous 
One Solution Cell Proliferation Assay (Promega) according to manufacturer’s instructions, 
as described in Chapter 2, Section 2.5. 
4.2.5!Enzyme-linked Immunosorbent Assays (ELISAs) 
ELISAs were used to quantify APP and products of its proteolysis in cell lysate and media 
from BIN1-depleted cells. For each assay, an initial optimisation was carried out to 
determine the appropriate amount of sample to be used. A four-point standard curve was 
used for optimisation, with the aim of reaching sufficient detection levels to fall within the 
exponential phase of the curve. For all assays, absorbance readings were converted to 
protein concentration values per ml of sample using a standard curve and then expressed as 
Antibody Host Supplier Dilution 
WB ICC 
BIN1 Mouse Abcam 0.48 µg/ml 0.48 µg/ml 
APP A4 (N-terminal, amino acids 66-
81 of APP, clone 22C11) 
Mouse Millipore N/A 1.33 µg/ ml 
BACE1 (C-terminal, amino acids 485-
501 of BACE1) 
Rabbit Millipore N/A 1 µg/ ml 
PSEN1 Rabbit Abcam 1 µg/ml N/A 
ADAM10 Rabbit Abcam 0.2 µg/ml N/A 
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a concentration per mg of total cell protein, according to protein concentration values 
calculated by BCA assay, described in Chapter 2, Section 2.3.2. These values were finally 
presented as a mean percentage of the non-transfected control for GFP siRNA-treated and 
BIN1-depleted cells. 
4.2.5.1! Quantification of APP 
For quantification of intracellular APP, the Human APP DuoSet ELISA kit (R&D 
Systems, Minneapolis, Minnesota, USA) and was used according to manufacturer’s 
guidelines (Thomas et al., 2011). Briefly, the capture antibody (4 µg/ml) was adsorbed to a 
96-well plate in PBS at RT overnight. Unbound sites were blocked with 1% BSA and 5% 
sucrose in PBS for 1 hour at RT. Samples were diluted 1/10 in PBS supplemented with 1% 
BSA quantified in duplicate using a six-point standard curve (0-20 ng/ml). The biotinylated 
detection antibody was used at 300 ng/ml and detected using streptavidin-HRP and o-
Phenylenediamine dihydochloride (Sigma). The reaction was stopped after 35 min by the 
addition of 2.5M H2SO4 and the plate was then read at 492nm on a uQuant plate reader. 
4.2.5.2! Quantification of APP fragments (Aβ40, sAPPα, sAPPβ and βCTF) and 
BACE1 
For analysis of extracellular Aβ40, sAPPα and sAPPβ and intracellular β-CTF and BACE1, 
ELISA kits (IBL, Hamburg, Germany) were used according to manufacturer’s instructions. 
Briefly, 48 hours post-transfection, cell media from siRNA-treated samples was quantified 
in duplicate using a standard curve on plates pre-coated with the capture antibody. Lysate 
samples for intracellular proteins (β-CTF and BACE1) were quantified singularly in order 
to use sufficient sample for detection with a limited stock volume while the extracellular 
proteins (Aβ40, sAPPα and sAPPβ) were quantified in duplicate. After adsorbing samples 
to pre-coated plates, an enzyme conjugate was added at 4°C for 60 minutes and detected 
using TMB substrate solution for 30 minutes at RT. TMB stop solution was added to stop 
the reaction and the plate read at 450nm on a uQuant plate reader. 
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4.3!Results 
4.3.1!Optimisation of siRNA-mediated BIN1 Depletion 
4.3.1.1! Level of knockdown 
In order to deplete BIN1 protein levels in the hCMEC/D3 cell line, two siRNA 
oligonucleotides targeting full-length BIN1 protein were independently tested. Both 
siRNAs significantly decreased BIN1 expression by >73% compared to non-transfected 
cells (Figure 4.1) while siRNA targeting GFP did not affect BIN1 protein expression 
compared to non-transfected cells and was therefore used as a control for siRNA 
treatment. While both siRNAs significantly reduced the protein levels of BIN1 (siRNA ‘a’: 
74% reduction p = 0.02, siRNA ‘b’: 90% reduction p = 0.003), the results of using siRNA 
‘a’ were less consistent than the 90% BIN1 protein depletion of siRNA ‘b’ (Figure 4.1) 
therefore siRNA ‘b’ was chosen for use in all future studies. The level of BIN1 depletion 
was quantified by Western blotting and further visualised by immunocytochemistry, which 
confirmed the depletion of BIN1 protein Figure 4.2. BIN1 depletion did not cause any 
gross changes in cell morphology or apparent cytoskeletal defects, as visualised with F-actin 
staining (Figure 4.2). All three conditions show a similar filamentous distribution of actin 
throughout the cytoplasm and peripheral staining, most likely representing the plasma 
membrane, suggesting that the overall cell structure and cytoskeleton was not affected by 
BIN1 depletion. 
4.3.1.2! Cell viability 
To assess any effect of the siRNA treatment on cell viability, a colorimetric cell 
proliferation assay was used which measures the reduction of MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) to formazan by viable 
cells, allowing for quantification of cell viability in culture. There was no significant 
difference in the absorption measurements between non-transfected, GFP siRNA and 
BIN1-depleted cells suggesting no effect of siRNA treatment or BIN1 depletion on cell 
viability (p > 0.05 using a two-tailed unpaired Student’s t test, Figure 4.3). 
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A) 
 
 
 
 
 
 
B)  
Figure 4.1: Optimisation of siRNA-mediated BIN1 depletion 
A) A representative Western blot demonstrating successful knockdown of BIN1 protein 48 
hours after exposure to separate siRNAs targeting BIN1 (a and b) in hCMEC/D3 cells.  
B) Quantification of BIN1 depletion 48 hours post-transfection shows significant 
knockdown using each siRNA expressed as a mean percentage of non-transfected cells (n 
= 3, ** = p<0.01 using a two-tailed unpaired Student’s t test, error bars = standard error of 
the mean (SEM). 
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Figure 4.2: Visualisation of BIN1 depletion using siRNA b 
Representative images of immunocytochemical staining of BIN1 (green) and F-actin (red) 
in non-transfected, GFP siRNA-treated and BIN1-depleted hCMEC/D3 cells. Nuclei are 
stained for DAPI, scale bar = 50 µm. 
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Figure 4.3: Quantification of cell viability upon treatment with GFP and BIN1 
siRNA 
Absorbance readings following an MTS colorimetric cell proliferation assay expressed as a 
percentage of non-transfected cells (100%). Values represent the mean, n = 3, error bars = 
SEM, p > 0.05 using a two-tailed unpaired Student’s t test. 
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4.3.2!Levels of APP Components with BIN1 Depletion 
4.3.2.1! Extracellular Aβ40 
To investigate whether BIN1 may affect the proteolytic cleavage of APP to produce Aβ, 
levels of Aβ40 were analysed in the extracellular media of non-transfected, GFP siRNA-
treated and BIN1-depleted cells by ELISA. The levels of extracellular Aβ40 indicated a 
30% decrease for BIN1-depleted cells compared to non-transfected, however this did not 
reach significance when compared to GFP siRNA-treated cells (Figure 4.4, p > 0.05 using 
a two-tailed unpaired Student’s t test). It should be noted that the levels of Aβ40 in the 
conditioned media ranged from 0.576 – 4.476 pg/ml which was at the low end of the 
detection limit of 1.56 pg/ml for the ELISA. Due to the low levels of Aβ40, it was 
anticipated that the level of Aβ42 produced would be beyond the limits of reliable 
detection for these cells as Aβ40 is produced at considerably higher levels than Aβ42 in vivo 
and in cultured BMECs (Mawuenyega et al., 2010, Kitazume et al., 2010). Aβ42 levels were 
therefore not analysed. 
4.3.2.2! β-CTF 
To further scrutinise the effect of BIN1 depletion on Aβ40 production, levels of the 
intracellular β-CTF, which undergoes β-cleavage to produce Aβ, were analysed. As it 
remains membrane-associated, intracellular β-CTF levels may allow a more detectable 
proxy for Aβ production. Indeed, β-CTF levels for all samples ranged from 1.680 – 2.982 
pmol/L, well within the detection range of 0.19 – 12 pmol/L for the assay. Interestingly, in 
contrast to Aβ40 levels, a 40% increase in the intracellular β-CTF was observed with BIN1 
depletion compared to GFP siRNA-treated cells (p < 0.05 using a two-tailed unpaired 
Student’s t test,  
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Figure 4.5).  
4.3.2.3! APP 
The increase in β-CTF may be a result of increased internalisation of APP into the cell, 
therefore levels of intracellular APP were then quantified. APP levels in diluted samples 
ranged from 5.169 – 15.259 ng/ml, allowing for accurate readings within the detectable 
limit of 0.625 – 20 ng/ml. Total APP levels within the cell lysates were calculated at 55.262 
– 194.870 ng/mg total protein. This large variation was observed between rather than 
within experiments and this was therefore overcome by expressing concentrations as a 
percentage of the non-transfected control. No significant difference was observed in total 
intracellular APP levels between BIN1-depleted and GFP siRNA-treated cells (p > 0.05 
using a two-tailed unpaired Student’s t test, (Figure 4.6). This was further supported by 
immunocytochemistry which was used to observe total APP and cell surface APP alone, in 
the absence of cell permeabilisation (Figure 4.12Figure 4.13). Overall levels of staining, 
although not quantitative, looked similar across conditions further suggesting there was no 
change in the levels of APP within the cell or on the cell surface. The observed localisation 
of APP is further described in Section 4.3.4. 
4.3.2.4! sAPPα and APPβ  
To further elucidate whether the increase in β-CTF was a result of a change at the β-
cleavage stage of APP processing, the amount of sAPPβ in the extracellular media was 
quantified. However, levels ranged from 0 – 0.262 ng/ml which fell outside the detectable 
range of the assay (0.78 – 50 ng/ml) therefore reliable quantification of sAPPβ levels could 
not be established. Levels of sAPPα, on the other hand, ranged from 0.458 – 11.261 
ng/ml, within the detectable range of the assay but showed large variation between samples 
and no significant difference with BIN1 depletion (p > 0.05 using a two-tailed Mann-
Whitney test, Figure 4.7). These results suggest that the amyloidogenic processing of APP 
is perturbed by BIN1 depletion as an increase in β-CTF levels was observed. However, 
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increased β-cleavage of APP cannot be determined from these results due to the low levels 
of sAPPβ detected and lack of change in extracellular Aβ40 levels. With no change in 
extracellular sAPPα levels, a change in the non-amyloidogenic processing of APP is not 
suggested. Collectively, these findings do show a change in the amyloid pathway as a result 
of BIN1 depletion. Due to the established involvement of BIN1 in endocytic trafficking, 
this may be suggestive of perturbation in this mechanism. 
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Figure 4.4: Quantification of extracellular Aβ40 upon BIN1 depletion 
Aβ40 protein levels in the conditioned media of GFP and BIN1-depleted cells, detected by 
ELISA and expressed as a percentage of non-transfected cells (100%). The mean level of 
Aβ40 in non-transfected cells was 2.44 pg/mg total protein.  Values represent the mean of 
six biological replicates, error bars = SEM, p > 0.05 using a two-tailed unpaired Student’s t 
test. 
 
 
 
 
 
 
 
 
 
Figure 4.5: Quantification of intracellular β-CTF upon BIN1 depletion  
β-CTF protein levels in GFP and BIN1-depleted cells, detected by ELISA and expressed as 
a percentage of non-transfected cells (100%). The mean level of β-CTF in non-transfected 
cells was 1.27 pg/mg total protein. Values represent the mean of nine biological replicates, 
error bars = SEM, * = p<0.05 using a two-tailed unpaired Student’s t test.  
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Figure 4.6: Quantification of total cellular APP upon BIN1 depletion 
Total APP protein levels in GFP and BIN1-depleted cells, detected by ELISA and 
expressed as a percentage of non-transfected cells. Values represent the mean of nine 
biological replicates, error bars = SEM, p > 0.05 using a two-tailed unpaired Student’s t 
test. 
 
 
 
 
 
 
 
Figure 4.7: Quantification of extracellular sAPPα upon BIN1 depletion 
Levels of sAPPα in the conditioned media of GFP and BIN1-depleted cells, detected by 
ELISA and expressed as a percentage of non-transfected cells. Values represent the mean 
of ten biological replicates, error bars = SEM, p > 0.05 using a two-tailed Mann-Whitney 
test. 
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4.3.3!APP Proteolytic Enzymes 
4.3.3.1! BACE1 
With previous studies indicating that depletion of BIN1 in vitro impairs the endosomal 
trafficking of BACE1, leading to intracellular accumulation, it was important to examine 
BACE1 levels with BIN1 depletion in the hCMEC/D3 cells. The level of cellular BACE1 
showed no significant difference in BIN1-depleted cells compared to GFP siRNA-treated 
cells (p > 0.05 using a two-tailed unpaired Student’s t test, Figure 4.8), suggesting that the 
increase in β-CTF may not be a result of increased β-secretase cleavage of APP by BACE1. 
Next the intracellular localisation of BACE1 was examined.  BACE1 largely showed a 
punctate, likely vesicular, distribution in the majority of cells with some cells exhibiting 
accumulation in the perinuclear region (Figure 4.9). In support of the ELISA data, 
although not quantitative, no gross differences in BACE1 levels were apparent with BIN1 
depletion and its localisation was also unaffected, showing a similar distribution across 
conditions (Figure 4.9). 
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Figure 4.8: Quantification of cellular BACE1 upon BIN1 depletion 
Total BACE1 protein levels in GFP and BIN1-depleted cells, detected by ELISA and 
expressed as a percentage of non-transfected cells. Values represent the mean of eight 
biological replicates, error bars = SEM, p > 0.05 using a two-tailed unpaired Student’s t 
test.
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Figure 4.9: BACE1 expression with BIN1 depletion 
Representative immunofluorescence images of BACE1 expression in non-transfected, 
GFP siRNA-treated and BIN1-depleted hCMEC/D3 cells. Images were taken at x40 
magnification with DAPI used to stain the nuclei, scale bar = 50 µm.   
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4.3.3.2! Presenilin 1 
PSEN1 encodes the catalytic subunit of the γ-secretase complex and has over 200 
identified mutations that cause fAD through altered γ-secretase function resulting in 
increased production of longer Aβ oligomers such as Aβ42 (Borchelt et al., 1996, Scheuner 
et al., 1996). As an increase in β-CTF was observed, with no obvious signs of increased 
internalisation of APP, it is possible that alteration of γ-secretase cleavage occurs with 
BIN1 depletion resulting in an accumulation of β-CTF due to less proteolysis into Aβ. 
PSEN1 protein levels were therefore examined in hCMEC/D3 cells with BIN1 depletion 
by Western blotting. Two bands were produced when blots were probed for PSEN1, the 
first at 58 kDa corresponding to the full-length protein whereas the much smaller band at 
25 kDa may represent the N-terminal fragment (Figure 4.10A). Indeed, PSEN1 is 
proteolytically cleaved at its large hydrophilic loop domain and is detected predominantly 
as stable N- and C-terminal fragments at 28 and 18 kDa, respectively (Thinakaran et al., 
1996). This endoproteolysis is thought to remove the loop domain that otherwise inhibits 
substrate binding and therefore activates PSEN1 (Knappenberger et al., 2004). The images 
of full-length and N-terminal PSEN1 presented in Figure 4.10A were derived from 
separate blots, as sufficiently quantifiable bands for the full-length protein were only 
obtained on a gel that had been run too far for the N-terminal fragment to remain. For this 
reason, the full-length protein required normalization to α-tubulin rather than GAPDH as 
this larger protein remained on the gel. Further optimisation would ensure both fragments 
could be detected on the same blot for more accurate quantification.  
There was no significant difference in PSEN1 holoprotein (58 kDa) expression with BIN1 
depletion compared to GFP siRNA-treated cells (p > 0.05 using a two-tailed unpaired 
Student’s t test, Figure 4.10B). The third replicate blot for the PSEN1 N-terminal fragment 
(25 kDa) was unreliable and was therefore excluded from analysis. This left only two blots 
for densitometry analysis. According to the GraphPad statistical software used, both SEM 
and t test calculations are valid with a sample of 2 (http://www.graphpad.com). Therefore, 
statistical analysis was carried out and showed no significant change in PSEN N-terminal 
fragment levels with BIN1 depletion compared to GFP siRNA-treated cells (p > 0.05 using 
a two-tailed unpaired Student’s t test, Figure 4.10C). This suggests that BIN1 depletion did 
not affect levels of PSEN1, therefore it is unlikely that a change in γ-secretase cleavage was 
driving the changes observed in the amyloidogenic pathway with BIN1 depletion. 
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4.3.3.3! ADAM10 
ADAM10 (A disintegrin and metalloproteinase domain-containing protein 10) is a 
membrane-bound protease and is one of the major APP α-secretases, cleaving APP within 
the Aβ domain, thus preventing Aβ generation (Asai et al., 2003). In order to explore 
whether the increase in β-CTF with BIN1 depletion may have been associated with a 
change in the α-cleavage of APP, levels of ADAM10 protein were measured by Western 
blot. As ADAM10 is subject to intramembrane proteolysis (Tousseyn et al., 2009), multiple 
bands were detected, with a strong band appearing at ~99 kDa followed by two bands at 
~75 kDa and ~69 kDa and the lowest bands at ~59 and ~55 kDa (Figure 4.11A). All 
bands were produced across all conditions with no apparent difference observed in total 
ADAM10 protein levels upon BIN1 depletion. Unfortunately, clear bands for the 
housekeeping gene GAPDH were unable to be achieved in two of the four blots generated. 
Figure 4.11B shows densitometry analysis of total ADAM10 expression from the two blots 
that successfully produced GAPDH bands, showing no significant difference between 
BIN1-depleted and GFP siRNA-treated cells (p > 0.05 using a two-tailed unpaired 
Student’s t test). Collectively these findings suggest that BIN1 depletion does not affect the 
amyloidogenic processing of APP by influencing secretase expression and therefore β-CTF 
may be increased in BIN1-depleted cells by an alternative method. 
  
                                                                                                                    
                                                                                                                    Chapter 4: Results 
 
 
135 
 
  
 
 
 
 
 
  
  
A) 
Figure 4.10: PSEN1 expression with BIN1 depletion 
A) Representative Western blots showing expression of the PSEN1 holoprotein (full 
length) and N-terminal fragment. 
B) Densitometry analysis of full length PSEN1 expression, normalised to GAPDH 
expression and expressed as a percentage of non-transfected cells, n = 3, error bars = 
SEM, p > 0.05 using a two-tailed unpaired Student’s t test. 
C)  Densitometry analysis of PSEN1 C-terminal fragment expression, normalised to α-
tubulin expression and expressed as a percentage of non-transfected cells, n = 2, error bars 
= SEM, p > 0.05 using a two-tailed unpaired Student’s t test. 
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Figure 4.11: ADAM10 expression with BIN1 depletion 
A) Representative Western blots showing expression of all detected ADAM10 protein 
domains in non-transfected, GFP siRNA-treated and BIN1 depleted hCMEC/D3 cells.  
B) Densitometry analysis of total ADAM10 expression, normalised to GAPDH expression 
and expressed as a percentage of non-transfected cells, n = 2, error bars = SEM, p > 0.05 
using a two-tailed unpaired Student’s t test.  
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4.3.4!Localisation of APP and BACE1 
With no gross changes in levels of key components of the APP proteolytic enzymes, the 
localisation of APP with BIN1 depletion was then investigated to see if this gave any 
mechanistic insights into the increase in βCTF. Immunocytochemistry was used to observe 
total APP and cell surface APP alone, in the absence of cell permeabilisation. Intracellular 
APP showed a strong uniform pattern of cytoplasmic staining which was filamentous in 
nature, appearing to follow a similar pattern to the actin cytoskeleton, previously observed 
with F-actin staining (Figure 4.2). This localisation pattern did not differ between 
conditions and was therefore not affected by GFP or BIN1 siRNA treatment (Figure 4.12) 
Extracellular APP staining, however, revealed a patchy, discontinuous distribution of APP 
in all conditions, suggesting low levels of expression in the plasma membrane (Figure 4.13). 
Immunoreactivity was high in the perinuclear region of some cells with the area overlying 
the nucleus, identified by DAPI staining, most frequently devoid of staining. Some cells 
(approximately 60%) were devoid of extracellular staining altogether. Across each 
coverslip, areas of enhanced filamentous staining were observed, much like those in the 
permeabilised condition, suggesting intracellular staining had occurred but the degree of 
this staining was not affected by siRNA treatment. 
The colocalisation of APP with BACE1 was also analysed to investigate whether the 
increase in β-CTF levels with BIN1 depletion was related to increased intracellular 
encounters between APP and BACE1. APP and BACE1 showed a strong degree of 
colocalisation in the cytoplasm of non-transfected hCMEC/D3 cells (Figure 4.14). This 
staining was considered specific to APP and BACE1 as it did not differ from control 
conditions where each antibody was used in isolation (Figure 4.15). With BIN1 depletion, 
however there was no observable change in the localisation pattern of BACE1 and APP 
and they remained both expressed abundantly in the cytoplasm (Figure 4.14).  
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Figure 4.12: APP expression with BIN1 depletion 
Representative immunofluorescence images of APP expression in non-transfected, GFP 
siRNA-treated and BIN1-depleted hCMEC/D3 cells. Images were taken at x40 
magnification with DAPI used to stain the nuclei, scale bar = 50 µm. 
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Figure 4.13: Extracellular APP expression with BIN1 depletion 
Representative immunofluorescence images of APP expression without permeabilisation in 
non-transfected, GFP siRNA-treated and BIN1-depleted hCMEC/D3 cells. Images were 
taken at x40 magnification with DAPI used to stain the nuclei, scale bar = 50 µm. 
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Figure 4.14: Colocalisation of BACE1 and APP with BIN1 depletion 
Representative immunofluorescence images of BACE1 and APP expression in non-
transfected, GFP siRNA-treated and BIN1-depleted hCMEC/D3 cells. Both antibodies 
were also used in isolation to confirm specificity. Images were taken at x40 magnification 
with DAPI used to stain the nuclei, scale bar = 25 µm   
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Figure 4.15: Staining of APP, BACE1 and secondary antibodies in isolation 
Representative images of hCMEC/D3 cells stained with APP (top left, green) and BACE1 
(bottom left, red) in isolation to illustrate that the same localisation pattern was observed 
compared to when the antibodies were used sequentially in the colocalisation experiment. 
The secondary antibodies used in this chapter did not confer background staining as 
illustrated in these representative images for Alexa-488 mouse (top right, green) and Alexa-
594 Rabbit (bottom right, red). DAPI was used to stain the nuclei, scale bar = 25 µm. 
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4.4!Discussion 
In this chapter, significant depletion of BIN1 by 90% has been demonstrated in 
hCMEC/D3 cells to create a model by which to assess the role of BIN1 in APP processing 
at the BBB. It has been demonstrated that depletion of BIN1 does not affect the 
proliferation of cells, suggesting it is not an essential component for cell viability, consistent 
with previous findings from a Bin1 null mouse model (Muller et al., 2003). While no 
significant differences in the levels of APP and Aβ40 were observed, a significant increase 
in the C-terminal fragment of APP as a result of β-cleavage, β-CTF, was found with BIN1 
depletion, suggesting the amyloidogenic processing of APP is affected by BIN1 depletion. 
Analysis of sAPPα and sAPPβ fragments, however, did not further elucidate this 
mechanism due to high variability between samples and levels falling beyond the 
detectability limit of the assay, respectively. Key components of the APP proteolytic 
enzymes, ADAM10, BACE1 and PSEN1 suggested there was no change in the levels of α, 
β and γ-secretases, respectively. This is indicative that the alteration in amyoidogenic 
processing of APP with BIN1 depletion is not the result of a change in levels of APP 
proteolytic enzymes. 
4.4.1!BIN1 has a Role in the Amyloidogenic Processing of 
APP 
With no apparent effect on intracellular APP following BIN1 depletion, it is suggestive that 
BIN1 is not involved in the internalisation of APP and this cannot account for the increase 
in β-CTF observed. This is consistent with previous work by Glennon et al. (2013), where 
siRNA-mediated knockdown of BIN1 in the human neuroblastoma SH-SY5Y cell line had 
no significant effect on intracellular APP expression. In addition, no change was detected 
in Aβ40, Aβ42 or sAPPα levels in the conditioned media, providing further support for the 
present study which reports no change in sAPPα and Aβ40 with BIN1 depletion compared 
to GFP siRNA-treated cells. Very low levels of Aβ40 were detected in the media of 
hCMEC/D3 cells therefore any small change in levels may not have been detected. Indeed, 
undetectable levels of endogenous Aβ have previously been reported in human BMECs 
where only upon overexpression of APP770 were Aβ40 and Aβ42 detectable in the culture 
media (Kitazume et al., 2010). Intracellular Aβ levels were not analysed in the present 
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study. Intracellular Aβ is often difficult to quantify as evidence suggests that Aβ40 is rapidly 
shipped out of cells (Koo and Squazzo, 1994) and is drastically diluted once in media. 
While sAPPβ levels were undetectable in the hCMEC/D3 cell media, Glennon et al. (2013) 
reported no change with BIN1 depletion in SH-SY5Y cells, further suggesting that BIN1 
depletion does not affect the amyloidogenic processing of APP. The authors also reported 
that while BIN1 protein levels were decreased in sAD frontal cortex compared to age-
matched controls, this did not correlate with soluble Aβ, insoluble Aβ or Aβ load, 
suggesting that depletion of BIN1 does not impact on the generation of Aβ peptides in the 
brain (Glennon et al., 2013). The authors suggested that the BIN1 homologue, AMPH1, 
could be involved in a compensatory mechanism when BIN1 is depleted, however this is 
yet to be investigated. 
The present findings do suggest an enhancement of the amyloidogenic pathway with BIN1 
depletion as indicated by increased βCTF, either in terms of increased production or 
decreased clearance. In support of this, a recent study reported that siRNA-mediated 
depletion of Bin1 in mouse neuroblastoma N2a cells and non-neuronal HeLa cells 
enhanced the amyloidogenic processing of APP (Miyagawa et al., 2016). Western blotting 
showed that BACE1 levels increased by approximately 50% and 30% with Bin1 depletion 
in N2a and HeLa cells, respectively, compared to non-targeting siRNA-treated cells while 
secreted Aβ40 and Aβ42 also showed a significant increase in both cell lines. Furthermore, 
a BACE1 activity assay in the membrane fractions of N2a cells revealed that the increase in 
BACE1 expression corresponded to increased activity with BIN1 depletion. While the 
present findings indicate no significant difference in secreted Aβ40 or BACE1 expression, 
Miyagawa et al. (2016) reported no effect on intracellular APP levels, consistent with our 
findings. Both studies therefore suggest an enhancement of the amyloidogenic pathway 
with BIN1 depletion, without affecting the levels of intracellular APP. The lack of change 
in BACE1 expression in the present study does not rule out a change in BACE1 activity 
levels and this remains to be quantified through an in vitro activity assay.  
Miyagawa et al. (2016) attributed the increase in BACE1 levels and activity to impaired 
intracellular trafficking of BACE1. This was based on evidence that labelled BACE1 was 
remained in early endosomes of HeLa cells 120 minutes after labelling in BIN1-depleted 
cells, whereas a large fraction had disappeared from control cells by this time point. In 
addition, a significant reduction of BACE1 in late endosome/lysosome compartments was 
observed in Bin1-depleted N2a cells, suggesting defective endocytic trafficking of BACE1 
                                                                                                                    
                                                                                                                    Chapter 4: Results 
 
 
144 
beyond the early endosomes. The present study did not observe any gross changes in the 
localisation of BACE1 with BIN1 depletion, while enhanced BACE1 staining in the 
perinuclear region was clearly apparent with BIN1 depletion in the study by Miyagawa et al. 
(2016). Unfortunately, time did not allow for an analysis of BACE1 colocalisation with 
early endocytic markers, such as early endosome antigen 1 (EEA1) and while BACE1 
accumulation was not apparent, it would be interesting to investigate whether enhanced 
localisation in early endosomes is observed with BIN1 depletion in the hCMEC/D3 cell 
line. BACE1 did show a strong pattern of colocalisation with APP in the present study, 
supporting previous evidence that BACE1 is involved in APP processing in BMECs 
(Devraj et al., 2016), however this distribution was not affected by BIN1 depletion. APP 
localisation also remained the same across conditions, showing strong filamentous staining 
throughout the cytoplasm, consistent with that previously reported in astrocytes (Young et 
al., 1999) while cortical neurons display a vesicular-like distribution with multiple fine 
fluorescent puncta (Allinquant et al., 1994). In the absence of detergent, staining was 
patchy and approximately 60% of cells showed a lack of staining altogether, consistent with 
that previously reported in embryonic cortical neurons (Allinquant et al., 1994). This 
suggests that APP may be poorly expressed in hCMEC/D3 cell membranes or resides 
within vesicular structures near the cell surface or membrane invaginations. 
It is interesting that, despite BIN1 depletion previously resulting in increased Aβ 
production in both a neuronal and non-neuronal cell line (Miyagawa et al., 2016), the 
present study does not show this effect in a brain endothelial cell line. The increase in β-
CTF without an increase in intracellular APP may suggest upregulation of the 
amyloidogenic processing of APP, however changes in any of the products of its 
proteolysis could not be detected to support this. This may suggest that levels are below 
detection to observe small changes or that β-CTF accumulation has occurred as a result of 
a change in β- and/or γ-secretase activity or impaired clearance/degradation of β-CTF.  
The data presented are not suggestive of a change in β-secretase activity as a result of BIN1 
depletion, contrary to aforementioned studies (Miyagawa et al., 2016, Ubelmann et al., 
2017). Firstly, while an increase in β-secretase cleavage is likely to result in an increase in β-
CTF, this would also be expected to increase the amount of sAPPβ produced by the same 
cleavage event. Unfortunately, levels of sAPPβ were too low to detect in the conditioned 
media therefore this could not be measured reliably. Secondly, an increase in Aβ40 would 
also be expected if an increase in β-secretase cleavage had occurred, as previously reported 
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(Miyagawa et al., 2016, Ubelmann et al., 2017) whereas no change in Aβ40 was observed. 
Finally, no change in BACE1 expression levels or cellular localisation was found in BIN1-
depleted hCMEC/D3 cells, suggesting that in this cell line BIN1 depletion does not affect 
the processing of APP by β-secretase cleavage.  
The presence of at least five separate protein bands for the α-secretase ADAM10 was 
expected given the known existence of an unprocessed pro-form as well as the mature 
enzyme (Anders et al., 2001), the proteolytic shedding known to occur in this protein 
(Tousseyn et al., 2009) and the possibility of ADAM10 splice variants or degradative 
products. However, there was no observable difference in expression across all detected 
bands between non-transfected, GFP siRNA-treated and BIN1 depleted cells. Coupled 
with the lack of change in sAPPα levels detected with BIN1 depletion, these results suggest 
that α-secretase expression was not affected by BIN1 depletion. However, it should be 
noted that ADAM10 is not the only putative α-secretase and other members of the ADAM 
family, in addition to several signaling cascades, can activate/increase α-secretase 
processing of APP. An in vitro α-secretase activity assay would be required to elucidate 
whether the α-cleavage of APP was affected by BIN1 depletion.  
Although an increase in β-CTF was observed, no corresponding change in Aβ40 was 
detected with BIN1 depletion. It is possible that a change in γ-secretase activity occurred 
with BIN1 depletion resulting in increased β-CTF but the effect was too minor to be 
detectable in the Aβ40 ELISA, due to the low endogenous Aβ40 levels in these cells.  The 
levels of PSEN1 were therefore examined with BIN1 depletion as an indicator of γ-
secretase activity.  The lack of significant change in PSEN1 expression suggests that there 
was no change in the amount of γ-secretase available to alter proteolytic activity. However, 
protein levels of enzyme components cannot be considered an accurate measure of 
enzymatic activity as changes in γ-secretase activity have previously been reported in the 
absence of a change in PSEN1 levels (Burns et al., 2003). It would therefore be necessary 
to carry out a γ-secretase activity assay to determine this. Furthermore, the intracellular 
localisation of components of the γ-secretase complex were not examined. This is highly 
relevant to the production of Aβ as PSEN1 and PSEN2 have been demonstrated to have 
very different subcellular locations in wild-type MEFs, with PSEN2 showing strong 
enrichment in late endosomes and lysosome compartments while PSEN1 was broadly 
distributed in the cell (Sannerud et al., 2016). The restricted compartmentalisation of 
PSEN2 in late endosomes/lysosomes results in selective cleaving of substrates within these 
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vesicles, such as APP, generating a pool of intracellular Aβ. In the context of the present 
study, it would be interesting to explore the cellular distribution of both PSEN1 and 
PSEN2 with BIN1 depletion, given that this mediates the substrates they interact with and 
the ultimate production of Aβ. Moreover, while the levels of extracellular Aβ are often 
considered an indicator of intracellular Aβ levels, there is evidence suggesting the levels of 
these Aβ pools can independently vary. For example, when PSEN1 knockout MNT-1 
human melanoma cells were transduced with β-CTF, less Aβ40 and Aβ42 was secreted 
compared to control cells but a significant increase in intracellular Aβ levels was recorded 
(Sannerud et al., 2016). The low levels of extracellular Aβ40 in the present study suggest 
that detection of intracellular Aβ may be challenging, however this analysis may provide 
further mechanistic insights on the consequences of BIN1 depletion on intracellular 
amyloidogenic processing and clearance.   
4.4.2!Does BIN1 have a Cell Type-specific Role in BMECs? 
Due to considerable alternative slicing, it is well documented that BIN1 is involved in 
multiple functional roles (Tan et al., 2013) and perhaps the role of BIN1 in BMECs of the 
BBB differs considerably from both neurons and other somatic cell types. Indeed, 
Ubelmann et al. (2017) reported that depletion of Bin1 in mouse primary cortical neurons 
resulted in a major reduction in BACE1 recycling to the plasma membrane in neuronal 
axons. However, only a minor reduction in BACE1 recycling was detected in the cell 
bodies and dendrites, suggesting Bin1 has a compartmentalised role within neuronal axons. 
The endocytic recycling defect as a result of Bin1 depletion was rescued by expression of 
siRNA-resistant neuronal Bin1, demonstrating a role for neuronal Bin1 in BACE1 
recycling. While neurons can be considered to exhibit polarity in terms of signals 
propagating in one direction from dendrites to axons, endothelial and epithelial cells 
exhibit apical-basolateral polarity. In addition to a compartmentalised role in the axonal 
domain of neurons, BIN1 has recently been implicated in the regulation of endocytic 
transport of apical, but not basolateral, proteins in polarised mouse mammary epithelial 
cells (Nakajo et al., 2016). It is possible that BIN1 may also have a similar role specific to 
the apical domain in BMECs which may not become apparent in the present experimental 
design due to a lack of established polarity in culture. This is an important aspect to 
consider in BBB models and therefore presents an avenue for future research, which will 
be further discussed in Chapter 7. 
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4.4.3!β-CTF Toxicity Independent of Aβ  
The increase in β-CTF with BIN1 depletion, in the absence of significant changes in Aβ 
production are particularly interesting in light of emerging evidence that β-CTF may 
contribute to sAD pathogenesis, independent of Aβ (Kim et al., 2016). Endosomal 
abnormalities, in the form of enlarged Rab5-positive vesicles, are among the earliest 
neuropathological features of AD (Cataldo et al., 2000) and induction of AD-like 
endosomal pathology has been observed in fibroblasts by overexpressing β-CTF (Jiang et 
al., 2010). In this study, pharmacologically inhibition of γ-secretase reduced Aβ40 and 
Aβ42 production but increased β-CTF levels and led to AD-like endosome dysfunction. 
Expression of a mutant form of APP that cannot undergo beta-cleavage, however, had no 
effect on endosomes (Jiang et al., 2010). These findings suggest that β-CTF but not Aβ or 
α-CTF is implicated in endocytic dysfunction in AD.  
β-CTF has also been implicated in endosomal dysfunction in transgenic mouse models. 
Accumulation of β-CTF was observed in the hippocampus of triple-transgenic mice 
overexpressing mutant APP, Tau and physiological levels of mutant PSEN1 (Lauritzen et 
al., 2012). Accumulation of β-CTF was reported from 3 months of age in enlarged 
structures expressing the lysosomal enzyme cathepsin B and lysosomal associated 
membrane protein-1 (Lamp1). This accumulation further increased by the pharmacological 
blockade of γ-secretase. While extracellular Aβ deposits and tau tangles were observed, 
intracellular Aβ was only detectable several months after β-CTF, also in enlarged cathepsin 
B-positive structures, and extracellular Aβ deposits were detected from 12 months of age 
onwards.  Double-transgenic mice lacking the PSEN1 mutation also showed β-CTF 
accumulation, demonstrating it cannot be accounted for by loss of PSEN1 function 
preventing γ-cleavage. Aged double transgenic mice also showed very few extracellular Aβ 
plaques and both Aβ40 and Aβ42 levels were very low suggesting that β-CTF accumulation 
did not correlate with Aβ load. Much like the present study, increased β-CTF did not 
correspond with increased Aβ production, suggesting a mechanism of impaired β-CTF 
clearance instead of increased production. Furthermore, the findings by Lauritzen et al. 
(2012) suggested that β-CTF was the earliest detectable amyloidogenic catabolite. It is 
possible that accumulation of β-CTF may precede further pathological changes that would 
not be detectable in vitro, such as the present study, as the time courses studied in vitro are 
too short to develop all of the pathologies that would be seen in AD. 
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The accumulation of β-CTF in enlarged structures positive for the lysosomal markers 
cathepsin B and Lamp1 in the triple transgenic mouse model suggested a link between β-
CTF and endosomal-autophagic-lysosomal (EAL) pathology (Lauritzen et al., 2012). Kim 
et al. (2016) extended these findings to elucidate a novel mechanism by which 
accumulation of β-CTF is both an effect, and a cause of EAL dysfunction. Of particular 
interest in this study was the GTPase rab5 which regulates early endosomes and has 
previously shown upregulation in individuals with MCI and sAD (Ginsberg et al., 2010). 
Kim et al. (2016) showed that rab5 activation was significantly decreased when β-CTF 
levels were increased in N2a cells, either by overexpressing wild-type APP or inhibiting γ-
secretase cleavage, compared to control cells expressing endogenous levels of β-CTF. The 
authors further showed that β-CTF recruits the rab5 effector APPL1 (adaptor protein 
containing pleckstrin homology domain, phosphotyrosine binding domain and leucine 
zipper motif) to rab5 endosomes. Here, it stabilises active GTP-rab5, leading to accelerated 
endocytosis, endosome enlargement and impaired axonal transport of endosomes (Kim et 
al., 2016). This was consistent with their findings that β-CTF levels were elevated in sAD 
cerebral cortex samples whereas APP and α-CTF levels were unaltered compared to age-
matched controls (Kim et al., 2016). Collectively, these findings suggest the involvement of 
a pathological loop whereby β-CTF accumulation can occur as a result of impaired 
endocytic trafficking but can also be the cause of it, further exacerbating the impairment. 
This could indeed be the case with BIN1 depletion and it is therefore important to explore 
endocytic function in this cell model. 
4.4.4!Conclusions 
This chapter presents evidence on the role of BIN1 in APP processing within the novel 
context of the BBB. BIN1 depletion results in a significant increase in intracellular β-CTF 
levels, without impacting intracellular APP levels or secreted Aβ40 or sAPPα. Furthermore, 
protein levels of key α- β- and γ-secretases were unchanged with BIN1 depletion, indicative 
of no alteration in enzymatic activity, however activity levels were not measured. 
Collectively, the data do not compliment the literature which has described the 
involvement of BIN1 in regulating BACE1 intracellular trafficking. However, this work 
presents a novel context for examining the role of BIN1 in APP processing and such 
experiments have not previously been reported in BMECs. While it is possible that cell-
type specificity may account for the disparity between the present results and the literature, 
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the polarised nature of BMECs in vivo may be involved in BIN1 function therefore future 
work would include the establishment of polarity in culture. This will be further discussed 
in Chapter 7.  Enzyme activity assays have also been cited as an important aspect of future 
work in order to elucidate any change in secretase activity levels with BIN1 depletion. 
Moreover, the increase in β-CTF in the absence of increased secretion of Aβ40 is 
suggestive of altered endosomal trafficking resulting in impaired degradation of β-CTF and 
possibly not an overall increase in the amyloidogenic processing of APP. With the well-
established role of BIN1 in CME and downstream endocytic trafficking, the following 
chapter will examine CME function in this BIN1-depleted cell model. 
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Chapter 5 
5! The Role of BIN1 in Clathrin-Mediated 
Endocytosis at the BBB 
 
5.1!Introduction 
Chapter 5 furthers investigations into the role of BIN1 in APP processing at the BBB by 
exploring its previously recognised role in CME. Much research into BIN1 function within 
the context of AD to date has focused on its involvement in endocytic recycling in neurons 
(See Chapter 1, Section 1.4). However, CME is also an important mechanism for 
transcytosis at the BBB and defects in transcytosis have been implicated in impaired 
clearance of Aβ from the brain (Erickson and Banks, 2013). With mounting evidence 
implicating BIN1 in endocytic trafficking in both neuronal and non-neuronal cells (Tan et 
al., 2013), it brings into question whether BIN1 may provide an important endocytic 
function in endothelial cells at the BBB. This chapter utilises siRNA-mediated depletion of 
BIN1 in hCMEC/D3 cells to examine the effect on key CME-related proteins, endocytic 
uptake and recycling. 
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5.1.1! Endocytosis at the BBB 
The crucial function of the BBB in regulating the flux of molecules between the circulating 
blood in the brain microvasculature and the CNS relies heavily on different vesicular 
transport pathways. Molecules can enter the cell by a variety of endocytic mechanisms and 
are shuttled through an internal membrane system for metabolic utilisation or degradation 
via the lysosomes (Smith and Gumbleton, 2006). This highly regulated internal membrane 
system is also involved in the transport of newly synthesised proteins from the ER through 
the Golgi to the plasma membrane where they may be exocytosed or replace those proteins 
and membrane components captured by endocytosis. In polarised cells, such as BMECs, 
both apical and basolateral membranes partake in endocytosis with each possessing their 
own endosomal compartments (Shivas et al., 2010). This allows endocytosed receptors to 
return to their original membrane, maintaining the receptor composition at these separate 
domains. Three major types of endocytosis have been definitively identified and defined in 
BMECs: non-specific fluid-phase endocytosis (Guillot et al., 1990), adsorptive-mediated 
endocytosis (Raub and Audus, 1990) and receptor-mediated endocytosis (Fishman et al., 
1987), encompassing the most common CME.  
5.1.1.1! Fluid-phase endocytosis 
Fluid-phase endocytosis is the non-specific uptake of solutes from the immediate 
extracellular environment by inward budding of the plasma membrane. It is ubiquitous 
throughout tissue cell types but its low level in BMECs is considered a defining feature of 
the BBB (Keaney and Campbell, 2015). Horseradish peroxidase (HRP) is a 40 kDa plant 
glycoprotein that does not bind the plasma membrane or undergo transcytosis at the BBB 
and is instead sequestered into endocytic vesicles for degradation in the lysosome (Noble et 
al., 1994). Early studies used HRP internalisation in mouse BMECs as a measure of fluid-
phase endocytosis, noting that its rate of uptake was 10-fold less than the absorptive-
mediated endocytic marker wheat germ agglutinin (WGA) (Banks and Broadwell, 1994). 
Morphological studies of the BBB using transmission electron microscopy (TEM) showed 
poor internalisation of HRP within mouse BMECs (Reese and Karnovsky, 1967). Dextrans 
are another example of fluid-phase endocytic markers. They are hydrophilic 
polysaccharides that when conjugated to a fluorescent tag, have been used extensively as an 
index of fluid-phase endocytosis in BBB transport studies. Dextran uptake studies have 
                                                                                                                              
                                                                                                 Chapter 5: Results 
 
 
152 
also shown low levels of fluid phase endocytosis to be present in BMECs. A comparison 
between endothelial cells of the brain and the periphery estimated that rates of fluid-phase 
endocytosis of fluorescently-labelled dextran were 30-40-fold less in BMECs than in aortic 
vascular endothelial cells (Mizuguchi et al., 1994). 
5.1.1.2! Adsorptive-mediated endocytosis 
Adsorptive-mediated endocytosis (AME) is also a non-specific process but occurs to a 
greater extent and rate than fluid-phase endocytosis at the BBB. It requires an excess 
positive charge on the molecule, which allows it to bind to the cell surface through 
electrostatic interactions with the negatively-charged plasma membrane. WGA is a member 
of the lectin family and an example of cargo internalised by AME through its interactions 
with negatively-charged oligosaccharides on the cell surface. AME occurs to a greater 
extent than fluid-phase endocytosis at the BBB. Banks and Broadwell (1994) traced HRP-
labelled WGA through mouse and rat brain capillary endothelium in vivo showing a 10-fold 
increase in uptake compared to HRP alone. The HRP-WGA showed accumulation both in 
endosomes and lysosomes and was detected in cells and processes of the neuropil four 
hours after intravenous injection, illustrating the adsorptive transcytosis of WGA across the 
BBB. 
5.1.1.3! Receptor-mediated endocytosis 
Two main pathways have been identified for receptor-mediated endocytosis: the clathrin-
dependent and the caveolar/lipid raft-dependent endocytic pathways (Doherty and 
McMahon, 2009). CME is the best characterised mechanism for mediating the 
internalisation of ligand-bound membrane receptors into cells. As previously described in 
Chapter 1, Section 1.4.1, CME is a ubiquitous cellular mechanism involving the binding of 
a specific ligand to its cell surface receptor facilitating uptake of the receptor-ligand 
complex. The receptor and bound ligand may be recycled back to the plasma membrane 
from which it originally budded. An example of a complex that is trafficked in this manner 
is the transferrin receptor (TfR) and its iron-binding ligand transferrin (Tf) (Iacopetta and 
Morgan, 1983). Alternatively, both receptor and ligand may be trafficked via early 
endosomes to lysosomes for degradation. In polarised cells, such as BMECS, ligand-bound 
receptors may bypass the lysosomal system and enter the transcytotic pathway, resulting in 
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the ultimate delivery of the ligand to a different plasma membrane domain (Descamps et 
al., 1996). This is evident in apical to basolateral transport across BMECs. In order for this 
to occur, the endocytosed material must be selectively retrieved from the early endosomes 
or it will continue onto MVBs, late endosomes and lysosomes for degradation (Preston et 
al., 2014).  
 
At the BBB, up to 20 receptors have been identified that are involved in receptor-mediated 
endocytosis, with the majority using CCVs to commence transcytosis between the apical 
and basolateral membranes (Preston et al., 2014). Despite the importance and complexity 
of receptor-mediated endocytic mechanisms at the BBB, low endocytic activity relative to 
peripheral endothelial cells is one of the key properties of BMECs with only 15% of the 
number of endocytic vesicles of an equivalently-sized skeletal muscle capillary endothelial 
cell (Coomber and Stewart, 1986). The technical challenge of visualising such infrequent 
events may in part account for our limited knowledge of how cargo destined for 
transcytosis is trafficked through BMECs. 
5.1.2!Transcytosis 
From the recycling endosome, cargo can either be recycled directly back to the plasma 
membrane or progress further down the transcytotic pathway, fusing with late endosomes, 
mostly found in the perinuclear region. While cargo destined for degradation is sorted into 
endocytic carrier vesicles to the lysosome, MVBs can arise from the inward budding of the 
late endosome which creates intraluminal vesicles. These are then released as exosomes at 
the plasma membrane. Extracellular microvesicles from BMECs have been successfully 
isolated and characterised, containing in excess of 1000 proteins, among which were 
receptors known to undergo CME such as the TfR and LRP1 (Haqqani et al., 2013).  
For successful transcytosis to occur through BMECs, internalised cargo and/or receptors 
from one membrane must traverse the cell for exocytosis on the opposite membrane. The 
relative composition at these respective domains is therefore crucial to BMEC function and 
the ultimate homeostasis of the brain (Shivas et al., 2010). Differences in lipid composition 
between the two membranes have been identified, showing that the basolateral membrane 
contains more caveolae, flask-shaped membrane invaginations which form at 
microdomains rich in glycosphingolipids and sphingomyelin (Bendayan et al., 2006). The 
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distribution of target receptors is specific to apical or basolateral domains and is an 
important determinant of the direction of transcytosis. The receptor for Tf, for example, is 
found on the apical side of BMECs, largely limiting its transport in the direction of blood-
to-brain (Roberts et al., 1993). Bidirectional transport of molecules may utilise specific 
basolateral and apical receptors. For example, the efflux of Aβ, implicated in AD 
pathogenesis, involves the efflux transporter LRP1 while Aβ influx is mediated by RAGE, 
as described in Chapter 1, Section 1.6.4. 
The mechanisms controlling transcytosis in BMECs are still poorly understood, but 
evidence has been gathered from studies in other polarised cell types. With both 
membranes internalising cargo-bound receptors through to recycling endosomes, cargo 
must bypass the lysosome system and be directed for exocytosis at the appropriate 
membrane, while proteins and lipids must be correctly recycled back to their membrane of 
origin to maintain polarity (Shivas et al., 2010). In epithelial cells, separate early endosome 
compartments exist such that apically endocytosed and basolaterally endocytosed cargo are 
segregated (Bomsel et al., 1990). Thompson et al. (2007) found that apical and basolateral 
proteins were pre-sorted into separate membrane subdomains within the same recycling 
endosome in Madin-Darby Canine Kidney (MDCK) epithelial cells, but only once 
polarisation had been achieved by growing at confluency. This sorting was not observed in 
non-polarised Chinese hamster ovary (CHO) cells (Thompson et al., 2007). 
5.1.3!Transferrin Transport at the BBB 
Tf is the principal iron-carrying protein in plasma (Bradbury, 1997) and is an archetypal 
substrate for CME. Tf and its receptor are ubiquitously expressed, providing researchers 
with an accessible system for measuring CME using fluorescently-labelled Tf which can be 
traced into the cell. The TfR is a 90kDa homodimer which spans the plasma membrane 
and mediates the entry of two molecules of iron-bound Tf (holotransferrin) at a time by 
CME. Within the N- and C- terminal domain of the transferrin protein are hydrophilic 
binding clefts for oxidised iron (Fe3+) (MacGillivray et al., 1983). Upon iron binding, a 
conformational change in the protein is induced which enhances affinity for the TfR 
present on the cell surface (Young et al., 1984).  
The TfR complex is endocytosed via CCVs and trafficked to the early endosome where Tf-
bound iron dissociates in the acidic environment and is reduced from Fe3+ to Fe2+ (Dautry-
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Varsat et al., 1983). This releases Fe2+ into the endosome for active transport into the 
cytoplasm by a divalent metal transporter. Within BMECs, Fe2+ can then cross the 
basolateral membrane by active transporters such as ferroportin (Wu et al., 2004). Once 
iron is released from Tf, it is termed apotransferrin and remains bound to the TfR within 
the acidic endosome. Apotransferrin is then recycled back to the plasma membrane, where 
it was initially internalised, for release into the extracellular fluid at physiological pH, 
allowing it to bind iron once more.  
Tf transport at the BBB has been extensively investigated as it not only enters via CME but 
also crosses the BBB by transcytosis (Descamps et al., 1996), providing an attractive target 
for drug transport studies. Descamps et al. (1996) showed that iron crosses bovine BMECs 
bound to Tf with approximately 75% being trafficked for release at the basolateral side 
(Descamps et al., 1996). Furthermore, the TfR transcytotic pathway has been successfully 
manipulated to deliver therapeutic antibodies to the brain. Yu et al. (2011) showed that a 
bispecific antibody targeting TfR and BACE1 successfully accumulated in the mouse brain 
leading to a greater reduction in brain Aβ than treatment with a monospecific BACE1 
antibody. Although a full understanding of the precise cellular mechanisms associated with 
TfR trafficking at the BBB remains unclear, the extensive literature available suggests that 
transferrin proposes a useful and reliable substrate for the demonstration of clathrin-
mediated endocytosis and recycling in BMECs. 
5.1.4!CME at the BBB with Relevance to AD 
In the context of AD, CME is crucial to APP processing. As previously described in 
Chapter 1, Section 1.4.3, alterations in the internalisation of APP via CME can influence 
whether APP enters the non-amyloidogenic or amyloidogenic pathway, therefore affecting 
the production of Aβ. CME at the BBB is also important for the transcytosis of exogenous 
Aβ across BMECs as LRP1, which mediates Aβ clearance, is internalised via CCPs (Zhao 
et al., 2015).  
The molecular mechanisms involved in LRP1-mediated Aβ clearance across the BBB have 
recently been analysed in more detail, implicating PICALM in regulating this process (Zhao 
et al., 2015). Decreased levels of PICALM were reported in AD brain endothelium and this 
was associated with ~50% diminished basolateral-to-apical transcytosis of Aβ in vitro, 
compared to age-matched controls. Using human brain endothelial monolayers, binding of 
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Aβ to the ectodomain of LRP1 was shown to initiate CME of the Aβ-LRP1 complex. 
PICALM, clathrin heavy chain (CHC) and AP2 bound to LRP1 within 30s of Aβ40 
addition, however, while CHC and AP2 dissociated rapidly, consistent with uncoating of 
the CCV, PICALM remained associated with LRP1 for up to 4 min. PICALM and the 
Aβ40-LRP1 complex trafficked to Rab5-positive early endosomes, but not late endosomes 
or lysosomes, and were found to associate with the ERC marker Rab11. Depletion of 
PICALM by siRNA inhibited Aβ40 basolateral-to-apical transendothelial transport, 
suggesting it is critical for maintaining the endosomal trafficking of Aβ throughout the 
basolateral-to-apical transcytotic pathway (Zhao et al., 2015). These findings are of 
particular interest to the present study as the association of PICALM with sAD was initially 
established through genome-wide association studies, much like BIN1 (Harold et al., 2009, 
Lambert et al., 2009, Seshadri et al., 2010, Lambert et al., 2013). Furthermore, the 
associated variants are not within the coding region of PICALM but ~88kb 5’ of the gene 
itself (Harold et al., 2009, Lambert et al., 2013), suggesting the variant may mediate sAD 
risk by affecting PICALM gene expression. Indeed, the sAD-associated PICALM SNP 
rs659023G was significantly associated with decreased expression of PICALM in PBMCs, 
demonstrating a cis-regulatory effect (Raj et al., 2012). AD risk loci upstream of the BIN1 
gene have also been implicated in transcriptional regulation of BIN1 (Chapuis et al., 2013, 
Raj et al., 2012). This was demonstrated in SH-SY5Y, HEK and PBMCs, suggesting that 
AD-associated genetic variants upstream of the BIN1 gene may confer expression changes 
in BIN1 in both neuronal and non-neuronal cell types. 
Zhao and colleagues concluded their findings by using CRISPR/Cas9 genome editing to 
generate isogenic iPSC lines for the two homozygous allelic variants of the highly validated 
and replicated rs3851179 PICALM SNP, whose rs3851179A allele is associated with a 
reduced risk of AD compared to the rs3851179G allele (Harold et al., 2009, Lambert et al., 
2009, Lambert et al., 2013). Upon differentiation into endothelial cells, they found that the 
rs3851179A-expressing lines had 72–78% higher expression levels of PICALM mRNA and 
protein, with 120% higher Aβ clearance than the rs3851179G allele (Zhao et al., 2015). 
Given that both PICALM and BIN1 have been identified as sAD susceptibility loci and are 
implicated in CME pathways, these findings bring to question whether they may both be 
implicated in AD pathogenesis through defective endocytic mechanisms. While the 
involvement of PICALM in endocytic trafficking at the BBB has been demonstrated (Zhao 
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et al., 2015), the potential role that BIN1 might play in endocytic trafficking at the BBB is 
yet to be explored. 
5.1.5!Aims of this Chapter 
Within the context of the aforementioned literature, the increase in β-CTF levels following 
BIN1-depletion in hCMEC/D3 cells demonstrated in Chapter 4 may be indicative of 
perturbed endocytic mechanisms in this cell line. The aim of this chapter therefore was to 
investigate whether BIN1 depletion affects CME and recycling in the hCMEC/D3 cell line, 
as an in vitro model of the BBB. To address this research question, BIN1 protein was 
depleted using siRNA and compared to cells treated with GFP siRNA as a non-targeting 
control. Analysis of endocytic protein expression was carried out by Western blotting while 
CME itself was measured by Alexa-488-conjugated transferrin uptake. Endocytic recycling 
was analysed by chasing transferrin-pulsed cells with unlabeled transferrin and measuring 
its depletion over time. An analysis of the BIN1 isoforms expressed in hCMEC/D3 cells 
allowed for further interpretation of the data, shedding new light on the role of BIN1 in 
non-neuronal cell types.  
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5.2!Experimental Design 
5.2.1!BIN1 Depletion in hCMEC/D3 cells 
Cell plating and depletion of BIN1 protein was performed as previously described in 
Chapter 2, Section 2.2 and confirmed by Western blotting as described in Chapter 2, 
Section 2.3. 
5.2.2!Western Blotting 
Western blotting was performed as described in Chapter 2, Section 2.3 using the primary 
antibodies detailed in Table 5.1 with 10-20 µg protein used per sample, run on a 10% 
acrylamide gel. Some of the blots investigating AP2, CHC and PICALM with BIN1 
depletion were carried out by Catherine Matheson and Robert Greening as part of a final 
year project, co-supervised by myself. All densitometry analysis was independently analysed 
by the students and myself. Due to the large size of the AMPH1 protein, a 7% acrylamide 
gel was prepared. Mouse whole brain lysate was used as a positive control for AMPH1 
expression, with 2 µg protein loaded per well. Samples were prepared, as previously 
described, by Lelos et al., (2011) from 22-month-old Tg2576 (TG) and wild-type mice. 
Briefly, following dissection, tissue was homogenised at 75 mg/ml in 2% wt/vol SDS and 
supplemented with 1× protease inhibitor cocktail III (Calbiochem, Nottingham, England). 
Tissue was incubated with agitation overnight and centrifuged at 100,000 x g for 1 hour 
and the soluble supernatant fraction diluted 1:40 in EC buffer (20 mM 
Na2HPO4/NaH2PO4, 0.2 mM EDTA, 0.4 M NaCl, 0.2% BSA, 0.05% CHAPS, 0.05% 
NaN3, pH 7) for use. Quantification of protein was calculated by densitometry analysis 
normalising to GAPDH expression, previously described in Chapter 2, Section 2.3.6. A 
sample size (n) of at least 3 replicates was used for all quantified experiments, with n 
defined as a biological replicate performed on one passage of cells with separate reagents to 
any other replicates.   
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Table 5.1: Primary antibodies used for Western blotting in Chapter 5 
Protein Species Supplier Working concentration 
BIN1 Mouse Abcam 0.48 µg/ml 
AP2µ2 Mouse BD Biosciences 0.5 µg/ml 
CHC Mouse BD Biosciences 0.25 µg/ml 
PICALM Rabbit Millipore  
(See Appendix II) 
0.66 µg/ml 
AMPH1 Rabbit Abcam 0.133 µg/ml 
GAPDH Mouse Abcam 0.13 µg/ml 
 
5.2.3!AP2 depletion  
Depletion of AP2µ2 was performed as described for BIN1 depletion in Chapter 4, Section 
4.2.1 using the siRNA sequence 5’-AAGUGGAUGCCUUUCGGGUCA-3’ (Eurofins) 
previously demonstrating successful knockdown (Moody et al., 2015). An optimisation 
experiment was performed to determine the concentration of oligonucleotide that would 
achieve consistent AP2µ2 depletion for future experiments. Final concentrations ranging 
from 25-75 nM were used for optimisation alongside matching concentrations of GFP 
siRNA as controls. The concentration of oligofectamine and length of transfection and all 
other methods were kept consistent throughout, as previously described in Chapter 4, 
Section 4.2.1. AP2µ2 depletion was confirmed by Western blotting, as described in Section 
5.2.2. 
5.2.4!Transferrin Uptake 
Uptake of Alexa-488-conjugated transferrin (Alexa-48-Tf) was performed according to 
previously published methods (Thomas et al., 2016, Al Soraj et al., 2012). Cells were 
cultured in 6-well or 12-well plates and transfected with GFP siRNA or BIN1 siRNA, as 
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described in Chapter 4, Section 4.2.1. As a measure of endocytosis, uptake of Alexa-488-Tf 
was quantified 48 hours post-transfection. Firstly, cells were washed twice with OptiMEM 
and serum-starved with OptiMEM with 0.2% BSA for 30 min at 37°C. After a further two 
washes with OptiMEM, cells were incubated with 7.8 µg/ml (100 nM) Alexa-488-Tf 
diluted in OptiMEM for 5, 15, 30 and 60 minutes. An optimisation experiment was carried 
out with non-transfected cells to determine the maximum time point to be used, when 
Alexa-488-Tf levels plateaued. Cells without the addition of ligand were incubated at 37°C 
for the duration of the assay to act as a time 0 control. Cells were harvested on ice by 
washing twice with ice-cold PBS, once with ice-cold acid wash (0.2 M acetic acid, 0.2 M 
NaCl, pH 2.0) and a further three times with RT PBS. Trypsin (0.05%, ThermoFisher 
Scientific) was added to cells and incubated at RT until the cells were in suspension before 
adding the same volume of trypsin inhibitor solution (500 µg/ml trypsin inhibitor, 75 
µg/ml DNase, 1% BSA in PBS). The cell suspension was then centrifuged at 325 x g at 
4°C for 3 min, the pellet washed twice with ice-cold PBS, resuspended in 500 µl 75 µg/ml 
DNAse, 1% BSA in PBS and transferred to fluorescence-activated cell sorting (FACS) 
tubes via 30 µm filters (Sysmex, Milton Keynes, England). The geometric mean of 
fluorescent intensity for at least 10,000 events was measured by flow cytometry using the 
BD FACSverse (BD Biosciences, Oxford, England) with debris and doublets gated out.  
5.2.5!Alexa-488-Tf Recycling 
Cells were cultured in 12-well plates and transfected with GFP siRNA or BIN1 siRNA, as 
described in Chapter 4, Section 4.2.1. Following two washes with OptiMEM, cells were 
pulsed with 7.8 µg/ml Alexa-488-Tf for 60 min at 37°C. Cells were washed 6 times with 
RT PBS and chased with 100 µg/ml unlabelled holotransferrin (Sigma) in OptiMEM for 
7.5, 15, 30 and 60 min at 37°C. For each time point, a control sample was washed 6 times 
in ice-cold PBS and chased with 100 µg/ml unlabelled holotransferrin at 4°C for 7.5, 15, 30 
and 60 min to inhibit endocytic pathways. For the time 0 controls, cells were harvested 
immediately after the pulse as follows. Plates were placed on ice and washed three times 
with ice-cold PBS, once with ice-cold acid wash (0.2 M acetic acid, 0.2 M NaCl, pH 2.0) 
and a further three times with ice-cold PBS. Cells were trypsinised on ice with 0.05% 
trypsin until in suspension before adding the same volume of trypsin inhibitor solution. 
Cell suspension was then centrifuged at 325 x g at 4°C for 3 min, the pellet washed once 
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with ice-cold 75 µg/ml DNAse, 1% BSA in PBS and, resuspended in 500µl before 
transferring to FACs tubes via 30 µm filters. Fluorescent intensity of at least 10,000 events, 
with debris and doublets gated out, was measured by FACS using the BD FACSverse.  
5.2.6!Immunocytochemistry Conditions 
Cells were fixed in 100% methanol and immunocytochemistry was carried out as described 
in Chapter 2, Section 2.4 with three replicates per experiment and representative images 
shown. The early endosome marker EEA1 (rabbit polyclonal antibody, Abcam) was used 
at 1.67 µg/ml. 
5.2.7!Identification of BIN1 mRNA Isoforms 
In order to determine which BIN1 isoforms are expressed in the hCMEC/D3 cell line, 
total RNA was extracted from cultures, the region of interest amplified by polymerase 
chain reaction (PCR), cloned and sequenced.  
5.2.7.1! Total RNA extraction and quantification 
Cells were harvested by treatment with Trypsin/EDTA as described in Chapter 2, Section 
2.1.2 and counted using by trypan blue exclusion method (Chapter 2, Section 2.1.5) to 
ensure no more than 1 x 107 cells were used. Cells were transferred to an RNase-free 
polypropylene centrifuge tube (ThermoFisher Scientific) and centrifuged at 455 x g for 5 
min. Supernatant was completely removed and the total RNA prepared from the cell pellet 
immediately using the RNeasy® Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. RNA was eluted in 30 µl RNase-free water and concentration 
and absorption ratios determined using a Nanodrop 800 (ThermoFisher Scientific). A ratio 
of A260nm to A280nm above a value of 2.0 indicated a suitable level of RNA and the absence of 
contaminating protein. 
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5.2.7.2! cDNA synthesis from total RNA 
A QuantiTect Reverse Transcription Kit (Qiagen) was used for the elimination of genomic 
DNA and creation of cDNA from 1 µg RNA according to manufacturer’s instructions. 
The cDNA was stored at -20°C. 
5.2.7.3! Polymerase Chain Reaction (PCR) primer design 
While the entire BIN1 mRNA was too large a fragment for standard PCR amplification, 
the area containing the CLAP domain, with the most potential for variability due to 
alternative splicing events, was targeted for PCR amplification. Primer sequences 
(Eurofins) were designed to amplify the region between exon 11 and exon 15, neither of 
which are subject to alternative splicing. The sequences were as follows: 5’-
TGTCAGTGGCCGTGTAGTC-3’, 5’-CCCGAGATCAGAGTCAACCA-3’. PCR 
primers were designed in silico using the Primer 3 web resource 
(www.http://bioinfo.ut.ee/primer3) with default settings and an average length of 20 base 
pairs and GC content less than 80%.  
5.2.7.4! PCR primer optimisation 
For optimisation, each PCR reaction contained 6.67 ng/µl cDNA or equivalent volume of 
nuclease-free water as a negative control, 1.6 mM deoxynucleotides (dNTPs), 0.23 µM of 
each primer, 1.2 µl 10x PCR buffer (Qiagen) and 0.06 µl Hot Start Taq polymerase 
(Qiagen) made up to a total volume of 12 µl with nuclease-free water. A gradient PCR was 
carried out, with a melting temperature (Tm) range of 52 – 60 ºC, incorporating the Tm 
specified by the manufacturer for each primer. Samples were incubated under the following 
conditions in thermocyclers (Bio-Rad): 95°C for 15 min, 35 cycles of 95°C for 40 s, Tm for 
40 s and 72°C for 1 min followed by a final incubation at 72°C for 10 min. The Tm of 57 
ºC was considered to give the strongest band for each isoform and was therefore chosen 
for amplification. In order to generate enough PCR product for cloning, the reaction was 
scaled up to 25 µl in volume. Following amplification, samples were cooled to 4°C before 
further use or frozen for long-term storage at -20 °C. 
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5.2.7.5! Agarose Gel Electrophoresis 
Post-PCR samples were analysed using a 2% (w/v) agarose gel in 0.5X Tris/Borate/EDTA 
buffer (ThermoFisher Scientific) containing 0.1 µg/ml Ethidium Bromide (Sigma). Agarose 
solution was heated until clear and cooled slightly before pouring into a gel mould with 
appropriate gel comb and left to cool until solid. PCR products were diluted in 6x purple 
gel loading dye (New England Biolabs, Ipswich, Massachusetts, USA) and run at 100 V 
alongside 10 µl Quick-Load 100 bp DNA ladder (New England BioLabs) until sufficient 
separation of bands was achieved. 
5.2.7.6! DNA Clean-up 
Amplified DNA was purified using the QIAquick PCR Purification Kit (Qiagen), 
according to manufacturer’s instructions and quantified using a Nanodrop 800. 
5.2.7.7! Ligation 
The pGEM®-T Vector (Promega) was used to insert amplified cDNA fragments for 
molecular cloning according to the manufacturer’s instructions. The ligation reaction 
combined 50 ng pGEM®-T vector, 5 µl 2X rapid ligation buffer, 8.3 ng PCR product and 
3 Weiss units T4 DNA Ligase made up to a final volume of 10 µl in nuclease-free water 
and was incubated at 4°C overnight to produce the maximum number of transformants. A 
negative control ligation reaction was set up alongside using an equal volume nuclease-free 
water in place of the PCR product. 
5.2.7.8! Transformation 
High-efficiency DH5α™ competent cells (ThermoFisher Scientific) were thawed on ice 
and gently mixed before combining 50 µl with 2 µl ligation reaction (separate reactions for 
the positive and negative ligations). The tubes were gently mixed and incubated on ice for 
20 min before heat-shocking the cells in a 42°C water bath for 30 s and immediately 
returning to the ice for 2 min. Cells were incubated with 920 µl RT SOC medium, added 
directly to tubes, for 1 hour at 37°C. Meanwhile, growth plates were prepared using 
lysogeny broth (LB) agar (Sigma) containing 100 µg/ml ampicillin (Sigma) and left to 
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solidify before spreading 200 µl cell culture per plate and incubating overnight at 37°C to 
allow colony formation. Plates could then be stored at 4°C before colonies were picked for 
screening. 
5.2.7.9! PCR Screening 
A total of 48 samples were picked at random from individual colonies using a P10 pipette 
tip and added to the following PCR mix: 0.24 mM dNTPs, 0.234 mM of each primer, 2.5 
µl 10x PCR buffer and 0.125 µl Hot Start Taq polymerase made up to a total volume of 12 
µl with nuclease-free water. The remainder of cells on the same tip were added to a 
corresponding growth plate containing 50 µl LB broth and 100 µg/ml ampicillin and 
incubated for 6 hours at 37°C. A total of 48 colonies were picked for screening and 
incubated in thermocyclers alongside a negative control without any DNA and a positive 
control with 4 µl cDNA substituted with 4 µl water according to the aforementioned 
incubation times in section 5.2.7.3. Samples were electrophoresed as previously described 
in section 5.2.7.5 and 18 colonies were selected that represented the full range of fragment 
sizes observed from the screen, including at least 3 samples of each size. 
5.2.7.10!Isolation of plasmid DNA 
Cultures from the selected colonies were expanded at 37°C with shaking at 225 rpm 
overnight in 3 ml LB broth with 100 µg/ml ampicillin. One third of the culture was mixed 
with 100 µl DMSO and snap-frozen on dry ice before storing at -80°C. Plasmid DNA was 
isolated from the remaining 2 ml culture using the QIAprep Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions and quantified using a Nanodrop 800. 
5.2.7.11!DNA sequencing 
Isolated plasmid DNA was sent for Sanger sequencing via Source Bioscience (Nottingham, 
England) and the results visualised using UCSC Genome Browser (www.genome.ucsc.edu). 
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5.3!Results 
5.3.1!BIN1 Depletion and CME-related Protein Expression 
To explore any indicator of CME disturbance, expression levels of key endocytic proteins 
were analysed by Western blotting following BIN1 depletion.  
5.1.1.1! AP2 expression 
As the most important adaptor protein involved in the linking cargo to nucleating clathrin 
at the plasma membrane during CME, AP2 is a major hub of protein-protein interactions 
at the CCP and a change in its expression would be highly indicative of alterations in this 
process. Depletion of the µ2 subunit of the AP2 complex has been shown to severely 
inhibit receptor-mediated endocytosis of transferrin (Motley et al., 2003), therefore an 
analysis of AP2µ2 expression levels following BIN1 depletion was carried out. AP2µ2 was 
detected as a single band at ~50 kDa (Figure 5.1A). Using a two-tailed unpaired Student’s t 
test, it was determined that there was no significant difference in AP2µ2 expression 
between BIN1-depleted and GFP siRNA-treated cells (p > 0.05, two-tailed unpaired 
Student’s t test, Figure 5.1B). 
5.3.1.1! Clathrin Heavy Chain 
The clathrin protein functions as a heterohexamer, formed of three light chains and three 
heavy chains. Depletion of clathrin heavy chain has been shown to inhibit CME, with no 
CCPs or CCVs detected (Motley et al., 2003). Any change in protein levels of clathrin 
heavy chain (CHC) may be indicative of a change in the frequency of CCP/CCV formation 
and this was therefore analysed upon BIN1 depletion. A single band at ~169 kDa was 
observed for CHC (Figure 5.2A). There was no significant different between CHC protein 
levels in BIN1-depleted cells and GFP siRNA-treated cells (p > 0.05, two-tailed unpaired 
Student’s t test, Figure 5.2B).  
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5.3.1.2! PICALM  
PICALM levels were of particular interest in this cell line due to the aforementioned study 
implicating PICALM in the regulation of Aβ transcytosis at the BBB (Zhao et al., 2015). It 
would therefore be interesting to investigate whether depletion of BIN1 protein has an 
impact on PICALM expression which may implicate a potential role for BIN1 in this 
process. PICALM is known to express multiple isoforms (Parikh et al., 2014). While only a 
single band was readily detectable at ~ 64 kDa, evidence of a larger band at ~ 76 kDa was 
apparent in some blots but this did not reach measurable levels in all replicates (Figure 
5.3A). No significant difference in levels of the strongest PICALM isoform was detected 
with BIN1 depletion compared to GFP siRNA-treated cells (p > 0.05 using a two-tailed 
unpaired Student’s t test), suggesting BIN1 does not impact levels of this key CME-related 
protein, in addition to AP2 and CHC (Figure 5.3B). As the efflux of Aβ across the BBB is 
mediated by LRP1, which undergoes CME, LRP1 levels in hCMEC/D3 cells were 
analysed with a view to comparing these levels between BIN1-depleted and GFP siRNA-
treated cells. However, unfortunately LRP1 protein was not reliably detectable in non-
transfected hCMEC/D3 lysate by Western blotting (data not shown) therefore this analysis 
was not pursued. 
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A)  
 
 
 
 
 
B) 
Figure 5.1: AP2µ2 protein levels in BIN1-depleted hCMEC/D3 cells 
A) Representative Western blot showing levels of AP2µ2 protein in non-transfected, GFP 
siRNA and BIN1-depleted hCMEC/D3 cells. 
B) Quantification of AP2µ2 expression based on densitometry analysis, expressed as mean 
percentage expression of non-transfected cells after normalisation to GAPDH, error bars 
= SEM, n = 4, p > 0.05 using a two-tailed unpaired Student’s t test. 
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A) 
 
 
 
 
 
B) 
Figure 5.2: Clathrin heavy chain protein levels in BIN1-depleted hCMEC/D3 cells 
A) A representative Western blot showing levels of CHC protein in non-transfected, GFP 
siRNA and BIN1-depleted hCMEC/D3 cells. 
B) Quantification of CHC expression based on densitometry analysis, expressed as mean 
percentage expression of non-transfected cells after normalisation to GAPDH, error bars 
= SEM, n = 4, p > 0.05 using a two-tailed unpaired Student’s t test. 
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A)  
 
 
 
 
 
B)  
Figure 5.3: PICALM protein levels in BIN1-depleted hCMEC/D3 cells 
A) A representative Western blot showing levels of PICALM protein in non-transfected, 
GFP siRNA and BIN1-depleted hCMEC/D3 cells. 
B) Quantification of PICALM expression based on densitometry analysis of four biological 
replicates, expressed as mean percentage expression of non-transfected cells, error bars = 
SEM, p > 0.05 using a two-tailed unpaired Student’s t test. 
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5.3.2!Alexa-488-Tf Uptake as a Measure of CME in 
hCMEC/D3 cells  
5.3.2.1! Optimisation of Alexa-488-Tf Uptake in hCMEC/D3 cells 
To further examine mechanistically whether the observed changes in APP processing were 
related to the involvement of BIN1 in CME in BMECs, the effect of BIN1 depletion on 
Tf internalisation was analysed. The TfR is expressed on the endothelium of brain 
capillaries (Jefferies et al., 1984) and is known to undergo CME on the luminal membrane 
with rapid recycling back to the cell surface (Roberts et al., 1993). Firstly, a time-course of 
transferrin exposure was carried out using flow cytometry to visualise the rate at which 
Alexa 488-conjugated transferrin was internalised into non-transfected hCMEC/D3 cells. 
This was used to determine the time points required to best compare transferrin levels for 
subsequent experiments.  
Levels of transferrin uptake rose sharply from 0-30 minutes, increasing 3.5-fold in the first 
5 minutes (Figure 5.4). The 5 minute time point has frequently been used in the literature 
for comparisons of transferrin uptake as the rapid uptake has been shown to saturate after 
this time (Muller et al., 2003, Xiao et al., 2012). While the rate of uptake in hCMEC/D3 
cells slowed after 5 minutes, it still increased over 2.2-fold between 5-15 minutes and 
plateaued after 30 minutes, peaking between 60-90 minutes after Alexa-488-Tf exposure 
(Figure 5.4). A slight reduction in Alexa-488-Tf levels was evident at 90 minutes compared 
to 60 minutes, suggesting the rate of recycling back to the plasma membrane was higher 
than the rate of uptake. It was therefore decided that the maximum time point for 
subsequent studies should be 60 minutes as no further increase in Alexa-488-Tf levels was 
observed after this time. Further time points selected included 5 minutes, to make 
comparisons with the aforementioned literature, in addition to 15 and 30 mins so that a full 
time-course could be plotted. 
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Figure 5.4: Alexa-488-Tf uptake in non-transfected hCMEC/D3 cells 
Quantification of Alexa-488-Tf internalisation over a time course of 90 minutes. Values 
represent the geometric mean, n = 3, error bars = SEM. 
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5.3.2.2! Establishment of a positive control for CME inhibition 
In order to make comparisons with a positive control for impaired Tf internalisation, 
siRNA-mediated depletion of the µ2 subunit of the AP2 complex was used, as previously 
demonstrated (Moody et al., 2015). The aim of depleting AP2µ2 was to induce defects 
specific to early endocytic events, where AP2 is involved, rather than targeting other 
endocytic machinery, such as clathrin which also mediates post-Golgi vesicular transport 
and would therefore not be specific to CME (Motley et al., 2003). The TfR associates, via 
tyrosine-based motifs, with the phosphorylated µ2 subunit of AP2 (Olusanya et al., 2001) 
therefore depletion of this subunit impairs transferrin uptake (Motley et al., 2003). The 
concentration of AP2µ2 siRNA was optimised at 25, 50 and 75 nM in order to determine 
the lowest concentration necessary for significant protein depletion. Two distinct bands 
were detected for AP2µ2 at sizes 47 and 50 kDa (Figure 5.5A), whereas only one band was 
detectable in earlier analysis of AP2µ2 level with BIN1 depletion (Figure 5.1).  Both bands 
were measured for densitometry analysis and all three siRNA concentrations showed 
consistent AP2 depletion, however a significant 62% reduction in protein was only 
confirmed by using 25 nM siRNA (p<0.05, two-tailed unpaired Student’s t test Figure 
5.5B). This gave the highest level of knockdown and allowed the use of the lowest 
concentration of siRNA.  
To determine the effectiveness of the assay, Alexa-488-Tf uptake was analysed over a time-
course of 60 minutes in AP2µ2-depleted cells. After 5 minutes, a significant 48% reduction 
in Alexa-488-Tf uptake was evident compared to GFP siRNA-treated cells (p<0.01, two-
tailed unpaired Student’s t test) with Alexa-488-Tf levels increasing 1.4-fold in AP2µ2-
depleted cells compared to 2.7-fold in GFP siRNA-treated cells (Figure 5.6A). While the 
level of Alexa-488-Tf in AP2µ2-depleted cells remained significantly lower than GFP 
siRNA-treated cells across all time points, the rate of uptake remained similar after the 
initial 5 minute incubation with a 1.8-fold increase in AP2-depleted cells and a 1.9-fold 
increase in GFP siRNA-treated cells between 5-15 minutes.  
  
                                                                                                                              
                                                                                                 Chapter 5: Results 
 
 
173 
 
 
 
 
 
Figure 5.5: Optimisation of siRNA-mediated AP2µ2 depletion 
A) A representative Western blot demonstrating successful knockdown of AP2µ2 protein 
with the treatment of 3 different concentrations of siRNA in hCMEC/D3 cells.  
B) Quantification of both AP2µ2 bands shows significant depletion using 25µM siRNA 
expressed as a mean percentage of non-transfected cells, n = 3, * = p<0.05 using a two-
tailed unpaired Student’s t test, error bars = SEM. 
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5.3.3!The Effect of BIN1 Depletion on Alexa-488-Tf Uptake  
The same assay was then used to determine if BIN1 depletion affected Alexa-488-Tf 
uptake. There was no significant difference in Alexa-488-Tf levels between BIN1-depleted 
and GFP siRNA-treated cells across all time points (Figure 5.6B). Alexa-488-Tf levels 
increased by 2.9 and 2.6-fold for GFP siRNA-treated and BIN1-depleted cells, respectively. 
At all subsequent time points, very little difference was observed in Alexa-488-Tf uptake 
between the two conditions with a 1.9-fold rate of increase between 5-15 min. The rate of 
uptake began to plateau after 15 mins, reaching the highest level of fluorescence at 60 
minutes. Overall, a slower rate of uptake was observed compared to the optimisation 
experiment using untreated cells, suggesting that the siRNA treatment process in itself may 
have affected the rate of endocytic uptake.  
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A) 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
 
Figure 5.6: The effect of AP2µ2 or BIN1 depletion on Alexa-488-Tf uptake  
A) Quantification of Alexa-488-Tf internalisation with AP2µ2 depletion in comparison to 
GFP siRNA-treated cells over a time course of 60 minutes. Values represent the geometric 
mean, ** = p<0.01, two-tailed unpaired Student’s t test, error bars = SEM. 
B) Quantification of Alexa-488-Tf internalisation with BIN1 depletion in comparison to 
GFP siRNA-treated cells over a time course of 60 minutes. Values represent the geometric 
mean, n = 3, error bars = SEM. 
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5.3.4!The Effect of BIN1 Depletion on Alexa-488-Tf Recycling 
While BIN1 depletion did not affect Alexa-488-Tf uptake in hCMEC/D3 cells, BIN1 has 
been implicated in endocytic recycling (Pant et al., 2009, Miyagawa et al., 2016), therefore a 
pulse-chase assay was used to examine the recycling of Alexa-488-Tf back to the plasma 
membrane. Following transfection, cells were pulsed with Alexa 488-Tf for 60 minutes to 
saturation, before chasing with unlabeled holotransferrin for 0-60 minutes. In GFP siRNA-
treated cells, Alexa-488-Tf was rapidly recycled out of the cells during the chase phase at 
37°C, reaching a mean fluorescent intensity of 4458 by 60 minutes, near the mean 
background fluorescence level of 3338 (Figure 5.7). In contrast, cells maintained at 4ºC 
during the chase phase did not show a significant decrease across any time points, with 
92% of the fluorescence at time point 0 still remaining after 60 minutes in GFP siRNA-
treated cells. This suggests that the decrease in Alexa-488-Tf observed during the 37ºC 
chase was due to active endocytic recycling as endocytic pathways are inhibited at 4°C.  
With BIN1 depletion, Alexa-488-Tf followed the same pattern of recycling, with mean 
fluorescent intensity decreasing at the same rate as GFP siRNA-treated cells. A two-tailed 
unpaired Student’s t test confirmed there was no significant difference in Alexa-488-Tf 
levels between GFP siRNA-treated and BIN1-depleted cells across 7.5, 15, 30 and 60 
minutes (p>0.05). However, a significant difference was detected at the 0 time point (p < 
0.05) suggesting there was a difference in the level of Alexa-488-Tf uptake across the 60 
minute pulse (Figure 5.7). This brought into question the difference in methodology 
between the Alexa-488-Tf uptake and recycling experiments, particularly the temperature at 
which trypsinisation was carried out. In the uptake experiments, cells were trypsinised at 
RT to ensure the reaction would take place within the time-constraints of the experiment. 
However, it was observed that the cells could be trypsinised at 4°C within 15 minutes, 
therefore cells were trypsinised on ice in the recycling experiments to inhibit endocytic 
trafficking during this time. In light of this apparent difference in intracellular Alexa-488-Tf 
levels following the pulse period of the recycling experiment, the Alexa-488-Tf uptake 
experiment was repeated once more, but trypsinising on ice (results not shown). This 
showed no difference in fluorescence levels between GFP siRNA-treated and BIN1-
depleted cells across all time points, and replicated the results of the previous 3 uptake 
experiments where cells had been trypsinised at RT. This therefore assured confidence in 
the data.  
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Figure 5.7: The effect of BIN1 depletion of Alexa-488-Tf recycling 
Quantification of Alexa-488-Tf recycling with BIN1 depletion in comparison to GFP 
siRNA-treated cells after a 60 minute pulse at 37°C followed by chasing with unlabeled 
holotransferrin over a time course of 60 minutes. To illustrate inhibition of endocytic 
recycling, the chase was also performed at 4°C for each siRNA condition. Values represent 
the geometric mean, n = 3-4, error bars = SEM. 
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5.3.5!Early Endosome Morphology with BIN1 depletion 
Several recent studies, showing defective endocytic trafficking as a result of BIN1 
depletion, have also shown recapitulation of the enlarged endosome morphology that is an 
early feature of AD pathology (Cataldo et al., 2000, Miyagawa et al., 2016, Ubelmann et al., 
2017). Therefore, the early endosome marker, EEA1, was used to observe early endosome 
localisation and size in BIN1-depleted cells. EEA1 showed punctate cytoplasmic staining, 
suggestive of a vesicular distribution in the early endosomes (Figure 5.8). Consistent with a 
lack of impairment in Alexa-488-Tf recycling, the distribution and observed intensity of 
EEA1 staining was not altered by BIN1 depletion suggesting that early endosome 
abnormalities, often indicative of endocytic recycling dysfunction, did not occur. 
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Figure 5.8: EEA1 staining of Early Endosomes with BIN1 depletion 
Representative immunofluorescence images of EEA1 expression, a marker of early 
endosomes, in non-transfected, GFP siRNA-treated and BIN1-depleted hCMEC/D3 cells. 
Images were taken at x40 magnification with DAPI used to stain the nuclei, scale bar = 25 
µm.  
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5.3.6!Amphiphysin I Expression in hCMEC/D3 cells 
Amphiphysin 1 (AMPH1) is a BIN1 homologue which forms heterodimers with BIN1 to 
aid in endocytic uptake through interactions with dynamin (Wigge et al., 1997a). While no 
effect on Tf uptake was observed with BIN1 depletion, it is possible that AMPH1 may 
have compensated for the loss of BIN1 therefore Tf uptake was unaffected. As AMPH1 is 
considered to be brain-specific, its expression in the hCMEC/D3 cell line was investigated 
by Western blotting with a view to analysing any expression changes with BIN1 depletion. 
AMPH1 protein was not detectable in hCMEC/D3 cells lysates, despite exhibiting strong 
expression in mouse whole brain lysate (Figure 5.9). However, analysis of AMPH1 
expression with BIN1 depletion was not carried out and it therefore cannot be ruled out 
that these levels may have become detectable with BIN1 depletion. 
 
 
 
 
 
 
 
 
Figure 5.9: AMPH1 expression in hCMEC/D3 cells 
Western blot showing undetectable AMPH1 expression in hCMEC/D3 cell lysate 
compared to transgenic (TG) and wild-type (WT) mouse whole cortex lysate. Irrelevant 
bands have been removed for the purpose of figure readability.  
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5.3.7!BIN1 Isoform Expression in hCMEC/D3 cells 
All BIN1 isoforms contain an N-terminal domain which senses and generates membrane 
curvature and a C-terminal SH3 domain which mediates interactions with CME-related 
proteins such as dynamin and adaptor proteins (Wechsler-Reya et al., 1997). The CLAP 
domain, encoded by the alternatively-spliced exons 12a-d, is only found in brain-specific 
isoforms and is predicted to be critical for the recruitment of dynamin and its self-assembly 
at the CCP (Owen et al., 1998). Western blot analysis of BIN1 in hCMEC/D3 cells 
showed the presence of at least three different size bands at approximately 68, 58 and 55 
kDa (Figure 5.1), suggesting multiple isoforms are expressed in these cells. The brain-
specific isoform containing the CLAP domain has been shown to migrate at 90 kDa (De 
Rossi et al., 2016) therefore these results suggest the CLAP domain is not expressed in 
these cells, possibly explaining why there was no effect of BIN1 depletion on CME or 
recycling.  
In order to characterise the BIN1 isoforms expressed in hCMEC/D3 cells, total RNA was 
extracted from the cells and primers designed to specifically target the region containing 
the CLAP domain. The amplified region incorporated exons 11-15, of which exons 12a, 
12b, 12c, 12d and 13 are subject to alternative splicing. A sample of the PCR product was 
subject to gel electrophoresis to confirm amplification and 5 distinct bands were observed 
at approximately 455, 353, 311, 219 and 113 kb, representing considerable alternative 
splicing of this region (Figure 5.10). Taq DNA polymerase preferentially adds an adenine 
to the 3' end of the PCR product which allowed ligation of the PCR product to a pGEM®-
T Vector by complementary base pairing to the thymine residues on both 3’ ends of this 
open vector. The PCR products were transformed into DH5α™ cells and grown on agar 
containing ampicillin; the ampicillin resistance gene within the vector allowed the selective 
growth of colonies only from cells that had taken up the vector. In total, 48 colonies were 
selected for PCR screening which showed PCR products of varying lengths had been 
successfully cloned (Figure 5.10). Clones with more than one band were excluded and 
those showing a single band were selected for sequencing, incorporating at least three 
samples from each sized band. 
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A total of 18 PCR products were sequenced, 3 of which returned without any recognisable 
coding DNA and were therefore excluded from analysis (Figure 5.10). As expected, all 15 
PCR products contained exons 11, 14 and 15 which are expressed in all BIN1 isoforms. Of 
the alternatively spliced exons (12a, 12b, 12c, 12d and 13), the sequences either contained 
both exons 12a and 13, exon 12a alone, exon 13 alone or none at all (Figure 5.11). The 
isoforms that these can be attributed to include brain-specific and ubiquitous isoforms. The 
precise signature isoforms expressed cannot be determined as the presence of two further 
alternatively spliced exons (6a and 10) was not investigated. However, none of the isoforms 
sequenced contained the full complement of exons (12a-d) that encode the CLAP domain, 
suggesting this region is not expressed in hCMEC/D3 cells.  
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Figure 5.10 PCR amplification and cloning of BIN1 exons 11-15 in hCMEC/D3 cells 
A) A gel electrophoresis image of the PCR product amplified from hCMEC/D3 cDNA 
targeting exons 11-15 of the BIN1 gene. Distinct bands represent the different isoforms 
due to alternative splicing within this region. 
B) A representative PCR screen from 26 DH5α™colonies showing the variation in size 
within the amplified region (exons 11-15) of the BIN1 gene. Each well has been amplified 
from a single colony and therefore represents the PCR products ligated into the pGEM®-
T Vector that they contain. 
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7 Isoform 4 Brain
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Figure 5.12: Potential BIN1 isoforms expressed in hCMEC/D3 cells  
A schematic illustrating the full length BIN1 protein domain structure with 
corresponding exon structure and the target region for amplification between exons 
11-15 for RNA cloning and sequencing. The table shows the number of PCR 
products sequenced and which isoforms these correspond to, with schematics of the 
exon structure of each isoform(s) for clarity. The isoforms are depicted in full in 
Chapter 1, Figure 1.2. BAR, BAR domain; SH3, SH3 domain; MBD, Myc binding 
domain; CLAP, clathrin-associated protein binding region; PI, phosphoinositide 
binding region. Exons are numbered by reference to Wechsler-Reya et al. (1997). 
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5.4!Discussion 
In this chapter, the role of BIN1 in CME in the hCMEC/D3 human brain endothelial cell 
line has been investigated, in light of the previously observed increase in β-CTF levels, 
reported in Chapter 4. BIN1 depletion in hCMEC/D3 cells did not significantly affect the 
expression of key CME-related proteins AP2, CHC and PICALM or the uptake/recycling 
of Tf, a marker of CME. An analysis of the BIN1 isoforms expressed in hCMEC/D3 cells 
revealed that isoforms containing the full-length CLAP domain are not expressed in this 
cell line, collectively suggesting that BIN1 is not important for CME in hCMEC/D3 cells. 
5.4.1!BIN1 is not Crucial for CME in hCMEC/D3 cells 
The findings presented in this chapter suggest that BIN1 is not a crucial player in CME in 
BMECs. Firstly, analysis of AP2 expression upon BIN1 depletion showed no change in 
protein levels suggesting that early endocytic events were not perturbed in BIN1-depleted 
cells as AP2 function is specific to this early stage (Motley et al., 2003). Furthermore, 
unaltered levels of CHC with BIN1 depletion suggested there was not a change in the 
number of CME events occurring at the plasma membrane or within the cells, as clathrin is 
known to also be involved in intracellular membrane trafficking (Motley et al., 2003). 
PICALM expression was also unaffected by BIN1 depletion, further supporting the notion 
that BIN1 is not important for CME or endocytic trafficking mechanisms, such as the 
intracellular transcytosis of Aβ that PICALM has been shown to regulate in BMECs (Zhao 
et al., 2015). 
These results were further supported by measuring Tf uptake in AP2µ2-depleted cells 
which showed significant inhibition of Alexa-488-Tf uptake after just 5 minutes. This not 
only validates the assay as an effective measure of CME, but also demonstrates the 
importance of AP2 in this mechanism. In BIN1-depleted cells, however, Alexa-488-Tf 
uptake remained unaffected, further suggesting that BIN1 does not have a crucial role in 
CME in the hCMEC/D3 cell line. This is somewhat unexpected due to previous studies 
implicating BIN1 in CME based on two key lines of evidence. Firstly, the binding of 
certain isoforms with key endocytic machinery such as clathrin, AP2 and dynamin in 
neuronal cells (Butler et al., 1997, Ramjaun and McPherson, 1998) and macrophages (Gold 
et al., 2000). Secondly, the demonstration that Bin1 dominant negative mutants, lacking the 
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dynamin-binding SH3 domain, severely impaired CME in macrophages (Gold et al., 2000). 
Collectively, these studies suggest that BIN1 is involved in CME in both neuronal and 
non-neuronal cells and depletion of BIN1 may therefore result in CME dysfunction. 
However, the results from the present study do not support this hypothesis and suggest 
that BIN1 is not universally important for CME. Indeed, it has been shown that Bin1 
knockout MEFs and BIN1-depleted HeLa cells are not defective in Tf uptake (Muller et 
al., 2003, Pant et al., 2009). However, both Bin1 knockout MEFs and BIN1-depleted HeLa 
cells showed an approximately 3-fold and 2-fold increase in Tf uptake compared to 
controls, respectively (Muller et al., 2003, Pant et al., 2009). Pant and colleagues reported 
that this was a result of Tf accumulating in the juxtanuclear compartment of BIN1-
depleted HeLa cells due to delayed recycling back to the plasma membrane, suggesting that 
BIN1 may not be crucial for endocytic uptake, but may be important for intracellular 
endocytic trafficking.  
Indeed, clathrin-mediated endocytic mechanisms are not only limited to the plasma 
membrane. The presence of clathrin coats has been demonstrated in endosomes where 
they appear to mediate the sorting of ubiquitinated cargo towards degradation (Raiborg et 
al., 2002) and the recycling of proteins to the plasma membrane (Sachse et al., 2002). While 
BIN1 may not be involved in CME per se in BMECs, it may have a function in clathrin-
dependent intracellular endocytic sorting. Consistent with a role in endocytic recycling, 
BIN1 was found to be enriched on tubules of the ERC and important for the maintenance 
and correct functioning of these structures in mouse primary cortical neurons (Ubelmann 
et al., 2017). In this study, Bin1 was reported to regulate BACE1 trafficking as BACE1 
accumulated in early endosomes with Bin1 siRNA-mediated depletion, suggesting that the 
exit of BACE1 from early endosomes for recycling was impaired. Indeed, a greater number 
of neurons showed evidence of tubular carriers containing BACE1 with Bin1-depletion 
compared to controls (Ubelmann et al., 2017). Tubular endocytic carriers play an important 
role in mediating transport within the endocytic pathways and, upon scission, transport 
their cargo from the early endosomes/ERC to the plasma membrane. While the number 
and length of BACE1 tubular carriers also increased in Bin1-depleted axons, live imaging 
revealed that scission events, following tubule formation, were not observed. Instead, 
tubules remained stably associated with early endosomes, suggesting that Bin1 controls the 
scission, but not formation, of tubules in axons. In this manner, BACE1 tubule exit from 
axonal-early endosomes was inhibited by Bin1 depletion, leading to impaired BACE1 
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recycling, accumulation in early endosomes and increased Aβ generation (Ubelmann et al., 
2017). Collectively, the aforementioned findings by Pant et al. (2009) and Ubelmann et al. 
(2017) suggest that Bin1 does not have a necessary functional role in CME but is important 
for endocytic trafficking downstream of CME.  
In the hCMEC/D3 cell line used in the present study, however, there was no difference in 
the rate of Tf recycling with BIN1 depletion compared to GFP siRNA-treated cells 
suggesting, in these cells, it is not pivotal in the endocytic recycling process. Furthermore, 
several recent studies that have implicated BIN1 in regulating endocytic recycling have also 
demonstrated enlargement of EEA1-positive early endosomes with BIN1 depletion 
(Miyagawa et al., 2016, Ubelmann et al., 2017), recapitulating an early pathological feature 
of AD (Cataldo et al., 2000). Early endosome morphology was therefore investigated in the 
present study but no difference was observed between conditions, suggesting that 
accumulation of cargo in the early endosomes did not occur with BIN1 depletion and 
therefore supporting the notion that BIN1 is not crucial for endocytic recycling in 
hCMEC/D3 cells. 
5.4.2!Asymmetry of Endocytic Processes 
The endosomal trafficking route of Tf in BMECs, unlike other non-neuronal cell types 
used in BIN1-depletion studies, involves the apical to basolateral transcytosis of the 
receptor-bound Tf due to the establishment of polarity at the BBB (Descamps et al., 1996). 
While the Tf recycling assay can be used as an indicator of transcytotic function, it does not 
represent an accurate measure of transport across polar domains and it therefore still 
remains to be investigated whether BIN1 has a role in transcytosis at the BBB. BMECs are 
known to be well polarised in vivo, with distinct apical and basolateral domains, segregated 
by tight junctions (Shivas et al., 2010). While the hCMEC/D3 cell line has been shown to 
express the Par/aPKC planar cell polarity complex, which contributes to the regulation of 
tight junction integrity and apical-basolateral polarity (Artus et al., 2014), the tightness of 
the monolayers formed in this cell line is relatively low compared to in vivo levels (Weksler 
et al., 2005). Many drug transport studies that have used the hCMEC/D3 cell line, culture 
the cells on transwell filters which allow cells to feed both apically and basolaterally and 
thereby carry out metabolic activities in a more natural fashion. This aids polarisation; 
hCMEC/D3 monolayers display five-fold higher concentrations of TJ proteins on 
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transwell filters than on plastic coverslips (Weksler et al., 2013). In the present study, cells 
were cultured on fibronectin-coated culture vessels. With the aim of the study to 
investigate basic endocytic function with BIN1 depletion, rather than transcytotic activity, 
it was not deemed necessary to establish polarity in the culture system. However, an effect 
on CME and recycling cannot be ruled out, had the culture system been designed to grow 
cells in a polarised fashion, with the establishment of apical and basolateral domains. Since 
the cells used in this study may lack the polarisation seen in vivo, it is possible that BIN1 
may have a role in the trafficking of cargo to a particular domain, which could not be 
detected by the Tf recycling study. Indeed, BIN1 has recently been implicated in the 
transport of apical-directed proteins in polarised epithelial cells of the small intestine 
(Nakajo et al., 2016). Depletion of Bin1 in mouse small intestine organoids resulted in 
altered localisation of apical proteins but not basolateral proteins, suggesting Bin1 is 
involved in apical protein transport through generation of membrane tubules at the ERC 
(Nakajo et al., 2016). This is of particular interest due to the similar structural nature of 
intestinal epithelial cells and brain endothelial cells, with both possessing apical-basolateral 
polarity and intercellular tight junctions. It would therefore be interesting to investigate 
BIN1 depletion in polarised BMECs and to analyse the trafficking of specific apical and 
basolateral proteins in this culture system. 
5.4.3!Is BIN1 Acting Alone? 
It was thought to be a possibility that AMPH1 may be acting in compensation for the loss 
of BIN1 in the hCMEC/D3 cells. Indeed, in vitro analysis of both AMPH1 and BIN1 
simultaneous knockdown resulted in a significant decrease in Tf uptake after 7 minutes 
incubation in human retinal pigment epithelial cells (Meinecke et al., 2013). Furthermore, 
overexpression of either Amph1 or Bin1 blocked CME in COS cells and this defect was 
rescued by their coexpression, illustrating the important role of the heterodimer in 
endocytic function (Wigge et al., 1997a). The expression of either protein alone, however, 
had a dominant-negative effect. Nevertheless, in the hCMEC/D3 cell line AMPH1 failed 
to reach detectable levels by Western blot. AMPH1 protein expression with BIN1 
depletion was not investigated therefore it cannot be ruled out that AMPH1 may reach 
detectable levels with BIN1 depletion. 
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5.4.4!Endocytic Cargo Specificity  
As a positive control for inhibition of CME, AP2µ2 was depleted in hCMEC/D3 cells. 
While depletion to undetectable levels was not achieved by siRNA transfection, significant 
impairment of transferrin uptake was successfully demonstrated at the level of AP2µ2 
depletion achieved, supporting previous findings in HeLa cells (Moody et al., 2015). 
Interestingly, however, AP2–depleted HeLaM cells were capable of internalising EGF and 
an LDL receptor chimera, but were defective in Tf uptake (Motley et al., 2003), suggesting 
that AP2 is not essential for CCV formation but has a cargo-selective requirement in CME 
and that alternative adaptors may facilitate EGF and LDL uptake. While Tf was used in the 
present study as a universal marker of CME, given the selectivity displayed by AP2, it is 
possible that BIN1 also has a cargo-specific role in CME. While BIN1 depletion does not 
affect transferrin uptake in hCMEC/D3 cells, suggesting BIN1 is not essential for CME, it 
cannot be ruled out that it plays a role in the specific endocytic uptake of other cargo. In 
the future, it would be interesting to trace APP through endosomal trafficking with BIN1 
depletion in order to further investigate the increase observed in β-CTF and whether 
perturbed endocytic trafficking of APP may be involved. 
5.4.5!Tissue-specific Isoform Expression 
With BIN1 subject to extensive alternative splicing, displaying a tissue-specific pattern of 
isoform expression, it remained to be investigated which BIN1 isoforms were expressed in 
human BMECs. The region of interest in this study focused on BIN1 exons 12a-d, which 
collectively encode the CLAP, involved in interactions with the endocytic mediators 
clathrin and AP2 (Ramjaun and McPherson, 1998). The presence of an isoform containing 
exon 12a but not 12b-d of the CLAP domain or 13 was found in hCMEC/D3 cells. While 
the functional relevance of the individual exons that comprise the CLAP domain has not 
been elucidated, this isoform has previously been attributed to an aberrant splicing event 
that relieves MYC inhibition by BIN1 (Ge et al., 1999).  This melanoma-specific isoform is 
thought to be associated with the loss of the tumour suppressor activity of BIN1(Ge et al., 
1999). Its expression has previously been reported in human cell lines: WI-38, HeLa, and 
Rh-30 but not normal non-neuronal murine tissues, suggesting it may be functionally 
redundant but is expressed in cell lines to promote immortalisation or establishment 
(Wechsler-Reya et al., 1997). 
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Of the 18 DNA fragments sequenced from extracted hCMEC/D3 RNA, none contained 
the full complement of exons required to encode the CLAP domain, supporting the 
findings that BIN1 does not have a pivotal role in CME in these cells. These findings are 
supported by RNAseq analysis of the mouse cerebral cortex, where only exon 12a of the 
CLAP domain was detected in sequenced transcripts from BMECs (Zhang et al., 2014). 
The importance of the CLAP domain to the function of BIN1 in CME is unclear. Several 
studies have demonstrated its involvement, including (Slepnev et al., 1998) who 
demonstrated that overexpression of the central domain of Amph1 (amino acids 250-588), 
incorporating the CLAP domain between amino acids 378-422 (Ramjaun and McPherson, 
1998), blocks Tf uptake. This is of relevance to BIN1 as the sequence of amino acids 
within this region is conserved between Amph1 and Bin1 (Slepnev et al., 1998), suggesting 
that the CLAP domain of BIN1 may also be important for Tf uptake. Interestingly, 
overexpression of the human BIN1 neuronal isoform 1 in rat hippocampal neurons has 
been shown to significantly decrease Tf uptake, while overexpression of the human BIN1 
ubiquitous isoform 9, which lacks the CLAP domain, did not affect Tf uptake (Calafate et 
al., 2016). This suggests that isoforms lacking the CLAP domain, such as those expressed 
in hCMEC/D3 cells, are not important for CME and supports the lack of effect on Tf 
uptake in the present study. Collectively, these studies suggest that the CLAP domain may 
be required for CME and therefore may explain the lack of effect on Tf uptake with BIN1 
depletion in hCMEC/D3 cells.  
However, all BIN1 isoforms still contain the BAR domain, involved in inducing membrane 
curvature, and the SH3 domain, which binds dynamin (Casal et al., 2006), therefore BIN1 
may still have a role in endocytosis in these cells, independent of clathrin. Indeed, despite 
non-neuronal BIN1 isoforms lacking the CLAP domain, BIN1 depletion has been shown 
by different groups to have an effect on endocytic processes in HeLa cells, a non-neuronal 
cell line (Pant et al., 2009, Miyagawa et al., 2016). Specifically, depletion of BIN1 in these 
studies resulted in intracellular accumulation of internalised cargo, suggesting that the 
general function of BIN1 is to regulate intracellular trafficking of cargo from the early 
endosome to the degradation pathway. The specific cargo Miyagawa and colleagues 
investigated was BACE1. By expressing BIN1 mutants lacking either the BAR domain or 
the SH3 domain, pulldown assays revealed that it was the BAR domain that was required 
for the binding of BIN1 with BACE1. Therefore, while the CLAP domain may be 
important in CME processes that take place at the plasma membrane in neurons, such as 
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synaptic vesicle endocytosis, it is the BAR domain, common to all BIN1 isoforms, that is 
involved in intracellular trafficking of cargo. This notion, however, is not in agreement with 
the findings of the present study where no accumulation of Tf was detected with BIN1 
depletion, nor was BACE1 accumulation observed in Chapter 4. Should BIN1 have the 
same role in intracellular trafficking in hCMEC/D3 cells that is observed in HeLa cells, 
higher levels of Tf, and BACE1, would be expected in the BIN1-depleted cells as its 
recycling back to the plasma membrane is impaired. 
The CLAP domain is not the only alternatively spliced region within BIN1 of interest in 
the context of CME. Exon 6a (often referred to as exon 7 in the literature) is present only 
in 3 of the brain-specific isoforms (Chapter 1, Figure 1.2) and has been shown to promote 
an interaction between dynamin 2 and Bin1 (Ellis et al., 2012). N2a cells transiently 
expressing Bin1 isoforms including or lacking exon 6a were used to analyse the uptake of 
Tf. Inclusion of exon 6a did not affect Bin1 protein levels but resulted in a significant 
increase in Tf uptake whereas overexpression of Bin1 lacking exon 6a inhibited Tf uptake 
(Ellis et al., 2012). As Bin1 can homodimerise and heterodimerise with Amph1, the 
overexpression of an isoform lacking exon 6a may have sequestered endogenous exon 6a-
containing Bin1 and Amph1, thus preventing functional interactions with dynamin 2. This 
suggests that BIN1 exon 6a strongly promotes interactions with dynamin 2 and is therefore 
important for efficient endocytosis in neuronal cells. Furthermore, in COS-7 cells, 
fibroblast-like cells derived from monkey kidney tissue, plasma membrane targeting was 
shown to be dependent on the presence of Bin1 exon 6a while the CLAP domain was not 
required for Bin1 membrane localisation (Ramjaun et al., 1999). In both COS-7 cells and 
rat brain extracts, the presence of exon 6a also resulted in a greater degree of Bin1 
dimerisation (Ramjaun et al., 1999). Taken together, these studies support a role for BIN1 
exon 6a in dynamin interactions, membrane targeting and dimerisation during endocytosis. 
While the expression of isoforms containing exon 6a in the hCMEC/D3 cell line was not 
directly addressed, none of the exon combinations that were sequenced correspond to 
exon 6a-containing isoforms, suggesting they are not expressed in BMECs. In support of 
this, a recent study quantified BIN1 transcript levels in human anterior cingulate brain 
tissue samples and showed that exon 6a-containing BIN1 transcript levels were positively 
associated with synaptophysin expression (a neuronal marker) but not with von Willebrand 
Factor (VWF) and CD31, markers of endothelial cells (De Rossi et al., 2016). Therefore, 
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the lack of isoforms expressing the CLAP domain or exon 6a supports our findings 
suggesting that BIN1 may not participate in CME in hCMEC/D3 cells. 
This recent study by De Rossi et al. (2016) explored BIN1 expression and isoform diversity 
in the human brain, providing novel insights into a possible non-neuronal role for BIN1. 
They reported that, unlike AMPH1, the majority of BIN1 immunoreactivity is not 
associated with neurons in the human brain and that its isoform distribution greatly differs 
between white and grey matter. The majority of BIN1 isoforms expressed in the brain 
corresponded to ~65-75 kDa (De Rossi et al., 2016), the reported size of the ubiquitous 
BIN1 isoforms and of similar size to those shown in the present study in hCMEC/D3 
cells. While De Rossi et al. (2016) reported these smaller isoforms were present in both the 
grey matter and white matter, the ~90 kDa isoform, containing the CLAP domain, was 
only expressed in grey matter at lower levels. This suggests that the expression of BIN1 
isoforms in the brain is diverse and this may reflect diverse functions in different cell types. 
Furthermore, RT-PCR analysis of human brain samples showed the expression of 7 
different BIN1 isoforms that lacked the full CLAP domain, of which, 6 did not contain 
exon 6a, further supporting the suggestion that a large proportion of BIN1 expressed in 
the brain may not participate in CME (De Rossi et al., 2016).  
5.4.6!Conclusions 
Collectively, the findings presented in this chapter suggest that BIN1 isoforms expressed in 
hCMEC/D3 cells do not function in CME and BIN1 is therefore not a requirement for 
this mechanism. This is consistent with the findings from Chapter 4, where no difference 
was observed in intracellular APP levels with BIN1 depletion, suggesting the increase in β-
CTF is not attributed to an increase in total APP uptake. It is important to acknowledge 
that only one siRNA was used throughout this analysis and it would be beneficial to 
replicate the results using a different siRNA sequence to validate the findings. 
Furthermore, the hCMEC/D3 cells used in the present study were not cultured in such a 
way to represent the polarised nature of the brain endothelial cells in vivo. While the uptake 
and recycling studies can be considered an indicator of transport mechanisms at the BBB, 
it would be interesting to repeat these assays in a culture system that established apical and 
basolateral domains in the cells. This would also allow an assay of transcytosis mechanisms 
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adherent monolayer on tissue culture vessels. Had time allowed, investigating AMPH1 
expression with BIN1 depletion would have shed light on the possibility of a compensatory 
mechanism with BIN1 depletion, while optimisation of LRP1 antibodies may have 
permitted analyses of LRP1 expression. 
While no change in the endocytic recycling of transferrin was observed, it is possible that 
β-CTF accumulation occurred with BIN1 depletion due to impaired trafficking to the 
lysosome. As transferrin is rapidly recycled back to the plasma membrane, this assay does 
not allow for an assessment of trafficking to the lysosome for degradation. However, 
Miyagawa et al. (2016) have shown impaired lysosomal trafficking of BACE1 in BIN1-
depleted N2A cells whereby BACE1 protein levels were significantly reduced in late 
endosomes/lysosomes compared with the control cells. Therefore, it seems plausible that 
Bin1 may have a role in endocytic trafficking to the lysosome and this presents a further 
avenue for research. In addition, while clathrin-dependent mechanisms may not be 
affected, the dynamin-binding and membrane curvature function of ubiquitous BIN1 may 
be involved in clathrin-independent endocytic mechanisms and this is yet to be 
investigated. 
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Chapter 6 
BIN1: Endocytic Function Beyond 
Clathrin-associated Mechanisms 
6! 6 
6.1!Introduction 
This chapter aims to further explore the mechanism by which BIN1 depletion increases 
intracellular β-CTF levels in hCMEC/D3 cells through exploring the role of BIN1 in a 
clathrin-independent context. Despite the absence of the CLAP domain in hCMEC/D3 
BIN1 isoforms, the N-terminal BAR domain is still capable of inducing the curvature of 
membranes (Peter et al., 2004, Picas et al., 2014) while the C-terminal SH3 domain binds to 
dynamin (Picas et al., 2014), which is involved in other forms of endocytosis. Therefore, it 
was expected that these mechanisms would be important in terms of their contribution 
towards CME in hCMEC/D3 cells. With no evidence of this, the function of BIN1 in 
membrane curvature and dynamin recruitment may be more apparent in other clathrin-
independent forms of endocytosis. The plasma membrane is involved in the lateral 
compartmentalisation of molecules destined for internalisation at the cell surface. 
Microdomains of the plasma membrane are enriched in cholesterol and sphingolipids that 
assist this compartmentalisation role. Endocytosis of ligands and receptors at these 
microdomains occurs via clathrin-independent lipid raft endocytosis. Caveolae are 
caveolin-1 (CAV1)-enriched smooth invaginations of the plasma membrane that form a 
subdomain of lipid rafts. Clathrin-independent methods of endocytosis are explored in the 
present chapter in addition to the trafficking of these lipid raft-mediated vesicles to the 
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lysosomal system. Hypothesising that the increase in β-CTF levels could be attributed to 
impaired lysosomal clearance with BIN1 depletion, indicators of lysosomal function are 
analysed within the chapter to further scrutinise the role of BIN1 at the BBB. 
6.1.1!  Clathrin-independent Endocytosis 
There are many mechanisms of endocytosis at the BBB that take place independent of 
CME, including non-specific processes such as fluid-phase and adsorptive endocytosis, as 
previously described in Chapter 5. Clathrin, CAV1 and flotillin-1 define three separate 
types of region within the plasma membrane that can all undergo internalization (Glebov et 
al., 2006). Flotillin and caveolar endocytosis are both clathrin-independent and will be 
further described in Section 6.1.2. 
6.1.2!Trafficking via Lipid Rafts  
Whereas the plasma membrane is mostly composed of phospholipids, lipid rafts exist as 
distinct lipid-ordered regions with a high concentration of sphingolipids and cholesterol 
that can coalesce to serve as a signaling platform or function in membrane trafficking 
(Simons and Sampaio, 2011). These lipid microdomains were first described in epithelial 
cells in the early 1990s as membrane structures that are insoluble to detergents such as 
Triton X-100 and therefore float in low density fractions (Brown and Rose, 1992). While 
much is now known about the mechanistic details of CME and its structural component 
clathrin, far less is known about clathrin-independent endocytosis (CIE). While CME is 
dependent on dynamin for vesicle scission (Wigge et al., 1997b, Owen et al., 1998), CIE 
can be dynamin-dependent, such as caveolar endocytosis (Oh et al., 1998) while flotillin-
dependent endocytosis may be dependent (Meister et al., 2014) or independent of dynamin 
(Glebov et al., 2006), depending on the cargo or cellular context.  
6.1.2.1! Flotillin-mediated endocytosis 
The flotillin proteins were first thought to associate with caveolae, flask shape 
invaginations at the membrane surface involved in caveolar endocytosis (Bickel et al., 
1997). However, flotillin-1 has since been shown to reside in punctate plasma membrane 
structures and specific endocytic compartments distinct from CCPs and CAV1-positive 
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caveolae (Glebov et al., 2006). Although functionally distinct, flotillin-1 and flotillin-2 are 
both ubiquitously expressed and share 47% homology (Edgar and Polak, 2001). 
Functionally, flotillins have been implicated in signal transduction and cellular migration 
and adhesion in addition to membrane trafficking (Meister et al., 2014). The idea that 
flotillins establish an endocytic pathway independent of clathrin and caveolin was based on 
findings that flotillin-1 levels increased in early endocytic vesicles following fluid-phase 
uptake of magnetic nanoparticles but flotillin-1 did not colocalise with the CME marker Tf 
or with clathrin (Glebov et al., 2006). Furthermore, co-overexpression of flotillin-1 and 2 in 
HeLa cells was sufficient to generate flotillin-positive membrane invaginations that did not 
colocalise or disrupt CAV1 distribution (Frick et al., 2007). In this study, flotillin-1 and 2 
were shown to coassemble into microdomains, distinct from CAV1-positive caveolae. This 
induced membrane curvature, the formation of invaginations morphologically similar to 
caveolae and resulted in the accumulation of intracellular vesicles (Frick et al., 2007).  
Flotillin-mediated endocytosis has been implicated in APP trafficking and Aβ production. 
Flotillin-1 was identified to directly interact with the intracellular domain of APP, AICD, in 
a screen of human brain cDNA, suggesting flotillin-1 may be involved in the recruitment 
of APP to lipid rafts (Chen et al., 1999). Schneider et al. reported that flotillin-2 depletion 
impaired APP endocytosis in mouse N2a neuroblastoma cells and primary hippocampal 
neurons, resulting in reduced production of Aβ (Schneider et al., 2008). This was shown to 
be due to a significant reduction in APP clustering at the plasma membrane, suggesting 
that flotillin-2 promotes the clustering of APP which enhances its endocytosis rate via 
CME. While this effect was not found for flotillin-1 depletion (Schneider et al., 2008), 
Bitsikas et al. (2014) reported that MEFs from Flotillin-1 knockout mice ectopically 
expressing human APP and PSEN1 showed a small reduction in APP endocytosis. 
However, no difference in APP clustering was observed with Flotillin-1 knockout in this 
study. Collectively, these studies suggest that flotillin-1 and -2 may be involved in the 
endocytic uptake of APP. 
6.1.2.2! Caveolar endocytosis 
One of the most researched methods of clathrin-independent endocytosis is that involving 
caveolae. Caveolae are a specific form of lipid raft defined by 50-100nm pits in the plasma 
membrane, rich in the transmembrane caveolin proteins and with a characteristic flask 
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shape. Caveolae form at lipid raft domains and are capable of mediating non-specific 
adsorptive-mediated endocytosis, the trafficking of some membrane receptors and are 
important in cell signalling (Razani and Lisanti, 2001).  
Caveolins are cholesterol-binding membrane proteins that exist in three related forms: 
CAV1, -2, and -3. Whole mouse brain tissue analysis initially indicated a lack of caveolin 
proteins and corresponding mRNA in the brain, however it was later established that both 
CAV1 and -2 are expressed in the endothelium of the brain microvasculature (Schlachetzki 
and Pardridge, 2003). Within the brain, CAV1 and 2 are primarily expressed in endothelial 
cells whereas CAV3 is expressed in astrocytes (Ikezu et al., 1998b). While flotillins are the 
major markers of lipid rafts in neurons (Lang et al., 1998), expression of caveolin proteins 
has been identified in neurons (Galbiati et al., 1998). CAV1 is the main protein component 
of caveolae and its overexpression in caveolae-deficient cells induces the formation of 
plasma membrane invaginations indistinguishable from normal caveolae, suggesting that 
CAV1 is necessary for this process (Lipardi et al., 1998). CAV1 binds cholesterol and 
sphingolipids (Murata et al., 1995, Fra et al., 1995), the two primary components of lipid 
rafts, and its association with cholesterol is important for caveolae biogenesis (Rothberg et 
al., 1992). The ability of CAV1 to self-oligomerise into higher order complexes (Schlegel 
and Lisanti, 2000) allows a meshwork to form which is thought to act synergistically with 
cholesterol and distort the plasma membrane, driving the invagination of caveolae (Hoop 
et al., 2012). 
Later, CAV2 was isolated through microsequencing of adipocyte-derived caveolin-enriched 
membranes and identified as a CAV1-related protein, sharing 38% sequence identity to 
CAV1 (Scherer et al., 1996). CAV2 was coexpressed with CAV1 in all analysed tissues, 
however, unlike CAV1, CAV2 was found to exist mainly as a monomer. CAV2 is not 
required for caveolae formation, with the caveolar membrane system remaining intact in 
cav2-deficient mice (Razani et al., 2002). However, CAV2 has been shown to undergo 
phosphorylation which allows it to positively regulate CAV1-dependent caveolae formation 
(Sowa et al., 2003). CAV3 is a muscle-specific protein, sharing 60% homology with CAV1, 
and is associated with T-tubules during development, which are thought to form by the 
repeated budding of caveolae (Parton et al., 1997). In addition to caveolins, scaffolding 
proteins such as cavins are found within caveolae and are thought to be the major 
structural component (Parton and Collins, 2016). Cavin was shown to colocalise with 
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CAV1 in lipid rafts and was important for maintaining the expression level of CAV1 in 
adipocytes (Liu and Pilch, 2008). 
Although diverse functions have been identified for caveolae, their physiological role in 
different cell types and tissues is not fully understood. CAV1 is expressed in many different 
cell types but shows particularly high expression in peripheral endothelial cells (Lisanti et 
al., 1994), which indeed contain a large number of caveolae (Sowa, 2011). The transcytosis 
of macromolecules was the first proposed function for caveolae (Palade and Bruns, 1968) 
and the caveolae-mediated intracellular and transcellular transport of insulin and albumin 
has since been demonstrated in cultured lung and aortic endothelial cells (Schnitzer et al., 
1994). SV40 and cholera toxin subunit B (ctxB) have been extensively studied as potential 
caveolar cargoes as both ligands bind the ganglioside GM1, which is found in caveolae 
(Neu et al., 2008). However, internalization of ctxB has also been demonstrated to also 
take place via both clathrin-dependent and clathrin-independent mechanisms with caveolae 
contributing to ctxB uptake (Torgersen et al., 2001). Initially caveolar endocytosis was 
thought to mirror CME with the caveolae pinching off into a caveosome. The caveosome 
was described as an immobile intermediate compartment, rich in CAV1 and distinct from 
normal endosomes, involved in the trafficking from caveolae to the ER and was not 
labelled by fluid-phase markers or ligands of CME (Pelkmans et al., 2001). The neutral pH 
and lack of LysoTracker accumulation in the caveosome made it distinct from existing 
endocytic compartments and it was thought to be a means of cell entry for some 
viruses/toxins to avoid the lysosomal pathway (Pelkmans et al., 2001). However, more 
recently this has been questioned and it is now thought that caveolae internalise and fuse 
with the early endosome as endogenous CAV1 has been observed in early endosomes but 
not late endosomes and lysosomes (Hayer et al., 2010). Under normal conditions, 
endogenous CAV1 is found in early endosomes but when highly overexpressed, CAV1 
accumulated in late endocytic compartments positive for Rab7 and Lamp1, markers of late 
endosomes and lysosomes respectively which were not tested in the original study. The 
neutral pH of CAV1-containing organelles recorded in the original study has since been 
revised by the authors as it was determined using SV40 as a probe at a time point when the 
virus may have reached the neutral environment of the ER (Hayer et al., 2010).  
With regards to caveolar endocytosis at the BBB, an unusually low rate of transcytosis has 
been identified as one of the unique properties of BMECs, relative to peripheral 
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endothelial cells. Recently, a mechanism has been described through which the unique lipid 
composition of BMECs is maintained in order to specifically inhibit caveolae-mediated 
transcytosis and maintain BBB integrity (Andreone et al., 2017). Lipidomic analysis showed 
that the lipid signature of mouse BMECs differs from that of lung endothelial cells, which 
do not possess the restrictive barrier properties of BMECs, by a significant enrichment in 
lipids containing the omega-3 fatty acid docosahexaenoic acid (DHA) (Andreone et al., 
2017). DHA is a highly unsaturated fatty acid that disrupts liquid-ordered caveolae 
domains. This suggests that the lipid composition and corresponding suppression of 
caveolae-mediated transcytosis in BMECs may be crucial to maintain the relative 
impermeability of the BBB. Furthermore, changes in caveolar-endocytic mechanisms are 
therefore likely to impact on the barrier properties of BMECs. 
6.1.3!Lipids Rafts and the Amyloidogenic Processing of APP 
In addition to the aforementioned interaction between flotillin and APP in Section 6.1.2.1, 
there is strong evidence implicating lipid rafts in the processing of APP but the precise 
mechanism is still to be elucidated and there are contradictions in the literature. Numerous 
studies have suggested that the amyloidogenic processing of APP occurs at lipid rafts as 
APP, BACE1 and γ-secretase have been found to localise in these regions (Wahrle et al., 
2002, Ehehalt et al., 2003). Lipid rafts have also demonstrated critical involvement in 
regulating Aβ generation through the association of BACE1 and APP with detergent-
resistant membranes in a cholesterol-dependent manner (Simons et al., 1998, Riddell et al., 
2001). Cholesterol plays a crucial role in maintaining lipid rafts in a functional state and the 
demonstration that cholesterol ablation disrupts lipid rafts, resulting in inhibition of Aβ 
production without affecting sAPPα levels in hippocampal neurons, implicates lipid rafts in 
the amyloidogenic processing of APP (Simons et al., 1998). Furthermore, BACE1 has been 
found within a unique raft population distinct from caveolae and this association was 
perturbed with cholesterol depletion, suggesting that the partitioning of BACE1 into lipid 
rafts may underlie the cholesterol sensitivity of Aβ production (Riddell et al., 2001). Indeed, 
the majority of β-CTF in CHO cells cofractionated with BACE1 in lipid raft fractions 
(Riddell et al., 2001). 
The cytoplasmic domain of APP has been shown to physically associate with CAV1, the 
depletion of which prevented α-secretase processing of APP suggesting that caveolae play a 
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pivotal role in the α-cleavage of APP (Ikezu et al., 1998a). However, this colocalisation is 
not sufficient to prove true caveolar compartmentalization as in CHO cells, BACE1, APP 
and Psen1 did not show colocalisation with Cav1 (Riddell et al., 2001). Nevertheless, while 
only a minor proportion of APP was shown to cofractionate with BACE1 in lipid rafts 
(Riddell et al., 2001), it is only a small percentage of total cell APP that is processed via the 
β-secretase cleavage pathway under normal physiological conditions (Selkoe, 1994). Cordy 
et al. showed that relatively little BACE1 is found in lipid rafts of the SH-SY5Y 
neuroblastoma cell line but when BACE1 was targeted exclusively to lipid raft domains by 
a glycosylphosphatidylinositol anchor, secretion of sAPPβ and Aβ was significantly 
increased (Cordy et al., 2003). This effect was reversed when lipid rafts were disrupted by 
depleting cholesterol, suggesting that the amyloidogenic processing of APP occurs 
predominantly in lipid rafts and BACE1 is the rate-limiting enzyme.  
Inflated levels of cholesterol have been linked to increased levels of βCTFs and amyloid 
load in the CNS (Refolo et al., 2000), suggesting APP is more readily processed by β-
secretase under these conditions. Altered cholesterol levels may therefore alter the 
distribution of APP and BACE1 in lipid rafts or affect enzymatic activity. Cholesterol 
accumulation is a key hallmark of Niemann-Pick type C (NPC) disease and much research 
in this field has provided information regarding the relationship between cholesterol and 
Aβ. NPC is a lysosomal storage disease caused by mutations in the NPC1 or NPC2 genes 
resulting in impaired trafficking and accumulation of free cholesterol in the late 
endosomal/lysosomal compartments leading to increased β-CTF and Aβ formation 
(Yamazaki et al., 2001). Using an NPC in vitro model (CHO NPC1-/- cells), which shows 
accumulation of free cholesterol, Kosicek et al. (2010) showed that APP and CTFs 
redistributed to lipid raft fractions compared to wild-type cells. Furthermore, increased 
distribution of APP and CTFs were found in lipid raft fractions upon γ-secretase inhibition 
in NPC cells compared to wild-type, suggesting that lipid rafts are the likely site of APP 
amyloidogenic processing upon NPC1 dysfunction.  
6.1.4!Lysosomal Dysfunction and β-CTF Accumulation 
Increasing evidence suggests that NPC and AD are likely to share a common underlying 
feature; dysfunctional clearance of cargo via the secretory-endocytic-autophagic-lysosomal-
exocytic network (Boland and Platt, 2015). Figure 6.1 shows a schematic of the endo-
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lysosomal portion of this network and in particular, illustrates the trafficking of APP and 
the products of its amyloidogenic proteolysis. APP is endocytosed from the plasma 
membrane into endocytic vesicles which fuse with early endosomes. Here, β-cleavage of 
APP releases sAPPβ and β-CTF, which remains membrane-bound. Aβ is then released by 
γ-cleavage and the components are either trafficked to the lysosome via the late endosome 
for degradation or exocytosed at the plasma membrane.  
In addition to enlarged rab5-positive early endosomes, upregulation of lysosomal processes 
and accumulation of lysosomes has been reported as an early feature of AD and implicates 
the lysosomal system in Aβ pathology (Cataldo et al., 1994). The increase in β-CTF levels 
with BIN1 depletion in the present study may be indicative of β-CTF accumulation due to 
impaired lysosomal degradation. Indeed, in the brains of NPC mouse models, cholesterol 
accumulation has been associated with a large accumulation of β-CTF (Burns et al., 2003). 
The levels and activity of β -secretase and α-secretase remained unaffected but the activity 
of γ-secretase was increased by over 50% in NPC mice compared with wild type littermate 
controls. The accumulation of β-CTF in NPC mice compared to controls suggests that the 
increase in γ-secretase activity was not sufficient to clear all of the β-CTF and that β-CTF 
clearance mechanisms may be defective in NPC mice (Burns et al., 2003). Boland et al. 
(2010) also reported the accumulation of β-CTFs in three mouse models of lysosomal 
storage diseases, suggesting that defective lysosomal flux causes impaired lysosomal 
proteolysis of β-CTFs. Furthermore, Rab proteins are involved in the regulation of 
compartmentalised membrane trafficking and can be perturbed in lysosomal storage 
diseases (Choudhury et al., 2004). This is of particular interest to the present study as 
recently, Rab8 was shown to form a complex involving Bin1 that regulates transport of 
apical-directed proteins from the endocytic recycling complex in polarised intestinal 
epithelial cells (Nakajo et al., 2016). The authors further showed enlargement of lysosomes 
after Bin1 depletion in mouse intestinal organoids, suggestive of defective lysosomal 
degradation. Therefore, it seems plausible that BIN1 may have a role in normal functioning 
of the lysosome.  
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Figure 6.1: The Endo-Lysosomal trafficking of APP and Products of its 
Amyloidogenic Processing 
A schematic depicting the endo-lysosomal trafficking of APP, Aβ, β-CTF and sAPPβ. 
Newly synthesised APP is transported from the Golgi to the plasma membrane where it is 
rapidly endocytosed into endocytic vesicles which fuse with early endosomes. Here, β-
cleavage of APP releases sAPPβ and β-CTF which remains membrane-bound. Aβ is then 
released by γ-cleavage and the components are either trafficked to the lysosome via the late 
endosome for degradation or exocytosed at the plasma membrane. Adapted from Boland 
and Platt (2015) 
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6.1.5!Aims of this Chapter 
This chapter aims to investigate whether BIN1 is involved in endo-lysosomal trafficking, 
hypothesising that depletion of BIN1 expression in human brain endothelial cells impairs 
lysosome function and alters the amyloidogenic pathway. Furthermore, while BIN1 does 
not appear to have a crucial role in CME in the hCMEC/D3 cell line, CIE can also be 
dynamin-dependent and involves curvature of the plasma membrane. Therefore, the 
dynamin-recruiting and membrane-bending properties of BIN1 may have a role in CIE. 
This hypothesis will be analysed through protein expression of key CIE-related proteins in 
addition to trafficking of lipid raft markers. 
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6.2!Experimental Design 
6.2.1!BIN1 Depletion in hCMEC/D3 cells 
Cell culture and depletion of BIN1 protein was performed as previously described in 
Chapter 4, Section 4.2.1 and confirmed by Western blotting as described in Chapter 2, 
Section 2.3.  
6.2.2!Immunofluorescent Staining 
Immunocytochemistry was used to observe lysosome morphology using lysosomal 
associated membrane protein-2 (LAMP2) (mouse monoclonal antibody, 0.32 µg/ml, 
Developmental Studies Hybridoma Bank, Iowa, US) and CAV2 expression (0.25 µg/ml, 
BD Biosciences) and was carried out as described in Chapter 2, Section 2.4 with three 
replicates per experiment and representative images shown. Cells were fixed in 100% 
methanol as described in Chapter 2, Section 2.4.2. 
6.2.3!LysoTracker Staining 
In order to label acidic organelles within cells, a live cell stain using LysoTracker was 
performed. Cells were plated and transfected as previously described in Chapter 2, Section 
2.2 in 8-well glass bottom chamber slides (Ibidi, Martinsried, Germany). Forty-eight hours 
post-transfection, cells were washed 3x in RT PBS before adding 200 µl/well of 200 nM 
LysoTracker Green (ThermoFisher Scientific) in PBS and incubating at 37°C for 5 min, 
protected from light. Cells were washed 3x in RT PBS before incubating with 4 µg/ml 
Hoechst® dye (Sigma) in PBS for 10 min at RT, protected from light, to stain the nuclei. 
Cells were immediately live imaged on the Axio Observer A1 microscope with three 
replicates per experiment and representative images shown. 
6.2.4!Western Blotting 
Western blotting was performed as described in Chapter 2, Section 2.3 using the primary 
antibodies detailed in Table 6.1, 10-20 µg protein was used per well and run on a 10% 
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acrylamide gel. Some of the blots investigating CAV1, Caveolin-2, flotillin-1 and flotillin-2 
with BIN1 depletion were carried out by Catherine Matheson and Robert Greening as part 
of their final year undergraduate (BSc Pharmacy) projects, co-supervised by myself. All 
densitometry analysis was independently analysed by the students and myself. 
Quantification of protein was calculated by densitometry analysis normalising to GAPDH 
expression, previously described in Chapter 2, Section 2.3.6. 
 
Table 6.1: Primary antibodies used for Western blotting in Chapter 6 
Protein Host Species Supplier Working 
concentration 
CAV1 Rabbit Cell Signalling 0.08 µ/ml 
CAV2 Mouse BD Biosciences 0.5 µg/ml 
Flotillin-1 Mouse BD Biosciences 0.5 µg/ml 
Flotillin-2 Rabbit Novus 0.98 µg/ml 
GAPDH Mouse Abcam 0.13 µg/ml 
 
6.2.5!Fluorescence Staining of Free Cholesterol 
Filipin can bind to complexes of cholesterol and other lipids (Arthur et al., 2011) and was 
therefore used to observe cholesterol localisation in cells. Cells were fixed in 4% PFA on 
pre-sterilised coverslips, as previously described in Chapter 2, Section 2.4.1, washed three 
times with PBS and incubated with 150 µg/ml filipin complex (Sigma) in EGM-2 medium 
for 30 min at room temperature, protected from light. Cells were washed once with EGM-
2 and twice with PBS and mounted on glass slides with SlowFade Gold antifade mountant. 
Cells were imaged on the Axio Observer A1 microscope with three replicates per 
experiment and representative images shown. 
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6.2.6!Cholera Toxin Subunit B Trafficking 
CtxB binds ganglioside GM1 in the plasma membrane and has previously been used as a 
marker for lipid raft transport (Nichols et al., 2001). In order to optimise the analysis of 
CtxB trafficking, different chase times and CtxB concentrations were tested. Cells were 
seeded on pre-sterilised fibronectin-coated glass coverslips at a density of 84,000 cells per 
cm2, as previously described in Chapter 2, Section 2.1.2 and allowed to adhere overnight. 
Medium was removed and cells pulsed with 2 µg/ml ffluorescein isothiocyanate-
conjugated CtxB (FITC-CtxB) in chilled EGM-2 media for 30 min in a cool box to allow 
binding to plasma membrane GM1 without endocytosis proceeding. Cells were washed 
once with EGM-2 media at 37°C before chasing with EGM-2 media at 37˚C for 45, 60, 75 
or 90 min. This experiment was repeated, incorporating a 0 min chase control and 
increasing concentrations of CtxB (2, 5, 10 and 20µg/ml) over a time course of 0, 1, 2 or 3 
hours.  Following the chase, cells were backwashed three times for 10 min with 1% BSA 
and 0.1% heparin in chilled EGM2 medium to remove surface labelling, followed by two 
washes with RT PBS and fixed in 4% PFA at RT for 10 min, as described in Chapter 2, 
Section 2.4.1. Coverslips were mounted onto glass slides using SlowFade Gold Antifade 
Mountant (ThermoFisher). Slides were imaged on the Axio Observer A1 microscope. 
6.2.7!CAV1 Depletion 
Depletion of CAV1 was performed as described for BIN1 depletion in Chapter 2, section 
2.2 using the siRNA sequence 5’-AGACGAGCUGAGCGAGAAG-3’ (Eurofins). This 
siRNA was used at a final concentration of 50 nM, which has previously been used to 
demonstrate successful knockdown (Al Soraj et al., 2012). CAV1 depletion was confirmed 
by Western blotting, as described in Section 6.2.4. 
6.2.8!Genistein Inhibitor Treatment 
To selectively inhibit caveolar endocytosis, cells were pre-incubated for 30 min with 200 
µM genistein in phenol red-free OptiMEM medium (ThermoFisher Scientific) before 
BODIPY- LacCer addition, as described in Section 6.2.9. 
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6.2.9!BODIPY-Lactosylceramide Trafficking 
Fluorescent boron-dipyrromethene (BODIPY)-labelled lactosylceramide (LacCer, 
ThermoFisher Scientific) was used as a marker for caveolar endocytosis. Cells were washed 
twice with RT PBS before pulse labelling with l µM BODIPY-LacCer in HEPES/HBSS 
solution (10 µM HEPES in Hanks Buffered Salt Solution, both ThermoFisher Scientific) 
for 30 min at 10 °C to load the plasma membrane. For each condition, a sample without 
the addition of BODIPY-LacCer was included to measure background fluorescence levels. 
Cells were washed 3x with ice-cold phenol red-free OptiMEM medium (ThermoFisher 
Scientific) followed by chasing for 15 min at 4°C or 37°C in phenol red-free OptiMEM. 
Cells were then back exchanged to remove surface labelling by washing with 5% BSA in 
PBS 6 x 10 min on ice with gentle agitation. Cells were kept on ice, washed twice with ice-
cold PBS and ice-cold trypsin (0.05%, ThermoFisher Scientific) was added to cells and the 
plate incubated on ice until the cells were in suspension. An equal volume of ice-cold 
trypsin inhibitor solution (500µg/ml trypsin inhibitor, 75µg/ml DNase, 1% BSA in PBS) 
was added to cells and the cell suspension centrifuged at 325 x g at 4°C for 3 min. The 
pellet was resuspended in 0.33 mM Trypan Blue (Sigma) in PBS and incubated at 4°C for 
30 min. Cells were washed three times with ice-cold PBS by centrifugation as previously 
described, resuspended in 500µl ice-cold PBS and transferred to FACs tubes via 30µm 
filters. The geometric mean of fluorescent intensity for at least 10,000 events was measured 
by flow cytometry using the BD FACSverse with debris and doublets gated out.  
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6.3!Results 
6.3.1!Assessing Lysosome Function with BIN1 depletion 
6.3.1.1! Lysosomal morphology 
In order to explore whether increased β-CTF with BIN1 depletion was a result of impaired 
lysosomal clearance, the morphology of lysosomes was examined by fluorescent 
microscopy. Expansion of the late endosome and lysosome compartments can be 
indicative of lysosomal dysfunction (Platt et al., 2012). LysoTracker is a fluorescent, cell 
permeable probe that selectively accumulates in acidic organelles and provides a means by 
which the morphology and relative fluorescence of the late endosome/lysosome 
compartments can be observed in live cells with BIN1 depletion. Fluorescently-labelled 
LysoTracker was observed in all hCMEC/D3 cells, showing strong punctate staining which 
was particularly prominent in the perinuclear region, as identified by its location relative to 
DAPI-stained nuclei (Figure 6.2). There was no observable difference in the strength of 
fluorescence or localisation of staining with BIN1 depletion compared to GFP siRNA-
treated cells. As LysoTracker can label other acidic compartments and is therefore not 
limited to lysosomes, antibodies against lysosome-associated membrane proteins (LAMPs) 
present a more specific approach. LAMP2B has previously been used to demonstrate 
aberrant lysosome morphology in Bin1-depleted mouse intestinal organoids (Nakajo et al., 
2016) and was therefore used to specifically label lysosomes in hCMEC/D3 cells. 
LAMP2B showed more diffuse punctate staining than LysoTracker, consistent with its 
more specific labelling pattern (Figure 6.3). All cells showed positive staining for LAMP2B 
and the puncta showed accumulation at the perinuclear region in the majority of cells, 
however distribution throughout the cytoplasm was also observed. The localisation and 
strength of fluorescence was not affected by GFP siRNA treatment compared to non-
transfected cells and also remained consistent with BIN1 depletion compared to GFP 
siRNA treatment, suggesting that reduced levels of BIN1 do not cause gross 
morphological changes in lysosomes. 
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Figure 6.2: Live cell images of LysoTracker-stained acidic organelles 
Representative images taken of live cells stained with LysoTracker Green which marks 
acidic organelles, such as lysosomes, in non-transfected, GFP siRNA-treated and BIN1-
depleted hCMEC/D3 cells. Images taken at x40 magnification, scale bar = 25 µm. 
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Figure 6.3: Fluorescent images of LAMP2B expression with BIN1 depletion 
Representative images of lysosomal marker, LAMP2B, expression in non-transfected, GFP 
siRNA-treated and BIN1-depleted hCMEC/D3 cells. Images taken at x40 magnification, 
scale bar = 25 µm. 
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6.3.1.2! Cholesterol transport 
While the gross morphology of lysosomes appeared unaffected by BIN1 depletion, 
impaired lysosome function may occur in the absence of morphological changes. 
Lysosome dysfunction often causes accumulation of cholesterol and glycosphingolipids 
(GSLs) in the lysosomes. This is a result of reduced breakdown, as cholesterol and GSLs 
should normally be found in the perinuclear ERC following internalisation in lipid rafts (te 
Vruchte et al., 2004). To analyse cholesterol localisation with BIN1 depletion, fixed cells 
were stained with filipin, a cytochemical probe specific for cholesterol. Cholesterol was 
found in small puncta, predominantly localised to the perinuclear region and there was 
significant plasma membrane staining with evidence of diffuse staining throughout the 
cytoplasm or underlying membrane (Figure 6.4). Crucially, no observable difference in 
cholesterol localisation or staining intensity was shown between non-transfected, GFP 
siRNA-treated and BIN1-depleted cells, suggesting a reduction in BIN1 does not impact 
on lysosome function. 
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Figure 6.4: Cholesterol localisation in hCMEC/D3 cells with BIN1 depletion 
Representative fluorescent images showing specific staining of free cholesterol with filipin 
in non-transfected, GFP siRNA treated and BIN1 depleted hCMEC/D3 cells. Cholesterol 
staining is present throughout the plasma membrane and shows particularly intense 
staining in the perinuclear region (example indicated by red arrow). Images were taken at 
x40 magnification, scale bar = 25 µm.  
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6.3.2!Clathrin-independent Endocytosis 
While no clear indicators of lysosome function were observed, the secondary objective of 
this study was to investigate whether BIN1 has a role in clathrin-independent mechanisms 
of endocytosis in the hCMEC/D3 cell line. Indeed, several aforementioned lines of 
evidence have suggested that amyloidogenic processing of APP occurs in lipid raft 
fractions. The expression levels of key CIE proteins, flotillin-1, CAV1 and CAV2 were 
investigated with BIN1 depletion by Western blotting. 
6.3.2.1! Flotillin-1 and 2 expression 
Flotillin-1 and 2 associate with cholesterol-enriched lipid non-caveolar microdomains and 
are important for clathrin-independent endocytosis (Glebov et al., 2006) and APP 
processing (Schneider et al., 2008). Flotillin-1 and 2 expression was detected in 
hCMEC/D3 cells with a single band at approximately 45 kDa and 48 kDa, respectively 
(Figure 6.5). The level of expression of flotillin-1 was not affected by BIN1 depletion 
(Figure 6.6). Due to time constraints, only two replicates of flotillin-2 expression were 
possible with one suggesting a small increase in expression compared to GFP siRNA-
treated cells and the other a small decrease. Overall, no significant change in level of 
flotillin-2 was observed with BIN1 depletion compared to GFP siRNA-treated cells 
(Figures 6.5 and 6.7), suggesting that the expression of flotillins was not affected by a 
reduction in BIN1 expression.  
6.3.2.2! Expression of the caveolins 
The caveolins are the major protein components of cholesterol- and GSL-rich flask-shaped 
invaginations of plasma membrane caveolae. Both CAV1 and CAV2 showed strong 
expression in hCMEC/D3 cells with single bands at approximately 21 kDa and 22 kDa 
respectively (Figure 6.5). CAV1 showed consistent expression which did not alter with 
BIN1 depletion in comparison to GFP siRNA-treated cells (Figure 6.8), however there was 
evidence of an 86% increase in CAV2 expression, compared to GFP siRNA-treated cells 
which was statistically significant upon densitometry analysis (Figure 6.9, p = 0.03 using a 
two-tailed unpaired Student’s t test). The increase in CAV2 expression was further 
demonstrated by immunocytochemistry (Figure 6.10) which showed enhanced intensity of 
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fluorescence in BIN1-depleted cells compared to non-transfected and GFP siRNA-treated. 
In all conditions, CAV2 showed faint punctate expression throughout the cells with 
particularly enhanced expression in the perinuclear region in the majority of cells and at the 
lateral edges of some cells. Although not compared to other markers or CAV1 expression, 
the pattern of CAV2 expression did not observably differ with BIN1 depletion compared 
to GFP siRNA and non-transfected cells. Collectively, this data suggests that BIN1 
depletion results in an increase in CAV2 expression but does not affect its localisation. 
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Figure 6.5: Expression of key clathrin-independent endocytic proteins with BIN1 
depletion 
Representative Western blots of Flotillin-1, Flotillin-2, CAV1 and Caveolin-2 expression in 
non-transfected, GFP siRNA treated and BIN1 depleted hCMEC/D3 cells. GAPDH was 
used as a housekeeping protein. 
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Figure 6.6: Quantification of Flotillin-1 expression with BIN1 depletion 
Quantification of flotillin-1 expression based on densitometry analysis, expressed as mean 
percentage expression of non-transfected cells after normalisation to GAPDH, error bars 
= SEM, n = 4, p > 0.05 using a two-tailed unpaired Student’s t test. 
  
 
 
 
 
 
 
 
 
 
Figure 6.7: Quantification of Flotillin-2 expression with BIN1 depletion 
Quantification of flotillin-2 expression based on densitometry analysis, expressed as mean 
percentage expression of non-transfected cells after normalisation to GAPDH, n = 2, p > 
0.05 using a two-tailed unpaired Student’s t test.  
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Figure 6.8: Quantification of CAV1 expression with BIN1 depletion 
Quantification of CAV1 expression based on densitometry analysis, expressed as mean 
percentage expression of non-transfected cells after normalisation to GAPDH, error bars 
= SEM, n = 4, p > 0.05 using a two-tailed unpaired Student’s t test. 
 
 
 
 
 
 
 
 
Figure 6.9: Quantification of CAV2 expression with BIN1 depletion 
Quantification of CAV2 expression based on densitometry analysis, expressed as mean 
percentage expression of non-transfected cells after normalisation to GAPDH, error bars 
= SEM, n = 4, * = p < 0.05 using a two-tailed unpaired Student’s t test.  
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Figure 6.10: Caveolin-2 expression in hCMEC/D3 cells with BIN1 depletion 
Representative fluorescent images showing CAV2 expression in non-transfected, GFP 
siRNA treated and BIN1-depleted hCMEC/D3 cells. CAV2 is expressed predominantly in 
the perinuclear region (example indicated with white arrow) and the intensity of staining is 
more pronounced in BIN1-depleted cells, suggesting increased expression. Images were 
taken at x40 magnification, scale bar = 25 µm. 
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6.3.3!Lipid Raft/Caveolar Endocytosis and Trafficking  
CAV2 has previously been implicated in the regulation of caveolae (Sowa et al., 2003), 
therefore, the increase in CAV2 expression with BIN1 depletion provides rationale for 
investigating the function of caveolar endocytosis. Furthermore, impaired fusion of late 
endosomes to lysosomes results in the accumulation of glycosphingolipids in lysosomal 
storage diseases such as NPC, therefore analyzing the trafficking of lipids enriched within 
lipid rafts may also give an indication of lysosome function. 
6.3.3.1! CtxB trafficking 
CtxB binds the plasma membrane ganglioside GM1 which is found in cholesterol- and 
GSL-rich microdomains (lipid rafts) at the plasma membrane and is endocytosed via lipid 
raft/caveolar endocytosis (Orlandi and Fishman, 1998). FITC-labelled CtxB was used in 
this study as a marker of lipid raft transport from the plasma membrane to late 
endosomes/lysosomes by a pulse-chase assay (Lachmann et al., 2004). This assay would 
not only give an indication of altered lipid raft trafficking but also lysosome dysfunction 
that would be indicated by trapped lysosomal CtxB which cannot exit to the Golgi.  
In order to optimise the assay in the hCMEC/D3 cell line, four different chase time points 
were used (0, 1, 2 and 3 hours) in non-transfected cells to determine the optimal time point 
to observe CtxB trafficking to the Golgi. Widespread faint punctate staining was observed 
in all conditions, including a non-stained control condition (Figure 6.11), which was 
therefore considered to be autofluorescence. Across all time points, a very small population 
(<1%) of cells exhibited positive staining, predominantly in the perinuclear region, 
suggestive of Golgi staining, as represented in Figure 6.11, with Hoechst staining the 
nuclei. Figure 6.12 shows representative comparisons of positive CtxB staining between the 
time points and also across different concentrations of CtxB, ranging from 2-20 µg/ml. 
The 0 min chase control was incorporated to visualise surface staining of CtxB which 
indeed showed diffuse plasma membrane staining on a small number of cells. After 1-3 
hours chase, staining was more intense in the perinuclear region compared to 0 hours. 
However, no observable difference in the number of cells showing positive Golgi staining 
was noted between time points. Increasing concentrations of CtxB at 2, 5, 10 and 20 µg/ml 
were used in an attempt to optimise the number of positively-stained cells. While the 
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background punctate staining appeared to increase slightly with CtxB concentration, the 
number of positively-stained cells did not (Figure 6.12). This suggested that GM1 
expression in the hCMEC/D3 cell line was not sufficient for CtxB to be used as a marker 
for lipid raft trafficking and an alternative method was sought to analyse this.  
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Figure 6.11: CtxB staining GM1 ganglioside in non-transfected hCMEC/D3 cells 
Representative examples of FITC-CtxB (2 µg/ml) staining in hCMEC/D3 cells. A) 
Positive Golgi staining after a 1 hour chase is shown (white arrows), taken at x 40 
magnification with Hoechst staining the nuclei. B) A representative image taken at x20 
magnification to illustrate the low percentage (<1%) of cells showing positive FITC-CtxB 
staining in all conditions. C) The non-stained control had no CtxB applied yet showed 
diffuse punctate staining, confirming that this is a result of background fluorescence. Scale 
bar = 25 µm.  
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Figure 6.12: Optimisation of concentration and chase time for CtxB staining of 
hCMEC/D3 cells  
Representative fluorescent images of hCMEC/D3 cells pulsed with 2 – 20 µg/ml FITC-
CtxB and chased for 0-3 hours to optimise the number of cells showing positive staining. 
Increased background punctate staining was evident in the 20 µg/ml conditions compared 
to 2 µg/ml.  With no chase (0 hours), CtxB showed plasma membrane staining (example 
indicated with red arrow) with perinuclear staining evident after 1-3 hours (examples 
identified with white arrows), suggestive of Golgi localisation. Images taken at x40 
magnification, Scale bar = 25 µm. 
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6.3.3.2! BODIPY-LacCer trafficking 
BODIPY-LacCer is a fluorescent analogue of the globoside lactosylceramide (Sharma et al., 
2003) which is internalised from the plasma membrane by a caveolar-related mechanism 
and subsequently targeted to the Golgi apparatus (Singh et al., 2003). CAV1 is required for 
caveolar endocytosis and inhibition of LacCer uptake has previously been demonstrated 
upon CAV1 depletion (Al Soraj et al., 2012). Therefore, siRNA-mediated depletion of 
CAV1 was performed to establish a control for inhibition of LacCer uptake. CAV1 siRNA 
successfully depleted levels of CAV1 protein by 82%, which was confirmed by Western 
blotting (Figure 6.13). CAV1 expression was not affected by BIN1-depletion (Figure 6.13). 
When cells were chased at 37°C, considerable uptake of BODIPY-LacCer was apparent by 
the nearly 10-fold increase in fluorescence compared to those chased at 4°C, where 
inhibition of LacCer uptake was observed (Figure 6.13). A two-way ANOVA was used to 
determine the effect of temperature and siRNA treatment on LacCer uptake. There was a 
significant effect of temperature on LacCer uptake (p<0.001), demonstrating that uptake of 
LacCer in these cells is an active endocytic process as endocytic pathways are inhibited at 
4°C. However, there was no significant effect of siRNA treatment on LacCer uptake after a 
15 min chase at 37°C, suggesting that BIN1 is not central to the uptake of LacCer. 
Surprisingly, CAV1 depletion did not affect LacCer uptake, suggesting that CAV1 is not 
crucial for caveolar uptake in these cells. CAV1 depletion was intended as a positive 
control for inhibition of LacCer uptake, based on previous findings in other cell types (Al 
Soraj et al., 2012) and the well-documented role of CAV1 in caveolar uptake (Lisanti et al., 
1994, Lipardi et al., 1998, Razani et al., 2001). The sensitivity of this assay for measuring 
caveolar uptake was therefore questioned and alternative means of inhibition sought in 
order to test this. 
The internalisation of caveolae is facilitated by the actin cytoskeleton. Genistein is a 
tyrosine kinase inhibitor which causes local disruption of the actin cytoskeleton at 
endocytic sites and has been extensively used as an inhibitor of caveolar endocytosis (Singh 
et al., 2003, Vercauteren et al., 2010, Mougeolle et al., 2015). BODIPY-LacCer uptake was 
analysed in hCMEC/D3 cells with and without genistein treatment. Chasing cells at 4°C 
inhibited LacCer uptake to the same extent in both genistein-treated and non-treated cells. 
Unfortunately, time constraints only permitted the completion of two replicates, however, 
at 37°C, Genistein treatment resulted in a significant 30% reduction in LacCer uptake 
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compared to non-treated control cells (p<0.01 using a two-tailed unpaired Student’s t test, 
Figure 6.14) suggesting successful inhibition of CIE.  
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Figure 6.13: LacCer Uptake with BIN1 depletion to measure Caveolar Endocytosis 
A) A representative Western blot showing successful siRNA-mediated depletion of CAV1 
which did not affect BIN1 levels. 
B) Quantification of BODIPY-LacCer trafficking in BIN1-depleted cells in comparison to 
CAV1-depleted, GFP siRNA-treated and non-transfected cells. BODIPY-LacCer was 
chased for 15 min at 4°C or 37°C before washing off surface-bound fluorescence and 
analysing intracellular fluorescence by FACs. There was no significant difference with 
CAV1 or BIN1 depletion compared to GFP siRNA-treated or non-transfected cells but a 
significant difference in mean fluorescent intensity between 4°C and 37°C (p<0.001, two-
way ANOVA). Values represent the geometric mean, n= 3-4, error bars = SEM.  
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Figure 6.14: LacCer Uptake with Genistein Treatment to inhibit CIE 
Quantification of BODIPY-LacCer trafficking in Genistein-treated cells in comparison to 
non-treated cells. BODIPY-LacCer was chased for 15 min at 4°C or 37°C before washing 
off surface-bound fluorescence and analysing intracellular fluorescence by FACs. Values 
represent the geometric mean, n = 2, ** = p<0.01 using a two-tailed unpaired Student’s t 
test. 
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6.4!Discussion 
This chapter aimed to investigate the relationship between BIN1 and endocytic trafficking 
to the lysosome, independent of clathrin-mediated mechanisms, in order to ascertain the 
involvement of BIN1 in the amyloidogenic processing of APP in BMECs. Firstly, 
morphological indicators of lysosome dysfunction were analysed, including lysosome 
morphology and cholesterol localisation. Both LysoTracker and, more specifically 
LAMP2B, were used as lysosome markers and a change in morphology or localisation of 
these with BIN1 depletion was not observed. Cholesterol localisation was also unaffected 
by BIN1 depletion, suggesting no impairment in lysosome function. Next, the expression 
of flotillin-1, flotillin-2, CAV1 and CAV2, key proteins involved in CIE, was analysed. 
While Ffotillin-1 and 2 and CAV1 showed no difference in levels, CAV2 showed a 
significant increase in expression with BIN1 depletion. In order to assess the function of 
caveolar endocytosis, markers of lipids found in lipid rafts were examined. CtxB, which 
binds GM1, did not show enough positive staining in the cells to reliably assess its 
trafficking. However, considerable uptake of BODIPY-LacCer was demonstrated in these 
cells, but this was not altered with BIN1 depletion therefore suggesting that BIN1 is not 
important for CIE in hCMEC/D3 cells. 
6.4.1!Lysosome Morphology is not Affected by BIN1 depletion 
Endolysosomal/autophagic alterations are well-recognised early neuropathological features 
of AD, including enlarged early endosomes, lysosome abnormalities and the progressive 
accumulation of autophagic vacuoles ( Cataldo et al., 1994, Cataldo et al., 2000, Nixon et 
al., 2005). Impairment of autophagy has also been associated with some lysosomal storage 
diseases, caused by impaired degradation of some membrane lipids, such as NPC, which is 
associated with severe neurodegeneration in early life (Platt et al., 2012). Accumulation of 
sphingolipids, by the addition of exogenous GSLs to human H4, HeLa and HEK293 cells, 
has been shown to result in the marked accumulation of APP-CTFs due to decreased 
lysosome-dependent degradation of APP-CTFs (Tamboli et al., 2011). Prominent 
accumulation of APP-CTFs was also reported in primary human fibroblasts obtained from 
patients with lysosomal storage diseases (Tamboli et al., 2011). These findings suggested 
that sphingolipid accumulation affects autophagic flux and impairs the clearance of APP-
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CTFs. Impaired lysosomal function has also previously been associated with β-CTF 
accumulation in neurons of 3-month-old triple transgenic AD mice, harbouring mutations 
in PSEN1, APP, and MAPT (Lauritzen et al., 2012). The β-CTF accumulation was found 
within enlarged cathepsin B and Lamp1-positive structures and was not associated with Aβ 
load. Furthermore, a small but significant increase in γ-secretase activity was reported, 
suggesting that the accumulation of β-CTF was unlikely to be accounted for by impaired γ-
secretase function and may be due to defective lysosomal clearance (Lauritzen et al., 2016). 
This thesis therefore set out to investigate whether the increase in βCTF with BIN1 
depletion, in the absence of changes in Aβ, is associated with lysosomal defects. The results 
have shown that BIN1 depletion in the hCMEC/D3 cell line did not inflict observable 
morphological changes on lysosomes, as assessed by LysoTracker and LAMP2B staining. 
LysoTracker showed a high intensity of staining which resided in the perinuclear region, 
with minimal, if any, LysoTracker accumulating in peripheral lysosomes. This was also 
supported by LAMP2B staining which showed a greater number of puncta in the 
perinuclear region, however these were more diffuse than LysoTracker and peripheral 
staining was more frequently observed in cells. This is consistent with previous reports of 
LysoTracker staining acidic organelles in human adipose microvascular endothelial cells 
where a greater accumulation of puncta was observed in the perinuclear region whereas 
dextran conjugated to Alexa- Fluor-647, a pH-insensitive lysosome marker, showed more 
widespread staining throughout the cell (Johnson et al., 2016). The authors concluded that 
the position of lysosomes within the cell determines their luminal pH as this pattern of 
heterogeneity in LysoTracker staining across the cell was due to peripheral lysosomes being 
less acidic than juxtanuclear ones. While the intensity of LysoTracker staining in the 
present study suggested there was no change in lysosome acidity with BIN1 depletion, pH 
is a crucial indicator of lysosome function and this was not explicitly measured in the 
present study. This could be investigated by examining the ratio of dextran-conjugated 
fluorescent reporters, one of which is pH-dependent, which would allow a comparison of 
lysosomal pH between non-transfected, GFP siRNA-treated and BIN1-depleted cells.  
The lack of change in lysosome structure with BIN1 depletion suggests there was unlikely 
to be a gross impairment in lysosome function and that the increase in β-CTF observed 
may not be due to defective degradation and clearance via the lysosomal pathway. While 
very little is available in the literature regarding the relationship between BIN1 and 
lysosomal function, siRNA-mediated depletion of Bin1 in mouse intestinal organoids 
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resulted in the gross enlargement of lysosomes, using lamp2 as a marker (Nakajo et al., 
2016). Furthermore, accumulation of dipeptidyl peptidase IV, a membrane glycoprotein 
predominantly expressed at the apical membrane of polarised cells (Alfalah et al., 2002), 
was found in the enlarged lamp2-positive structures of Bin1-depleted organoids. 
Collectively these findings suggest that Bin1 is involved in transporting cargo to the apical 
membrane in intestinal epithelial cells and with Bin1 depletion, apical proteins accumulated 
in lysosomes possibly due to the accumulation of unsorted apical proteins in the ERC 
which may fuse or mature into lysosomes (Nakajo et al., 2016). This was investigated in a 
polarised in vitro context and may therefore relate to a possible function in BMECs. 
However, in the present study, no effect of BIN1 depletion on lysosome morphology was 
observed, suggesting the function of BIN1 in endocytic trafficking may differ between cell 
types. Nevertheless, polarisation was not established in the hCMEC/D3 cells in the present 
study, therefore apical and basolateral cargo may not have been distinguished and any 
defect in trafficking of apical cargo could not be observed. This presents an avenue for 
future study that will be further discussed in Chapter 7. 
6.4.2!Cholesterol Localisation with BIN1 Depletion 
Cellular cholesterol is either stored as free cholesterol or cholesterol esters in the form of 
cytoplasmic droplets (Ikonen, 2008). Filipin selectively stains free cholesterol, which is an 
essential structural component of cell membranes. Within the cell, cholesterol is abundant 
in the endocytic recycling compartment (Mukherjee et al., 1998), a perinuclear 
compartment which is responsible for most of the recycling of plasma membrane 
receptors. Cholesterol is also enriched in lipid rafts on the plasma membrane (Ikonen, 
2008). Lysosome dysfunction often causes accumulation of free cholesterol in the 
lysosomes which can inhibit Rab GTPases, which promote endocytic recycling (te Vruchte 
et al., 2004). Abnormal distribution and transport of cholesterol has been linked to many 
neurodegenerative diseases including Huntington’s, NPC and AD (Vance, 2012). In NPC, 
filipin staining is often used as a diagnostic criteria to identify the accumulation of free 
cholesterol in the lysosomes of cultured skin fibroblasts (Hankey, 2008). Consistent with 
the lysosome morphology, no change in cholesterol localisation or membrane content was 
observed with BIN1 depletion in hCMEC/D3 cells, suggesting that lysosome function and 
cholesterol trafficking was not impaired. However, cholesterol levels were not quantified 
therefore this would be required to confirm these findings. In all conditions, cholesterol 
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was localised to the perinuclear region, suggestive of ERC staining, while diffuse cell-wide 
staining was consistent with its presence throughout the cell membrane. In support of the 
previous findings on lysosome morphology, the lack of change in cholesterol localisation 
with BIN1 depletion suggests that BIN1 is not crucial for normal lysosome function in 
hCMEC/D3 cells. Therefore, impaired lysosome function may not account for the 
increase in β-CTF observed with BIN1 depletion in these cells and BIN1 may affect the 
processing of APP through a different pathway. 
6.4.3!The Role of BIN1 in Clathrin-independent Endocytosis 
Cholesterol is highly enriched in lipid raft fractions, however, the utility of filipin in 
analysing lipid raft function is limited as when applied in vitro, it disrupts caveolae and 
inhibits lipid raft endocytosis by sequestering cholesterol (Orlandi and Fishman, 1998). In 
order to investigate clathrin-independent mechanisms of endocytosis with BIN1 depletion, 
firstly expression levels of key CIE proteins, flotillin-1, flotillin-2, CAV1 and CAV2, were 
measured. While the flotillins are thought to define a clathrin-independent pathway of 
endocytosis (Glebov et al., 2006), they have been implicated in the clathrin-mediated 
endocytosis of APP (Schneider et al., 2008). Furthermore, (John et al., 2014) reported that 
flotillins directly bind to the cytoplasmic tail of BACE1 and depletion of flotillin-1 or -2 in 
HeLa cells showed a significant increase in BACE1 levels, particularly in the perinuclear 
region. In the flotillin-2-depleted cells, an increase in β-CTF but not APP levels was 
observed, suggesting that flotillin-2 knockdown increased the expression and endosomal 
localization of BACE1, resulting in increased amyloidogenic processing of APP (John et 
al., 2014).  
The aforementioned study by (John et al., 2014) draws many parallels with studies 
investigating BIN1 depletion and its involvement in BACE1 endocytic recycling (Miyagawa 
et al., 2016, Ubelmann et al., 2017). A possible relationship between BIN1 and flotillin-
mediated endocytic trafficking remains to be investigated, therefore an analysis of flotillin 
levels with BIN1 depletion in the present study aimed to explore this. Both flotillin-1 and 
flotillin-2 expression were readily detectable in hCMEC/D3 cells, however levels did not 
appear to alter with BIN1 depletion. While APP processing has been shown to be altered 
by flotillin-2 depletion (John et al., 2014), BIN1 depletion did not affect levels of flotillin-1 
or -2 in the present study, suggesting the increase in β-CTF with BIN1 depletion is unlikely 
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to have been brought about by flotillin-mediated mechanisms. However, flotillin-mediated 
internalisation was not explicitly measured in the present study due to the lack of change in 
flotillin levels. This would be an interesting further experiment in order to elucidate 
whether flotillin-mediated endocytosis is affected by BIN1 depletion.  
6.4.3.1! The Effect of BIN1 Depletion on the Expression of Caveolins  
The results presented in this chapter show that CAV1 levels were unaffected while CAV2 
protein levels were increased with BIN1 depletion. The molecular mechanism of caveolae 
assembly is not fully understood, however CAV1 is known to be required for this process 
(Razani et al., 2001). Many studies have suggested that CAV1 is sufficient to drive caveolae 
biogenesis and CAV2 may modulate the actions of CAV1 in this process (Sowa et al., 
2003). In polarised cells such as epithelial and endothelial cells, sorting of proteins destined 
for the two plasma membrane domains occurs in the Golgi where separate apical and 
basolateral vesicles form to deliver cargo to the required destinations (Mellman and 
Nelson, 2008). While CAV1 is present on both the apical and basolateral domains of 
MDCK polarised epithelial cells, CAV2 is strongly enriched on the basolateral membrane 
and vesicles (Scheiffele et al., 1998). CAV1/2 heteroligomers are incorporated into 
basolateral-directed vesicles in the Golgi whereas CAV1 homoligomers are incorporated 
into apical-directed vesicles (Scheiffele et al., 1998). LNCaP cells, human prostate 
adenocarcinoma cells which are devoid of caveolin expression and caveolae, were used to 
show that coexpression of CAV1 and CAV2 promote the formation of caveolae on the 
basolateral surface (Sowa et al., 2003). It should be noted, however, that inducing 
expression of a protein in cells which do not endogenously express that protein can often 
lead to the formation of non-specific and/or unnatural protein interactions (Park, 2008). 
The authors further demonstrated that CAV2 is phosphorylated by casein kinase 2 at 
serines 23 and 36 and that this is a crucial step in the formation of plasma membrane-
attached caveolae (Sowa et al., 2003). However, expression of a mutant CAV2 which 
cannot be phosphorylated showed no detectable caveolae formation but a 3-fold increase 
in the number of smooth vesicles in close proximity to the plasma membrane compared to 
cells expressing wild-type CAV2 (Sowa et al., 2003). This suggests that the phosphorylation 
of CAV2 may regulate the exocytosis/endocytosis of CAV1-dependent vesicles, therefore 
emphasising the importance of CAV2 in caveolar endocytosis. The increase in CAV2 
expression with BIN1 depletion in the present study may indicate alterations in caveolar-
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related endocytic mechanisms. This is of particular significance to AD as CAV1 has been 
identified as an important regulator of γ-secretase activity by modulating the partitioning of 
γ-secretase between caveolar and non-caveolar membranes (Kapoor et al., 2010). 
The increase in CAV2 expression with BIN1 depletion is particularly interesting in light of 
recent findings suggesting BIN1 is involved in the regulation of apical-directed transport in 
polarised epithelial cells. BIN1-depleted small intestine organoids showed a significant 
accumulation of apical-directed proteins in lysosomes, but not basolateral proteins (Nakajo 
et al., 2016). While Sowa et al. (2003) reported the involvement of CAV2 in the formation 
of caveolae at the basolateral surface of rat kidney epithelial cells, Cav-2 depletion in 
Caenorhabditis elegans was shown to cause a specific defect in the uptake of BODIPY-LacCer 
from the apical side of intestinal cells (Parker et al., 2009). Studies investigating CAV2 in 
endocytic trafficking in BMECs remain to be conducted, however it may be that depletion 
of BIN1 in the hCMEC/D3 cell line results in increased basolateral-directed transport 
and/or decreased apical-directed transport, hence showing an increase in CAV2 expression 
but no observable change in CAV1 expression. Indeed, caveolae have shown a polarised 
distribution in rat BMECs with 1.7-fold greater numbers at the basolateral compared to the 
apical membrane (Bendayan et al., 2006) therefore analysis of caveolar endocytosis in a 
polarised culture system with BIN1 depletion would be important for future work. With 
regards to AD pathogenesis, this could have consequences for clearance of Aβ or other 
toxins across BMECs or possibly affect the composition of apical/basolateral membranes 
which may impact the barrier properties BMECs. In order to investigate caveolar 
endocytosis, trafficking of CtxB was used as a marker of this mechanism. 
6.4.3.2! The role of BIN1 in Lipid-raft Trafficking 
GM1, the receptor for CtxB, is clustered in detergent-insoluble lipid rafts in the plasma 
membrane and its internalisation is dependent on and mediated by these cholesterol- and 
GSL-rich microdomains (Orlandi and Fishman, 1998). Trafficking of CtxB was optimised 
with the aim of visualising lipid raft endocytosis with BIN1 depletion. Unfortunately, 
insufficient positive CtxB staining was obtained with non-transfected cells to make reliable 
comparisons between conditions. This may be due to low expression levels of the GM1 
ganglioside in the plasma membrane of hCMEC/D3 cells, which has not previously been 
reported, as sufficient expression is necessary for this to be a valid method. Indeed, GM1 
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ganglioside was shown to be readily detectable in cultured astrocytes, neuroblastoma cells 
(SH-SY5Y), and pheochromocytoma cells (PC12) cells but not brain-derived endothelial 
cells (Yamamoto et al., 2007). Furthermore, analysis of the GSL composition of the human 
BMEC line SV-HCECs showed that GM3 and GM2 were the major gangliosides present, 
with GM1 only representing 3% of the population (Duvar et al., 2000). LacCer, however, 
comprised 36% of the total neutral glycosphingolipids (Duvar et al., 2000) and has the 
benefit of a well-characterised fluorescent analogue available therefore presented a more 
quantifiable marker for lipid raft trafficking. Furthermore, the specificity of CtxB as a raft 
marker is controversial, since ctxB/GM1 have been found to be internalised not only by 
CIE, but also via CCPs and thus CME (Hansen and Nichols, 2009). Therefore, 
considerable rationale was presented for analysing lipid raft endocytosis by alternative 
means. 
Glycosphingolipids, such as LacCer, are internalised from the plasma membrane via a 
clathrin-independent, caveolar-related mechanism (Singh et al., 2003). They are delivered to 
the early endosomes, where they are fractionated into two major pools, one that is 
transported via late endosomes to the Golgi apparatus and the other that is returned to the 
plasma membrane via the ERC (Sharma et al., 2003). Cells with lysosomal trafficking 
defects, such as cultured fibroblasts from patients with NPC, show abnormalities in the 
intracellular trafficking of lipids (Chen et al., 1999). In pulse-chase experiments, BODIPY-
LacCer accumulates in endosomes and lysosomes rather than being targeted to the Golgi as 
it is in normal cells. While such gross changes observed in lipid storage diseases would not 
be expected with BIN1 depletion in hCMEC/D3 cells, given the subtle effects 
demonstrated in this thesis so far, quantification of internalization via CIE may suggest an 
effect on this mechanism. LacCer is internalised by a clathrin-independent, caveolar-related 
route and has been shown to colocalise with Cav1 in vesicular structures upon endocytosis 
in rat fibroblasts (Singh et al., 2003). Since it was shown to be one of the major GSLs 
found in the SV-HCEC cells, also a human BMEC cell line (Duvar et al., 2000), it was used 
as a marker to investigate the function of CIE with BIN1 depletion in hCMEC/D3 cells. 
Despite an increase in CAV2 levels, the present study shows no significant difference in 
LacCer uptake with BIN1 depletion, suggesting that BIN1 is not important for CIE in 
hCMEC/D3 cells. While a positive control demonstrating LacCer uptake inhibition in this 
assay was not achieved using CAV1 siRNA, further discussed in Section 6.4.3.3, inhibition 
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of LacCer was achieved by genistein treatment. Despite the use of only two replicates in 
this assay, a preliminary conclusion can be reached suggesting that BIN1 depletion does 
not affect LacCer uptake in hCMEC/D3 cells and may not be crucial for caveolar 
endocytosis. This finding is important in the context of BMECs at the BBB as inhibition of 
caveolar endocytosis has recently been demonstrated as a mechanism by which the 
restrictive permeability of the BBB is maintained (Andreone et al., 2017). Should BIN1 
depletion have resulted in a change in LacCer uptake in hCMEC/D3 cells, this may have 
implications for the permeability of BBB, which is often compromised in AD (Zipser et al., 
2007). 
6.4.3.3! CAV1 depletion did not affect LacCer uptake 
Surprisingly, CAV1 depletion in the hCMEC/D3 cell line did not have a significant effect 
on BODIPY-LacCer uptake. This is in contrast to a previous study using the same siRNA 
for CAV1 in HeLa cells which showed a 50% reduction in BODIPY-LacCer uptake over a 
15 min chase period (Al Soraj et al., 2012). Furthermore, when C2C12 mouse myoblast 
cells were subjected to oxidative stress, causing degradation of Cav1, a significant reduction 
in BODIPY-LacCer uptake was observed (Mougeolle et al., 2015). Other groups have 
successfully applied siRNA methods to deplete CAV1 in alternative caveolar endocytic 
assays. Albumin is predominantly transported through a caveolae-mediated pathway and 
impairment of albumin uptake has been demonstrated with siRNA-mediated-Cav1 
depletion in mouse aortic endothelial cells (Gonzalez et al., 2004), human umbilical vein 
endothelial cells (HUVECs) (Pavlides et al., 2014) and in lung endothelial cells of Cav1 
knockout mice (Schubert et al., 2001). While siRNA-mediated CAV1 depletion has 
previously been investigated in the hCMEC/D3 cell line (Zhong et al., 2010), the effect on 
LacCer uptake is yet to be reported. However, Zhong et al. (2010) investigated siRNA-
mediated CAV1 depletion in the hCMEC/D3 cell line in relation to the relationship 
between CAV1 and Pgp expression, reporting that Pgp expression was not affected by 
CAV1 depletion. This was inconsistent with previous findings in bovine BMECs, which 
proposed that Pgp activity may be modulated by Cav1, suggesting that the results of Cav1 
depletion in these cells may be different to other cells. Furthermore, while the present 
results may suggest that CAV1 is not required for caveolar uptake in hCMEC/D3 cells, it is 
important to acknowledge evidence that sphingolipids can enter cells by multiple 
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mechanisms (Hansen and Nichols, 2009). Therefore, in the present study, LacCer was 
considered a marker for CIE and not specifically caveolae-mediated pathways. 
Furthermore, uptake of LacCer has been demonstrated in human colon carcinoma Caco-2 
cells, with very low CAV1 mRNA and undetectable CAV1 protein levels, suggesting other 
pathways are likely to be responsible for LacCer endocytosis in this cell line (Ilina et al., 
2015). Alternative endocytic processes may have been responsible for LacCer 
internalization in the hCMEC/D3 cell line and/or these may have compensated for the 
lack of CAV1. Crucially, demonstration of the sensitivity of the BODIPY-LacCer uptake 
assay was not achieved through CAV1 depletion therefore an alternative means of CIE 
inhibition was used. 
6.4.3.4! Genistein 
Genistein is a tyrosine kinase inhibitor which causes local disruption of the actin 
cytoskeleton at endocytic sites and has previously been shown to inhibit LacCer uptake in a 
variety of cell lines (Vercauteren et al., 2010, Mougeolle et al., 2015). In the present study, 
treatment of hCMEC/D3 cells with genistein induced a 30% reduction in BODIPY-
LacCer uptake that reached statistical significance based on two replicates. While further 
replications of this study will be necessary to confirm the validity of the findings, a small 
but significant level of inhibition of LacCer uptake by genistein is suggested. This level of 
inhibition, however, was not comparable to previous findings where genistein was shown 
to inhibit LacCer uptake by 65% in C2C12 mouse myoblasts (Mougeolle et al., 2015) and 
70% in D407 retinal pigment epithelial cells(Vercauteren et al., 2010). However, the extent 
to which this inhibition occurs varies between cell lines. Vercauteren et al. (2010) 
highlighted the different sensitivities of cell lines for individual inhibitors or treatments, 
including genistein where the inhibition level of LacCer uptake ranged from 30-70% across 
five different cell lines. The level of inhibition in the present study was therefore 
comparable to one of the cells lines analysed, an African green monkey kidney epithelial 
cell line (Vercauteren et al., 2010). This suggests that the extent to which LacCer is 
internalised by CIE varies between cell types. Optimisation of this experiment may have 
resulted in a greater level of LacCer uptake inhibition as Vercauteren et al. (2010) reported 
that the optimal inhibitor conditions in the cell lines assessed were a pre-treatment with 
400 µM genistein for 2 hours and continued incubation with the inhibitor during the 
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application of the BODIPY-LacCer. This is double the concentration of genistein used in 
the present study and the inhibitor was only applied for 30 min before LacCer incubation 
in the hCMEC/D3 cells, and not during, therefore an optimisation of these conditions may 
yield a greater degree of inhibition. Nevertheless, a significant reduction in LacCer uptake 
with genistein treatment in the present study suggests that the sensitivity of this assay may 
be sufficient for hCMEC/D3 cells and is therefore a reliable measure of CIE. In light of 
this, the present findings suggest that BIN1 may not be important for CIE in hCMEC/D3 
cells. 
As with the use of LacCer as a marker for CIE, the use of inhibitors in endocytic assays 
must be carefully interpreted as their specificity can often be questioned (Vercauteren et al., 
2010). While LacCer internalization was inhibited by 80% with genistein in rat fibroblasts 
without affecting Tf uptake (Singh et al., 2003), genistein treatment inhibited both LacCer 
uptake and Tf uptake in D407 human retinal pigment epithelial cells by 70% and 80%, 
respectively (Vercauteren et al., 2010). This suggests that endocytic mechanisms can vary 
greatly between cell types. The effect of genistein treatment on CME through analysis of 
Tf uptake was not examined in the present study. Caution must therefore be exercised 
when interpreting results from studies using single measures of endocytic uptake and future 
work for the present study would include the utilisation of additional methods of CIE 
inhibition and CIE markers in order to replicate findings.  
6.4.4!Conclusions 
In summary, the present study has demonstrated that BIN1 depletion does not impact 
lysosome morphology or cholesterol trafficking in hCMEC/D3 cells. While the levels of 
flotillins were unaffected, CAV2 showed a significant increase with BIN1 depletion, 
however CIE, as assessed by LacCer trafficking, was not affected. Further work would 
include investigating the intracellular localisation of LacCer after trafficking, as while levels 
may not have considerably changed, altered trafficking may have still occurred with BIN1 
depletion. Furthermore, apical and basolateral trafficking cannot be segregated in this non-
polarised culture system and the aforementioned literature suggests that this is important 
for CIE mechanisms in endothelial cells. The establishment of apical-basolateral polarity in 
hCMEC/D3 cell culture as a future direction for research in the role of BIN1 will be 
further discussed in Chapter 7. 
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Chapter 7 
General Discussion 
7! 7 
7.1! Summary of Aims and Key Findings 
The overall aim of this study was to investigate the functional role of BIN1 in the context 
of endocytic mechanisms in the brain to gain insight into the molecular pathogenesis of 
AD. To achieve this aim, two major objectives were explored: 
•! Utilising novel advances in the development of induced pluripotent stem cells 
(iPSCs) in order to create a more accurate neuronal cell model to study the role of 
BIN1 and endocytic mechanisms in neurons. 
•! To generate a transient BIN1-depleted brain endothelial cell model to investigate 
the role of BIN1 in APP processing and endocytic function at the BBB.  
BIN1 has been implicated in sAD by a number of GWAS (Seshadri et al., 2010, Naj et al., 
2011, Hollingworth et al., 2011, Lambert et al., 2013) and is the second most significantly 
associated susceptibility locus for sAD after APOE (Lambert et al., 2013). With multiple 
tissue-specific isoforms, the functions of BIN1 are wide-ranging and its involvement in 
mediating sAD risk is not fully understood. BIN1 is thought to play a critical role in CME 
and was recently shown to regulate intracellular trafficking of BACE1 (Miyagawa et al., 
2016). This finding in both neuronal and non-neuronal cell lines emphasises the need to 
investigate BIN1 function in multiple sAD-relevant cell types. Table 7.1 summarises the 
key findings of this study.  
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Table 7.1: Summary of the Key Aims and Findings of this Thesis 
Chapter Aims Key findings 
3 
To characterise and successfully 
differentiate PBMC-derived iPSCs 
into cortical glutamatergic neurons. 
iPSCs derived from PBMCs can be 
directed to differentiate into cortical 
neurons through dual SMAD 
inhibition. 
4 
To achieve depletion of total BIN1 in 
a human brain endothelial cell line and 
to characterise its role in APP 
processing in hCMEC/D3 BMECs. 
BIN1 depletion results in a significant 
increase in intracellular β-CTF levels, 
without impacting intracellular APP 
levels or extracellular Aβ40 or sAPPα. 
Protein levels of key α- β- and γ-
secretases were unchanged with BIN1 
depletion. 
BIN1 depletion did not affect BACE1 
or APP localisation. 
5 
To investigate whether BIN1 
depletion affects CME and recycling 
in the hCMEC/D3 cell line. 
BIN1 depletion does not affect Tf 
uptake or recycling in the hCMEC/D3 
cell line. 
The BIN1 isoforms expressed in 
hCMEC/D3 cells are not required for 
CME or recycling. 
6 
To explore whether BIN1 is involved 
in endo-lysosomal trafficking and/or 
CIE in hCMEC/D3 cells. 
BIN1 depletion does not impact 
lysosome morphology or cholesterol 
trafficking in hCMEC/D3 cells. 
BIN1-depleted cells show an increase 
in CAV2 protein expression but 
LacCer trafficking, a marker of CIE, is 
not affected. 
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In Chapter 3, a novel cortical neuronal model was created through the differentiation of an 
iPSC line derived from PBMCs. The limitations and wider applications of this work have 
been extensively discussed in Chapter 3, therefore the general discussion will focus on the 
main body of the thesis investigating BIN1 function in hCMEC/D3 cells and the wider 
context of this work within the field of AD research. 
In Chapter 4, the involvement of BIN1 in APP processing in hCMEC/D3c cells was 
investigated using siRNA-mediated depletion of all BIN1 protein isoforms. While no 
significant differences in the levels of APP and Aβ40 were observed with BIN1 depletion, 
a significant increase in β-CTF was found, suggesting that BIN1 may be involved in the 
amyloidogenic processing of APP. The mechanism from which this increase originated 
could not be further elucidated from levels of sAPPα as no significant change was detected 
with BIN1 depletion and a high level of variability was shown between samples. 
Furthermore, levels of sAPPβ fell beyond the detectability limit of the assay. The present 
findings do suggest an enhancement of the amyloidogenic pathway with BIN1 depletion, 
indicated by increased βCTF, either in terms of increased production or decreased 
clearance. A change in levels of key α-, β- and γ- secretases was not detected, suggesting 
that the increase in β-CTF may not be due to altered secretase activity. However, only 
overall levels of ADAM10, BACE1 and PSEN1 were analysed and not the enzymatic 
activity levels. 
It is possible that an increase in the amount of APP being directed down the 
amyloidogenic pathway may have occurred without a change in secretase activity. Indeed, 
this was demonstrated by Miyagawa et al. (2016) when BIN1 depletion resulted in 
enhanced cleavage of APP by increased encounters with BACE1 due to endocytic 
trafficking defects. Nevertheless, Chapter 5 showed no change in CME or recycling, 
measured by internalization and trafficking of Alexa-488-Tf, with BIN1 depletion. These 
findings were, however, consistent with the lack of change in APP levels reported in 
Chapter 4, suggesting the increase in β-CTF was not due to increased internalization of 
APP by CME, and therefore may be sure to increased colocalisation with cleavage 
enzymes.  Furthermore, the absence of BIN1 isoforms expressing the CLAP domain 
indicate that BIN may not be necessary for the proper functioning of CME in hCMEC/D3 
cells. 
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Chapter 6 investigated a potential role for BIN1 in endocytic trafficking to the lysosome, 
independent of clathrin-mediated mechanisms. LysoTracker, LAMP2B and cholesterol 
staining suggested that BIN1 depletion did not inflict observable morphological changes 
on lysosomes or gross abnormalities in lysosome function. This suggests that BIN1 is not 
vital for the proper functioning of these organelles, at least in terms of the parameters 
measured in this study. Flotillin-1, flotillin-2 and CAV1, key proteins involved in CIE, 
showed no change in levels, however, CAV2 showed a significant increase in protein levels, 
leading to analysis of the function of CIE with BIN1 depletion in hCMEC/D3 cells. 
BODIPY-LacCer was used as a marker for CIE and FACs analysis showed no change in 
fluorescence with BIN1 depletion, suggesting the internalization of LacCer was not 
affected. This suggests that BIN1 may not be necessary for CIE in hCMEC/D3 cells and 
supports the lack of change in flotillin-1, flotillin-2 and CAV1 levels, however this finding 
does not further elucidate the functional relevance of increased CAV2 levels with BIN1 
depletion. The demonstration of decreased LacCer uptake with Genistein treatment 
suggests that the assay is an effective measure of caveolar endocytosis, however, as 
previously discussed in Chapter 6, the extent to which LacCer uptake was inhibited by 
Genistein was not comparable to the majority of studies in the literature ( Vercauteren et 
al., 2010, Mougeolle et al., 2015). The sensitivity of this assay therefore requires further 
optimisation, however, initial results suggest that, despite increasing CAV2 expression 
levels, BIN1 depletion may not impact CIE. 
CAV2 has shown strong enrichment on the basolateral membrane and in basolateral 
vesicles of MDCK polarised epithelial cells (Scheiffele et al., 1998) and involvement in the 
formation of caveolae at the basolateral surface of rat kidney epithelial cells (Sowa et al., 
2003), suggesting it may be involved in CIE from the basolateral domain. However, in 
Caenorhabditis elegans, Cav2 was predominantly expressed in the apical membrane of 
intestinal cells and Cav2 null mutants were defective in the uptake of BODIPY-LacCer 
suggesting Cav2 was involved in apical trafficking (Parker et al., 2009). Indeed, endocytosis 
of Fm4-64, a plasma membrane marker, was perturbed at the apical, but not the basolateral 
membrane (Parker et al., 2009). Collectively, these data suggest that CAV2 may have a 
domain-specific role in polarised cells. A change in caveolar endocytosis with BIN1 
depletion could have crucial implications for BBB permeability. Recently, it has been 
demonstrated that the lipid composition of BMECs inhibits specifically caveolae-mediated 
transcytosis in order to maintain BBB integrity (Andreone et al., 2017). While no defect in 
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LacCer uptake was identified with BIN1 depletion in the present study, it is possible that 
BIN1 may have a polarised role in BMECs which the present non-polarised culture system 
was not capable of detecting. Therefore, a role for BIN1 in endocytic trafficking in BMECs 
cells cannot be ruled out based on the present findings. 
7.2! Is an Increase in β-CTF Sufficient to be a Key Driver in AD 
Pathogenesis? 
The increase in β-CTF with BIN1 depletion is a key indication of altered amyloidogenic 
processing of APP, despite no change being detected in Aβ40 levels. Indeed, there is much 
emerging evidence that β-CTF may contribute to sAD pathogenesis, independent of Aβ 
(Kim et al., 2016). In particular, that β-CTF accumulation may contribute to endocytic 
dysfunction in AD (Jiang et al., 2010). In APP-overexpressing fibroblasts, Jiang et al. (2010) 
showed that either depletion of APP by shRNA or decreasing β-CTF production by 
inhibiting BACE1 reversed the pathologic endocytic changes observed in these cells, 
including endosome enlargement and accelerated uptake. Crucially, inhibition of γ-secretase 
in these cells, which reduced Aβ40 and Aβ42 production but increased β-CTF levels, also 
lead to AD-like endosome dysfunction, highlighting the importance of Aβ-independent 
pathogenic roles of β-CTF in AD. While demonstrating a novel link between the 
generation of βCTF and pathological endosomal effects that are not mediated by Aβ, this 
study was conducted in APP-overexpressing cells which are not representative of 
physiological levels of APP in sAD.  
In the context of the present study, BMECs express APP751 and APP770 and the expression 
of these isoforms is higher in endothelial cells of cerebral blood vessels compared with 
peripheral arteries (Kitazume et al., 2010). While the expression of specific APP isoforms 
was not analysed in the present study, hCMEC/D3 cells have shown comparable APP 
expression levels to primary human BMECs in culture (Urich et al., 2012). Therefore 
suggesting that the expression level of APP in hCMEC/D3 cells is physiologically 
representative. It has been demonstrated that BMECs are capable of proteolytically 
processing APP to produce Aβ (Kitazume et al., 2010). However, endogenous Aβ was not 
detectable in this study (Kitazume et al., 2010) and the overexpression of APP770 was 
required in order to demonstrate the amyloidogenic activity of BMECs. Furthermore, APP 
expression in BMECs was shown to be 53% of the expression levels in neurons (Forloni et 
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al., 1992), suggesting that the BBB may contribute to APP processing to a lesser extent 
than neurons in the brain.  Therefore, it brings into question the extent to which the 
increase in β-CTF observed in this study could be a key driver in AD pathogenesis. 
Nevertheless, the increase in β-CTF in the present study may be indicative of perturbations 
in other cell mechanisms not directly measured. Indeed, BIN1 is thought to have multiple 
functions in different tissues (Tan et al., 2013) and the functional relevance of the BIN1 
isoforms in different cell types is still poorly understood. 
7.3! BIN1: a Protein of Multiple Functions 
The mechanism(s) by which BIN1 protein contributes to AD risk are currently unknown.  
BIN1 is member of the BAR family of proteins, that regulate membrane dynamics in a 
variety of cellular functions (Ren et al., 2006), and has been shown to interact and recruit 
dynamin (Meinecke et al., 2013). Much research has therefore focused on the involvement 
of BIN1 in endocytosis when attempting to elucidate the mechanism by which BIN1 
mediates AD risk. With 55% protein homology to AMPH1 (Butler et al., 1997), BIN1 has 
been proposed to function in synaptic vesicle endocytosis (Wigge and McMahon, 1998). 
However primary neurons from Bin1 knockout mice failed to demonstrate a defect in this 
mechanism, suggesting that BIN1 and AMPH1 may have divergent functions in the brain 
and reflecting the broad expression of BIN1 isoforms across several tissues (Muller et al., 
2003).  
While endocytosis is central to the amyloidogenic processing of APP (Carey et al., 2005), 
the lack of correlation established between BIN1 and Aβ pathology has shed doubt on the 
role of BIN1 in amyloidogenesis (Glennon et al., 2013). With over 10 alternatively-spliced 
isoforms showing specific tissue distribution and cellular localization, BIN1 has wide-
ranging functions that may be dependent on cell type. Within the human brain, BIN1 
isoform diversity has been demonstrated (De Rossi et al., 2016) with the majority of BIN1 
showing non-neuronal expression and predominantly localizing to mature 
oligodendrocytes. In this context, an association between BIN1 expression and 
oligodendrocyte myelination was identified (De Rossi et al., 2016). BIN1 has also been 
implicated in modulating the pathophysiological process involving tau by studies showing a 
direct interaction of BIN1 with the tau protein (Chapuis et al., 2013) in addition to the 
association of BIN1 expression with NFTs (Holler et al., 2014). Furthermore, neuronal 
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BIN1 isoform 1, containing the CLAP domain, has been proposed to control tau aggregate 
entry into the cell through negative regulation of CME (Calafate et al., 2016). Therefore, a 
decrease in neuronal BIN1 isoform 1, as has been demonstrated in AD brains (Holler et 
al., 2014), may promote the propagation of tau pathology by increasing CME, thus 
promoting tau aggregate internalisation. Clearly, there are multiple mechanisms by which 
BIN1 may mediate risk in sAD, in part due to its multiple functions in different tissues. 
The current BIN1 literature fails to fully investigate the functional relevance of the 
different isoforms. The present study shows, for the first time, that the absence of the 
CLAP domain in brain endothelial BIN1 isoforms may account for an alternative role in 
this cell type and the apparent lack of involvement in CME. For future studies, it is highly 
important to establish which BIN1 isoforms are expressed in the cell type of interest 
because different regions of the protein account for different functional roles. 
It must be acknowledged that, although this study suggests that BIN1 does not function in 
CME in BMECs, further work is required to confirm this. Firstly, the possibility of a 
compensatory mechanism involving AMPH1 was not fully elucidated in this study due to 
low expression levels in control hCMEC/D3 cells. While levels may have become 
detectable with BIN1-depletion, this was not investigated as it was deemed unlikely. 
Furthermore, a cargo-specific role for BIN1 in endocytic trafficking is also a possibility as 
analysis was limited to Tf, a well-regarded CME marker. Indeed, it has been demonstrated 
that depletion of PICALM in N2a cells did not affect transferrin uptake but resulted in a 
significant decrease in APP internalization, suggesting that the effect of PICALM on 
endocytosis is cargo-specific (Xiao et al., 2012). BIN1 may also have cargo-specific 
properties that would not have been revealed through analysis of transferrin trafficking. 
Although the results presented indicated no change in levels or localisation of APP with 
BIN1 depletion, future studies would include analysing the trafficking of specific cargo, 
such as APP. 
7.4! BIN1 and Barrier Function 
Beyond a possible role in APP processing, it would be interesting to investigate whether 
BIN1 is involved in maintaining the barrier function of BMECs. Evidence indicates a 
critical role for cerebrovascular dysfunction in AD and impairment of the BBB is thought 
to contribute to disease pathogenesis. Post-mortem studies in AD patients have shown 
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accumulation of blood-derived proteins in the hippocampus and cortex due to BBB 
breakdown in these regions (Zipser et al., 2007). While BBB breakdown occurs during 
normal ageing, it was shown to be more pronounced in individuals with MCI compared to 
age-matched controls, suggesting loss of BBB integrity may contribute to early cognitive 
impairment (Montagne et al., 2015). In addition to faulty BBB clearance of Aβ through 
deregulated LRP1/RAGE-mediated transport, previously discussed in Chapter 1, other 
transport mechanisms such as that involving glucose transporter 1 (GLUT1) have been 
implicated in AD (Winkler et al., 2015). GLUT1 is expressed at the BBB, in BMECs and 
astrocytes, but not in neurons and mediates glucose transport into the brain. Reduced 
GLUT1 levels have been reported in the cerebral microvessels of AD patients (Simpson et 
al., 1994). GLUT1 deficiency in the endothelium of mice overexpressing APP generates 
multiple parallel pathogenic mechanisms including diminished glucose uptake, 
microvasculature leakage, accelerated brain Aβ deposition and progressive neuronal loss 
(Winkler et al., 2015). The reduction in BBB GLUT1 expression may therefore exacerbate 
Alzheimer's disease cerebrovascular degeneration. 
GLUT1 is internalised into mammalian cells by CIE (Eyster et al., 2009) and recycles via 
the Arf6 pathway, requiring Rab GTPases and receptor mediated endocytosis/Eps15 
homology-domain containing 1 (RME-1/EHD1) family proteins (Chen et al., 2010). RME-
1/EHD1 proteins, as key components of the recycling endosome, are involved in 
endosome-to-plasma membrane transport and have been shown to colocalise with 
AMPH1, the only amphiphysin gene in C. elegans. It is therefore possible that BIN1 could 
be involved in the endocytic transport of other BBB transport proteins, such as GLUT1, 
and could contribute to BBB dysfunction in AD in ways that are yet to be investigated. 
Perturbed endocytic recycling mechanisms could be crucial for the functionality of the 
BBB, particularly in maintaining its polarisation by ensuring the appropriate distribution of 
receptors at the apical and basolateral domains.  
Indeed, BIN1 has recently been implicated in polarised endocytic trafficking in intestinal 
epithelial cells. Nakajo et al. (2016) identified a novel Rab8-binding protein complex 
involving Bin1, dynamin and EH domain-binding protein 1-like protein 1 (Ehbp1l1) which 
localises to the ERC and generates membrane tubules containing apical cargo proteins. In 
mouse intestinal organoids, siRNA-mediated depletion of BIN1 resulted in the missorting 
of apical proteins and induced the accumulation of apical but not basolateral membrane 
proteins in lysosomes (Nakajo et al., 2016). This study demonstrated a mechanism whereby 
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BIN1 was involved in the regulation of apical-directed transport in polarised cells and 
therefore provides rationale for establishing polarity to enable distinction between apical 
and basolateral domains when investigating BIN1 function in the hCMEC/D3 cell line. It 
is possible that BIN1 could be involved in apical/basolateral-specific transport in BMECs, 
which could go undetected in the present experimental design due to lack of established 
polarisation in culture. This may have an impact on barrier function by altering the protein 
composition of each membrane domain. Bin1 has been implicated in gut-immune barrier 
function whereby Bin1 -/- mice exhibit higher transendothelial electrical resistance and 
decreased paracellular transepithelial flux compared to wild-types, resulting in suppression 
of experimental colitis (Chang et al., 2012). Bin1 was subsequently followed up as an 
immunotherapy target with altered expression of tight junction proteins in mice treated 
with Bin1 monoclonal antibody following experimentally-induced colitis (Thomas et al., 
2016). This presents an interesting area for investigation at the BBB; whether BIN1 
depletion affects the expression of tight junction proteins and endothelial barrier 
properties. The culture method used in the current project may not have been suitable for 
such studies as the inability to detect LRP1 in these cells suggested that relevant proteins 
may not have been expressed at endogenous levels. Analysis of barrier function would have 
required culturing BMECs in a manner to develop TJs and polarisation, further discussed 
in Section 7.5, and was unfortunately beyond the timeframe of this thesis.   
Endothelial cells are considered a specialised type of epithelial cell that line the interior of 
blood vessels whereas epithelial cells line the cavity of tissues throughout the body. While 
endothelial cells lining the brain microvasculature may carry out a different function to 
peripheral endothelial/epithelial cells, both have defined basolateral and apical domains 
and are involved in barrier formation. When making comparisons between barriers of the 
CNS and the periphery, it is important to establish which BIN1 isoforms are expressed in 
each cell type as this can determine their function. Although very few studies detail the 
BIN1 isoforms expressed in the cells they are examining, DuHadaway et al. (2003) reported 
that rat intestinal epithelial cells appear to express the ubiquitous isoforms 9 and 10 in 
addition to the aberrant cancer isoform containing exon 12a. In the present study, these 
isoforms were also suggested to be expressed in the hCMEC/D3 cell line therefore the role 
of BIN1 polarised trafficking and/or barrier function in intestinal epithelial cells may also 
apply to BMECs and other tissues. Furthermore, in the study by Nakajo et al. (2016),  the 
association between Bin1 and the Ehbp1l1 was mediated by the SH3 domain, which is 
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common to all BIN1 isoforms. Therefore, this involvement in apical-directed cargo 
transport may be a mechanism common to all BIN1 isoforms in polarised cells. This could 
have relevance for the BBB in AD as defective apical-directed transport in BMECs may 
alter the composition of receptors at the apical membrane which could impact transcytosis 
and barrier function of the BBB.  
7.5! The hCMEC/D3 Cell Line as a BBB Model 
The hCMEC/D3 cell line was used in the present study as it offers a well characterised, 
easy to use in vitro model of the human BBB. As the initial aim of this study was to 
investigate APP processing and basic endocytic function with BIN1 depletion, the cells 
were cultured as a monolayer on fibronectin-coated plates without the establishment of 
apical and basolateral domains. Many studies, however, have cultured hCMEC/D3 cells on 
semipermeable transwell filter inserts which mimic the blood (apical) side, whereas the well 
in which the insert sits mimics the brain (basolateral) side. The microporous membrane 
(0.4 µm) allows the exchange of small molecules and secreted growth factors between the 
two compartments. When cultured in this manner, endothelial cells are able to form a tight 
barrier, which is often measured by TEER and their permeability to hydrophilic molecules 
as paracellular permeability markers (Weksler et al., 2005). While the endocytic and 
recycling assays used in the present study can be considered an initial indicator of 
transcytosis in BMECs, adapting the culture method by utilising transwell inserts would 
offer the opportunity to investigate endocytic trafficking and transcytosis in a polarised 
context with BIN1 depletion. This adaptation was beyond the timeframe of the current 
project but is an important avenue for future research, investigating the potential role of 
BIN1 in barrier function of BMECs. 
While the hCMEC/D3 cell line provides an easily accessible model for BBB studies, it has 
been suggested that BMECs are particularly affected by culturing in isolation, possibly due 
to the loss of their native environment within the NVU. A global transcriptome analysis 
which compared the hCMEC/D3 cell line with human primary BMECs and published 
analysis of freshly isolated mouse BECs identified a large proportion of probe sets showing 
different expression levels in hCMEC/D3 cells compared to human primary BMECs, with 
2% probe sets exhibiting at least a 10-fold change (Daneman et al., 2010a). Most of the 
genes showing higher expression in hCMEC/D3 were involved in DNA repair, RNA 
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processing, mitosis and the immune/virus response, likely a consequence of the 
immortalization procedure. This transcriptomic analysis also revealed that TJ proteins, 
including Claudin-5, Occludin and JAM2 are expressed at low levels in comparison to 
freshly isolated mouse BMECs data while cell surface receptors LRP1 and RAGE are 
expressed at low levels in hCMEC/D3 cells, human primary BMECs and the freshly 
prepared mouse BMECs. Furthermore, the cultured cells in this study failed to maintain 
high levels of key BBB transporters such as SLC family members and ABC transporters. 
This data therefore suggests that BMECs lose their unique protein expression pattern 
outside of their native environment and display a more generic endothelial cell phenotype.  
7.6! Alternative in vitro Models of the BBB 
Many in vitro models of the BBB have been implemented to investigate drug permeation 
mechanisms however, to date, no unified method has been described for establishing a 
blood-brain barrier model. Many in vitro animal BBB models using primary or low passage 
porcine, bovine, rat or mouse cells generally report relatively high TEER values and low 
paracellular permeability (Helms et al., 2016). However, the isolation and purification 
procedure is time-consuming and produces minimal yields with a poor lifespan. 
Furthermore, differences in the expression of transporters and efflux pumps have been 
reported in animal BMECs compared to human (Uchida et al., 2011), rendering their 
relevance for the study of human disease uncertain. While some of the BBB-specific 
transporters and enzymes are expressed at much lower levels in immortalised cell lines, 
they have the advantage of an enhanced ability to proliferate in culture over primary 
models. For these reasons, an immortalised human cell line was used in the present study. 
To better mimic the anatomic structure of the in vivo BBB, BMECs are often co-cultured 
with other cells, such as astrocytes and pericytes, that directly contribute to the barrier 
properties of BBB. A co-culture model whereby astrocytes were seeded to the underside of 
transwell filters and BMECs seeded on top, mimicking the structure of the NVU, resulted 
in significantly higher TEER than BMECs alone, directly reflecting increased structural 
integrity of the BBB (Wang et al., 2015). Another method by which improved barrier 
tightness has been achieved in culture is by subjecting hCMEC/D3 monolayers to 
physiological shear stress to mimic blood flow in a microfluidic device, which increased 
TEER approximately three-fold (Griep et al., 2013). This is because shear stress positively 
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affects endothelial cell physiology and tight junction formation (van der Meer et al., 2010). 
This has been extended with tissue engineering technology to develop in vitro 3D human 
vessels composed of a scaffold mesh with primary HUVECs, smooth muscle cells and 
astrocytes in a semi-pulsatile flow bioreactor system which have been used to model the 
BBB (Robert et al., 2017).  
BBB models based on stem cell-derived endothelial cells have also started to emerge in the 
literature. Human ESC and iPSC-derived endothelial cells have demonstrated many BBB 
attributes including organised tight junctions, polarised transporter activity and TEER and 
molecular permeability that correlates well with in vivo brain uptake (Lippmann et al., 2012). 
Recently, Yamamizu et al. (2017) have designed a co-culture system with the four cell 
populations of the NVU, BMECS, pericytes, neurons and astrocytes, derived from human 
iPSCs. This not only provides a robust and reproducible human BBB model, expressing 
specific transporters and receptors and showing low permeability properties, but also 
allows the investigation of cell-cell interactions at the NVU which has so far been limited in 
in vitro studies.  
7.7! Conclusions and Future Work 
This thesis has investigated the role of BIN1, a sAD risk gene, in the novel context of brain 
endothelial cells that comprise the BBB. The findings that BIN1 depletion in hCMEC/D3 
cells affects the amyloidogenic processing of APP but does not appear to impact on CME 
or recycling suggests an alternative role for BIN1 at the BBB to its role in endocytic 
trafficking previously reported in the literature in other cell types. Elucidation of the role of 
BIN1 in BMECs requires further investigation, particularly in light of an increase in CAV2 
with BIN1 depletion but no apparent effect on CIE. Figure 7.1 summarises the working 
hypotheses as a result of this thesis which remain to be elucidated, including a role in CME 
that may have been compensated for in the present study. Although there is strong 
evidence for a role of BIN1 in endocytosis, other functions must be considered in the 
context of other brain cell types that may be involved in sAD pathogenesis. Of particular 
note is the predominant expression of BIN1 in oligodendrocytes and white matter in the 
brain (De Rossi et al., 2016). BIN1 cellular expression did not associate with neurofibrillary 
tangle pathology or senile plaques in AD brains, nor did it fit the overall distribution 
profiles of microglia, activated microglia, and astrocytes (De Rossi et al., 2017). Together 
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with evidence of differential expression of different BIN1 isoforms in the AD brain 
(Holler et al., 2014), these findings suggest that future research in the BIN1 field should 
involve elucidating isoform-specific functions in non-neuronal cell types in the brain. With 
regards to the present study, extending the experimental design to hCMEC/D3 cells 
cultured in a transwell assay for establishment of polarity has been cited as a future 
objective. Furthermore, this would allow an investigation of the role of BIN1 in barrier 
function of BMECs and this could be extended to the aforementioned alternative BBB 
models. It also remains to be elucidated whether the identified sAD risk variants 30kb 
upstream of the BIN1 gene affect BIN1 isoform expression and a thorough analysis of this 
in different brain cell types would be important given the apparent varied function of BIN1 
in the brain.  
 
  
Involvement in CME, 
which can be 
compensated for by 
other accessory proteins
Functions in caveolar
endocytosis, potentially 
in a polarised fashion
Involvement in 
intracellular 
membrane 
curvature and 
trafficking
Working hypotheses for BIN1 function in brain endothelial cells
Figure 7.1: Working hypotheses on the potential role for BIN1 in brain endothelial 
cells as a result of the findings from this thesis 
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In conclusion, this thesis has shed new light on the possible role of BIN1 in APP 
processing and associated endocytic mechanisms in a novel in vitro context. The 
demonstration that BIN1 is not important for the normal functioning of CME suggests 
there may be other mechanisms by which it mediates sAD risk. AD is likely to be a 
multifactorial disease and BIN1 may act in combination with other risk factors to induce 
greater pathological effects than might be seen than in the present model. In the context of 
the currently available literature, it is clear that BIN1 is involved in diverse mechanisms 
within the brain, dependent on the cellular context, and much work still remains to identify 
the mechanisms by which BIN1 mediates its risk on sAD. 
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Figure A1: Omission of primary antibodies for immunocytochemistry negative 
controls 
Representative images showing the application of goat-anti-rabbit 488 with goat-anti-
mouse 594 without primary antibody and goat-anti-rat 488 without primary antibody to 
demonstrate the minimal level of background staining in immunocytochemistry 
experiments.  
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Appendix II 
The PICALM antibody used in Chapter 5 was developed by a collaboration with Millipore 
and was validated by Thomas et al. (2016) using siRNA targeting PICALM (Figure A2). 
 
 
 
 
 
 
Figure A2: Validity report for PICALM 19291 antibody showing specificity and 
depletion with PICALM siRNA 
A) Western blot showing PICALM bands using Millipore corporation antibody 19291 in 
Mog cells, HeLa cells and Mouse cortex. Mog = MOG G UVW Human brain astrocytoma 
Established from an anaplastic astrocytoma of normal adult brain 
B) Western blot showing PICALM bands using the Millipore corporation 19291 antibody 
after GFP siRNA and PICALM siRNA (PI) treatment.   
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